10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q/A

Amendment No. 1

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___ 

Commission File Number 001-31792

CNO Financial Group, Inc.

Delaware	75-3108137
State of Incorporation	IRS Employer Identification No.
11825 N. Pennsylvania Street
Carmel, Indiana  46032	(317) 817-6100
Address of principal executive offices	Telephone

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:  Yes [ X ]  No [   ]

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes [ X ]  No [   ]

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  Large accelerated filer [ X ]  Accelerated filer [   ] Non-accelerated filer [   ] Smaller reporting company [   ]

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):  Yes [   ] No [ X ]

Shares of common stock outstanding as of October 23, 2012:  227,011,634

EXPLANATORY NOTE

This Quarterly Report on Form 10-Q/A ("Form 10-Q/A") is being filed as Amendment No. 1 (the "Amendment") to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, which was filed with the Securities and Exchange Commission on November 1, 2012 (the "Original Form 10-Q"). This Form 10-Q/A is being filed to amend the consolidated balance sheet as of September 30, 2012; the consolidated statement of comprehensive income for the three and nine months ended September 30, 2012; the consolidated statement of shareholders' equity for the nine months ended September 30, 2012; and certain disclosures in the notes to the consolidated financial statements. Management and the Audit and Enterprise Risk Committee of CNO Financial Group, Inc. (the "Company") concluded that an inadvertent error involving a component of the calculation of accumulated other comprehensive income existed in the Original Form 10-Q that requires correction. The correction of this error had no impact on net income, earnings per share or cash flows. In addition, the correction had no impact on results, cash flows or capital measures calculated in accordance with statutory accounting principles.

Pursuant to generally accepted accounting principles, we are required to adjust certain balance sheet accounts to reflect the impact resulting from assuming that unrealized gains and losses on available for sale securities are realized and the proceeds are invested in securities earning current market yields. Such adjustments are commonly referred to as “shadow adjustments” and may include adjustments to: (i) deferred acquisition costs; (ii) the present value of future profits; (iii) loss recognition reserves; and (iv) income taxes. The net impact of these shadow adjustments is recognized in accumulated other comprehensive income. Amounts related to the shadow adjustments for certain long-term care products previously reported in our Original Form 10-Q have been corrected and are described in the note to the consolidated financial statements entitled "Correction to Previously Issued Financial Statements" contained herein. Shadow adjustments will vary from period to period and are primarily dependent upon the amount of unrealized gains or losses related to available for sale securities and the estimated gross profits of certain lines of business.

As a result of the correction, management has also re-assessed the effectiveness of its disclosure controls and procedures and internal control over financial reporting and concluded that they were not effective as of the end of the period covered by this report on Form 10-Q/A because of a material weakness in internal control over financial reporting. Specifically, controls in place to ensure the accurate calculation of shadow adjustments impacting accumulated other comprehensive income did not operate effectively. Therefore, management has subsequently concluded that the Company's disclosure controls and procedures were not effective as of the end of the period covered by this report. As a result of the identification of the error that led to the amendment of our Original Form 10-Q and the related reassessment of disclosure controls and procedures and internal control over financial reporting, we have emphasized the importance of performing and reviewing calculations consistent with the design of our internal control structure in an effort to ensure controls operate effectively. The Company believes this action has remediated the material weakness. The material weakness in internal control over financial reporting is further discussed in Item 4 contained herein.

The following sections have been amended from the Original Form 10-Q as a result of the restatement described above:

•Part I - Item 1. Financial Statements

•Part I - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

•Part I - Item 4. Controls and Procedures

This Form 10-Q/A also includes as exhibits, certifications from our Chief Executive Officer and Chief Financial Officer dated as of the date of this filing. Except as described above, no other sections have been amended from the Original Form

10-Q. This Form 10-Q/A does not reflect information or events occurring after the November 1, 2012 filing date of the Original Form 10-Q, or modify or update disclosures set forth in the Original Form 10-Q, except to reflect the corrections discussed above.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		Page
Item 1.	Financial Statements
	Consolidated Balance Sheet as of September 30, 2012 and December 31, 2011	3
	Consolidated Statement of Operations for the three and nine months ended September 30, 2012 and 2011	5
	Consolidated Statement of Comprehensive Income for the three and nine months ended September 30, 2012 and 2011	6
	Consolidated Statement of Shareholders’ Equity for the nine months ended September 30, 2012 and 2011	7
	Consolidated Statement of Cash Flows for the nine months ended September 30, 2012 and 2011	8
	Notes to Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	59
	Cautionary Statement Regarding Forward-Looking Statements	59
	Overview	60
	Critical Accounting Policies	64
	Results of Operations	64
	Premium Collections	87
	Liquidity and Capital Resources	92
	Investments	100
	Investment in Variable Interest Entities	109
	New Accounting Standards	111
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	111
Item 4.	Controls and Procedures	111
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	111
Item 1A.	Risk Factors	112
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	112
Item 5.	Other Information	112
Item 6.	Exhibits	113

2

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET

(Dollars in millions)

ASSETS

	September 30, 2012		December 31, 2011
	(Restated)
Investments:	(unaudited)
Fixed maturities, available for sale, at fair value (amortized cost:  September 30, 2012 - $21,825.7; December 31, 2011 - $21,779.1)	$	24,742.3	$	23,516.0
Equity securities at fair value (cost: September 30, 2012 - $174.0; December 31, 2011 - $177.0)	180.0		175.1
Mortgage loans	1,597.2		1,602.8
Policy loans	274.1		279.7
Trading securities	199.4		91.6
Investments held by variable interest entities	829.4		496.3
Other invested assets	265.0		202.8
Total investments	28,087.4		26,364.3
Cash and cash equivalents - unrestricted	415.3		436.0
Cash and cash equivalents held by variable interest entities	48.2		74.4
Accrued investment income	317.8		288.7
Present value of future profits	642.4		697.7
Deferred acquisition costs	623.4		797.1
Reinsurance receivables	2,967.7		3,091.1
Income tax assets, net	699.5		865.4
Assets held in separate accounts	15.7		15.0
Other assets	338.6		292.2
Total assets	$	34,156.0	$	32,921.9

(continued on next page)

The accompanying notes are an integral part of the

unaudited consolidated financial statements, which

include a summary of revisions to prior year balances in

connection with a change in accounting principle.

3

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET, continued

(Dollars in millions)

LIABILITIES AND SHAREHOLDERS' EQUITY

	September 30, 2012			December 31, 2011
	(Restated)
Liabilities:	(unaudited)
Liabilities for insurance products:
Interest-sensitive products	$	12,930.3		$	13,165.5
Traditional products	11,004.3			10,482.7
Claims payable and other policyholder funds	977.6			1,034.3
Liabilities related to separate accounts	15.7			15.0
Other liabilities	709.0			556.3
Investment borrowings	1,650.9			1,676.5
Borrowings related to variable interest entities	766.9			519.9
Notes payable – direct corporate obligations	1,035.1			857.9
Total liabilities	29,089.8			28,308.1
Commitments and Contingencies
Shareholders' equity:
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: September 30, 2012 - 229,506,690; December 31, 2011 – 241,304,503)	2.3			2.4
Additional paid-in capital	4,251.2			4,361.9
Accumulated other comprehensive income	1,234.4			781.6
Accumulated deficit	(421.7		)	(532.1		)
Total shareholders' equity	5,066.2			4,613.8
Total liabilities and shareholders' equity	$	34,156.0		$	32,921.9

The accompanying notes are an integral part of the

unaudited consolidated financial statements, which

include a summary of revisions to prior year balances in

connection with a change in accounting principle.

4

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF OPERATIONS

(Dollars in millions, except per share data)

(unaudited)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Revenues:
Insurance policy income	$	690.2		$	673.5		$	2,071.3		$	2,020.3
Net investment income (loss):
General account assets	349.4			338.2			1,045.7			1,016.5
Policyholder and reinsurer accounts and other special-purpose portfolios	39.1			(54.9		)	87.4			(14.4		)
Realized investment gains (losses):
Net realized investment gains, excluding impairment losses	32.2			33.5			98.4			64.9
Other-than-temporary impairment losses:
Total other-than-temporary impairment losses	(23.1		)	(2.9		)	(34.5		)	(26.3		)
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income	—			—			—			—
Net impairment losses recognized	(23.1		)	(2.9		)	(34.5		)	(26.3		)
Total realized gains	9.1			30.6			63.9			38.6
Fee revenue and other income	5.2			4.9			13.6			12.5
Total revenues	1,093.0			992.3			3,281.9			3,073.5
Benefits and expenses:
Insurance policy benefits	745.7			661.0			2,124.4			2,028.6
Interest expense	29.2			27.9			86.7			86.0
Amortization	60.9			58.6			215.8			224.1
Loss on extinguishment of debt	198.5			1.1			199.2			3.1
Other operating costs and expenses	217.5			182.0			617.8			527.8
Total benefits and expenses	1,251.8			930.6			3,243.9			2,869.6
Income (loss) before income taxes	(158.8		)	61.7			38.0			203.9
Income tax expense (benefit):
Income tax expense (benefit) on period income	(10.8		)	25.2			61.2			75.6
Decrease in valuation allowance for deferred tax assets	(143.0		)	(143.0		)	(143.0		)	(143.0		)
Net income (loss)	$	(5.0	)	$	179.5		$	119.8		$	271.3
Earnings per common share:
Basic:
Weighted average shares outstanding	231,481,000			246,965,000			236,555,000			249,673,000
Net income (loss)	$	(.02	)	$	.73		$	.51		$	1.09
Diluted:
Weighted average shares outstanding	231,481,000			302,708,000			292,983,000			306,085,000
Net income (loss)	$	(.02	)	$	.61		$	.45		$	.92

The accompanying notes are an integral part of the

unaudited consolidated financial statements, which

include a summary of revisions to prior year balances in

connection with a change in accounting principle.

5

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(Dollars in millions)

(unaudited)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Restated)						(Restated)
Net income (loss)	$	(5.0	)	$	179.5		$	119.8		$	271.3
Other comprehensive income, before tax:
Unrealized gains for the period	689.4			973.6			1,252.8			1,248.1
Amortization of present value of future profits and deferred acquisition costs	(38.0		)	(125.9		)	(114.2		)	(163.0		)
Amount related to premium deficiencies assuming the net unrealized gains had been realized	(267.6		)	(241.0		)	(380.7		)	(241.0		)
Reclassification adjustments:
For net realized investment gains included in net income	(4.6		)	(55.1		)	(57.2		)	(69.1		)
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains included in net income	1.7			3.9			5.9			3.7
Unrealized gains on investments	380.9			555.5			706.6			778.7
Change related to deferred compensation plan	(2.1		)	(2.4		)	(.5		)	(2.0		)
Other comprehensive income before tax	378.8			553.1			706.1			776.7
Income tax expense related to items of accumulated other comprehensive income	(135.2		)	(197.7		)	(253.3		)	(278.5		)
Other comprehensive income, net of tax	243.6			355.4			452.8			498.2
Comprehensive income	$	238.6		$	534.9		$	572.6		$	769.5

The accompanying notes are an integral part of the

unaudited consolidated financial statements, which

include a summary of revisions to prior year balances in

connection with a change in accounting principle.

6

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY

(Dollars in millions)

(unaudited)

	Common stock and additional paid-in capital			Accumulated other  comprehensive income  (loss)		Retained earnings  (accumulated deficit)			Total
Balance, December 31, 2010	$	4,426.7		$	252.7	$	(867.8	)	$	3,811.6
Net income	—			—		271.3			271.3
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $276.7)	—			495.0		—			495.0
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense of $1.8)	—			3.2		—			3.2
Cost of shares acquired	(55.7		)	—		—			(55.7		)
Stock option and restricted stock plans	10.8			—		—			10.8
Balance, September 30, 2011	$	4,381.8		$	750.9	$	(596.5	)	$	4,536.2
Balance, December 31, 2011	$	4,364.3		$	781.6	$	(532.1	)	$	4,613.8
Net income	—			—		119.8			119.8
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $248.9)	—			444.9		—			444.9
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense of $4.4)	—			7.9		—			7.9
Extinguishment of beneficial conversion feature related to the repurchase of convertible debentures	(24.0		)	—		—			(24.0		)
Cost of shares acquired	(99.5		)	—		—			(99.5		)
Dividends on common stock	—			—		(9.4		)	(9.4		)
Stock option and restricted stock plans	12.7			—		—			12.7
Balance, September 30, 2012 (Restated)	$	4,253.5		$	1,234.4	$	(421.7	)	$	5,066.2

The accompanying notes are an integral part of the

unaudited consolidated financial statements, which

include a summary of revisions to prior year balances in

connection with a change in accounting principle.

7

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS

(Dollars in millions)

(unaudited)

	Nine months ended
	September 30,
	2012			2011
Cash flows from operating activities:
Insurance policy income	$	1,802.3		$	1,791.8
Net investment income	1,010.0			1,065.0
Fee revenue and other income	13.6			12.5
Insurance policy benefits	(1,611.5		)	(1,555.7		)
Interest expense	(84.3		)	(70.5		)
Deferrable policy acquisition costs	(141.4		)	(164.9		)
Other operating costs	(558.6		)	(513.6		)
Taxes	(5.5		)	(2.4		)
Net cash provided by operating activities	424.6			562.2
Cash flows from investing activities:
Sales of investments	1,852.5			4,390.5
Maturities and redemptions of investments	1,365.4			853.3
Purchases of investments	(3,570.2		)	(6,363.8		)
Net sales of trading securities	47.2			307.2
Change in cash and cash equivalents held by variable interest entities	26.2			7.1
Other	(24.3		)	(23.4		)
Net cash used by investing activities	(303.2		)	(829.1		)
Cash flows from financing activities:
Issuance of notes payable, net	944.5			—
Payments on notes payable	(779.0		)	(130.7		)
Amounts related to extinguishment of debt	(206.4		)	—
Issuance of common stock	2.0			.6
Payments to repurchase common stock	(99.5		)	(55.7		)
Common stock dividends paid	(9.4		)	—
Amounts received for deposit products	986.0			1,285.8
Withdrawals from deposit products	(1,201.4		)	(1,272.0		)
Issuance of investment borrowings:
Federal Home Loan Bank	200.0			517.0
Related to variable interest entities	246.7			122.2
Payments on investment borrowings:
Federal Home Loan Bank	(200.0		)	(267.0		)
Related to variable interest entities and other	(.8		)	(100.4		)
Investment borrowings - repurchase agreements, net	(24.8		)	57.1
Net cash provided (used) by financing activities	(142.1		)	156.9
Net decrease in cash and cash equivalents	(20.7		)	(110.0		)
Cash and cash equivalents, beginning of period	436.0			571.9
Cash and cash equivalents, end of period	$	415.3		$	461.9

The accompanying notes are an integral part of the

unaudited consolidated financial statements, which

include a summary of revisions to prior year balances in

connection with a change in accounting principle.

8

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

BUSINESS AND BASIS OF PRESENTATION

The following notes should be read together with the notes to the consolidated financial statements included in our 2011 Annual Report on Form 10-K as retrospectively updated by the Current Report on Form 8-K filed on September 4, 2012 in connection with a change in accounting principle.

CNO Financial Group, Inc., a Delaware corporation (“CNO”), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products.  CNO became the successor to Conseco, Inc., an Indiana corporation (our “Predecessor”), in connection with our bankruptcy reorganization which became effective on September 10, 2003.  The terms “CNO Financial Group, Inc.”, the “Company”, “we”, “us”, and “our” as used in these financial statements refer to CNO and its subsidiaries or, when the context requires otherwise, our Predecessor and its subsidiaries.  We focus on serving the senior and middle-income markets, which we believe are attractive, underserved, high growth markets.  We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

Our unaudited consolidated financial statements reflect normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of our financial position, results of operations and cash flows for the periods presented.  As permitted by rules and regulations of the Securities and Exchange Commission (the “SEC”) applicable to quarterly reports on Form 10-Q, we have condensed or omitted certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).  We have reclassified certain amounts from the prior periods to conform to the 2012 presentation.  These reclassifications have no effect on net income or shareholders’ equity.  Results for interim periods are not necessarily indicative of the results that may be expected for a full year.

As discussed in the note to the consolidated financial statements entitled "Recently Issued Accounting Standards", we have adopted the provisions of Financial Accounting Standards Update No. 2010-26 (“ASU 2010-26”), effective January 1, 2012, which modified the definition of the types of costs incurred by insurance entities that could be capitalized in the acquisition of new and renewal contracts. Pursuant to the guidance, we elected to adopt the provisions on a retrospective basis. Accordingly, all prior periods presented have been retrospectively adjusted.

The balance sheet at December 31, 2011, presented herein, has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.

When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods.  For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals.  If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.

Our consolidated financial statements exclude the results of transactions between us and our consolidated affiliates, or among our consolidated affiliates.

CORRECTION TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS

As further described below, the consolidated balance sheet as of September 30, 2012; the consolidated statement of comprehensive income for the three and nine months ended September 30, 2012; the consolidated statement of shareholders' equity for the nine months ended September 30, 2012; and certain disclosures in the notes to the consolidated financial statements have been amended to correct an inadvertent error related to a component of accumulated other comprehensive income. The correction of this error had no impact on net income, earnings per share or cash flows. In addition, the correction had no impact on results, cash flows or capital measures calculated in accordance with statutory accounting principles.

9

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

Pursuant to GAAP, we are required to adjust certain balance sheet accounts to reflect the impact resulting from assuming that unrealized gains and losses on available for sale securities are realized and the proceeds are invested in securities earning current market yields. Such adjustments are commonly referred to as “shadow adjustments” and may include adjustments to: (i) deferred acquisition costs; (ii) the present value of future profits; (iii) loss recognition reserves; and (iv) income taxes. The net impact of these shadow adjustments is recognized in accumulated other comprehensive income. Amounts related to the shadow adjustments for certain long-term care products previously reported in our Form 10-Q for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on November 1, 2012, have been corrected. Shadow adjustments will vary from period to period and are primarily dependent upon the amount of unrealized gains or losses related to available for sale securities and the estimated gross profits of certain lines of business. The following summarizes the increase (decrease) to the principal items impacted by the corrections (dollars in millions):

	As reported in Form 10-Q		Corrections to shadow adjustments			As reported in Form 10-Q/A
Deferred acquisition costs	$	580.7	$	42.7		$	623.4
Income tax assets	594.5		105.0			699.5
Change in total assets			$	147.7
Liabilities for insurance products	$	24,593.5	$	334.4		$	24,927.9
Accumulated other comprehensive income	1,421.1		(186.7		)	1,234.4
Change to total liabilities and shareholders' equity			$	147.7
Comprehensive income:
For the three months ended September 30, 2012	$	425.3	$	(186.7	)	$	238.6
For the nine months ended September 30, 2012	$	759.3	$	(186.7	)	$	572.6

INVESTMENTS

We classify our fixed maturity securities into one of three categories: (i) “available for sale” (which we carry at estimated fair value with any unrealized gain or loss, net of tax and related adjustments, recorded as a component of shareholders’ equity); (ii) “trading” (which we carry at estimated fair value with changes in such value recognized as net investment income (classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios)); or (iii) “held to maturity” (which we carry at amortized cost).  We had no fixed maturity securities classified as held to maturity during the periods presented in these financial statements.

The trading account includes: (i) investments purchased with the intent of selling in the near term to generate income on price changes; and (ii) investments supporting certain insurance liabilities (including investments backing the market strategies of our multibucket annuity products) and certain reinsurance agreements. The change in fair value of these securities is recognized in income from policyholder and reinsurer accounts and other special-purpose portfolios (a component of net investment income). Investment income from trading securities backing certain insurance liabilities and certain reinsurance agreements is substantially offset by the change in insurance policy benefits related to certain products and agreements.  Prior to June 30, 2011, certain of our trading securities were held to offset the income statement volatility caused by the effect of interest rate fluctuations on the value of embedded derivatives related to our fixed index annuity products.  During the second quarter of 2011, we sold this trading portfolio and invested the proceeds in higher yielding investments which were classified as available for sale. See the note entitled “Accounting for Derivatives” for further discussion regarding these embedded derivatives.  The trading account also includes certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in value of these securities is recognized in realized investment gain (losses). Our trading securities totaled $199.4 million and $91.6 million at September 30, 2012 and December 31, 2011, respectively.

10

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments.  These amounts, included in shareholders’ equity as of September 30, 2012 and December 31, 2011, were as follows (dollars in millions):

	September 30, 2012			December 31, 2011
	(Restated)
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	$	9.6		$	(4.4	)
Net unrealized gains on all other investments	2,914.8			1,733.2
Adjustment to present value of future profits (a)	(200.7		)	(214.8		)
Adjustment to deferred acquisition costs	(458.0		)	(289.3		)
Adjustment to insurance liabilities	(334.4		)	—
Unrecognized net loss related to deferred compensation plan	(8.8		)	(8.3		)
Deferred income tax liabilities	(688.1		)	(434.8		)
Accumulated other comprehensive income	$	1,234.4		$	781.6

_________

(a) The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003 (the date our Predecessor emerged from bankruptcy).

At September 30, 2012, adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred income tax assets included $(166.5) million, $(150.8) million, $(334.4) million and $234.6 million, respectively, for premium deficiencies that would exist on certain long-term health products if unrealized gains on the assets backing such products had been realized and the proceeds from our sales of such assets were invested at then current yields.

At September 30, 2012, the amortized cost, gross unrealized gains and losses, estimated fair value, other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than- temporary impairments included in accumulated other comprehensive income
Corporate securities	$	14,586.6	$	2,265.7	$	(28.8	)	$	16,823.5	$	—
United States Treasury securities and obligations of United States government corporations and agencies	164.2		6.9		—			171.1		—
States and political subdivisions	1,785.6		267.9		(5.4		)	2,048.1		—
Debt securities issued by foreign governments	.8		—		—			.8		—
Asset-backed securities	1,391.3		92.0		(6.6		)	1,476.7		—
Collateralized debt obligations	327.6		5.2		(.8		)	332.0		—
Commercial mortgage-backed securities	1,400.7		142.7		(.8		)	1,542.6		—
Mortgage pass-through securities	18.8		1.4		—			20.2		—
Collateralized mortgage obligations	2,150.1		178.1		(.9		)	2,327.3		(7.3		)
Total fixed maturities, available for sale	$	21,825.7	$	2,959.9	$	(43.3	)	$	24,742.3	$	(7.3	)

11

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at September 30, 2012, by contractual maturity.  Actual maturities will differ from contractual maturities because certain borrowers may have the right to call or prepay obligations with or without penalties.  In addition, structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as “structured securities”) frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	178.3	$	180.7
Due after one year through five years	1,558.1		1,697.5
Due after five years through ten years	4,491.1		5,038.7
Due after ten years	10,309.7		12,126.6
Subtotal	16,537.2		19,043.5
Structured securities	5,288.5		5,698.8
Total fixed maturities, available for sale	$	21,825.7	$	24,742.3

Net Realized Investment Gains (Losses)

During the first nine months of 2012, we recognized net realized investment gains of $63.9 million, which were comprised of $89.0 million of net gains from the sales of investments (primarily fixed maturities) with proceeds of $1.9 billion, the increase in fair value of certain fixed maturity investments with embedded derivatives of $9.4 million, and $34.5 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

During the first nine months of 2011, we recognized net realized investment gains of $38.6 million, which were comprised of $64.9 million of net gains from the sales of investments (primarily fixed maturities) with proceeds of $4.4 billion and $26.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

At September 30, 2012, fixed maturity securities in default or considered nonperforming had an aggregate amortized cost of $.4 million and a carrying value of $.5 million.

Our fixed maturity investments are generally purchased in the context of a long-term strategy to fund insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities.  In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities.

During the nine months ended September 30, 2012, we sold $393.8 million of fixed maturity investments which resulted in gross investment losses (before income taxes) of $15.3 million.  We sell securities at a loss for a number of reasons including, but not limited to:  (i) changes in the investment environment; (ii) expectation that the market value could deteriorate further; (iii) desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; or (v) changes in expected cash flows.

There were no investments sold at a loss during the first nine months of 2012 that had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis for more than 12 months prior to the sale of the investment.

We regularly evaluate all of our investments with unrealized losses for possible impairment.  Our assessment of whether unrealized losses are “other than temporary” requires significant judgment.  Factors considered include:  (i) the extent to which fair value is less than the cost basis; (ii) the length of time that the fair value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for specific events, developments or circumstances likely to affect the value of the investment; (v) the investment’s rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on

12

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) whether we intend to sell the investment or it is more likely than not that circumstances will require us to sell the investment before recovery occurs; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values; (ix) projections of, and unfavorable changes in, cash flows on structured securities including mortgage-backed and asset-backed securities; (x) our best estimate of the value of any collateral; and (xi) other objective and subjective factors.

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio.  Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

Impairment losses on equity securities are recognized in net income.  The manner in which impairment losses on fixed maturity securities, available for sale, are recognized in the financial statements is dependent on the facts and circumstances related to the specific security.  If we intend to sell a security or it is more likely than not that we would be required to sell a security before the recovery of its amortized cost, the security is other-than-temporarily impaired and the full amount of the impairment is recognized as a loss through earnings.  If we do not expect to recover the amortized cost basis, we do not plan to sell the security, and if it is not more likely than not that we would be required to sell a security before the recovery of its amortized cost, less any current period credit loss, the recognition of the other-than-temporary impairment is bifurcated.  We recognize the credit loss portion in net income and the noncredit loss portion in accumulated other comprehensive income.

We estimate the amount of the credit loss component of a fixed maturity security impairment as the difference between amortized cost and the present value of the expected cash flows of the security.  The present value is determined using the best estimate of future cash flows discounted at the effective interest rate implicit to the security at the date of purchase or the current yield to accrete an asset-backed or floating rate security.  The methodology and assumptions for establishing the best estimate of future cash flows vary depending on the type of security.

For most structured securities, cash flow estimates are based on bond specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including excess spread, subordination and guarantees.  For corporate bonds, cash flow estimates are derived from scenario-based outcomes of expected corporate restructurings or the disposition of assets using bond specific facts and circumstances. The previous amortized cost basis less the impairment recognized in net income becomes the security’s new cost basis.  We accrete the new cost basis to the estimated future cash flows over the expected remaining life of the security, except when the security is in default or considered nonperforming.

The remaining noncredit impairment, which is recorded in accumulated other comprehensive income, is the difference between the security’s estimated fair value and our best estimate of future cash flows discounted at the effective interest rate prior to impairment.  The remaining noncredit impairment typically represents changes in the market interest rates, current market liquidity and risk premiums.  As of September 30, 2012, other-than-temporary impairments included in accumulated other comprehensive income of $7.3 million (before taxes and related amortization) related to structured securities.

13

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the three and nine months ended September 30, 2012 and 2011 (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Credit losses on fixed maturity securities, available for sale, beginning of period	$	(1.7	)	$	(1.6	)	$	(2.0	)	$	(6.1	)
Add:  credit losses on other-than-temporary impairments not previously recognized	—			—			—			—
Less:  credit losses on securities sold	—			.7			.3			5.2
Less:  credit losses on securities impaired due to intent to sell (a)	—			—			—			—
Add:  credit losses on previously impaired securities	—			—			—			—
Less:  increases in cash flows expected on previously impaired securities	—			—			—			—
Credit losses on fixed maturity securities, available for sale, end of period	$	(1.7	)	$	(.9	)	$	(1.7	)	$	(.9	)

__________

(a) Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.

Gross Unrealized Investment Losses

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active investment management. Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities.

14

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at September 30, 2012 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
States and political subdivisions	$	40.2	$	(2.0	)	$	68.7	$	(3.4	)	$	108.9	$	(5.4	)
Corporate securities	300.5		(9.2		)	278.1		(19.6		)	578.6		(28.8		)
Asset-backed securities	42.1		(.3		)	137.8		(6.3		)	179.9		(6.6		)
Collateralized debt obligations	12.7		(.1		)	47.2		(.7		)	59.9		(.8		)
Commercial mortgage-backed securities	16.0		(.1		)	14.3		(.7		)	30.3		(.8		)
Mortgage pass-through securities	—		—			2.0		—			2.0		—
Collateralized mortgage obligations	58.5		(.5		)	36.0		(.4		)	94.5		(.9		)
Total fixed maturities, available for sale	$	470.0	$	(12.2	)	$	584.1	$	(31.1	)	$	1,054.1	$	(43.3	)
Equity securities	$	2.1	$	(.1	)	$	—	$	—		$	2.1	$	(.1	)

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2011 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	9.1	$	—		$	.2	$	—		$	9.3	$	—
States and political subdivisions	6.9		(.2		)	155.4		(13.4		)	162.3		(13.6		)
Debt securities issued by foreign governments	.5		—			—		—			.5		—
Corporate securities	1,394.7		(57.0		)	466.2		(79.9		)	1,860.9		(136.9		)
Asset-backed securities	437.6		(14.5		)	147.5		(22.2		)	585.1		(36.7		)
Collateralized debt obligations	268.8		(6.3		)	1.7		—			270.5		(6.3		)
Commercial mortgage-backed securities	168.8		(5.2		)	33.0		(2.7		)	201.8		(7.9		)
Mortgage pass-through securities	1.2		—			2.2		(.1		)	3.4		(.1		)
Collateralized mortgage obligations	645.0		(20.8		)	29.7		(.6		)	674.7		(21.4		)
Total fixed maturities, available for sale	$	2,932.6	$	(104.0	)	$	835.9	$	(118.9	)	$	3,768.5	$	(222.9	)
Equity securities	$	41.6	$	(3.0	)	$	.4	$	—		$	42.0	$	(3.0	)

Based on management’s current assessment of investments with unrealized losses at September 30, 2012, the Company believes the issuers of the securities will continue to meet their obligations (or with respect to equity-type securities, the investment value will recover to its cost basis).  While we do not have the intent to sell securities with unrealized losses and it is not more likely than not that we will be required to sell securities with unrealized losses prior to their anticipated recovery, our intent on an individual security may change, based upon market or other unforeseen developments.  In such instances, if a loss

15

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

is recognized from a sale subsequent to a balance sheet date due to these unexpected developments, the loss is recognized in the period in which we had the intent to sell the security before its anticipated recovery.

EARNINGS PER SHARE

A reconciliation of net income and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands):

	Three months ended					Nine months ended
	September 30,					September 30,
	2012			2011		2012		2011
Net income (loss) for basic earnings per share	$	(5.0	)	$	179.5	$	119.8	$	271.3
Add:  interest expense on 7.0% Convertible Senior Debentures due 2016 (the “7.0% Debentures”), net of income taxes	—			3.7		11.1		11.1
Net income for diluted earnings per share	$	(5.0	)	$	183.2	$	130.9	$	282.4
Shares:
Weighted average shares outstanding for basic earnings per share	231,481			246,965		236,555		249,673
Effect of dilutive securities on weighted average shares:
7% Debentures	—			53,367		53,037		53,367
Stock option and restricted stock plans	—			2,353		2,639		2,712
Warrants	—			23		752		333
Dilutive potential common shares	—			55,743		56,428		56,412
Weighted average shares outstanding for diluted earnings per share	231,481			302,708		292,983		306,085

In the third quarter of 2012, interest expense of $3.7 million (net of income taxes) on the 7% Debentures was not added back to net income; and 56,651,000 equivalent common shares (comprised of 52,366,000 shares related to the 7% Debentures; 2,968,000 shares related to stock option and restricted stock plans; and 1,317,000 shares related to warrants) were not included in the diluted weighted average shares outstanding, because their inclusion would have been antidilutive in such period due to the net loss recognized by the Company.

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding for the period.  Restricted shares (including our performance shares) are not included in basic earnings per share until vested.  Diluted earnings per share reflect the potential dilution that could occur if outstanding stock options and warrants were exercised and restricted stock was vested.  The dilution from options, warrants and restricted shares is calculated using the treasury stock method.  Under this method, we assume the proceeds from the exercise of the options and warrants (or the unrecognized compensation expense with respect to restricted stock) will be used to purchase shares of our common stock at the average market price during the period, reducing the dilutive effect of the exercise of the options and warrants (or the vesting of the restricted stock). The dilution from our 7.0% Debentures is calculated using the "if converted" method. Initially, the 7.0% Debentures will be convertible into 182.1494 shares of our common stock for each $1,000 principal amount of 7.0% Debentures, which is equivalent to an initial conversion price of approximately $5.49 per share. The conversion rate is subject to adjustment following the occurrence of certain events in accordance with the terms of the 7.0% Debentures.

BUSINESS SEGMENTS

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; Other CNO Business, comprised primarily of products we no longer sell actively; and corporate operations, comprised of holding company activities and certain noninsurance company businesses.  

We measure segment performance by excluding realized investment gains (losses) and fair value changes in embedded derivative liabilities because we believe that this performance measure is a better indicator of the ongoing business and trends

16

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

in our business.  Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business.

Realized investment gains (losses) and fair value changes in embedded derivative liabilities depend on market conditions and do not necessarily relate to the underlying business of our segments.  Realized investment gains (losses) and fair value changes in embedded derivative liabilities may affect future earnings levels since our underlying business is long-term in nature and changes in our investment portfolio may impact our ability to earn the assumed interest rates needed to maintain the profitability of our business.

Operating information by segment was as follows (dollars in millions):

	Three months ended					Nine months ended
	September 30,					September 30,
	2012		2011			2012		2011
Revenues:
Bankers Life:
Insurance policy income:
Annuities	$	6.8	$	9.6		$	21.9	$	26.7
Health	335.1		334.0			1,010.6		1,017.1
Life	74.2		61.0			209.1		170.4
Net investment income (a)	221.6		158.0			642.1		564.5
Fee revenue and other income (a)	4.0		3.6			10.2		9.2
Total Bankers Life revenues	641.7		566.2			1,893.9		1,787.9
Washington National:
Insurance policy income:
Health	143.4		141.2			429.0		423.1
Life	3.6		3.9			11.6		11.8
Other	.8		.8			2.2		3.0
Net investment income (a)	50.9		47.3			151.9		140.3
Fee revenue and other income (a)	.3		.4			.8		.9
Total Washington National revenues	199.0		193.6			595.5		579.1
Colonial Penn:
Insurance policy income:
Health	1.3		1.4			4.0		4.5
Life	53.2		49.4			158.5		147.5
Net investment income (a)	9.9		10.1			30.1		30.9
Fee revenue and other income (a)	.2		.2			.6		.6
Total Colonial Penn revenues	64.6		61.1			193.2		183.5
Other CNO Business:
Insurance policy income:
Annuities	2.5		3.4			8.3		8.6
Health	6.2		6.9			19.3		21.3
Life	62.9		61.7			196.2		184.9
Other	.2		.2			.6		1.4
Net investment income (a)	86.7		74.6			259.2		256.0
Total Other CNO Business revenues	158.5		146.8			483.6		472.2
Corporate operations:
Net investment income	19.4		(6.7		)	49.8		10.4
Fee and other income	.7		.7			2.0		1.8
Total corporate revenues	20.1		(6.0		)	51.8		12.2
Total revenues	1,083.9		961.7			3,218.0		3,034.9

(continued on next page)

17

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

(continued from previous page)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Expenses:
Bankers Life:
Insurance policy benefits	$	434.6		$	360.6		$	1,252.2		$	1,174.3
Amortization	35.6			44.1			143.0			159.5
Interest expense on investment borrowings	1.3			1.2			4.1			3.5
Other operating costs and expenses	89.6			80.9			267.4			236.9
Total Bankers Life expenses	561.1			486.8			1,666.7			1,574.2
Washington National:
Insurance policy benefits	111.1			119.0			340.5			349.5
Amortization	11.2			10.8			34.7			35.6
Interest expense on investment borrowings	.7			.2			2.2			.2
Other operating costs and expenses	42.1			42.4			125.6			126.5
Total Washington National expenses	165.1			172.4			503.0			511.8
Colonial Penn:
Insurance policy benefits	38.3			36.0			120.0			112.7
Amortization	3.5			3.5			11.1			11.0
Other operating costs and expenses	25.4			22.9			73.9			66.3
Total Colonial Penn expenses	67.2			62.4			205.0			190.0
Other CNO Business:
Insurance policy benefits	157.1			111.5			401.0			358.2
Amortization	10.5			10.4			25.1			28.4
Interest expense on investment borrowings	5.0			5.3			15.1			15.2
Other operating costs and expenses	39.5			16.8			96.4			55.1
Total Other CNO Business expenses	212.1			144.0			537.6			456.9
Corporate operations:
Interest expense on corporate debt	16.3			18.7			50.4			58.6
Interest expense on borrowings of variable interest entities	5.8			2.4			14.5			8.4
Interest expense on investment borrowings	.1			.1			.4			.1
Loss on extinguishment of debt	198.5			1.1			199.2			3.1
Other operating costs and expenses	20.9			19.0			54.5			43.0
Total corporate expenses	241.6			41.3			319.0			113.2
Total expenses	1,247.1			906.9			3,231.3			2,846.1
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes:
Bankers Life	80.6			79.4			227.2			213.7
Washington National	33.9			21.2			92.5			67.3
Colonial Penn	(2.6		)	(1.3		)	(11.8		)	(6.5		)
Other CNO Business	(53.6		)	2.8			(54.0		)	15.3
Corporate operations	(221.5		)	(47.3		)	(267.2		)	(101.0		)
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	$	(163.2	)	$	54.8		$	(13.3	)	$	188.8

___________________

(a) It is not practicable to provide additional components of revenue by product or services.

18

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

A reconciliation of segment revenues and expenses to consolidated revenues and expenses is as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Total segment revenues	$	1,083.9		$	961.7		$	3,218.0		$	3,034.9
Net realized investment gains	9.1			30.6			63.9			38.6
Consolidated revenues	$	1,093.0		$	992.3		$	3,281.9		$	3,073.5
Total segment expenses	$	1,247.1		$	906.9		$	3,231.3		$	2,846.1
Insurance policy benefits - fair value changes in embedded derivative liabilities	4.6			33.9			10.7			33.9
Amortization related to fair value changes in embedded derivative liabilities	(1.6		)	(14.1		)	(4.0		)	(14.1		)
Amortization related to net realized investment gains	1.7			3.9			5.9			3.7
Consolidated expenses	$	1,251.8		$	930.6		$	3,243.9		$	2,869.6

ACCOUNTING FOR DERIVATIVES

Our fixed index annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the “participation rate”) of the amount of increase in the value of a particular index, such as the Standard & Poor’s 500 Index, over a specified period.  Typically, on each policy anniversary date, a new index period begins.  We are generally able to change the participation rate at the beginning of each index period during a policy year, subject to contractual minimums.  We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy’s return is linked.  We reflect changes in the estimated fair value of these options in net investment income (classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios).  Net investment gains (losses) related to fixed index products were $37.5 million and $(25.7) million in the nine months ended September 30, 2012 and 2011, respectively. These amounts were substantially offset by a corresponding change to insurance policy benefits.  The estimated fair value of these options was $81.9 million and $37.9 million at September 30, 2012 and December 31, 2011, respectively.  We classify these instruments as other invested assets.

The Company accounts for the options attributed to the policyholder for the estimated life of the annuity contract as embedded derivatives.  The expected future cost of options on fixed index annuity products is used to determine the value of embedded derivatives.  The Company purchases options to hedge liabilities for the next policy year on each policy anniversary date and must estimate the fair value of the forward embedded options related to the policies.  These accounting requirements often create volatility in the earnings from these products.  We record the changes in the fair values of the embedded derivatives in current earnings as a component of insurance policy benefits.  The fair value of these derivatives, which are classified as “liabilities for interest-sensitive products”, was $737.9 million at September 30, 2012 and $666.3 million at December 31, 2011. Prior to June 30, 2011, we maintained a specific block of investments in our trading securities account (which we carried at estimated fair value with changes in such value recognized as investment income from policyholder and reinsurer accounts and other special-purpose portfolios) to offset the income statement volatility caused by the effect of interest rate fluctuations on the value of embedded derivatives related to our fixed index annuity products.  During the second quarter of 2011, we sold this trading portfolio, which resulted in $6.7 million and $19.8 million of decreased earnings in the first nine months of 2012 and 2011, respectively, since the volatility caused by the accounting requirements to record embedded options at fair value were no longer being offset.

If the counterparties for the call options we hold fail to meet their obligations, we may have to recognize a loss.  We limit our exposure to such a loss by diversifying among several counterparties believed to be strong and creditworthy.  At

19

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

September 30, 2012, substantially all of our counterparties were rated “BBB+” or higher by Standard & Poor’s Corporation (“S&P”).

Certain of our reinsurance payable balances contain embedded derivatives.  Such derivatives had an estimated fair value of $6.0 million and $3.5 million at September 30, 2012 and December 31, 2011, respectively.  We record the change in the fair value of these derivatives as a component of investment income (classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios).  We maintain the investments related to these agreements in our trading securities account, which we carry at estimated fair value with changes in such value recognized as investment income (also classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios).  The change in value of these trading securities offsets the change in value of the embedded derivatives.

We purchase certain fixed maturity securities that contain embedded derivatives that are required to be bifurcated from the instrument and held at fair value on the consolidated balance sheet. For certain of these securities, we have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income for operational ease.

REINSURANCE

The cost of reinsurance ceded totaled $48.0 million and $58.3 million in the third quarters of 2012 and 2011, respectively, and $164.5 million and $176.3 million in the first nine months of 2012 and 2011, respectively. We deduct this cost from insurance policy income.  Reinsurance recoveries netted against insurance policy benefits totaled $56.4 million and $45.4 million in the third quarters of 2012 and 2011, respectively, and $172.2 million and $160.2 million in the first nine months of 2012 and 2011, respectively.

From time-to-time, we assume insurance from other companies.  Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs.  Reinsurance premiums assumed totaled $15.9 million and $18.1 million in the third quarters of 2012 and 2011, respectively, and $54.7 million and $64.6 million in the first nine months of 2012 and 2011, respectively.  Reinsurance premiums included amounts assumed pursuant to marketing and quota-share agreements with Coventry Health Care (“Coventry”) of $11.4 million and $12.8 million in the third quarters of 2012 and 2011, respectively, and $39.9 million and $47.6 million in the first nine months of 2012 and 2011, respectively.

See the note entitled “Accounting for Derivatives” for a discussion of the derivative embedded in the payable related to certain modified coinsurance agreements.

20

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

INCOME TAXES

The Company's interim tax expense is based upon the estimated annual effective tax rate for the respective period. Under authoritative guidance, certain items are required to be excluded from the estimated annual effective tax rate calculation. Such items include changes in judgment about the realizability of deferred tax assets resulting from changes in projections of income expected to be available in future years, and items deemed to be unusual, infrequent, or that can not be reliably estimated. In these cases, the actual tax expense or benefit applicable to that item is treated discretely and is reported in the same period as the related item. The reductions to the valuation allowance applicable to future years income were treated as discrete items in the three month periods ended September 30, 2012 and 2011. In addition, the loss on extinguishment of debt of $198.5 million was treated as a discrete item in the three month period ended September 30, 2012. The components of income tax expense were as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Current tax expense	$	2.4		$	2.3		$	9.1		$	7.2
Deferred tax expense (benefit)	11.1			22.9			76.4			68.4
Valuation allowance applicable to current year income	(31.8		)	—			(31.8		)	—
Income tax expense (benefit) calculated based on estimated annual effective tax rate	(18.3		)	25.2			53.7			75.6
Income tax expense (benefit) on discrete items:
Valuation allowance reduction applicable to income in future years	(111.2		)	(143.0		)	(111.2		)	(143.0		)
Deferred tax benefit related to loss on extinguishment of debt and other items	(24.3		)	—			(24.3		)	—
Total income tax benefit	$	(153.8	)	$	(117.8	)	$	(81.8	)	$	(67.4	)

A reconciliation of the U.S. statutory corporate tax rate to the estimated annual tax rate, before discrete items, reflected in the consolidated statement of operations is as follows:

	Nine months ended
	September 30,
	2012		2011
U.S. statutory corporate rate	35.0	%	35.0	%
Valuation allowance reduction applicable to current year income	(13.8	)	—
Nondeductible amounts	.5		1.8
State taxes	1.0		1.0
Provision for tax issues, tax credits and other	—		(.8	)
Estimated annual effective tax rate	22.7	%	37.0	%

21

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The components of the Company’s income tax assets and liabilities were as follows (dollars in millions):

	September 30, 2012			December 31, 2011
	(Restated)
Deferred tax assets:
Net federal operating loss carryforwards	$	1,366.2		$	1,445.2
Net state operating loss carryforwards	16.3			16.8
Tax credits	37.7			32.6
Capital loss carryforwards	305.4			342.3
Deductible temporary differences:
Insurance liabilities	754.8			744.4
Other	81.7			64.8
Gross deferred tax assets	2,562.1			2,646.1
Deferred tax liabilities:
Investments	(21.9		)	(24.2		)
Present value of future profits and deferred acquisition costs	(333.7		)	(363.7		)
Accumulated other comprehensive income	(688.1		)	(434.8		)
Gross deferred tax liabilities	(1,043.7		)	(822.7		)
Net deferred tax assets before valuation allowance	1,518.4			1,823.4
Valuation allowance	(795.4		)	(938.4		)
Net deferred tax assets	723.0			885.0
Current income taxes accrued	(23.5		)	(19.6		)
Income tax assets, net	$	699.5		$	865.4

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and net operating loss carryforwards (“NOLs”). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred income tax assets depends upon generating sufficient future taxable income during the periods in which our temporary differences become deductible and before our capital loss carryforwards and NOLs expire.

Based on our assessment, it appears more likely than not that $893 million of our NOLs and capital loss carryforwards will be realized through future taxable earnings. Accordingly, we have identified reductions to our deferred tax valuation allowance of $155.0 million, of which $143.0 million was recognized in the three months ended September 30, 2012 and $12.0 million will be recognized in the three months ended December 31, 2012, as we reflect the impact of a lower estimated annual effective tax rate on estimated income for the entire year. We will continue to assess the need for a valuation allowance in the future. If future results are less than projected, a valuation allowance may be required to reduce the deferred tax asset, which could have a material impact on our results of operations in the period in which it is recorded.

22

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

There are two principal components of the reduction to our valuation allowance for deferred tax assets in 2012. First, our 2012 taxable income (including taxable investment gains), is expected to exceed the amount previously reflected in our deferred tax valuation model, resulting in a reduction to the valuation allowance of $43.8 million. This reduction is reflected in the estimate of our annual effective tax rate and, therefore, will be recognized as follows: $31.8 million in the three months ended September 30, 2012 and $12.0 million in the three months ended December 31, 2012. In addition, our recent higher levels of operating income resulted in the projection of higher levels of future years taxable income based on evidence we consider to be objective and verifiable. This change is further described in the following paragraph and resulted in a reduction to the valuation allowance for deferred tax assets of $111.2 million, all of which was recognized in the three months ended September 30, 2012.

Our analysis at September 30, 2012, is consistent with the deferred tax valuation model used in the prior year. Our deferred tax valuation model reflects projections of future taxable income based on a normalized average annual taxable income for the last three years, plus 5 percent growth for the next five years and no growth thereafter. In our new projections, our three year average increased to $293 million, compared to $260 million in our prior projection. The projections used to support the recovery of our NOLs do not anticipate the use of tax planning strategies that we could consider in the future to avoid a tax benefit from expiring. We have evaluated each component of the deferred tax asset and assessed the effect of limitations and/or interpretations on the value of each component to be fully recognized in the future.

Recovery of our deferred tax assets is dependent on achieving the future taxable income used in our deferred tax valuation model and failure to do so would result in an increase in the valuation allowance in a future period.  Any future increase in the valuation allowance may result in additional income tax expense and reduce shareholders’ equity, and such an increase could have a significant impact upon our earnings in the future.  In addition, the use of the Company’s NOLs is dependent, in part, on whether the Internal Revenue Service (the “IRS”) ultimately agrees with the tax positions we have taken in our tax returns with respect to the allocation of cancellation of indebtedness income ("CODI") resulting from the bankruptcy of our Predecessor and the classification of the loss we recognized as a result of the transfer of the stock of Senior Health Insurance Company of Pennsylvania (“Senior Health”) to Senior Health Care Oversight Trust, an independent trust (the “Independent Trust”).

The Internal Revenue Code (the “Code”) limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of:  (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities).  There is no similar limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities).

Section 382 of the Code imposes limitations on a corporation’s ability to use its NOLs when the company undergoes an ownership change.  Future transactions and the timing of such transactions could cause an ownership change for Section 382 income tax purposes.  Such transactions may include, but are not limited to, additional repurchases under our share repurchase program, issuances of common stock (including upon conversion of our outstanding 7.0% Debentures), and acquisitions or sales of shares of CNO stock by certain holders of our shares, including persons who have held, currently hold or may accumulate in the future five percent or more of our outstanding common stock for their own account.  Many of these transactions are beyond our control.  If an additional ownership change were to occur for purposes of Section 382, we would be required to calculate an annual restriction on the use of our NOLs to offset future taxable income.  The annual restriction would be calculated based upon the value of CNO’s equity at the time of such ownership change, multiplied by a federal long-term tax exempt rate (3.02 percent at September 30, 2012), and the annual restriction could effectively eliminate our ability to use a substantial portion of our NOLs to offset future taxable income.  We regularly monitor ownership change (as calculated for purposes of Section 382) and, as of September 30, 2012, we were below the 50 percent ownership change level that would trigger further impairment of our ability to utilize our NOLs.

As of September 30, 2012, we had $3.9 billion of federal NOLs and $.9 billion of capital loss carryforwards. The following table summarizes the expiration dates of our loss carryforwards assuming the IRS does not ultimately agree with the positions we have taken with respect to the allocation of CODI and the loss on our investment in Senior Health, both as further described below (dollars in millions):

23

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

Year of expiration	Net operating loss carryforwards (a)						Capital loss			Total loss
	Life			Non-life			carryforwards			carryforwards
2013	$	—		$	—		$	836.7	(b)	$	836.7
2014	—			—			28.6			28.6
2015	—			—			7.2			7.2
2018	550.9		(a)	—			—			550.9
2021	29.5			—			—			29.5
2022	204.1			—			—			204.1
2023	—		(b)	2,602.8		(a)	—			2,602.8
2024	—			3.2			—			3.2
2025	—			118.8			—			118.8
2027	—			216.8			—			216.8
2028	—			.5			—			.5
2029	—			148.9			—			148.9
2031	—			28.0			—			28.0
Total	$	784.5		$	3,119.0		$	872.5		$	4,776.0

 _________________________

(a) The life/non-life allocation summarized above assumes the IRS does not ultimately agree with the tax position we have taken in our tax returns with respect to the allocation of CODI.  If the IRS ultimately agrees with our tax position, approximately $631 million of the non-life NOLs expiring in 2023 would be characterized as life NOLs expiring in 2018.

(b) The allocation of the capital loss carryforwards summarized above assumes the IRS does not ultimately agree with the tax position we have taken with respect to our investment in Senior Health, which was worthless when it was transferred to the Independent Trust in 2008. If the IRS ultimately agrees with our tax position of classifying this loss as ordinary, capital loss carryforwards expiring in 2013 would decrease and life NOLs expiring in 2023 would increase by $742 million.

We had deferred tax assets related to NOLs for state income taxes of $16.3 million and $16.8 million at September 30, 2012 and December 31, 2011, respectively.  The related state NOLs are available to offset future state taxable income in certain states through 2019.

In July 2006, the Joint Committee of Taxation accepted the audit and the settlement which characterized $2.1 billion of the tax losses on our Predecessor's investment in Conseco Finance Corp. as life company losses and the remaining $3.8 billion as non-life losses prior to the application of the CODI attribute reductions described below.

The Code provides that any income realized as a result of the CODI in bankruptcy must reduce NOLs. We realized $2.5 billion of CODI when we emerged from bankruptcy. Pursuant to the Company's interpretation of the tax law, the CODI reductions were all used to reduce non-life NOLs and this position has been taken in our tax returns. However, the IRS has issued a proposed adjustment which is not in agreement with our position. We have requested an appeal of the IRS proposed adjustment through their early appeals process. Due to uncertainties with respect to the position the IRS may take and limitations on our ability to utilize NOLs based on projected life and non-life income, we have consistently considered the $631 million of CODI to be a reduction to life NOLs when determining our valuation allowance, pending resolution. If the IRS ultimately agrees with our position that the $631 million of CODI is a reduction to non-life NOLs, our valuation allowance would be reduced by approximately $140 million based on the income projections used in determining our valuation allowance. The outcome of this uncertainty cannot be predicted.

We recognized a $742 million loss on our investment in Senior Health which was worthless when it was transferred to the Independent Trust in 2008. We have treated the loss as a capital loss when determining the deferred tax benefit we may receive. We also established a full valuation allowance as we believe we will not generate capital gains to utilize the benefit. However, due to uncertainties in the Code, we have reflected this loss as an ordinary loss in our tax return, contrary to certain

24

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

IRS rulings. If classifying this loss as ordinary is ultimately determined to be correct, our valuation allowance would be reduced by approximately $140 million based on the income projections used in determining our valuation allowance.

Tax years 2008 through 2010 are under examination by the IRS. This examination is expected to accelerate the resolution of the uncertainty related to the loss on our investment in Senior Health.  The Company’s various state income tax returns are generally open for tax years 2009 through 2011 based on the individual state statutes of limitation. Generally, for tax years which generate NOLs, capital losses or tax credit carryforwards, the statute of limitations does not close until the expiration of the statute of limitations for the tax year in which such carryforwards are utilized.

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

The following notes payable were direct corporate obligations of the Company as of September 30, 2012 and December 31, 2011 (dollars in millions):

	September 30, 2012			December 31, 2011
New Senior Secured Credit Agreement (as defined below)	$	675.0		$	—
7.0% Debentures	93.0			293.0
Previous Senior Secured Credit Agreement (as defined below)	—			255.2
6.375% Senior Secured Notes due October 2020 (the "6.375% Notes")	275.0			—
9.0% Senior Secured Notes due January 2018 (the “9.0% Notes”)	1.2			275.0
Senior Health Note due November 12, 2013 (the “Senior Health Note”)	—			50.0
Unamortized discount on New Senior Secured Credit Agreement	(5.5		)	—
Unamortized discount on 7.0% Debentures	(3.6		)	(12.9		)
Unamortized discount on Previous Senior Secured Credit Agreement	—			(2.4		)
Direct corporate obligations	$	1,035.1		$	857.9

6.375% Notes

On September 28, 2012, we issued $275.0 million in aggregate principal amount of 6.375% Notes pursuant to an Indenture, dated as of September 28, 2012 (the “6.375% Indenture”), among the Company, the subsidiary guarantors party thereto (the “Subsidiary Guarantors”) and Wilmington Trust, National Association, as trustee (the “Trustee") and as collateral agent (the “Collateral Agent”). The net proceeds from the issuance of the 6.375% Notes, together with the net proceeds from the New Senior Secured Credit Agreement (as defined below), were used to repay other outstanding indebtedness, as further described below, and for general corporate purposes.

The 6.375% Notes will mature on October 1, 2020. Interest on the 6.375% Notes accrues at a rate of 6.375% per annum and is payable semiannually in arrears on April 1 and October 1 of each year, commencing on April 1, 2013. The 6.375% Notes and the guarantees thereof (the “Guarantees”) are senior secured obligations of the Company and the Subsidiary Guarantors and rank equally in right of payment with all of the Company's and the Subsidiary Guarantors' existing and future senior obligations, and senior to all of the Company's and the Subsidiary Guarantors' future subordinated indebtedness. The 6.375% Notes are secured by a first-priority lien on substantially all of the assets of the Company and the Subsidiary Guarantors, subject to certain exceptions. The 6.375% Notes and the Guarantees are pari passu with respect to security and in right of payment with all of the Company's and the Subsidiary Guarantors' existing and future secured indebtedness under the New Senior Secured Credit Agreement (as defined below). The 6.375% Notes are structurally subordinated to all of the liabilities and preferred stock of each of the Company's insurance subsidiaries, which are not guarantors of the 6.375% Notes.

The Company may redeem all or part of the 6.375% Notes beginning on October 1, 2015, at the redemption prices set forth in the 6.375% Indenture. The Company may also redeem all or part of the 6.375% Notes at any time and from time to time prior to October 1, 2015, at a price equal to 100% of the aggregate principal amount of the 6.375% Notes to be redeemed, plus a “make-whole” premium and accrued and unpaid interest to, but not including, the redemption date. In addition, prior to

25

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

October 1, 2015, the Company may redeem up to 35% of the aggregate principal amount of the 6.375% Notes with the net cash proceeds of certain equity offerings at a price equal to 106.375% of the aggregate principal amount of the 6.375% Notes to be redeemed, plus accrued and unpaid interest to, but not including, the redemption date.

Upon the occurrence of a Change of Control (as defined in the 6.375% Indenture), each holder of the 6.375% Notes may require the Company to repurchase all or a portion of the 6.375% Notes in cash at a price equal to 101% of the aggregate principal amount of the 6.375% Notes to be repurchased, plus accrued and unpaid interest, if any, to, but not including, the date of repurchase.

The 6.375% Indenture contains covenants that, among other things, limit (subject to certain exceptions) the Company's ability and the ability of the Company's Restricted Subsidiaries (as defined in the 6.375% Indenture) to:

• incur or guarantee additional indebtedness or issue preferred stock;

• pay dividends or make other distributions to shareholders;

• purchase or redeem capital stock or subordinated indebtedness;

• make investments;

• create liens;

• incur restrictions on the Company's ability and the ability of its Restricted Subsidiaries to pay dividends or make other payments to the Company;

• sell assets, including capital stock of the Company's subsidiaries;

• consolidate or merge with or into other companies or transfer all or substantially all of the Company's assets; and

• engage in transactions with affiliates.

The 6.375% Indenture provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, breach of covenants in the 6.375% Indenture, failure to pay at maturity or acceleration of other indebtedness, a failure to pay certain judgments and certain events of bankruptcy and insolvency. Generally, if an event of default occurs, the Trustee or holders of at least 25% in principal amount of the then outstanding 6.375% Notes may declare the principal of and accrued but unpaid interest, including any additional interest, on all of the 6.375% Notes to be due and payable.

Under the 6.375% Indenture, the Company can make Restricted Payments (as such term is defined in the 6.375% Indenture) up to a calculated limit, provided that the Company's pro forma risk-based capital ratio exceeds 225% after giving effect to the Restricted Payment and certain other conditions are met. Restricted Payments include, among other items, repurchases of common stock and cash dividends on common stock (to the extent such dividends exceed $30 million in the aggregate in any calendar year). The limit of Restricted Payments permitted under the 6.375% Indenture is the sum of (x) 50% of the Company's “Net Excess Cash Flow” (as defined in the 6.375% Indenture) for the period (taken as one accounting period) from July 1, 2012 to the end of the Company's most recently ended fiscal quarter for which financial statements are available at the time of such Restricted Payment, (y) $175.0 million and (z) certain other amounts specified in the 6.375% Indenture. Based on the provisions set forth in the 6.375% Indenture and the Company's Net Excess Cash Flow for the period from July 1, 2012 through September 30, 2012, the Company could have made additional Restricted Payments under this 6.375% Indenture covenant of approximately $244 million as of September 30, 2012. This limitation on Restricted Payments does not apply if the Debt to Total Capitalization Ratio (as defined in the 6.375% Indenture) as of the last day of the Company's most recently ended fiscal quarter for which financial statements are available that immediately precedes the date of any Restricted Payment, calculated immediately after giving effect to such Restricted Payment and any related transactions on a pro forma basis, is equal to or less than 17.5%.

26

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

In connection with the issuance of the 6.375% Notes and execution of the 6.375% Indenture, the Company and the Subsidiary Guarantors entered into a security agreement, dated as of September 28, 2012 (the “Security Agreement”), by and among the Company, the Subsidiary Guarantors and the Collateral Agent, pursuant to which the Company and the Subsidiary Guarantors pledged substantially all of their assets to secure their obligations under the 6.375% Notes and the 6.375% Indenture, subject to certain exceptions as set forth in the Security Agreement.

New Senior Secured Credit Agreement

On September 28, 2012, the Company entered into a new senior secured credit agreement, providing for: (i) a $425.0 million six-year term loan facility; (ii) a $250.0 million four-year term loan facility; and (iii) a $50.0 million three-year revolving credit facility, with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the lenders from time to time party thereto (the “New Senior Secured Credit Agreement”). The New Senior Secured Credit Agreement is guaranteed by the Subsidiary Guarantors and secured by a first-priority lien (which ranks pari passu with the liens securing the 6.375% Notes) on substantially all of the Company's and the Subsidiary Guarantors' assets. As of September 30, 2012, the Company had borrowed in full the amounts available under each of the term loan facilities and no amounts have been borrowed under the revolving credit facility. The net proceeds from the New Senior Secured Credit Agreement, together with the net proceeds from the 6.375% Notes, were used to repay other outstanding indebtedness, as further described below, and for general corporate purposes.

The revolving credit facility includes an uncommitted subfacility for swingline loans of up to $5.0 million, and up to $5.0 million of the revolving credit facility is available for the issuance of letters of credit. The six-year term loan facility will amortize in quarterly installments in amounts resulting in an annual amortization of 1% and the four-year term loan facility will amortize in quarterly installments resulting in an annual amortization of 20% during the first and second years and 30% during the third and fourth years. Subject to certain conditions, the Company may incur additional incremental loans under the New Senior Secured Credit Agreement in an amount of up to $250.0 million.

Mandatory prepayments of the New Senior Secured Credit Agreement will be required, subject to certain exceptions, in an amount equal to: (i) 100% of the net cash proceeds from certain asset sales or casualty events; (ii) 100% of the net cash proceeds received by the Company or any of its restricted subsidiaries from certain debt issuances; and (iii) 100% of the amount of certain restricted payments made (including any common stock dividends and share repurchases) as defined in the New Senior Secured Credit Agreement provided that if, as of the end of the fiscal quarter immediately preceding such restricted payment, the debt to total capitalization ratio is: (x) equal to or less than 22.5%, but greater than 17.5%, the prepayment requirement shall be reduced to 33.33%; or (y) equal to or less than 17.5%, the prepayment requirement shall not apply.

Notwithstanding the foregoing, no mandatory prepayments pursuant to item (i) in the preceding paragraph shall be required if: (x) the debt to total capitalization ratio is equal or less than 20% and (y) either (A) the financial strength rating of certain of the Company's insurance subsidiaries is equal or better than A- (stable) from A.M. Best Company ("A.M. Best") or (B) the New Senior Secured Credit Agreement is rated equal or better than BBB- (stable) from S&P and Baa3 (stable) by Moody's Investor Services, Inc. ("Moody's").

The interest rates with respect to loans under: (i) the six-year term loan facility will be, at the Company's option, equal to a eurodollar rate, plus 3.75% per annum, or a base rate, plus 2.75% per annum, subject to a eurodollar rate “floor” of 1.25% and a base rate “floor” of 2.25% (such rate was 5.0 percent at September 30, 2012); (ii) the four-year term loan facility will be, at the Company's option, equal to a eurodollar rate, plus 3.25% per annum, or a base rate, plus 2.25% per annum, subject to a eurodollar rate “floor” of 1.00% and a base rate “floor” of 2.00% (such rate was 4.25 percent at September 30, 2012); and (iii) the revolving credit facility will be, at the Company's option, equal to a eurodollar rate, plus 3.50% per annum, or a base rate, plus 2.50% per annum, in each case, with respect to revolving credit facility borrowings only, subject to certain step-downs based on the debt to total capitalization ratio of the Company.

The New Senior Secured Credit Agreement contains covenants that limit the Company's ability to take certain actions and perform certain activities, including (each subject to exceptions as set forth in the New Senior Secured Credit Agreement):

• limitations on debt (including, without limitation, guarantees and other contingent obligations);

• limitations on issuances of disqualified capital stock;

27

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

• limitations on liens and further negative pledges;

• limitations on sales, transfers and other dispositions of assets;

• limitations on transactions with affiliates;

• limitations on changes in the nature of the Company's business;

• limitations on mergers, consolidations and acquisitions;

• limitations on dividends and other distributions, stock repurchases and redemptions and other restricted payments;

• limitations on investments and acquisitions;

• limitations on prepayment of certain debt;

• limitations on modifications or waivers of certain debt documents and charter documents;

• investment portfolio requirements for insurance subsidiaries;

• limitations on restrictions affecting subsidiaries;

• limitations on holding company activities; and

• limitations on changes in accounting policies.

In addition, the New Senior Secured Credit Agreement requires the Company to maintain (each as calculated in accordance with the New Senior Secured Credit Agreement): (i) a debt to total capitalization ratio of not more than 27.5 percent (such ratio was 21.5 percent at September 30, 2012); (ii) an interest coverage ratio of not less than 2.50 to 1.00 for each rolling four quarters (or, if less, the number of full fiscal quarters commencing after the effective date of the New Senior Secured Credit Agreement) (such ratio was not applicable for the period ended September 30, 2012); (iii) an aggregate ratio of total adjusted capital to company action level risk-based capital for the Company's insurance subsidiaries of not less than 250 percent (such ratio was 361 percent at September 30, 2012); and (iv) a combined statutory capital and surplus for the Company's insurance subsidiaries of at least $1,300.0 million (combined statutory capital and surplus at September 30, 2012, was $1,766.8 million).

The New Senior Secured Credit Agreement provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, incorrectness of any representation or warranty in any material respect, breach of covenants in the New Senior Secured Credit Agreement or other loan documents, cross default to certain other indebtedness, certain events of bankruptcy and insolvency, certain ERISA events, a failure to pay certain judgments, certain material regulatory events, the occurrence of a change of control, and the invalidity of any material provision of any loan document or material lien or guarantee granted under the loan documents. If an event of default under the New Senior Secured Credit Agreement occurs and is continuing, the Agent may accelerate the amounts and terminate all commitments outstanding under the New Senior Secured Credit Agreement and may exercise remedies in respect of the collateral.

In connection with the execution of the New Senior Secured Credit Agreement, the Company and the Subsidiary Guarantors entered into a guarantee and security agreement, dated as of September 28, 2012 (the “Guarantee and Security Agreement”), by and among the Company, the Subsidiary Guarantors and the Agent, pursuant to which the Subsidiary Guarantors guaranteed all of the obligations of the Company under the New Senior Secured Credit Agreement and the Company and the Subsidiary Guarantors pledged substantially all of their assets to secure the New Senior Secured Credit Agreement, subject to certain exceptions as set forth in the Guarantee and Security Agreement.

28

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

Pari Passu Intercreditor Agreement

In connection with the issuance of the 6.375% Notes and entry into the New Senior Secured Credit Agreement, the Agent and the Collateral Agent, as authorized representative with respect to the 6.375% Notes, entered into a Pari Passu Intercreditor Agreement, dated as of September 28, 2012 (the “Intercreditor Agreement”), which sets forth agreements with respect to the first-priority liens granted by the Company and the Subsidiary Guarantors pursuant to the 6.375% Indenture and the New Senior Secured Credit Agreement.

Under the Intercreditor Agreement, any actions that may be taken with respect to the collateral that secures the 6.375% Notes and the New Senior Secured Credit Agreement, including the ability to cause the commencement of enforcement proceedings against such collateral, to control such proceedings and to approve amendments to releases of such collateral from the lien of, and waive past defaults under, such documents relating to such collateral, will be at the direction of the authorized representative of the lenders under the New Senior Secured Credit Agreement until the earliest of: (i) the Company's obligations under the New Senior Secured Credit Agreement (or refinancings thereof) are discharged; (ii) the earlier of (x) date on which the outstanding principal amount of loans and commitments under the New Senior Secured Credit Agreement is less than $25.0 million and (y) the date on which the outstanding principal amount of another tranche of first-priority indebtedness exceeds the principal amount of loans and commitments under the New Senior Secured Credit Agreement; and (iii) 180 days after the occurrence of both an event of default under the 6.375% Indenture and the authorized representative of the holders of the New Notes making certain representations as described in the Intercreditor Agreement, unless the authorized representative of the lenders under the New Senior Secured Credit Agreement has commenced and is diligently pursuing enforcement action with respect to the collateral or the grantor of the security interest in that collateral (whether the Company or the applicable Subsidiary Guarantor) is then a debtor under or with respect to (or otherwise subject to) any insolvency or liquidation proceeding.

9.0% Notes

On September 28, 2012, the Company completed the cash tender offer for $273.8 million aggregate principal amount of the 9.0% Notes and received consents from such holders to proposed amendments to the indenture governing the 9.0% Notes (the "9.0% Indenture"). In addition, on September 28, 2012 (the “Initial Payment Date”), the Company, the Subsidiary Guarantors and Wilmington Trust, National Association (as successor by merger to Wilmington Trust FSB), as trustee, executed a first supplemental indenture to the 9.0% Indenture (the “Supplemental Indenture”) that eliminates substantially all of the restrictive covenants contained in the 9.0% Indenture and certain events of default and related provisions. The Supplemental Indenture became effective upon execution, and the amendments to the 9.0% Indenture became operative on the Initial Payment Date upon acceptance of and payment for the tendered 9.0% Notes by the Company.

On the Initial Payment Date, the Company paid an aggregate of $326.3 million in order to purchase the 9.0% Notes tendered prior to the Initial Payment Date (representing, in the aggregate, tender offer consideration of approximately $313.1 million, consent payments of approximately $8.2 million and accrued and unpaid interest to, but not including, the Initial Payment Date of approximately $5.0 million).

On September 28, 2012, the Company: (i) issued a notice of redemption to holders of the remaining $1.2 million aggregate principal amount of 9.0% Notes that were not tendered and remained outstanding following the Company's initial acceptance of and payments for the 9.0% Notes tendered in the tender offer prior to the Initial Payment Date; and (ii) deposited with the trustee of the 9.0% Notes sufficient funds to satisfy and discharge the 9.0% Indenture and to fund the make-whole redemption of the remaining outstanding 9.0% Notes and to pay accrued and unpaid interest on the redeemed notes to, but not including, the October 29, 2012 redemption date. Upon the satisfaction and discharge of the 9.0% Indenture, all of the collateral securing the 9.0% Notes was released and any remaining restrictive covenants and certain additional events of default contained in the 9.0% Indenture (as amended by the Supplemental Indenture) ceased to have effect. The remaining $1.2 million of 9.0% Notes were redeemed on October 29, 2012.

7.0% Debentures

In September 2012, the Company entered into a Debenture Repurchase Agreement (the “Debenture Repurchase Agreement”) with Paulson Credit Opportunities Master Ltd. and Paulson Recovery Master Fund Ltd. (collectively, the “Paulson Holders”), funds managed by Paulson & Co. Inc., that held $200.0 million in aggregate principal amount of the

29

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

Company's 7.0% Debentures. Pursuant to the Debenture Repurchase Agreement, the Company purchased from each of the Paulson Holders the 7.0% Debentures held by such Paulson Holder, for a cash purchase price of $355.1 million that provided for a 2.8% discount to the estimated fair market value of the 7.0% Debentures as defined in the Debenture Repurchase Agreement.

Previous Senior Secured Credit Agreement

In September 2012, the Company used a portion of the net proceeds from its offering of the 6.375% Notes, together with borrowings under the New Senior Secured Credit Agreement to repay the remaining $223.8 million principal amount outstanding under its credit agreement, dated as of December 21, 2010, by and among the Company, Morgan Stanley Senior Funding, Inc., as administrative agent, and the lenders from time to time party thereto (as amended, the "Previous Senior Secured Credit Agreement").

Also, in the first nine months of 2012, as required under the terms of the Previous Senior Secured Credit Agreement, we made mandatory prepayments of $31.4 million due to repurchases of our common stock and payment of a common stock dividend.

Senior Health Note

In March 2012, we paid in full the remaining $50.0 million principal balance on the Senior Health Note, which had been scheduled to mature in November 2013. The repayment in full of the Senior Health Note removed the previous restriction on our ability to pay cash dividends on our common stock.

Loss on Extinguishment of Debt

In the first nine months of 2012, we recognized a loss on extinguishment of debt totaling $199.2 million consisting of:

(i) $136.3 million (all of which was recognized in the third quarter of 2012) due to our repurchase of $200.0 million principal amount of 7.0% Debentures pursuant to the Debenture Repurchase Agreement described above and the write-off of unamortized discount and issuance costs associated with the 7.0% Debentures. Additional paid-in capital was also reduced by $24.0 million to extinguish the beneficial conversion feature associated with a portion of the 7.0% Debentures that were repurchased. As the Code limits the deduction to taxable income for losses on the redemption of convertible debt, a minimal tax benefit was recognized related to the repurchase of the 7.0% Debentures;

(ii) $57.8 million (all of which was recognized in the third quarter of 2012) related to the tender offer and consent solicitation for the 9.0% Notes; the write-off of unamortized issuance costs related to the 9.0% Notes; and other transaction costs; and

(iii) $5.1 million ($4.4 million of which was recognized in the third quarter of 2012) representing the write-off of unamortized discount and issuance costs associated with repayments of our Previous Senior Secured Credit Agreement.

30

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

Scheduled Repayment of our Direct Corporate Obligations

The scheduled repayment of our direct corporate obligations was as follows at September 30, 2012 (dollars in millions):

Year ending September 30,
2013	$	55.4
2014	54.3
2015	79.3
2016	79.3
2017	97.2
Thereafter	678.7
	$	1,044.2

INVESTMENT BORROWINGS

Three of the Company’s insurance subsidiaries (Conseco Life Insurance Company (“Conseco Life”), Washington National Insurance Company and Bankers Life and Casualty Company ("Bankers Life")) are members of the Federal Home Loan Bank (“FHLB”).  As members of the FHLB, Conseco Life, Washington National Insurance Company and Bankers Life have the ability to borrow on a collateralized basis from the FHLB.  Conseco Life, Washington National Insurance Company and Bankers Life are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings.  At September 30, 2012, the carrying value of the FHLB common stock was $82.5 million.  As of September 30, 2012, collateralized borrowings from the FHLB totaled $1.7 billion and the proceeds were used to purchase fixed maturity securities.  The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.  The borrowings are collateralized by investments with an estimated fair value of $2.0 billion at September 30, 2012, which are maintained in a custodial account for the benefit of the FHLB.  Such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet.  Interest expense of $21.3 million and $18.9 million in the first nine months of 2012 and 2011, respectively, was recognized related to the borrowings.

31

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following summarizes the terms of the borrowings (dollars in millions):

Amount		Maturity	Interest rate at
borrowed		date	September 30, 2012
$	100.0	November 2013	Variable rate – 0.515%
67.0		February 2014	Fixed rate – 1.830%
50.0		August 2014	Variable rate – 0.565%
100.0		August 2014	Variable rate – 0.476%
50.0		September 2015	Variable rate – 0.747%
150.0		October 2015	Variable rate – 0.571%
146.0		November 2015	Fixed rate – 5.300%
100.0		December 2015	Fixed rate – 4.710%
100.0		June 2016	Variable rate – 0.657%
75.0		June 2016	Variable rate – 0.621%
100.0		October 2016	Variable rate – 0.641%
50.0		November 2016	Variable rate – 0.684%
50.0		November 2016	Variable rate – 0.687%
100.0		June 2017	Variable rate – 0.751%
100.0		July 2017	Fixed rate – 3.900%
50.0		August 2017	Variable rate – 0.635%
75.0		August 2017	Variable rate – 0.577%
100.0		October 2017	Variable rate – 0.885%
37.0		November 2017	Fixed rate – 3.750%
50.0		July 2018	Variable rate – 0.917%
$	1,650.0

The variable rate borrowings are pre-payable on each interest reset date without penalty.  The fixed rate borrowings are pre-payable subject to payment of a yield maintenance fee based on current market interest rates.  At September 30, 2012, the aggregate fee to prepay all fixed rate borrowings was $51.6 million.

As part of our investment strategy, we may enter into repurchase agreements to increase our investment return. We account for these transactions as collateralized borrowings, where the amount borrowed is equal to the sales price of the underlying securities. Repurchase agreements involve a sale of securities and an agreement to repurchase the same securities at a later date at an agreed-upon price. We had no such borrowings outstanding at September 30, 2012. The primary risks associated with short-term collateralized borrowings are: (i) a substantial decline in the market value of the margined security; and (ii) that a counterparty may be unable to perform under the terms of the contract or be unwilling to extend such financing in future periods especially if the liquidity or value of the margined security has declined. Exposure is limited to any depreciation in value of the related securities.

At September 30, 2012, investment borrowings consisted of:  (i) collateralized borrowings from the FHLB of $1.7 billion; and (ii) other borrowings of $.9 million.

At December 31, 2011, investment borrowings consisted of:  (i) collateralized borrowings from the FHLB of $1.7 billion; (ii) repurchase agreements of $24.8 million; and (iii) other borrowings of $1.7 million.

32

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

CHANGES IN COMMON STOCK

Changes in the number of shares of common stock outstanding were as follows (shares in thousands):

Balance, December 31, 2011	241,305
Treasury stock purchased and retired	(12,894	)
Stock options exercised	692
Restricted stock vested	404		(a)
Balance, September 30, 2012	229,507

________

(a) Such amount was reduced by 143 thousand shares which were tendered to the Company for the payment of federal and state taxes owed on the vesting of restricted stock.

In May 2011, the Company announced a common share repurchase program of up to $100.0 million of the Company's outstanding common stock. In February 2012 and June 2012, the Company's board of directors approved, in aggregate, an additional $200.0 million to repurchase the Company's outstanding common stock. In the first nine months of 2012, we repurchased 12.9 million shares of common stock for $99.5 million pursuant to the program. The Company had remaining repurchase authority of $130.7 million as of September 30, 2012.

In May 2012, we initiated a common stock dividend program. In both the second and third quarters of 2012, dividends declared and paid on common stock were $0.02 per common share totaling $9.4 million.

SALES INDUCEMENTS

Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract.  Certain of our life insurance products offer persistency bonuses credited to the contract holders balance after the policy has been outstanding for a specified period of time.  These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP.  Such amounts are deferred and amortized in the same manner as deferred acquisition costs.  Sales inducements deferred totaled $3.1 million and $9.7 million during the nine months ended September 30, 2012 and 2011, respectively.  Amounts amortized totaled $20.5 million and $21.2 million during the nine months ended September 30, 2012 and 2011, respectively.  The unamortized balance of deferred sales inducements at September 30, 2012 and December 31, 2011 was $131.8 million and $149.2 million, respectively.  The balance of insurance liabilities for persistency bonus benefits was $36.6 million and $50.0 million at September 30, 2012 and December 31, 2011, respectively.

RECENTLY ISSUED ACCOUNTING STANDARDS

Accounting Standard Adopted on a Retrospective Basis

In October 2010, the Financial Accounting Standards Board ("FASB") issued authoritative guidance that modified the definition of the types of costs incurred by insurance entities that could be capitalized in the acquisition of new and renewal contracts.  The guidance impacts the timing of GAAP reported financial results, but has no impact on cash flows, statutory financial results or the ultimate profitability of the business.

The guidance specifies that an insurance entity shall only capitalize incremental direct costs related to the successful acquisition of new or renewal insurance contracts.  The guidance also states that advertising costs should be included in deferred acquisition costs only if the capitalization criteria in the direct-response advertising guidance is met.  The guidance was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2011. As permitted by the guidance, we elected to apply the provisions on a retrospective basis. The guidance reduced the balance of deferred acquisition costs, its amortization and the amount of costs capitalized. We are able to defer most commission payments, plus other costs directly related to the production of new business. The change did not impact the balance of the present value of future profits. Therefore, in contrast to the reduction in amortization of deferred acquisition costs, there was no change in the amortization of the present value of future profits.

33

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The adoption of ASU 2010-26 affected prior period information as follows (dollars in millions, except per share amounts):

	Three months ended							Nine months ended
	September 30, 2011							September 30, 2011
	As originally reported		Effect of adoption of ASU 2010-26			As adjusted		As originally reported		Effect of adoption of ASU 2010-26			As adjusted
Amortization	$	87.2	$	(28.6	)	$	58.6	$	325.4	$	(101.3	)	$	224.1
Other operating costs and expenses	127.6		54.4			182.0		367.1		160.7			527.8
Total benefits and expenses	904.8		25.8			930.6		2,810.2		59.4			2,869.6
Income before income taxes	87.5		(25.8		)	61.7		263.3		(59.4		)	203.9
Tax expense on period income	34.5		(9.3		)	25.2		96.9		(21.3		)	75.6
Net income	196.0		(16.5		)	179.5		309.4		(38.1		)	271.3
Earnings per common share:
Basic:
Net income	$	.79	$	(.06	)	$	.73	$	1.24	$	(.15	)	$	1.09
Diluted:
Net income	.66		(.05		)	.61		1.05		(.13		)	.92

	Nine months ended
	September 30, 2011
	As originally reported			Effect of adoption of ASU 2010-26			As adjusted
Cash flows from operating activities:
Deferrable policy acquisition costs	$	(328.6	)	$	163.7		$	(164.9	)
Other operating costs	(349.9		)	(163.7		)	(513.6		)
Net cash used by operating activities	562.2			—			562.2

Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For universal life or investment products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate.

When we realize a gain or loss on investments backing our universal life or investment-type products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust deferred acquisition costs for the change in amortization that would have been recorded if our fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We limit the total adjustment related to the impact of unrealized losses to the total of costs capitalized plus interest related to insurance policies issued in a particular year. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity.

34

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

We regularly evaluate the recoverability of the unamortized balance of the deferred acquisition costs. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the deferred acquisition costs may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the deferred acquisition costs over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years.

Changes in deferred acquisition costs were as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Restated)						(Restated)
Balance, beginning of period	$	653.5		$	975.5		$	797.1		$	999.6
Additions	46.7			58.3			141.4			164.9
Amortization	(44.5		)	(35.5		)	(146.4		)	(134.7		)
Amounts related to fair value adjustment of fixed maturities, available for sale	(32.3		)	(163.8		)	(168.7		)	(195.3		)
Balance, end of period	$	623.4		$	834.5		$	623.4		$	834.5

Adopted Accounting Standards

In June 2011, the FASB issued authoritative guidance to increase the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in shareholders' equity. Such guidance requires that all non-owner changes in shareholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement approach, the first statement should present total net income and its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income and the total of comprehensive income. The guidance was applied retrospectively and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of this guidance resulted in a change in the presentation of our financial statements but did not have any impact on our financial condition, operating results or cash flows. In December 2011, the FASB issued authoritative guidance to defer the requirement to present reclassification adjustments out of accumulated other comprehensive income to net income on the face of the financial statements. All other aspects of the original guidance are still effective.

In May 2011, the FASB issued authoritative guidance which clarifies or updates requirements for measuring fair value and for disclosing information about fair value measurements. The guidance clarifies: (i) the application of the highest and best use and valuation premise concepts; (ii) measuring the fair value of an instrument classified in a reporting entity's shareholders' equity; and (iii) disclosure of quantitative information about the unobservable inputs used in a fair value measurement that is categorized within Level 3 of the fair value hierarchy. The guidance changes certain requirements for measuring fair value or disclosing information about fair value measurements including: (i) measuring the fair value of financial instruments that are managed within a portfolio; (ii) application of premiums and discounts in a fair value measurement; and (iii) additional disclosures about fair value measurements. Such additional disclosures include a description of the valuation process used for measuring Level 3 instruments and the sensitivity of the Level 3 fair value measurement to changes in unobservable inputs and the interrelationships between those unobservable inputs, if any. The guidance was effective prospectively for interim and annual periods beginning after December 15, 2011. Refer to the note to our consolidated financial statements entitled "Fair Value Measurements" for additional disclosures required by this guidance. The adoption of this guidance expanded our disclosures, but did not have a material impact on our financial condition, operating results or cash flows.

35

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

LITIGATION AND OTHER LEGAL PROCEEDINGS

Legal Proceedings

The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts.  We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred.  The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict.  In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows.  In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies.  Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.

In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, many of the matters specifically identified below purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company can not reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters.  The Company reviews these matters on an ongoing basis.  When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.

Cost of Insurance Litigation

Valulife/Valuterm Litigation

On March 4, 2008, a complaint was filed in the United States District Court for the Central District of California, Celedonia X. Yue, M. D. on behalf of the class of all others similarly situated, and on behalf of the General Public v. Conseco Life Insurance Company, successor to Philadelphia Life Insurance Company and formerly known as Massachusetts General Life Insurance Company, Cause No. CV08-01506 CAS.  Plaintiff in this putative class action owns a Valulife universal life policy insuring the life of Ruth S. Yue originally issued by Massachusetts General Life Insurance Company in 1995.  Plaintiff is claiming breach of contract on behalf of the proposed national class and seeks injunctive and restitutionary relief pursuant to California Business & Professions Code Section 17200 and declaratory relief.  The putative class consists of all owners of Valulife and Valuterm universal life insurance policies issued by either Massachusetts General or Philadelphia Life and that were later acquired and serviced by Conseco Life.  Plaintiff alleges that members of the class will be damaged by increases in the cost of insurance (a non-guaranteed element ("NGE")) that are set to take place in the twenty first policy year of Valulife and Valuterm policies. No such increases had yet been applied to the subject policies.  During 2010, Conseco Life voluntarily agreed not to implement the cost of insurance rate increase at issue in this litigation and is following a process with respect to any future cost of insurance rate increases as set forth in the regulatory settlement agreement described below under the caption entitled "Regulatory Examinations and Fines". Plaintiff filed a motion for certification of a nationwide class and a California state class.  On December 7, 2009, the court granted that motion. On October 8, 2010, the court dismissed the causes of actions alleged in the California state class.  On January 19, 2011, the court granted the plaintiff's motion for summary judgment as to the declaratory relief claim and on February 2, 2011, the court issued an advisory opinion, in the form of a declaratory

36

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

judgment, as to what, in its view, Conseco Life could consider in implementing future cost of insurance rate increases related to its Valulife and Valuterm block of policies.  Conseco Life is appealing the court's January 19, 2011 decision and the plaintiff is appealing the court's decision to dismiss the California causes of action.  These appeals are pending. We believe this case is without merit, and intend to defend it vigorously.  

On November 15, 2011, a second complaint was filed by Dr. Yue in the United States District Court for the Central District on California, Celedonia X. Yue, M. D. on behalf of the class of all others similarly situated, and on behalf of the General Public v. Conseco Life Insurance Company, Cause No. CV11-9506 AHM (SHx), involving the same Valulife universal life policy described in the preceding paragraph. Plaintiff, for herself and on behalf of proposed members of a national class and a California class is claiming breach of contract, injunctive and restitutionary relief pursuant to California Business & Professions Code Section 17200, breach of the covenant of good faith and fair dealing, declaratory relief, and temporary, preliminary, and permanent injunctive relief. The putative class consists of all owners and former owners of Valulife and Valuterm universal life insurance policies issued by either Massachusetts General or Philadelphia Life and that were later acquired and serviced by Conseco Life. Plaintiff alleges that members of the classes will be damaged by increases in the cost of insurance (a NGE) that took place on or about November 1, 2011. Plaintiff filed a motion for a preliminary injunction and a motion for certification of a California class. On April 2, 2012, the court granted the plaintiff's motions, which Conseco Life is appealing. Pending the outcome of that appeal, Conseco Life is preliminarily enjoined from imposing the 2011 increase in the cost of insurance on the members of the California class. Plaintiff also filed a motion on March 20, 2012 for certification of a nationwide class. The court has stated that it will not issue a ruling prior to December 17, 2012 on plaintiff's motion for certification of a nationwide class.

Conseco Life has reached a tentative agreement with the plaintiff in the litigation described in the two preceding paragraphs regarding the material economic terms of a settlement, which would upon completion and court approval, resolve those cases as well as the Nicholas litigation described below. The parties are continuing to negotiate additional non-economic settlement terms. The settlement is expected to include a reduction in the cost of insurance increase implemented by Conseco Life in November 2011 and certain policy benefit enhancements. Any final settlement would be subject to a court fairness hearing after notice to the policyholders covered by the settlement, as well as other conditions.

On February 6, 2012, a complaint was filed in the United States District Court for the Northern District of Illinois, Daniel B. Nicholas, on behalf of himself and all others similarly situated v. Conseco Life Insurance Company, Cause No. 12cv845. Plaintiff in this putative class action owns a Valulife universal life policy insuring Plaintiff's life originally issued by Massachusetts General Life Insurance Company (now Conseco Life Insurance Company) in 1991. Plaintiff is claiming breach of contract on behalf of the proposed national class and seeks declaratory, injunctive, and supplemental relief. The putative class consists of all persons who own or have owned one or more universal life policies issued by Conseco Life which provide that the cost of insurance rates will be determined based upon expectations as to future mortality experience and who have experienced an increase in the cost of insurance rates. Plaintiff alleges that members of the class will be damaged by cost of insurance charges that were increased due to general economic downturn, Conseco Life's diminished investment yields, and mounting policy losses. On April 20, 2012, we announced that Conseco Life had reached a tentative settlement in the Nicholas case. On May 17, 2012, the court granted the motion to intervene which had been filed by the Plaintiff in the Yue litigation described above and venue has been transferred to the United States District Court for the Central District of California. The plaintiff in the Nicholas case has filed a motion for preliminary approval of the settlement in the United States District Court for the Central District of California.

In connection with the tentative settlement in the Nicholas litigation, the Company recorded a pre-tax charge of approximately $20 million in its Other CNO Business segment for the quarter ended March 31, 2012. The Company recorded an additional pre-tax charge of $21 million in its Other CNO Business segment for the quarter ended September 30, 2012 relating to the tentative agreement described above in the Yue litigation. The liability the Company has established related to the tentative settlement of these cases includes its best estimates of the costs of implementing the tentative settlement, if finalized and approved by the court. While the Company believes its estimates are adequate to cover these costs, the estimates are subject to significant judgment and it is possible that the estimates will prove insufficient to cover the actual costs.

Lifetrend Litigation

On December 24, 2008, a purported class action was filed in the U.S. District Court for the Northern District of California, Cedric Brady, et. al. individually and on behalf of all other similarly situated v. Conseco, Inc. and Conseco Life Insurance Company Case No. 3:08-cv-05746.  The plaintiffs allege that Conseco Life and Conseco, Inc. committed breach of

37

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

contract and insurance bad faith and violated various consumer protection statutes in the administration of various interest sensitive whole life products sold primarily under the name “Lifetrend” by requiring the payment of additional cash amounts to maintain the policies in force and by making changes to certain NGEs in their policies.  On April 23, 2009, the plaintiffs filed an amended complaint adding the additional counts of breach of fiduciary duty, fraud, negligent misrepresentation, conversion and declaratory relief.  On May 29, 2009, Conseco, Inc. and Conseco Life filed a motion to dismiss the amended complaint. On July 29, 2009, the court granted in part and denied in part the motion to dismiss.  The court dismissed the allegations that Conseco Life violated various consumer protection statutes, the breach of fiduciary duty count, and dismissed Conseco, Inc. for lack of personal jurisdiction.  

On July 2, 2009, a purported class action was filed in the U.S. District Court for the Middle District of Florida, Bill W. McFarland, and all those similarly situated v. Conseco Life Insurance Company, Case No. 3:09-cv-598-J-32MCR.  The plaintiff alleges that Conseco Life committed breach of contract and has been unjustly enriched in the administration, including changes to certain NGEs, of various interest sensitive whole life products sold primarily under the name “Lifetrend.” The plaintiff seeks declaratory and injunctive relief, compensatory damages, punitive damages and attorney fees.

Conseco Life filed a motion with the Judicial Panel on Multidistrict Litigation (“MDL”), seeking the establishment of an MDL proceeding consolidating the Brady case and the McFarland case into a single action.  On February 3, 2010, the Judicial Panel on MDL ordered these cases be consolidated for pretrial proceedings in the Northern District of California Federal Court. On July 7, 2010, plaintiffs filed an amended motion for class certification of a nationwide class and a California state class.  On October 6, 2010, the court granted the motion for certification of a nationwide class and denied the motion for certification of a California state class.  Conseco Life filed a motion to decertify the nationwide class on July 1, 2011. On December 20, 2011, the court issued an order denying Conseco Life's motion to decertify the class as to current policyholders, but granted the motion to decertify as to former policyholders. On March 5, 2012, the plaintiffs filed a motion for a preliminary injunction requesting that the court enjoin Conseco Life from imposing increased cost of insurance charges until trial with regard to 157 members of the class, and on July 17, 2012, the court granted a preliminary injunction as to 100 members of the class and denied the plaintiff's motion for a preliminary injunction as to the other 57 members. On September 27, 2012, the plaintiffs filed a motion for partial summary judgment on their breach of contract claim. On October 19, 2012, Conseco Life filed a motion to decertify the nationwide class, and on October 30, 2012, Conseco Life filed its motion for summary judgment. Trial in the MDL proceeding has been set for March 25, 2013.  We believe these cases are without merit and intend to defend them vigorously.

On October 25, 2012, a purported nationwide class action was filed in the United States District Court for the Central District of California, William Jeffrey Burnett and Joe H. Camp v. Conseco Life Insurance Company, CNO Financial Group, Inc., CDOC, Inc. and CNO Services, LLC, Case No. EDCV12-01715VAPSPX. The plaintiffs bring this action under Rule 23(B)(3) on behalf of various Lifetrend policyholders who since October 2008 have surrendered their policies or had them lapse. Such policyholders are no longer members of the class covered by the MDL litigation described in the previous paragraph after the court in the MDL litigation granted Conseco Life's motion to decertify as to former policyholders. Additionally, plaintiffs seek certification of a subclass of various Lifetrend policyholders who accepted optional benefits and signed a release pursuant to the regulatory settlement agreement described below under the caption entitled “Regulatory Examinations and Fines.” The plaintiffs allege breach of contract and seek declaratory relief, compensatory damages, attorney fees and costs. We believe this case is without merit and intend to defend it vigorously.

Other Litigation

On December 8, 2008, a purported Florida state class action was filed in the U.S. District Court for the Southern District of Florida, Sydelle Ruderman individually and on behalf of all other similarly situated v. Washington National Insurance Company, Case No. 08-23401-CIV-Cohn/Selzer. The plaintiff alleges that the inflation escalation rider on her policy of long-term care insurance operates to increase the policy's lifetime maximum benefit, and that Washington National Insurance Company breached the contract by stopping her benefits when they reached the lifetime maximum.  The Company takes the position that the inflation escalator only affects the per day maximum benefit.  The Plaintiff filed a motion for class certification, and the motion has been fully briefed by both sides.  The court has not yet ruled on the motion or set it for hearing. Additional parties have asked the court to allow them to intervene in the action, and on January 5, 2010, the court granted the motion to intervene and granted the plaintiff's motion for class certification.  The court certified a (B) (3) Florida state class alleging damages and a (B) (2) Florida state class alleging injunctive relief.  The parties reached a settlement of the (B) (3) class in 2010, which has been implemented. The amount recognized in 2010 related to the settlement in principle was not significant to the Company's consolidated financial condition, cash flows or results of operations. The plaintiff filed a

38

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

motion for summary judgment as to the (B) (2) class which was granted by the court on September 8, 2010.  The Company has appealed the court's decision and the appeal is pending.  On February 17, 2012, the Eleventh Circuit Court of Appeals referred the case to the Florida Supreme Court, which accepted jurisdiction of the case. We believe this case is without merit, and intend to defend it vigorously.  

On January 26, 2009, a purported class action complaint was filed in the United States District Court for the Northern District of Illinois, Samuel Rowe and Estella Rowe, individually and on behalf of themselves and all others similarly situated v. Bankers Life & Casualty Company and Bankers Life Insurance Company of Illinois, Case No. 09CV491.  The plaintiffs are alleging violation of California Business and Professions Code Sections 17200 et seq. and 17500 et seq., breach of common law fiduciary duty, breach of implied covenant of good faith and fair dealing and violation of California Welfare and Institutions Code Section 15600 on behalf of the proposed national class and seek injunctive relief, compensatory damages, punitive damages and attorney fees.  The plaintiff alleges that the defendants used an improper and misleading sales and marketing approach to seniors that fails to disclose all facts, misuses consumers' confidential financial information, uses misleading sales and marketing materials, promotes deferred annuities that are fundamentally inferior and less valuable than readily available alternative investment products and fails to adequately disclose other principal risks including maturity dates, surrender penalties and other restrictions which limit access to annuity proceeds to a date beyond the applicant's actuarial life expectancy. Plaintiffs have amended their complaint attempting to convert this from a California only class action to a national class action. In addition, the amended complaint adds causes of action under the Racketeer Influenced and Corrupt Organization Act (“RICO”); aiding and abetting breach of fiduciary duty and for unjust enrichment.  On September 13, 2010, the court dismissed the plaintiff's RICO claims.  On October 25, 2010, the plaintiffs filed a second amended complaint re-alleging their RICO claims.  On March 29, 2012, the court denied plaintiff's motion for certification of a nationwide class and denied plaintiff's motion for certification of a California class. The court allowed the plaintiff the opportunity to file a renewed motion for a California class, which the plaintiff did on May 21, 2012. On July 24, 2012, Bankers Life filed a motion for summary judgment. We believe this case is without merit, and intend to defend it vigorously. 

On August 23, 2012, a purported class action was filed in the United States District Court for the District of Massachusetts (Boston), Fay Glick, on behalf of herself and all others similarly situated, v. Bankers Life & Casualty Company, Case No. 1:12-cv-11579. The plaintiff is seeking injunctive and declaratory relief and damages arising from Bankers' alleged systematic business practices of delaying and/or denying the payment of claims for benefits provided for under its healthcare insurance policies and recovery of undisclosed interest that Bankers has charged on any policyholders who paid premiums on a monthly or “modal” basis (as opposed to paying premiums on an annual basis). We believe this case is without merit and intend to defend it vigorously.

Regulatory Examinations and Fines

Insurance companies face significant risks related to regulatory investigations and actions.  Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers.  We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities.  The ultimate outcome of these regulatory actions cannot be predicted with certainty.  In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.

The states of Pennsylvania, Illinois, Texas, Florida and Indiana led a multistate examination of the long-term care claims administration and complaint handling practices of Senior Health and Bankers Life, as well as the sales and marketing practices of Bankers Life.  On May 7, 2008, we announced a settlement among the state insurance regulators and Senior Health and Bankers Life.  This examination covered the years 2005, 2006 and 2007.  More than 40 states are parties to the settlement, which included a Senior Health fine of up to $2.3 million, with up to an additional $10 million payable, on the part of either Senior Health and/or Bankers Life, in the event the process improvements and benchmarks are not met.  The process improvement plan is being monitored by the lead states, and pursuant to the settlement agreement, the lead states are conducting a re-examination of Bankers Life to confirm compliance with the process improvements and benchmarks.

39

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

In October 2008, Conseco Life mailed notice to approximately 12,000 holders of its “Lifetrend” life insurance products to inform them of:  (i) changes to certain NGEs of their policies; and (ii) the fact that certain policyholders who were not paying premiums may have failed to receive a notice that their policy was underfunded and that additional premiums were required in order for the policyholders to maintain their guaranteed cash values.  In December 2008, Conseco Life mailed notice to approximately 16,000 holders of its CIUL3+ universal life policies to inform them of an increase in certain NGEs with respect to their policies.  Prior to or around the time that the notices were sent, Conseco Life had informed the insurance regulators in a number of states, including among others Indiana, Iowa and Florida, of these matters and the planned communication with the impacted policyholders.  Several states initiated regulatory actions and inquiries after the notices were sent by Conseco Life, and Conseco Life agreed to take no further actions with respect to those policies during the pendency of a market conduct examination.

After working with various state insurance regulators to review the terms of the Lifetrend and CIUL3+ policies, Conseco Life reached a settlement in principle with the regulators regarding issues involving these policies. During this regulatory review process, Conseco Life had been allowed to move forward with implementing the NGE changes in its CIUL3+ policies while the regulators continued their review.  Conseco Life had also resumed the administration of its Lifetrend policies with administrative changes in place but did not implement the NGE changes pending execution of the final settlement agreement with the regulators.  On June 30, 2010, we announced that Conseco Life had finalized a regulatory settlement agreement that requires the establishment of a $10 million fund for certain owners of its Lifetrend life insurance products and the payment of a $1 million assessment to participating jurisdictions.  Forty-seven jurisdictions, representing almost 98% percent of the Lifetrend policyholders, have signed the settlement agreement.  Conseco Life has notified consumers of the settlement and the increase in their NGEs.  As previously disclosed, we accrued for the financial impact of the settlement in our consolidated financial statements for year-end 2009.

In August 2011, we were notified of an examination to be done on behalf of a number of states for the purpose of determining compliance with unclaimed property laws by the Company and its subsidiaries.  We are continuing to provide information to the examiners in response to their requests. A total of 34 states and the District of Columbia are currently participating in this examination.

On April 5, 2012, we reported that our subsidiaries, Bankers Life and BLC Financial Services, Inc., a broker-dealer licensed in Illinois (“BLCFS”) (collectively “Bankers”), have reached a settlement with the State of Maine Office of Securities and three other state securities regulators regarding allegations that Bankers has acted as a broker-dealer and investment advisor without proper state licensing. Since 2005, Bankers Life and BLCFS had operated under arrangements with unaffiliated broker-dealers (licensed in all states in which Bankers Life operates) under which insurance agents with Bankers Life who became licensed as registered representatives and/or investment advisor representatives of the unaffiliated broker-dealer provided brokerage and investment advisory services to customers under the exclusive control of the unaffiliated broker-dealer. Following this settlement, Bankers Life has continued its arrangement whereby registered representatives of the unaffiliated broker-dealer, who are financial advisors, handle any securities transactions, and BLCFS has been eliminated from its prior role. By putting this legacy issue behind it, Bankers Life believes that this settlement provides additional clarity between the roles of agents and financial advisors and allows the company to continue to focus on providing the products and services its customers need. The consent order issued by Maine in connection with this settlement includes an acknowledgement by the state that the conduct of Bankers Life and BLCFS has resulted in no known direct consumer harm and that licensed agents or representatives of licensed broker-dealers or investment advisors other than Bankers participated in all securities transactions and at locations that were registered with the appropriate securities authorities as broker-dealer locations of broker-dealers other than Bankers. The settlement provides for the payment by Bankers of $9.9 million among the states where these dual agents were located for the period from 2005 - 2011. Bankers also agreed to pay certain costs of the investigation as well as past licensing and registration fees. CNO recorded a pre-tax charge of approximately $10 million in the first quarter of 2012 related to this settlement.

40

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

CONSOLIDATED STATEMENT OF CASH FLOWS

The following disclosures supplement our consolidated statement of cash flows.

The following reconciles net income to net cash provided by operating activities (dollars in millions):

	Nine months ended
	September 30,
	2012			2011
Cash flows from operating activities:
Net income	$	119.8		$	271.3
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization and depreciation	235.2			243.6
Income taxes	(87.3		)	(69.8		)
Insurance liabilities	242.8			244.4
Accrual and amortization of investment income	(123.1		)	62.9
Deferral of policy acquisition costs	(141.4		)	(164.9		)
Net realized investment gains	(63.9		)	(38.6		)
Loss on extinguishment of debt	199.2			3.1
Other	43.3			10.2
Net cash provided by operating activities	$	424.6		$	562.2

Non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions):

	Nine months ended
	September 30,
	2012		2011
Stock option and restricted stock plans	$	10.7	$	10.2

INVESTMENTS IN VARIABLE INTEREST ENTITIES

Based on our assessment, we have concluded that we are the primary beneficiary with respect to certain variable interest entities (“VIEs”), which are consolidated in our financial statements.  The following is a description of our significant investments in VIEs:

All of the VIEs are collateralized loan trusts that were established to issue securities and use the proceeds to principally invest in corporate loans and other permitted investments (including a new VIE which was consolidated in the first quarter of 2012).  The assets held by the trusts are legally isolated and not available to the Company.  The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company.  Repayment of the remaining principal balance of the borrowings of the VIEs is based on available cash flows from the assets.  The Company has no further commitments to the VIEs.

Certain of our insurance subsidiaries are noteholders of the VIEs.  Another subsidiary of the Company is the investment manager for the VIEs.  As such, it has the power to direct the most significant activities of the VIEs which materially impacts the economic performance of the VIEs.

41

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following table provides supplemental information about the assets and liabilities of the VIEs which have been consolidated in accordance with authoritative guidance (dollars in millions):

	September 30, 2012
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	829.4	$	—		$	829.4
Notes receivable of VIEs held by insurance subsidiaries	—		(78.5		)	(78.5		)
Cash and cash equivalents held by variable interest entities	48.2		—			48.2
Accrued investment income	3.9		—			3.9
Income tax assets, net	3.2		(2.3		)	.9
Other assets	10.9		—			10.9
Total assets	$	895.6	$	(80.8	)	$	814.8
Liabilities:
Other liabilities	$	52.0	$	(2.3	)	$	49.7
Borrowings related to variable interest entities	766.9		—			766.9
Notes payable of VIEs held by insurance subsidiaries	82.5		(82.5		)	—
Total liabilities	$	901.4	$	(84.8	)	$	816.6

	December 31, 2011
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	496.3	$	—		$	496.3
Notes receivable of VIEs held by insurance subsidiaries	—		(45.3		)	(45.3		)
Cash and cash equivalents held by variable interest entities	74.4		—			74.4
Accrued investment income	1.7		—			1.7
Income tax assets, net	6.8		(1.4		)	5.4
Other assets	7.7		—			7.7
Total assets	$	586.9	$	(46.7	)	$	540.2
Liabilities:
Other liabilities	$	30.3	$	(.1	)	$	30.2
Borrowings related to variable interest entities	519.9		—			519.9
Notes payable of VIEs held by insurance subsidiaries	49.3		(49.3		)	—
Total liabilities	$	599.5	$	(49.4	)	$	550.1

42

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The investment portfolios held by the VIEs are primarily comprised of corporate fixed maturity securities which are almost entirely rated as below-investment grade securities.  At September 30, 2012, such securities had an amortized cost of $827.7 million; gross unrealized gains of $5.0 million; gross unrealized losses of $3.3 million; and an estimated fair value of $829.4 million.

The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at September 30, 2012, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	3.0	$	3.0
Due after one year through five years	413.8		413.1
Due after five years through ten years	410.9		413.3
Total	$	827.7	$	829.4

During the first nine months of 2012, we recognized net realized investment losses on the VIE investments of $.1 million, which were comprised of $.3 million of net gains from the sales of fixed maturities, and $.4 million of writedowns of investments for other than temporary declines in fair value recognized through net income.  During the first nine months of 2011, we recognized net realized investment losses on the VIE investments of $.2 million, which were comprised of $3.3 million of net gains from the sales of fixed maturities, and $3.5 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

At September 30, 2012, there were no investments held by the VIEs that were in default.

During the first nine months of 2012, $28.0 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $.2 million.

At September 30, 2012, the VIEs held:  (i) investments with a fair value of $228.8 million and gross unrealized losses of $1.7 million that had been in an unrealized loss position for less than twelve months; and (ii) investments with a fair value of $74.7 million and gross unrealized losses of $1.6 million that had been in an unrealized loss position for greater than twelve months.

The investments held by the VIEs are evaluated for other-than-temporary declines in fair value in a manner that is consistent with the Company’s fixed maturities, available for sale.

In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager.  These structured securities include asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, residential mortgage-backed securities and collateralized mortgage obligations.  Our maximum exposure to loss on these securities is limited to our cost basis in the investment.  We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses.

At September 30, 2012, we hold investments in various limited partnerships, in which we are not the primary beneficiary, totaling $28.3 million (classified as other invested assets).  At September 30, 2012, we had unfunded commitments to these partnerships of $20.0 million.  Our maximum exposure to loss on these investments is limited to the amount of our investment.

43

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

FAIR VALUE MEASUREMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price.  We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, cash and cash equivalents, separate account assets and embedded derivatives.  We carry our company-owned life insurance policy, which is backed by a series of mutual funds, at its cash surrender value and our hedge fund investments at their net asset values; in both cases, we believe these values approximate their fair values. In addition, we disclose fair value for certain financial instruments, including mortgage loans and policy loans, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs.

The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information.  Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value.  Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value.

Valuation Hierarchy

There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable.

• Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities.  Our Level 1 assets primarily include cash and exchange traded securities.

• Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data.  Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies.  These models are primarily industry-standard models that consider various inputs such as interest rate, credit spread, reported trades, broker/dealer quotes, issuer spreads and other inputs that are observable or derived from observable information in the marketplace or are supported by observable levels at which transactions are executed in the marketplace.  Financial assets in this category primarily include:  certain public and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund and hedge fund investments; and most short-term investments; and non-exchange-traded derivatives such as call options to hedge liabilities related to our fixed index annuity products. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.

• Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions.  Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on non-binding broker prices or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information.  Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities.  Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.

At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value.  This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions.  Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. Any transfers between levels are

44

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

reported as having occurred at the beginning of the period. There were no significant transfers between Level 1 and Level 2 in the first nine months of 2012.

The vast majority of our fixed maturity and equity securities, including those held in trading portfolios and those held by consolidated VIEs, short-term and separate account assets use Level 2 inputs for the determination of fair value.  These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value.  Substantially all of our Level 2 fixed maturity securities and separate account assets were valued from independent pricing services.  Third party pricing services normally derive the security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information.  If there are no recently reported trades, the third party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are developed and discounted at an estimated risk-adjusted market rate.  The number of prices obtained for a given security is dependent on the Company’s analysis of such prices as further described below.

For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes.  These broker quotes are non-binding andrepresent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs.  Approximately 22 percent of our Level 3 fixed maturity securities were valued using unadjusted broker quotes or broker-provided valuation inputs.  The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs.  For these securities, we use internally developed valuations.  Key assumptions used to determine fair value for these securities may include risk-free rates, risk premiums, performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market.  For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are developed and discounted at an estimated market rate.  The pricing matrix utilizes a spread level to determine the market price for a security.  The credit spread generally incorporates the issuer’s credit rating and other factors relating to the issuer’s industry and the security’s maturity.  In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity.

As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value.  The Company’s analysis includes:  (i) a review of the methodology used by third party pricing services; (ii) where available, a comparison of multiple pricing services’ valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably stale; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties.  As a result of such procedures, the Company may conclude the prices received from third parties are not reflective of current market conditions.  In those instances, we may request additional pricing quotes or apply internally developed valuations.  However, the number of instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received.

The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company’s judgment of the inputs or methodologies used by the independent pricing services to value different asset classes.  Such inputs include:  benchmark yields, reported trades, broker dealer quotes, issuer spreads, benchmark securities, bids, offers and reference data.  The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments.

Except for exchange traded derivatives which are classified as Level 1, the fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotations; time value and volatility factors underlying options; market interest rates; and non-performance risk.  For certain embedded derivatives, we may use actuarial assumptions in the determination of fair value.

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at September 30, 2012 is as follows (dollars in millions):

45

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

	Quoted prices in active markets  for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	16,506.2	$	317.3	$	16,823.5
United States Treasury securities and obligations of United States government corporations and agencies	—		171.1		—		171.1
States and political subdivisions	—		2,048.1		—		2,048.1
Debt securities issued by foreign governments	—		.8		—		.8
Asset-backed securities	—		1,433.9		42.8		1,476.7
Collateralized debt obligations	—		—		332.0		332.0
Commercial mortgage-backed securities	—		1,540.3		2.3		1,542.6
Mortgage pass-through securities	—		18.2		2.0		20.2
Collateralized mortgage obligations	—		2,284.2		43.1		2,327.3
Total fixed maturities, available for sale	—		24,002.8		739.5		24,742.3
Equity securities:
Corporate securities	20.5		119.2		2.2		141.9
Venture capital investments	—		—		38.1		38.1
Total equity securities	20.5		119.2		40.3		180.0
Trading securities:
Corporate securities	—		49.3		.6		49.9
United States Treasury securities and obligations of United States government corporations and agencies	—		4.9		—		4.9
States and political subdivisions	—		17.1		—		17.1
Asset-backed securities	—		50.3		—		50.3
Collateralized debt obligations	—		—		7.0		7.0
Commercial mortgage-backed securities	—		43.6		—		43.6
Mortgage pass-through securities	—		.2		—		.2
Collateralized mortgage obligations	—		24.1		—		24.1
Equity securities	.9		1.4		—		2.3
Total trading securities	.9		190.9		7.6		199.4
Investments held by variable interest entities - corporate securities	—		829.4		—		829.4
Other invested assets:
Company-owned life insurance	—		112.3		—		112.3
Hedge funds	—		16.3		—		16.3
Derivatives	—		81.8		—		81.8
Total other invested assets	—		210.4		—		210.4
Cash and cash equivalents - unrestricted:
Cash	202.0		—		—		202.0
Cash equivalents and short-term investments	—		213.3		—		213.3
Total cash and cash equivalents - unrestricted	202.0		213.3		—		415.3
Cash and cash equivalents held by variable interest entities	48.2		—		—		48.2
Assets held in separate accounts	—		15.7		—		15.7
Total assets carried at fair value by category	$	271.6	$	25,581.7	$	787.4	$	26,640.7
Liabilities:
Liabilities for insurance products:
Interest-sensitive products - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	737.9	$	737.9
Interest-sensitive products - embedded derivatives associated with modified coinsurance agreement	—		—		6.0		6.0
Total liabilities for insurance products	—		—		743.9		743.9
Total liabilities carried at fair value by category	$	—	$	—	$	743.9	$	743.9

46

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

For those financial instruments disclosed at fair value, we use the following methods and assumptions to determine the estimated fair values:

Mortgage loans and policy loans.  We discount future expected cash flows for loans included in our investment portfolio based on interest rates currently being offered for similar loans to borrowers with similar credit ratings.  We aggregate loans with similar characteristics in our calculations.  The fair value of policy loans approximates their carrying value.

Insurance liabilities for interest-sensitive products.  We discount future expected cash flows based on interest rates currently being offered for similar contracts with similar maturities.

Investment borrowings, notes payable and borrowings related to variable interest entities.  For publicly traded debt, we use current fair values.  For other notes, we use discounted cash flow analyses based on our current incremental borrowing rates for similar types of borrowing arrangements.

The fair value measurements for our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions):

	September 30, 2012										December 31, 2011
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,718.3	$	1,718.3	$	1,597.2	$	1,735.4	$	1,602.8
Policy loans	—		274.1		—		274.1		274.1		279.7		279.7
Liabilities:
Insurance liabilities for interest-sensitive products excluding embedded derivatives (a)	—		—		12,186.4		12,186.4		12,186.4		13,165.5		13,165.5
Investment borrowings	—		1,702.5		—		1,702.5		1,650.9		1,735.7		1,676.5
Borrowings related to variable interest entities	—		748.3		—		748.3		766.9		485.1		519.9
Notes payable – direct corporate obligations	—		1,114.4		—		1,114.4		1,035.1		978.3		857.9

____________________

(a) The estimated fair value of insurance liabilities for interest-sensitive products was approximately equal to its carrying value at September 30, 2012.  This was because interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.

47

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The categorization of fair value measurements, by input level, for our fixed maturity securities, equity securities, trading securities, certain other invested assets, assets held in separate accounts and embedded derivative instruments included in liabilities for insurance products at December 31, 2011 is as follows (dollars in millions):

	Quoted prices in active markets  for identical assets or liabilities  (Level 1)		Significant other observable inputs (Level 2) (a)			Significant unobservable inputs  (Level 3) (a)			Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	15,594.4		$	278.1		$	15,872.5
United States Treasury securities and obligations of United States government corporations and agencies	—		303.8			1.6			305.4
States and political subdivisions	—		1,952.3			2.1			1,954.4
Debt securities issued by foreign governments	—		1.4			—			1.4
Asset-backed securities	—		1,334.3			79.7			1,414.0
Collateralized debt obligations	—		—			327.3			327.3
Commercial mortgage-backed securities	—		1,415.7			17.3			1,433.0
Mortgage pass-through securities	—		29.8			2.2			32.0
Collateralized mortgage obligations	—		2,051.2			124.8			2,176.0
Total fixed maturities, available for sale	—		22,682.9			833.1			23,516.0
Equity securities	17.9		87.3			69.9			175.1
Trading securities:
Corporate securities	—		67.6			—			67.6
United States Treasury securities and obligations of United States government corporations and agencies	—		4.9			—			4.9
States and political subdivisions	—		15.6			—			15.6
Asset-backed securities	—		.1			—			.1
Commercial mortgage-backed securities	—		—			.4			.4
Mortgage pass-through securities	—		.2			—			.2
Collateralized mortgage obligations	—		.7			—			.7
Equity securities	.7		1.4			—			2.1
Total trading securities	.7		90.5			.4			91.6
Investments held by variable interest entities	—		496.3			—			496.3
Other invested assets	—		159.9		(b)	—			159.9
Assets held in separate accounts	—		15.0			—			15.0
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	—		—			669.8		(c)	669.8

_____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) Includes company-owned life insurance and derivatives.

48

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

(c) Includes $666.3 million of embedded derivatives associated with our fixed index annuity products and $3.5 million of embedded derivatives associated with a modified coinsurance agreement.

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended September 30, 2012 (dollars in millions):

	September 30, 2012
	Beginning balance as of June 30, 2012 (a)			Purchases, sales, issuances and settlements, net (c)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		Transfers into Level 3		Transfers out of Level 3 (b)			Ending balance as of September 30, 2012			Amount of total gains (losses) for the three months ended September 30, 2012 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	321.0		$	14.0		$	—		$	7.3	$	12.5	$	(37.5	)	$	317.3		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.5			(1.5		)	—			—		—		—			—			—
States and political subdivisions	16.0			—			—			—		—		(16.0		)	—			—
Asset-backed securities	23.0			15.0			—			5.5		—		(.7		)	42.8			—
Collateralized debt obligations	330.1			(6.3		)	—			8.2		—		—			332.0			—
Commercial mortgage-backed securities	—			—			—			—		2.3		—			2.3			—
Mortgage pass-through securities	2.1			(.1		)	—			—		—		—			2.0			—
Collateralized mortgage obligations	4.5			(2.8		)	.1			1.0		44.6		(4.3		)	43.1			—
Total fixed maturities, available for sale	698.2			18.3			.1			22.0		59.4		(58.5		)	739.5			—
Equity securities:
Corporate securities	3.2			(1.0		)	—			—		—		—			2.2			—
Venture capital investments	58.0			—			(23.1		)	3.2		—		—			38.1			(23.1		)
Total equity securities	61.2			(1.0		)	(23.1		)	3.2		—		—			40.3			(23.1		)
Trading securities:
Corporate securities	—			—			—			—		.6		—			.6			—
States and political subdivisions	.5			—			—			—		—		(.5		)	—			—
Collateralized debt obligations	3.4			2.8			—			.8		—		—			7.0			.8
Total trading securities	3.9			2.8			—			.8		.6		(.5		)	7.6			.8
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(705.9		)	(22.7		)	(15.3		)	—		—		—			(743.9		)	(15.3		)

49

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.

(c) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the three months ended September 30, 2012 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	27.0		$	(13.0	)	$	—		$	—	$	14.0
United States Treasury securities and obligations of United States government corporations and agencies	—			(1.5		)	—			—		(1.5		)
Asset-backed securities	15.0			—			—			—		15.0
Collateralized debt obligations	—			(6.3		)	—			—		(6.3		)
Mortgage pass-through securities	—			(.1		)	—			—		(.1		)
Collateralized mortgage obligations	11.0			(13.8		)	—			—		(2.8		)
Total fixed maturities, available for sale	53.0			(34.7		)	—			—		18.3
Equity securities - corporate securities	—			(1.0		)	—			—		(1.0		)
Trading securities - collateralized debt obligations	2.8			—			—			—		2.8
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(23.5		)	.2			(10.2		)	10.8		(22.7		)

50

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the nine months ended September 30, 2012 (dollars in millions):

	September 30, 2012
	Beginning balance as of December 31, 2011 (a)			Purchases, sales, issuances and settlements, net (c)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		Transfers into Level 3		Transfers out of Level 3 (b)			Ending balance as of September 30, 2012			Amount of total gains (losses) for the nine months ended September 30, 2012 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	278.1		$	54.9		$	—		$	9.4	$	67.5	$	(92.6	)	$	317.3		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.6			(1.6		)	—			—		—		—			—			—
States and political subdivisions	2.1			—			—			—		—		(2.1		)	—			—
Asset-backed securities	79.7			11.4			(.2		)	5.8		.5		(54.4		)	42.8			—
Collateralized debt obligations	327.3			(11.6		)	—			16.3		—		—			332.0			—
Commercial mortgage-backed securities	17.3			—			—			.1		—		(15.1		)	2.3			—
Mortgage pass-through securities	2.2			(.2		)	—			—		—		—			2.0			—
Collateralized mortgage obligations	124.8			30.0			(.1		)	1.4		—		(113.0		)	43.1			—
Total fixed maturities, available for sale	833.1			82.9			(.3		)	33.0		68.0		(277.2		)	739.5			—
Equity securities:
Corporate securities	6.4			(1.0		)	(3.8		)	.6		—		—			2.2			(3.8		)
Venture capital investments	63.5			—			(26.0		)	.6		—		—			38.1			(26.0		)
Total equity securities	69.9			(1.0		)	(29.8		)	1.2		—		—			40.3			(29.8		)
Trading securities:
Corporate securities	—			—			—			.1		.5		—			.6			.1
States and political subdivisions	—			—			—			—		—		—			—			—
Collateralized debt obligations	—			7.0			—			—		—		—			7.0			—
Commercial mortgage-backed securities	.4			—			—			—		—		(.4		)	—			—
Total trading securities	.4			7.0			—			.1		.5		(.4		)	7.6			.1
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(669.8		)	(52.1		)	(22.0		)	—		—		—			(743.9		)	(22.0		)

51

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.

(c) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the nine months ended September 30, 2012 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	70.3		$	(15.4	)	$	—		$	—	$	54.9
United States Treasury securities and obligations of United States government corporations and agencies	—			(1.6		)	—			—		(1.6		)
Asset-backed securities	15.0			(3.6		)	—			—		11.4
Collateralized debt obligations	30.1			(41.7		)	—			—		(11.6		)
Mortgage pass-through securities	—			(.2		)	—			—		(.2		)
Collateralized mortgage obligations	45.3			(15.3		)	—			—		30.0
Total fixed maturities, available for sale	160.7			(77.8		)	—			—		82.9
Equity securities - corporate securities	—			(1.0		)	—			—		(1.0		)
Trading securities - collateralized debt obligations	7.0			—			—			—		7.0
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(75.3		)	41.9			(50.6		)	31.9		(52.1		)

52

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended September 30, 2011 (dollars in millions):

	September 30, 2011
	Beginning balance as of June 30, 2011			Purchases, sales, issuances and settlements, net (a)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in other comprehensive income (loss)			Transfers into Level 3		Transfers out of Level 3			Ending balance as of September 30, 2011			Amount of total gains (losses) for the three months ended September 30, 2011 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	361.8		$	(111.2	)	$	4.9		$	5.4		$	.5	$	(17.6	)	$	243.8		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.7			—			—			—			—		—			1.7			—
States and political subdivisions	—			—			—			.1			2.0		—			2.1			—
Asset-backed securities	170.7			1.2			—			—			4.1		(113.4		)	62.6			—
Collateralized debt obligations	193.5			72.7			—			(6.1		)	—		—			260.1			—
Mortgage pass-through securities	3.2			(.2		)	—			—			—		—			3.0			—
Collateralized mortgage obligations	204.1			3.6			—			.7			—		(30.2		)	178.2			—
Total fixed maturities, available for sale	935.0			(33.9		)	4.9			0.1			6.6		(161.2		)	751.5			—
Equity securities	44.6			27.3			—			(.3		)	—		—			71.6			—
Trading securities:
Collateralized mortgage obligations	—			—			—			—			—		—			—			—
Total trading securities	—			—			—			—			—		—			—			—
Investments held by variable interest entities:
Corporate securities	—			—			—			—			—		—			—			—
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(613.4		)	16.3			(44.8		)	—			—		—			(641.9		)	(44.8		)

____________

(a) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the three months ended September 30, 2011 (dollars in millions):

53

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1.8		$	(113.0	)	$	—		$	—	$	(111.2	)
Asset-backed securities	4.2			(3.0		)	—			—		1.2
Collateralized debt obligations	84.2			(11.5		)	—			—		72.7
Mortgage pass-through securities	—			(.2		)	—			—		(.2		)
Collateralized mortgage obligations	20.5			(16.9		)	—			—		3.6
Total fixed maturities, available for sale	110.7			(144.6		)	—			—		(33.9		)
Equity securities	27.3			—			—			—		27.3
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(33.1		)	41.7			(2.6		)	10.3		16.3

54

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the nine months ended September 30, 2011 (dollars in millions):

	September 30, 2011
	Beginning balance as of December 31, 2010			Purchases, sales, issuances and settlements, net (a)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in other comprehensive income (loss)			Transfers into Level 3		Transfers out of Level 3			Ending balance as of September 30, 2011			Amount of total gains (losses) for the nine months ended September 30, 2011 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1,907.8		$	(289.0	)	$	(16.1	)	$	12.7		$	39.0	$	(1,410.6	)	$	243.8		$	(11.5	)
United States Treasury securities and obligations of United States government corporations and agencies	2.0			—			—			(.3		)	—		—			1.7			—
States and political subdivisions	2.5			(2.8		)	(.1		)	.5			2.0		—			2.1			—
Asset-backed securities	182.3			(.6		)	—			2.5			15.1		(136.7		)	62.6			—
Collateralized debt obligations	256.5			3.5			1.8			(1.7		)	—		—			260.1			—
Mortgage pass-through securities	3.5			(.5		)	—			—			—		—			3.0			—
Collateralized mortgage obligations	197.1			48.5			(2.1		)	3.2			5.9		(74.4		)	178.2			—
Total fixed maturities, available for sale	2,551.7			(240.9		)	(16.5		)	16.9			62.0		(1,621.7		)	751.5			(11.5		)
Equity securities	6.9			64.0			—			.7			—		—			71.6			—
Trading securities:
Collateralized mortgage obligations	.4			(.4		)	—			—			—		—			—			—
Total trading securities	.4			(.4		)	—			—			—		—			—			—
Investments held by variable interest entities:
Corporate securities	6.7			(7.9		)	1.5			(.3		)	—		—			—			—
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(553.2		)	(35.0		)	(53.7		)	—			—		—			(641.9		)	(53.7		)

____________

(a) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the nine months ended September 30, 2011 (dollars in millions):

55

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1.8		$	(290.8	)	$	—		$	—	$	(289.0	)
States and political subdivisions	—			(2.8		)	—			—		(2.8		)
Asset-backed securities	4.1			(4.7		)	—			—		(.6		)
Collateralized debt obligations	106.6			(103.1		)	—			—		3.5
Mortgage pass-through securities	—			(.5		)	—			—		(.5		)
Collateralized mortgage obligations	94.5			(46.0		)	—			—		48.5
Total fixed maturities, available for sale	207.0			(447.9		)	—			—		(240.9		)
Equity securities	64.0			—			—			—		64.0
Trading securities:
Collateralized mortgage obligations	—			(.4		)	—			—		(.4		)
Investments held by variable interest entities:
Corporate securities	—			(7.9		)	—			—		(7.9		)
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(85.5		)	51.8			(28.4		)	27.1		(35.0		)

At September 30, 2012, 89 percent of our Level 3 fixed maturities, available for sale, were investment grade and 45 percent and 43 percent of our Level 3 fixed maturities, available for sale, consisted of collateralized debt obligations and corporate securities, respectively.

Realized and unrealized investment gains and losses presented in the preceding tables represent gains and losses during the time the applicable financial instruments were classified as Level 3.

Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and reinsurer accounts and other special-purpose portfolios, net realized investment gains (losses) or insurance policy benefits within the consolidated statement of operations or accumulated other comprehensive income within shareholders’ equity based on the appropriate accounting treatment for the instrument.

The amount presented for gains (losses) included in our net loss for assets and liabilities still held as of the reporting date primarily represents impairments for fixed maturities, available for sale, changes in fair value of trading securities and certain derivatives and changes in fair value of embedded derivative instruments included in liabilities for insurance products that exist as of the reporting date.

56

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at September 30, 2012 (dollars in millions):

	Fair value at September 30, 2012		Valuation technique(s)	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	212.4	Discounted cash flow analysis	Discount margins	1.95% - 3.27% (2.78%)
Asset-backed securities (b)	33.0		Discounted cash flow analysis	Discount margins	2.96% - 3.28% (3.15%)
Collateralized debt obligations (c)	339.0		Discounted cash flow analysis	Recoveries	61% - 66% (ramp over 24 months)
				Constant prepayment rate	20%
				Discount margins	1.30% - 10.00% (2.39%)
				Annual default rate	1.32% - 5.81% (3.27%)
				Portfolio CCC %	1.90% - 22.17% (12.78%)
Equity securities (d)	2.2		Discounted cash flow analysis	Recoveries	21%
Venture capital investments (e)	38.1		Market multiples	EBITDA multiple	4.8 - 29.0 (11.46)
				Revenue multiple	0.9 - 7.0 (4.2)
				Book equity multiple	0.8 - 3.8 (2.3)
Other assets categorized as Level 3 (f)	162.7		Unadjusted third-party price source	Not applicable	Not applicable
Total	787.4
Liabilities:
Interest sensitive products (g)	743.9		Discounted projected embedded derivatives	Projected portfolio yields	5.35% - 5.61% (5.55%)
				Discount rates	0.0 - 3.5% (1.3%)
				Surrender rates	4% - 43% (19%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Asset-backed securities - The significant unobservable input used in the fair value measurement of our asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(c) Collateralized debt obligations - The significant unobservable inputs used in the fair value measurement of our collateralized debt obligations relate to collateral performance, including default rate, recoveries and constant prepayment rate, as well as discount margins of the underlying collateral. Significant increases (decreases) in default rate in isolation would result in a significantly lower (higher) fair value measurement. Generally, a significant increase (decrease) in the constant prepayment rate and recoveries in isolation would result in a significantly higher (lower) fair value measurement. Generally a significant increase (decrease) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the annual default rate is accompanied by a directionally similar change in the assumption used for discount margins and portfolio CCC % and a directionally opposite change in the assumption used for constant prepayment rate and recoveries. A tranche's payment priority and investment cost basis could alter generalized fair value outcomes.

(d) Equity securities - The significant unobservable input used in the fair value measurement of our equity securities is the anticipated cash recovery. Significant increases (decreases) in the anticipated recovery would result in a significantly higher (lower) fair value measurement.

57

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(unaudited)

___________________

(e) Venture capital investments - The significant unobservable inputs used in the fair value measurement of our venture capital investments are the EBITDA multiple and revenue multiple. Generally, a significant increase (decrease) in the EBITDA or revenue multiples in isolation would result in a significantly higher (lower) fair value measurement.

(f) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(g) Interest sensitive products - The significant unobservable inputs used in the fair value measurement of our interest sensitive products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

58

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

In this section, we review the consolidated financial condition of CNO at September 30, 2012, and the consolidated results of operations for the three and nine months ended September 30, 2012 and 2011, and, where appropriate, factors that may affect future financial performance.  Please read this discussion in conjunction with the accompanying consolidated financial statements and notes.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our statements, trend analyses and other information contained in this report and elsewhere (such as in filings by CNO with the SEC, press releases, presentations by CNO or its management or oral statements) relative to markets for CNO’s products and trends in CNO’s operations or financial results, as well as other statements, contain forward-looking statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995.  Forward-looking statements typically are identified by the use of terms such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “project,” “intend,” “may,” “will,” “would,” “contemplate,” “possible,” “attempt,” “seek,” “should,” “could,” “goal,” “target,” “on track,” “comfortable with,” “optimistic” and similar words, although some forward-looking statements are expressed differently.  You should consider statements that contain these words carefully because they describe our expectations, plans, strategies and goals and our beliefs concerning future business conditions, our results of operations, financial position, and our business outlook or they state other “forward-looking” information based on currently available information.  The “Risk Factors” section of our 2011 Annual Report on Form 10-K provides examples of risks, uncertainties and events that could cause our actual results to differ materially from the expectations expressed in our forward-looking statements.  Assumptions and other important factors that could cause our actual results to differ materially from those anticipated in our forward-looking statements include, among other things:

• changes in or sustained low interest rates causing reductions in investment income, the margins of our fixed annuity and life insurance businesses, and sales of, and demand for, our products;

• expectations of lower future investment earnings may cause us to accelerate amortization, write down the balance of insurance acquisition costs or establish additional liabilities for insurance products;

• general economic, market and political conditions, including the performance and fluctuations of the financial markets which may affect the value of our investments as well as our ability to raise capital or refinance existing indebtedness and the cost of doing so;

• the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject;

• our ability to make anticipated changes to certain NGEs of our life insurance products;

• our ability to obtain adequate and timely rate increases on our health products, including our long-term care business;

• the receipt of any required regulatory approvals for dividend and surplus debenture interest payments from our insurance subsidiaries;

• mortality, morbidity, the increased cost and usage of health care services, persistency, the adequacy of our previous reserve estimates and other factors which may affect the profitability of our insurance products;

• changes in our assumptions related to deferred acquisition costs or the present value of future profits;

• the recoverability of our deferred tax assets and the effect of potential ownership changes and tax rate changes on their value;

• our assumption that the positions we take on our tax return filings, including our position that our 7.0% Debentures will not be treated as stock for purposes of Section 382 of the Code and will not trigger an ownership change, will not be successfully challenged by the IRS;

• changes in accounting principles and the interpretation thereof (including changes in principles related to accounting for deferred acquisition costs);

59

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

• our ability to continue to satisfy the financial ratio and balance requirements and other covenants of our debt agreements;

• our ability to achieve anticipated expense reductions and levels of operational efficiencies including improvements in claims adjudication and continued automation and rationalization of operating systems;

• performance and valuation of our investments, including the impact of realized losses (including other-than-temporary impairment charges);

• our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition;

• our ability to generate sufficient liquidity to meet our debt service obligations and other cash needs;

• our ability to maintain effective controls over financial reporting;

• our ability to continue to recruit and retain productive agents and distribution partners and customer response to new products, distribution channels and marketing initiatives;

• our ability to achieve eventual upgrades of the financial strength ratings of CNO and our insurance company subsidiaries as well as the impact of our ratings on our business, our ability to access capital, and the cost of capital;

• the risk factors or uncertainties listed from time to time in our filings with the SEC;

• regulatory changes or actions, including those relating to regulation of the financial affairs of our insurance companies, such as the payment of dividends and surplus debenture interest to us, regulation of the sale, underwriting and pricing of products, and health care regulation affecting health insurance products; and

• changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products or affect the value of our deferred tax assets.

Other factors and assumptions not identified above are also relevant to the forward-looking statements, and if they prove incorrect, could also cause actual results to differ materially from those projected.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by the foregoing cautionary statement.  Our forward-looking statements speak only as of the date made.  We assume no obligation to update or to publicly announce the results of any revisions to any of the forward-looking statements to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements.

The reporting of risk-based capital ("RBC") measures is not intended for the purpose of ranking any insurance company or for use in connection with any marketing, advertising or promotional activities.

OVERVIEW

We are a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products.  We focus on serving the senior and middle-income markets, which we believe are attractive, underserved, high growth markets.  We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; Other CNO Business, comprised primarily of products we no longer sell actively; and corporate operations, comprised of holding company activities and certain noninsurance company businesses.  The Company’s segments are described below:

• Bankers Life,which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents and sales managers supported by a network of community-based

60

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

branch offices.  The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company.  Bankers Life also markets and distributes Medicare Advantage plans primarily through a distribution arrangement with Humana, Inc. and Medicare Part D prescription drug plans ("PDP") through a distribution and reinsurance arrangement with Coventry.

• Washington National, which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite.  These products are marketed through Performance Matters Associates, Inc. ("PMA"), a wholly owned subsidiary, and through independent marketing organizations and insurance agencies including worksite marketing.  The products being marketed are underwritten by Washington National Insurance Company.

• Colonial Penn, which markets primarily graded benefit and simplified issue life insurance directly to customers through television advertising, direct mail, the internet and telemarketing.  The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company.

• Other CNO Business, which consists of blocks of interest-sensitive life insurance, traditional life insurance, annuities, long-term care insurance and other supplemental health products.  These blocks of business are not being actively marketed and were primarily issued or acquired by Conseco Life and Washington National Insurance Company.

Potential continuation of a low interest rate environment for an extended period of time.

Some of our products, principally traditional whole life, universal life, fixed rate and fixed index annuity contracts, expose us to the risk that changes in interest rates will reduce our spread (the difference between the amounts that we are required to pay under the contracts and the investment income we are able to earn on the investments supporting our obligations under the contracts). Our spread is a key component of our net income. In addition, investment income is an important component of the profitability of our health products, especially long-term care and supplemental health policies.

If interest rates were to decrease further or remain at low levels for an extended period of time, we may have to invest new cash flows or reinvest proceeds from investments that have matured or have been prepaid or sold at yields that have the effect of reducing our net investment income as well as the spread between interest earned on investments and interest credited to some of our products below present or planned levels. To the extent borrowers may prepay or redeem fixed maturity investments or mortgage loans in our investment portfolio, this could increase the impact of this risk. We can lower crediting rates on certain products to offset the decrease in spread. However, our ability to lower these rates may be limited by: (i) contractually guaranteed minimum rates; or (ii) competition. In addition, a decrease in crediting rates may not match the timing or magnitude of changes in investment yields. Currently, the vast majority of our products, with contractually guaranteed minimum rates, have crediting rates set at the minimum rate. As a result, further decreases in investment yields would decrease the spread we earn and such spread could potentially become a loss.

The following table summarizes the distribution of annuity and universal life account values by guaranteed interest crediting rates as of September 30, 2012 (dollars in millions):

Guaranteed	Fixed rate and fixed			Universal
rate	index annuities			life			Total
> 6.0% to 8.0%	$	.1		$	—		$	.1
> 5.0% to 6.0%	.2			36.7			36.9
> 4.0% to 5.0%	81.3			913.2			994.5
> 3.0% to 4.0%	1,730.4			1,200.3			2,930.7
> 2.0% to 3.0%	3,739.4			370.0			4,109.4
> 1.0% to 2.0%	1,306.4			5.0			1,311.4
1.0% and under	1,047.5			38.7			1,086.2
	$	7,905.3		$	2,563.9		$	10,469.2
Weighted average	2.49		%	3.98		%	2.85		%

In addition, during periods of declining or low interest rates, life and annuity products may be relatively more attractive to consumers, resulting in increased premium payments on products with flexible premium features, repayment of policy loans and increased persistency (a higher percentage of insurance policies remaining in force from year-to-year).

61

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Our expectation of future investment income is an important consideration in determining the amortization of insurance acquisition costs and analyzing the recovery of these assets as well as determining the adequacy of our liabilities for insurance products. Expectations of lower future investment earnings may cause us to accelerate amortization, write down the balance of insurance acquisition costs or establish additional liabilities for insurance products, thereby reducing net income in the future periods.

The blocks of business in our Other CNO Business segment are particularly sensitive to changes in our expectations of future interest rates. Since many of these blocks are not expected to generate future profits, the entire impact of adverse changes to our earlier estimate of future gross profits is recognized in earnings in the period such changes occur. For example, in the third quarters of 2012 and 2011, we recognized a pre-tax reduction in earnings of approximately $43 million and $13 million, respectively, in the Other CNO Business segment primarily due to increases in future loss reserves resulting from decreased projected future investment yields related to investments backing our interest-sensitive insurance products. The earnings reduction in the third quarter of 2012 resulted from our review of interest rate assumptions on all of our products. As a result of this review, we lowered our current new money rate assumption to 4.75 percent and lowered the ultimate new money rate we expect to achieve over time by 50 basis points, to rates ranging from 6.35 percent to 7.00 percent depending on the specific product.

The following summarizes hypothetical scenarios which assume immediate and permanent reductions to interest rates based on tests performed in December 2011, and recently updated to reflect the current interest rate environment. We estimate that the pre-tax charge resulting from a hypothetical immediate and permanent 10 basis point decrease to assumed spreads related to our universal life and investment-type products would be approximately $55 million. In addition, we estimate that the pre-tax charge resulting from a hypothetical immediate and permanent 50 basis point decrease to assumed investment earnings rates related to products other than universal life and investment-type products would be approximately $50 million.

The following summarizes a hypothetical stress scenario related to the effect of continued low new money rates on our portfolio yields based on a test originally performed in June 2012, and recently updated. The scenario assumed new money rates of 4.75 percent that remain level for five years, and then grade from this level to a long-term yield assumption over time. We estimate that this scenario would result in an after-tax charge of $20 million to $50 million primarily related to an increase in future loss reserves resulting from decreased projected future investment yields on investments backing our interest-sensitive and long-term care insurance products. In addition, we estimate that this scenario would result in an approximate unfavorable after-tax investment income effect of $10 million to $15 million during 2013 and $25 million to $30 million during 2014. Under this hypothetical scenario, insurance liabilities reported under statutory accounting principles would also increase by up to $50 million, which would result in a reduction to our consolidated RBC ratio of approximately 10 percentage points.

Although the hypothetical revisions described in the scenarios summarized in the previous two paragraphs are not currently required or anticipated, we believe similar changes could occur based on past variances in experience and our expectations of the ranges of future experience that could reasonably occur. We have assumed that revisions to assumptions resulting in such adjustments would occur equally among policy types, ages and durations within each product classification. Any actual adjustment would be dependent on the specific policies affected and, therefore, may differ from such estimates. In addition, the impact of actual adjustments would reflect the net effect of all changes in assumptions during the period.

62

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

The following summarizes our earnings for the three and nine months ending September 30, 2012 and 2011 (dollars in millions, except per share data):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Earnings before net realized investment gains, fair value changes in embedded derivative liabilities, corporate interest expense, loss on extinguishment of debt and income taxes (“EBIT” a non-GAAP financial measure) (a):
Bankers Life	$	80.6		$	79.4		$	227.2		$	213.7
Washington National	33.9			21.2			92.5			67.3
Colonial Penn	(2.6		)	(1.3		)	(11.8		)	(6.5		)
Other CNO Business	(53.6		)	2.8			(54.0		)	15.3
EBIT from business segments	58.3			102.1			253.9			289.8
Corporate Operations, excluding corporate interest expense	(6.7		)	(27.5		)	(17.6		)	(39.3		)
EBIT	51.6			74.6			236.3			250.5
Corporate interest expense	(16.3		)	(18.7		)	(50.4		)	(58.6		)
Income before loss on extinguishment of debt, net realized investment gains, fair value changes in embedded derivative liabilities and taxes	35.3			55.9			185.9			191.9
Tax expense on operating income	9.7			23.1			65.5			71.4
Net operating income	25.6			32.8			120.4			120.5
Net realized investment gains (net of related amortization and taxes)	4.8			17.3			37.6			22.7
Fair value changes in embedded derivative liabilities (net of related amortization and taxes)	(2.0		)	(12.9		)	(4.4		)	(12.9		)
Loss on extinguishment of debt, net of income taxes	(176.4		)	(.7		)	(176.8		)	(2.0		)
Net income (loss) before valuation allowance for deferred tax assets	(148.0		)	36.5			(23.2		)	128.3
Decrease in valuation allowance for deferred tax assets	143.0			143.0			143.0			143.0
Net income (loss)	$	(5.0	)	$	179.5		$	119.8		$	271.3
Per diluted share:
Net operating income	$	.11		$	.12		$	.45		$	.43
Net realized investment gains, net of related amortization and taxes	.02			.06			.13			.07
Fair value changes in embedded derivative liabilities, net of related amortization and taxes	(.01		)	(.04		)	(.02		)	(.04		)
Loss on extinguishment of debt, net of income taxes	(.76		)	—			(.60		)	(.01		)
Decrease in valuation allowance for deferred tax assets	.62			.47			.49			.47
Net income (loss)	$	(.02	)	$	.61		$	.45		$	.92

____________

(a) Management believes that an analysis of EBIT provides a clearer comparison of the operating results of the Company from period to period because it excludes:  (i) corporate interest expense; (ii) loss on extinguishment of debt; (iii) net realized investment gains; and (iv) fair value changes in embedded derivative liabilities that are unrelated to the Company’s underlying fundamentals.  Net realized investment gains or losses include: (i) gains or losses on the sales of investments; (ii) other-than-temporary impairments recognized through net income; and (iii) changes in fair value of certain fixed maturity investments with embedded derivatives. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.

63

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

CRITICAL ACCOUNTING POLICIES

Refer to “Critical Accounting Policies” in our 2011 Annual Report on Form 10-K for information on our other accounting policies that we consider critical in preparing our consolidated financial statements.

RESULTS OF OPERATIONS

The following tables and narratives summarize the operating results of our segments for the periods presented (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Income (loss) before net realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization, loss on extinguishment of debt and income taxes (a non-GAAP measure) (a):
Bankers Life	$	80.6		$	79.4		$	227.2		$	213.7
Washington National	33.9			21.2			92.5			67.3
Colonial Penn	(2.6		)	(1.3		)	(11.8		)	(6.5		)
Other CNO Business	(53.6		)	2.8			(54.0		)	15.3
Corporate operations	(23.0		)	(46.2		)	(68.0		)	(97.9		)
	35.3			55.9			185.9			191.9
Net realized investment gains (losses), net of related amortization:
Bankers Life	12.7			23.5			38.6			27.8
Washington National	(3.0		)	1.6			3.6			.6
Colonial Penn	2.6			3.5			7.1			4.8
Other CNO Business	(5.7		)	2.1			6.9			2.9
Corporate operations	.8			(4.0		)	1.8			(1.2		)
	7.4			26.7			58.0			34.9
Fair value changes in embedded derivative liabilities, net of related amortization:
Bankers Life	(3.0		)	(19.2		)	(6.6		)	(19.2		)
Other CNO Business	—			(.6		)	(.1		)	(.6		)
	(3.0		)	(19.8		)	(6.7		)	(19.8		)
Loss on extinguishment of debt:
Corporate operations	(198.5		)	(1.1		)	(199.2		)	(3.1		)
Income (loss) before income taxes:
Bankers Life	90.3			83.7			259.2			222.3
Washington National	30.9			22.8			96.1			67.9
Colonial Penn	—			2.2			(4.7		)	(1.7		)
Other CNO Business	(59.3		)	4.3			(47.2		)	17.6
Corporate operations	(220.7		)	(51.3		)	(265.4		)	(102.2		)
Income (loss) before income taxes	$	(158.8	)	$	61.7		$	38.0		$	203.9

____________________

(a) These non-GAAP measures as presented in the above table and in the following segment financial data and discussions of segment results exclude net realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization, loss on extinguishment of debt and before income taxes.  These are considered non-GAAP financial measures.  A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

64

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

These non-GAAP financial measures of “income (loss) before net realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization, loss on extinguishment of debt and before income taxes” differ from “income (loss) before income taxes” as presented in our consolidated statement of operations prepared in accordance with GAAP due to the exclusion of before tax realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization and loss on extinguishment of debt.  We measure segment performance excluding these items because we believe that this performance measure is a better indicator of the ongoing businesses and trends in our business. Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business. Realized investment gains (losses) and fair value changes in embedded derivative liabilities depend on market conditions and do not necessarily relate to decisions regarding the underlying business of our segments.  However, “income (loss) before net realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization, loss on extinguishment of debt and before income taxes” does not replace “income (loss) before income taxes” as a measure of overall profitability. We may experience realized investment gains (losses), which will affect future earnings levels since our underlying business is long-term in nature and we need to earn the assumed interest rates on the investments backing our liabilities for insurance products to maintain the profitability of our business.  In addition, management uses this non-GAAP financial measure in its budgeting process, financial analysis of segment performance and in assessing the allocation of resources. We believe these non-GAAP financial measures enhance an investor’s understanding of our financial performance and allows them to make more informed judgments about the Company as a whole.  These measures also highlight operating trends that might not otherwise be transparent.  The table above reconciles the non-GAAP measure to the corresponding GAAP measure.

General: CNO is the top tier holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products. We distribute these products through our Bankers Life segment, which utilizes a career agency force, through our Colonial Penn segment, which utilizes direct response marketing, and through our Washington National segment, which utilizes independent producers.

65

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Bankers Life (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Premium collections:
Annuities	$	171.7		$	264.1		$	525.9		$	745.4
Medicare supplement and other supplemental health	327.3			328.0			988.1			994.7
Life	81.3			65.5			226.8			183.9
Total collections	$	580.3		$	657.6		$	1,740.8		$	1,924.0
Average liabilities for insurance products:
Annuities:
Mortality based	$	229.4		$	240.0		$	231.6		$	243.0
Fixed index	2,872.1			2,412.9			2,792.6			2,276.3
Deposit based	4,515.4			4,750.5			4,579.4			4,792.0
Medicare supplement and other supplemental health	4,710.0			4,564.0			4,665.9			4,527.8
Life:
Interest sensitive	450.8			431.8			445.6			425.8
Non-interest sensitive	532.9			437.7			507.4			417.5
Total average liabilities for insurance products, net of reinsurance ceded	$	13,310.6		$	12,836.9		$	13,222.5		$	12,682.4
Revenues:
Insurance policy income	$	416.1		$	404.6		$	1,241.6		$	1,214.2
Net investment income:
General account invested assets	205.4			194.3			610.6			582.1
Fixed index products	16.2			(36.3		)	31.5			(17.6		)
Fee revenue and other income	4.0			3.6			10.2			9.2
Total revenues	641.7			566.2			1,893.9			1,787.9
Expenses:
Insurance policy benefits	362.4			333.6			1,063.9			1,022.5
Amounts added to policyholder account balances:
Annuity products and interest-sensitive life products other than fixed index products	36.9			40.0			112.0			121.3
Fixed index products	35.3			(13.0		)	76.3			30.5
Amortization related to operations	35.6			44.1			143.0			159.5
Interest expense on investment borrowings	1.3			1.2			4.1			3.5
Other operating costs and expenses	89.6			80.9			267.4			236.9
Total benefits and expenses	561.1			486.8			1,666.7			1,574.2
Income before net realized investment gains and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes	80.6			79.4			227.2			213.7
Net realized investment gains	14.1			26.5			42.6			31.3
Amortization related to net realized investment gains	(1.4		)	(3.0		)	(4.0		)	(3.5		)
Net realized investment gains, net of related amortization	12.7			23.5			38.6			27.8
Insurance policy benefits - fair value changes in embedded derivative liabilities	(4.6		)	(30.7		)	(10.3		)	(30.7		)
Amortization related to fair value changes in embedded derivative liabilities	1.6			11.5			3.7			11.5
Fair value changes in embedded derivative liabilities, net of related amortization	(3.0		)	(19.2		)	(6.6		)	(19.2		)
Income before income taxes	$	90.3		$	83.7		$	259.2		$	222.3

66

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Health benefit ratios:
All health lines:
Insurance policy benefits	$	302.1		$	287.5		$	898.6		$	890.1
Benefit ratio (a)	90.2		%	86.1		%	88.9		%	87.5		%
Medicare supplement:
Insurance policy benefits	$	125.5		$	122.5		$	376.2		$	369.5
Benefit ratio (a)	67.8		%	68.4		%	68.2		%	68.5		%
PDP:
Insurance policy benefits	$	8.5		$	9.8		$	29.1		$	37.5
Benefit ratio (a)	74.8		%	76.1		%	73.1		%	85.2		%
PFFS:
Insurance policy benefits	$	(.1	)	$	(.5	)	$	(.3	)	$	(1.3	)
Benefit ratio (a)	N/A			N/A			N/A			N/A
Long-term care:
Insurance policy benefits	$	168.2		$	155.7		$	493.6		$	484.4
Benefit ratio (a)	121.4		%	109.7		%	117.9		%	112.7		%
Interest-adjusted benefit ratio (b)	74.7		%	65.5		%	71.9		%	69.3		%

____________________

(a) We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.

(b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Bankers Life’s long-term care products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income.  These are considered non-GAAP financial measures.  A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of “interest-adjusted benefit ratios” differ from “benefit ratios” due to the deduction of imputed interest income on the accumulated assets backing the insurance liabilities from the product’s insurance policy benefits used to determine the ratio.  Interest income is an important factor in measuring the performance of health products that are expected to be inforce for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time.  Actual interest income will vary from imputed interest income. The net cash flows from long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases).  Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by the imputed interest income earned on the accumulated assets.  The interest-adjusted benefit ratio reflects the effects of such interest income offset.  Since interest income is an important factor in measuring the performance of this product, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance.  We utilize the interest-adjusted benefit ratio in measuring segment performance because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business.  However, the “interest-adjusted benefit ratio” does not replace the “benefit ratio” as a measure of current period benefits to current period insurance policy income.  Accordingly, management reviews both “benefit ratios” and “interest-adjusted benefit ratios” when analyzing the financial results attributable to these products.  The imputed investment income earned on the accumulated assets backing Bankers Life’s long-term care reserves was $64.7 million and $62.8 million in the three months ended September 30, 2012 and 2011, respectively, and $192.7 million and $186.6 million in the nine months ended September 30, 2012 and 2011, respectively.

Total premium collections were $580.3 million in the third quarter of 2012, down 12 percent from 2011, and were $1,740.8 million in the first nine months of 2012, down 9.5 percent from 2011.  See “Premium Collections” for further analysis of Bankers Life’s premium collections.

67

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Average liabilities for insurance products, net of reinsurance ceded were $13.3 billion in the third quarter of 2012, up 3.7 percent from 2011, and were $13.2 billion in the first nine months of 2012, up 4.3 percent from 2011.  The increase in such liabilities was primarily due to increases in annuity, health and life reserves resulting from new sales of these products.

Insurance policy income is comprised of premiums earned on policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies.

Net investment income on general account invested assets (which excludes income on policyholder accounts and other special-purpose portfolios) was $205.4 million in the third quarter of 2012, up 5.7 percent from 2011, and was $610.6 million in the the first nine months of 2012, up 4.9 percent from 2011.  The average balance of general account invested assets was $14.3 billion and $13.7 billion in the third quarters of 2012 and 2011, respectively.  The average yield on these assets was 5.76 percent and 5.67 percent in the third quarters of 2012 and 2011, respectively.  The average balance of general account invested assets was $14.2 billion and $13.5 billion in the first nine months of 2012 and 2011, respectively.  The average yield on these assets was 5.74 percent and 5.76 percent in the first nine months of 2012 and 2011, respectively. The increase in general account invested assets is primarily due to sales and increased persistency of our annuity and health products in recent periods. The increase in net investment income in the 2012 periods primarily reflects the growth in general account invested assets. Investing in higher yielding investments, slightly higher prepayment income and reduction to turnover rates to preserve higher yielding investments has resulted in maintaining (or slightly improving) overall yields in this segment when compared to the prior year. However, current market conditions are more challenging and we expect to see the overall yield decline in future periods.

Net investment income related to fixed index products represents the change in the estimated fair value of options which are purchased in an effort to offset or hedge certain potential benefits accruing to the policyholders of our fixed index products. Our fixed index products are designed so that the investment income spread earned on the related insurance liabilities is expected to be more than adequate to cover the cost of the options and other costs related to these policies.  Net investment income (loss) related to fixed index products was $16.2 million and $(36.3) million in the third quarters of 2012 and 2011, respectively, and was $31.5 million and $(21.6) million in the first nine months of 2012 and 2011, respectively. Such amounts were mostly offset by the corresponding charge (credit) to amounts added to policyholder account balances for fixed index products.  Such income and related charges fluctuate based on the value of options embedded in the segment’s fixed index annuity policyholder account balances subject to this benefit and to the performance of the index to which the returns on such products are linked. For periods prior to June 30, 2011, net investment income related to fixed index products also included income on trading securities which were held to offset the change in estimated fair values of the embedded derivatives related to our fixed index products caused by interest rate fluctuations. During the second quarter of 2011, we sold this trading portfolio and invested the proceeds in higher yielding investments. Such trading account income was nil and $4.0 million in the three and nine months ended September 30, 2011, respectively.  

Insurance policy benefits fluctuated as a result of the factors summarized below for benefit ratios.  Benefit ratios are calculated by dividing the related insurance product’s insurance policy benefits by insurance policy income.

The Medicare supplement business consists of both individual and group policies.  Government regulations generally require us to attain and maintain a ratio of total benefits incurred to total premiums earned (excluding changes in policy benefit reserves), after three years from the original issuance of the policy and over the lifetime of the policy, of not less than 65 percent on individual products and not less than 75 percent on group products, as determined in accordance with statutory accounting principles.  Since the insurance product liabilities we establish for Medicare supplement business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Our insurance policy benefits reflected reserve redundancies from prior years of $14.8 million and $13.3 million in the first nine months of 2012 and 2011, respectively.  Excluding the effects of prior period claim reserve redundancies, our benefit ratios would have been 70.9 percent in both the first nine months of 2012 and 2011.  

The insurance policy benefits on our PDP business result from our quota-share reinsurance agreement with Coventry.  Insurance margins (insurance policy income less insurance policy benefits) on the PDP business were $2.9 million and $3.1 million in the third quarters of 2012 and 2011, respectively, and were $10.8 million and $6.5 million in the nine months ended September 30, 2012 and 2011, respectively.  In the first nine months of 2012 and 2011, reserves related to the previously terminated Private-Fee-For-Service ("PFFS") business were released due to favorable claim developments resulting in insurance policy benefits of $(.3) million and $(1.3) million, respectively.

68

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

The net cash flows from our long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) which will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio typically increases, but the increase in reserves is partially offset by investment income earned on the accumulated assets.  The benefit ratio on our long-term care business in the Bankers Life segment was 121.4 percent and 109.7 percent in the third quarters of 2012 and 2011, respectively, and was 117.9 percent and 112.7 percent in the first nine months of 2012 and 2011, respectively.  The interest-adjusted benefit ratio on this business was 74.7 percent and 65.5 percent in the third quarters of 2012 and 2011, respectively, and was 71.9 percent and 69.3 percent in the first nine months of 2012 and 2011, respectively.  Since the insurance product liabilities we establish for long-term care business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate.  Our insurance policy benefits reflected reserve redundancies from prior years of $13.7 million and $19.6 million in the first nine months of 2012 and 2011, respectively. Excluding the effects of prior year claim reserve redundancies, our benefit ratios would have been 121.1 percent and 117.3 percent in the first nine months of 2012 and 2011, respectively.

Over the past several years, we have implemented rate increases in the long-term care block in the Bankers Life segment. In October 2010, we commenced additional rate increase filings on certain long-term care blocks.  We expect to implement rate increases of approximately $35 million after approval from all states.  Approximately $34 million of approvals had been received as of September 30, 2012.  In the first nine months of both 2012 and 2011, the income before income taxes in the Bankers Life segment reflected a reduction in insurance policy benefits partially offset by additional amortization of insurance acquisition costs due to the impacts of recent rate increases. These impacts netted to approximately $15 million and $17 million in the first nine months of 2012 and 2011, respectively, and include:  (i) the reduction in liabilities for policyholders choosing to lapse their policies rather than paying higher rates; (ii) the reduction in liabilities for policyholders choosing to reduce their coverages to achieve a lower cost; offset by (iii) the increase in the liabilities related to waiver of premium benefits to reflect higher premiums after the rate increases; and (iv) increased amortization of insurance acquisition costs resulting from the increase in lapses. The net impacts described above are expected to be lower in future periods, since our pending rate increases will be fully implemented.

Amounts added to policyholder account balances for annuity products and interest-sensitive life products were $36.9 million in the third quarter of 2012, down 7.8 percent from 2011, and were $112.0 million in the first nine months of 2012, down 7.7 percent from 2011.  The weighted average crediting rate for these products was 3.0 percent and 3.1 percent in the third quarters of 2012 and 2011, respectively, and 3.0 percent and 3.1 percent in the first nine months of 2012 and 2011, respectively. The average liabilities of the deposit-based annuity block were $4.6 billion and $4.8 billion in the first nine months of 2012 and 2011, respectively. 

Amounts added to fixed index products based on change in value of the indices will generally fluctuate with the corresponding related investment income accounts described above.

Amortization related to operations includes amortization of deferred acquisition costs and the present value of future profits. Deferred acquisition costs and the present value of future profits are collectively referred to as “insurance acquisition costs.” Insurance acquisition costs are generally amortized either:  (i) in relation to the estimated gross profits for universal life and investment-type products; or (ii) in relation to actual and expected premium revenue for other products.  In addition, for universal life and investment-type products, we are required to adjust the total amortization recorded to date through the statement of operations if actual experience or other evidence suggests that earlier estimates of future gross profits should be revised. Accordingly, amortization for universal life and investment-type products is dependent on the profits realized during the period and on our expectation of future profits.  For other products, we amortize insurance acquisition costs in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits.  Bankers Life’s amortization expense was $35.6 million and $44.1 million in the third quarters of 2012 and 2011, respectively, and was $143.0 million and $159.5 million in the nine months ended September 30, 2012 and 2011, respectively.  During the first quarter of 2011, we experienced higher policy lapses than we anticipated on our Medicare supplement products, including lapses where policyholders terminated their current policy and purchased a lower cost policy offered through this segment.  These lapses reduced our estimates of future expected premium income and, accordingly, we recognized additional amortization expense of $6 million.  Amortization expense related to our annuity block also decreased in the 2012 periods, as compared to 2011, due to higher persistency on this business.

Interest expense on investment borrowings represents interest expense on collateralized borrowings as further described in the note to the consolidated financial statements entitled “Investment Borrowings”.

69

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Other operating costs and expenses in our Bankers Life segment were $89.6 million in the third quarter of 2012, up 11 percent from 2011, and were $267.4 million in the first nine months of 2012, up 13 percent from 2011.  Other operating expenses in first nine months of 2012 increased primarily due to higher legal and regulatory expenses, including a $10 million settlement with state securities regulators. Other operating costs and expenses include the following (dollars in millions):

	Three months ended				Nine months ended
	September 30,				September 30,
	2012		2011		2012		2011
Expenses related to the marketing and quota-share agreements with Coventry	$	2.5	$	1.7	$	6.3	$	6.3
Commission expense and agent manager benefits	15.7		11.3		44.6		39.8
Other operating expenses	71.4		67.9		216.5		190.8
Total	$	89.6	$	80.9	$	267.4	$	236.9

Net realized investment gains (losses)fluctuate each period.  During the first nine months of 2012, net realized investment gains in this segment included $51.3 million of net gains from the sales of investments (primarily fixed maturities) and $8.7 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During the first nine months of 2011, net realized investment gains in this segment included $36.6 million of net gains from the sales of investments (primarily fixed maturities) and $5.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

Amortization related to net realized investment losses is the increase or decrease in the amortization of insurance acquisition costs which results from realized investment gains or losses.  When we sell securities which back our universal life and investment-type products at a gain (loss) and reinvest the proceeds at a different yield, we increase (reduce) the amortization of insurance acquisition costs in order to reflect the change in estimated gross profits due to the gains (losses) realized and the resulting effect on estimated future yields.  Sales of fixed maturity investments resulted in an increase in the amortization of insurance acquisition costs of $1.4 million and $3.0 million in the third quarters of 2012 and 2011, respectively, and $4.0 million and $3.5 million in the nine months ended September 30, 2012 and 2011, respectively.

Insurance policy benefits - fair value changes in embedded derivative liabilities represents fair value changes due to fluctuations in the interest rates used to discount embedded derivative liabilities related to our fixed index annuities. Prior to June 30, 2011, we held certain trading securities to offset the income statement volatility caused by the interest rate fluctuations. In the second quarter of 2011, we sold this trading portfolio.

Amortization related to fair value changes in embedded derivative liabilities is the increase or decrease in the amortization of insurance acquisition costs which results from changes in interest rates used to discount embedded derivative liabilities related to our fixed index annuities.

70

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Washington National (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Premium collections:
Medicare supplement and other supplemental health	$	143.6		$	141.2		$	430.4		$	427.2
Life	3.0			4.1			10.8			12.3
Total collections	$	146.6		$	145.3		$	441.2		$	439.5
Average liabilities for insurance products:
Medicare supplement and other supplemental health	$	2,414.5		$	2,436.9		$	2,421.0		$	2,436.2
Non-interest sensitive life	200.3			198.7			199.9			202.0
Total average liabilities for insurance products, net of reinsurance ceded	$	2,614.8		$	2,635.6		$	2,620.9		$	2,638.2
Revenues:
Insurance policy income	$	147.8		$	145.9		$	442.8		$	437.9
Net investment income:
General account invested assets	50.8			47.3			151.8			140.3
Trading account income related to reinsurer accounts	(.9		)	2.6			.6			3.6
Change in value of embedded derivatives related to modified coinsurance agreements	1.0			(2.6		)	(.5		)	(3.6		)
Fee revenue and other income	.3			.4			.8			.9
Total revenues	199.0			193.6			595.5			579.1
Expenses:
Insurance policy benefits	111.1			119.0			340.5			349.5
Amortization related to operations	11.2			10.8			34.7			35.6
Interest expense on investment borrowings	.7			.2			2.2			.2
Other operating costs and expenses	42.1			42.4			125.6			126.5
Total benefits and expenses	165.1			172.4			503.0			511.8
Income before net realized investment gains (losses) and income taxes	33.9			21.2			92.5			67.3
Net realized investment gains (losses)	(3.0		)	1.6			3.6			.6
Income before income taxes	$	30.9		$	22.8		$	96.1		$	67.9
Health benefit ratios:
Medicare supplement:
Insurance policy benefits	$	18.6		$	23.4		$	59.2		$	71.7
Benefit ratio (a)	63.8		%	69.9		%	65.6		%	69.1		%
Supplemental health:
Insurance policy benefits	$	84.5		$	88.7		$	263.6		$	259.5
Benefit ratio (a)	74.2		%	82.4		%	77.8		%	81.3		%
Interest-adjusted benefit ratio (b)	47.5		%	53.9		%	50.9		%	52.4		%

71

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

_________________

(a) We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.

(b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Washington National’s supplemental health products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income.  These are considered non-GAAP financial measures.  A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of “interest-adjusted benefit ratios” differ from “benefit ratios” due to the deduction of imputed interest income on the accumulated assets backing the insurance liabilities from the product’s insurance policy benefits used to determine the ratio.  Interest income is an important factor in measuring the performance of health products that are expected to be inforce for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time. Actual interest income will vary from imputed interest income.  The net cash flows from supplemental health products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases).  Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by the imputed interest income earned on the accumulated assets.  The interest-adjusted benefit ratio reflects the effects of such interest income offset. Since interest income is an important factor in measuring the performance of these products, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance.  We utilize the interest-adjusted benefit ratio in measuring segment performance because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business.  However, the “interest-adjusted benefit ratio” does not replace the “benefit ratio” as a measure of current period benefits to current period insurance policy income. Accordingly, management reviews both “benefit ratios” and “interest-adjusted benefit ratios” when analyzing the financial results attributable to these products.  The imputed investment income earned on the accumulated assets backing the supplemental health reserves was $30.3 million and $30.7 million in the three months ended September 30, 2012 and 2011, respectively, and $91.3 million and $92.3 million in the nine months ended September 30, 2012 and 2011, respectively.

Total premium collections were$146.6 million in the third quarter of 2012, up .9 percent from 2011, and were$441.2 million in the first nine months of 2012, up .4 percent from 2011.  See “Premium Collections” for further analysis.

Average liabilities for insurance products, net of reinsurance ceded were $2.6 billion in the third quarter of 2012, down .8 percent from 2011, and were $2.6 billion in the first nine months of 2012, down .7 percent from 2011.

Insurance policy income is comprised of premiums earned on traditional insurance policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies. Such income increased slightly during the 2012 periods, as supplemental health premiums have increased and Medicare supplement premiums have decreased consistent with sales.

Net investment income on general account invested assets (which excludes income on policyholder and reinsurer accounts) was $50.8 million in the third quarter of 2012, up 7.4 percent from 2011, and was $151.8 million in the first nine months of 2012, up 8.2 percent from 2011.  The average balance of general account invested assets was $3.7 billion and $3.3 billion in the third quarters of 2012 and 2011, respectively.  The average yield on these assets was 5.54 percent and 5.80 percent in the third quarters of 2012 and 2011.  The average balance of general account invested assets was $3.7 billion and $3.2 billion in the first nine months of 2012 and 2011, respectively.  The average yield on these assets was 5.52 percent and 5.89 percent in the first nine months of 2012 and 2011.  The increase in general account invested assets is primarily due to the increase in invested assets purchased with the proceeds from collateralized borrowings from the FHLB pursuant to an investment borrowing program that commenced in this segment in June 2011. The decline in average yield is primarily due to lower yields related to the variable rate investments purchased with the proceeds from collateralized borrowings from the FHLB.

Trading account income related to reinsurer accounts primarily represents the income on trading securities which are held to act as hedges for embedded derivatives related to certain modified coinsurance agreements.  The income on our trading account securities is designed to substantially offset the change in value of embedded derivatives related to modified coinsurance agreements described below.

72

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Change in value of embedded derivatives related to modified coinsurance agreements is described in the note to our consolidated financial statements entitled “Accounting for Derivatives.” We have transferred the specific block of investments related to these agreements to our trading securities account, which we carry at estimated fair value with changes in such value recognized as trading account income. The change in the value of the embedded derivatives has largely been offset by the change in value of the trading securities.

Insurance policy benefits fluctuated as a result of the factors summarized below for benefit ratios.  Benefit ratios are calculated by dividing the related insurance product’s insurance policy benefits by insurance policy income.

The benefit ratios on Washington National’s Medicare supplement products have been impacted by increases in policyholder lapses following our premium rate increase actions. We establish active life reserves for these policies, which are in addition to amounts required for incurred claims. When policies lapse, active life reserves for such lapsed policies are released, resulting in decreased insurance policy benefits (although such decrease is substantially offset by additional amortization expense).  In addition, the insurance product liabilities we establish for our Medicare supplement business are subject to significant estimates and the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate.  Our insurance policy benefits reflected claim reserve redundancies from prior years of $1.2 million and nil in the first nine months of 2012 and 2011, respectively. Excluding the effects of prior year claim reserve redundancies, our benefit ratios for the Medicare supplement block would have been 66.9 percent and 69.1 percent in the first nine months of 2012 and 2011, respectively.  Government regulations generally require us to attain and maintain a ratio of total benefits incurred to total premiums earned (excluding changes in policy benefit reserves), after three years from the original issuance of the policy and over the lifetime of the policy, of not less than 65 percent on these products, as determined in accordance with statutory accounting principles.  Insurance margins (insurance policy income less insurance policy benefits) on these products were $10.7 million and $10.1 million in the third quarters of 2012 and 2011, respectively, and were $31.1 million and $32.2 million in the nine months ended September 30, 2012 and 2011, respectively.

Washington National’s supplemental health products (including specified disease, accident and hospital indemnity products) generally provide fixed or limited benefits.  For example, payments under cancer insurance policies are generally made directly to, or at the direction of, the policyholder following diagnosis of, or treatment for, a covered type of cancer. Approximately three-fourths of our supplemental health policies inforce (based on policy count) are sold with return of premium or cash value riders.  The return of premium rider generally provides that after a policy has been inforce for a specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy.  The cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned. Accordingly, the net cash flows from these products generally result in the accumulation of amounts in the early years of a policy (reflected in our earnings as reserve increases) which will be paid out as benefits in later policy years (reflected in our earnings as reserve decreases which offset the recording of benefit payments).  As the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by investment income earned on the accumulated assets. The benefit ratio will fluctuate depending on the claim experience during the year.  Insurance margins (insurance policy income less insurance policy benefits) on these products were $29.4 million and $19.0 million in the third quarters of 2012 and 2011, respectively, and were $75.0 million and $59.8 million in the nine months ended September 30, 2012 and 2011, respectively. The increase in margin in the 2012 periods is primarily related to higher insurance policy income and favorable claim experience. In addition, we recognized a $3.9 million out-of-period adjustment in the third quarter of 2011, which decreased the insurance margin on these products.

Amortization related to operations includes amortization of insurance acquisition costs.  Insurance acquisition costs are generally amortized in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits.  Such amounts were generally consistent with the related premium revenue.  A revision to our current assumptions could result in increases or decreases to amortization expense in future periods.

Interest expense on investment borrowings represents $.7 million and $.2 million of interest expense on collateralized borrowings in the three months ended September 30, 2012 and 2011, respectively, and $2.2 million and $.2 million in the nine months ended September 30, 2012 and 2011, respectively, as further described in the note to the consolidated financial statements entitled "Investment Borrowings".

73

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Other operating costs and expenses in the 2012 periods were comparable to the same periods in 2011.  Other operating costs and expenses include commission expense of $18.7 million and $17.4 million in the third quarters of 2012 and 2011, respectively, and $52.2 million and $50.1 million in the nine months ended September 30, 2012 and 2011, respectively.

Net realized investment gains (losses) fluctuate each period.  During the first nine months of 2012, net realized investment gains in this segment included $13.0 million of net gains from the sales of investments (primarily fixed maturities) and $9.4 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During the first nine months of 2011, net realized investment gains included $6.5 million of net gains from the sales of investments (primarily fixed maturities) and $5.9 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

Colonial Penn (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Premium collections:
Life	$	53.0		$	49.2		$	158.1		$	147.1
Supplemental health	1.2			1.4			3.7			4.4
Total collections	$	54.2		$	50.6		$	161.8		$	151.5
Average liabilities for insurance products:
Annuities-mortality based	$	76.4		$	77.3		$	76.7		$	77.9
Supplemental health	15.0			16.1			15.2			16.3
Life:
Interest sensitive	18.1			20.2			19.0			20.4
Non-interest sensitive	605.8			590.2			602.0			588.6
Total average liabilities for insurance products, net of reinsurance ceded	$	715.3		$	703.8		$	712.9		$	703.2
Revenues:
Insurance policy income	$	54.5		$	50.8		$	162.5		$	152.0
Net investment income:
General account invested assets	9.9			10.1			30.1			30.9
Fee revenue and other income	.2			.2			.6			.6
Total revenues	64.6			61.1			193.2			183.5
Expenses:
Insurance policy benefits	38.2			35.7			119.4			112.0
Amounts added to annuity and interest-sensitive life product account balances	.1			.3			.6			.7
Amortization related to operations	3.5			3.5			11.1			11.0
Other operating costs and expenses	25.4			22.9			73.9			66.3
Total benefits and expenses	67.2			62.4			205.0			190.0
Loss before net realized investment gains and income taxes	(2.6		)	(1.3		)	(11.8		)	(6.5		)
Net realized investment gains	2.6			3.5			7.1			4.8
Income (loss) before income taxes	$	—		$	2.2		$	(4.7	)	$	(1.7	)

This segment's results are significantly impacted by the adoption of the new accounting standard related to deferred acquisition costs. We are no longer able to defer most of Colonial Penn's direct response advertising costs although such costs generate predictable sales and future inforce profits. The amount of our investment in new business during a particular period will have a significant impact on this segment's results. Based on our current advertising plan, we expect this segment to report a modest level of earnings in the fourth quarter of 2012.

74

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Total premium collections increased by 7.1 percent, to $54.2 million, in the third quarter of 2012, as compared to the same period in 2011, and by 6.8 percent, to $161.8 million, in the first nine months of 2012, as compared to the same period in 2011.  See “Premium Collections” for further analysis of Colonial Penn’s premium collections.

Insurance policy income is comprised of premiums earned on policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies. The increase in such income reflects the growth in the block of business.

Net investment income on general account invested assets (which excludes income on policyholder and reinsurer accounts) was $9.9 million in the third quarter of 2012, down 2.0 percent from 2011, and was $30.1 million in the first nine months of 2012, down 2.6 percent from 2011.  The average balance of general account invested assets was $673.5 million and $679.5 million in the third quarters of 2012 and 2011, respectively.  The average yield on these assets was 5.90 percent and 5.93 percent in the third quarters of 2012 and 2011, respectively. The average balance of general account invested assets was $678.8 million and $680.5 million in the first nine months of 2012 and 2011, respectively.  The average yield on these assets was 5.92 percent and 6.06 percent in the first nine months of 2012 and 2011, respectively.

Insurance policy benefits increased in the 2012 periods due to growth in the segment.

Amortization related to operations includes amortization of insurance acquisition costs.  Insurance acquisition costs in the Colonial Penn segment are amortized in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits.  Such amounts were generally consistent with the related premium revenue and gross profits for such periods and the assumptions we made when we established the present value of future profits.  A revision to our current assumptions could result in increases or decreases to amortization expense in future periods.

Other operating costs and expenses increased in the 2012 periods primarily due to higher marketing expenses.

Net realized investment gains fluctuate each period.  During the first nine months of 2012, net realized investment gains in this segment included $7.7 million of net gains from the sales of investments (primarily fixed maturities) and $.6 million of writedowns of investments for other than temporary declines in fair value recognized through net income.  During the first nine months of 2011, net realized investment gains in this segment included $5.1 million of net gains from the sales of investments (primarily fixed maturities) and $.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

75

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Other CNO Business (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Premium collections:
Annuities	$	.9		$	3.3		$	3.0		$	13.4
Other health	6.1			6.7			19.5			21.5
Life	40.3			44.0			126.5			139.3
Total collections	$	47.3		$	54.0		$	149.0		$	174.2
Average liabilities for insurance products:
Annuities:
Mortality based	$	221.5		$	234.3		$	225.4		$	237.3
Fixed index	510.5			607.6			532.3			630.6
Deposit based	635.6			651.1			635.7			655.6
Separate accounts	15.6			16.4			15.6			17.3
Other health	479.6			481.3			480.1			481.7
Life:
Interest sensitive	2,329.1			2,484.6			2,370.6			2,506.0
Non-interest sensitive	782.1			780.6			770.6			792.3
Total average liabilities for insurance products, net of reinsurance ceded	$	4,974.0		$	5,255.9		$	5,030.3		$	5,320.8
Revenues:
Insurance policy income	$	71.8		$	72.2		$	224.4		$	216.2
Net investment income:
General account invested assets	82.3			85.4			250.3			261.2
Fixed index products	3.3			(8.4		)	6.0			(4.3		)
Trading account income related to policyholder accounts	1.1			(2.4		)	2.9			(.9		)
Total revenues	158.5			146.8			483.6			472.2
Expenses:
Insurance policy benefits	122.7			86.7			299.5			261.4
Amounts added to policyholder account balances:
Annuity products and interest-sensitive life products other than fixed index products	29.4			28.9			86.6			90.8
Fixed index products	5.0			(4.1		)	14.9			6.0
Amortization related to operations	10.5			10.4			25.1			28.4
Interest expense on investment borrowings	5.0			5.3			15.1			15.2
Other operating costs and expenses	39.5			16.8			96.4			55.1
Total benefits and expenses	212.1			144.0			537.6			456.9
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes	(53.6		)	2.8			(54.0		)	15.3
Net realized investment gains (losses)	(5.4		)	3.0			8.8			3.1
Amortization related to net realized investment gains (losses)	(.3		)	(.9		)	(1.9		)	(.2		)
Net realized investment gains (losses), net of related amortization	(5.7		)	2.1			6.9			2.9
Insurance policy benefits - fair value changes in embedded derivative liabilities	—			(3.2		)	(.4		)	(3.2		)
Amortization related to fair value changes in embedded derivative liabilities	—			2.6			.3			2.6
Fair value changes in embedded derivative liabilities, net of related amortization	—			(.6		)	(.1		)	(.6		)
Income (loss) before income taxes	$	(59.3	)	$	4.3		$	(47.2	)	$	17.6

76

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Health benefit ratios:
Long-term care:
Insurance policy benefits	$	17.5		$	15.7		$	47.5		$	47.4
Benefit ratio (a)	282.4		%	227.5		%	246.1		%	223.1		%
Interest-adjusted benefit ratio (b)	169.9		%	126.1		%	137.3		%	127.1		%

____________________

(a) We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.

(b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Other CNO Business long-term care products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income.  These are considered non-GAAP financial measures.  A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of “interest-adjusted benefit ratios” differ from “benefit ratios” due to the deduction of imputed interest income on the accumulated assets backing the insurance liabilities from the product’s insurance policy benefits used to determine the ratio.  Interest income is an important factor in measuring the performance of health products that are expected to be inforce for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time.  Actual interest income will vary from imputed interest income. The net cash flows from long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases).  Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by the imputed interest income earned on the accumulated assets.  The interest-adjusted benefit ratio reflects the effects of such interest income offset.  Since interest income is an important factor in measuring the performance of these products, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance.  We utilize the interest-adjusted benefit ratio in measuring segment performance because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business.  However, the “interest-adjusted benefit ratio” does not replace the “benefit ratio” as a measure of current period benefits to current period insurance policy income. Accordingly, management reviews both “benefit ratios” and “interest-adjusted benefit ratios” when analyzing the financial results attributable to these products.  The imputed investment income earned on the accumulated assets backing the long-term care reserves was $7.0 million and $7.0 million in the three months ended September 30, 2012 and 2011, respectively, and $21.0 million and $20.4 million in the nine months ended September 30, 2012 and 2011, respectively.

Total premium collections were$47.3 million in the third quarter of 2012, down 12 percent from 2011, and were$149.0 million in the first nine months of 2012, down 14 percent from 2011.  The decrease in collected premiums was primarily due to policyholder redemptions and lapses. See “Premium Collections” for further analysis.

Average liabilities for insurance products, net of reinsurance ceded were $5.0 billion in the third quarter of 2012, down 5.4 percent from 2011, and were $5.0 billion in the first nine months of 2012, down 5.5 percent from 2011.  The decrease in such liabilities was primarily due to policyholder redemptions and lapses.

Insurance policy income is comprised of policyholder charges on our interest-sensitive products and premiums earned on traditional insurance policies which provide mortality or morbidity coverage.  The increase in insurance policy income in the first nine months of 2012 is primarily due to increased policyholder charges from the implementation of changes to certain NGEs related to certain interest-sensitive life products; partially offset by lower premium revenue.

Net investment income on general account invested assets (which excludes income on policyholder and reinsurer accounts) was $82.3 million in the third quarter of 2012, down 3.6 percent from 2011, and was $250.3 million in the first nine months of 2012, down 4.2 percent from 2011.  The average balance of general account invested assets was $5.6 billion and $5.9 billion in the third quarters of 2012 and 2011, respectively.  The average yield on these assets was 5.91 percent and 5.82 percent in the third quarters of 2012 and 2011, respectively. The average balance of general account invested assets was $5.6 billion

77

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

and $5.9 billion in the first nine months of 2012 and 2011, respectively.  The average yield on these assets was 5.91 percent in both the first nine months of 2012 and 2011. Investing in higher yielding investments, slightly higher prepayment income and reduction to turnover rates to preserve higher yielding investments has resulted in maintaining (or slightly improving) overall yields in this segment when compared to the prior year. However, current market conditions are more challenging and we expect to see the overall yield decline in future periods.

Net investment income related to fixed index products represents the change in the estimated fair value of options which are purchased in an effort to offset or hedge certain potential benefits accruing to the policyholders of our fixed index products. Our fixed index products are designed so that the investment income spread earned on the related insurance liabilities is expected to be more than adequate to cover the cost of the options and other costs related to these policies.  Net investment income (loss) related to fixed index products was $3.3 million and $(8.4) million in the third quarters of 2012 and 2011, respectively, and was $6.0 million and $(4.1) million in the nine months ended September 30, 2012 and 2011, respectively. Such amounts were mostly offset by the corresponding charge (credit) to amounts added to policyholder account balances for fixed index products.  Such income and related charges fluctuate based on the value of options embedded in the segment’s fixed index annuity policyholder account balances subject to this benefit and to the performance of the index to which the returns on such products are linked. For periods prior to June 30, 2011, net investment income related to fixed index products also included income (loss) on trading securities which were held to offset the change in estimated fair values of embedded derivatives related to our fixed index products caused by interest rate fluctuations.  During the second quarter of 2011, we sold this trading portfolio and invested the proceeds in higher yielding investments. Such trading account income (loss) was nil and $(.2) million in the three and nine months ended September 30, 2011, respectively.  

Trading account income related to policyholder accounts represents the income on investments backing the market strategies of certain annuity products which provide for different rates of cash value growth based on the experience of a particular market strategy.  The income on our trading account securities is designed to substantially offset certain amounts included in insurance policy benefits related to the aforementioned annuity products.

Insurance policy benefitswere affected by a number of items as summarized below.

During the third quarters of 2012 and 2011, we were required to recognize approximately $43 million and $13 million, respectively, of additional increases to future loss reserves primarily resulting from decreased projected future investment yields related to interest-sensitive insurance products.

The long-term care policies in this segment generally provide for indemnity and non-indemnity benefits on a guaranteed renewable or non-cancellable basis.  The benefit ratio on our long-term care policies was 282.4 percent and 227.5 percent in the third quarters of 2012 and 2011, respectively, and was 246.1 percent and 223.1 percent in the nine months ended September 30, 2012 and 2011, respectively.  Benefit ratios are calculated by dividing the product’s insurance policy benefits by insurance policy income. Since the insurance product liabilities we establish for long-term care business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Our insurance policy benefits reflected reserve deficiencies from prior years of $8.6 million and $4.8 million in the first nine months of 2012 and 2011, respectively.  Excluding the effects of prior year claim reserve deficiencies, our benefit ratios would have been 201.6 percent and 200.6 percent in the first nine months of 2012 and 2011, respectively.  These ratios reflect the level of incurred claims experienced in recent periods, adverse development on claims incurred in prior periods and lower policy income. The prior period deficiencies have primarily resulted from the impact of paid claim experience being different than prior estimates.

The net cash flows from long-term care products generally cause an accumulation of amounts in the early years of a policy (reflected in our earnings as reserve increases) which will be paid out as benefits in later policy years (reflected in our earnings as reserve decreases which offset the recording of benefit payments).  Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by investment income earned on the assets which have accumulated.  The interest-adjusted benefit ratio for long-term care products is calculated by dividing the insurance product’s insurance policy benefits less interest income on the accumulated assets backing the insurance liabilities by insurance policy income.  The interest-adjusted benefit ratio on this business was 137.3 percent and 127.1 percent in the first nine months of 2012 and 2011, respectively.  Excluding the effects of prior year claim reserve deficiencies, our interest-adjusted benefit ratios would have been 92.8 percent and 104.5 percent in the first nine months of 2012 and 2011, respectively.

In each quarterly period, we calculate our best estimate of claim reserves based on all of the information available to us at that time, which necessarily takes into account new experience emerging during the period.  Our actuaries estimate these claim reserves using various generally recognized actuarial methodologies which are based on informed estimates and

78

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

judgments that are believed to be appropriate.  As additional experience emerges and other data become available, these estimates and judgments are reviewed and may be revised.  Significant assumptions made in estimating claim reserves for long-term care policies include expectations about the:  (i) future duration of existing claims; (ii) cost of care and benefit utilization; (iii) interest rate utilized to discount claim reserves; (iv) claims that have been incurred but not yet reported; (v) claim status on the reporting date; (vi) claims that have been closed but are expected to reopen; and (vii) correspondence that has been received that will ultimately become claims that have payments associated with them.

Amounts added to policyholder account balances for annuity products and interest-sensitive life products were $29.4 million in the third quarter of 2012, up 1.7 percent from 2011, and were $86.6 million in the first nine months of 2012, down 4.6 percent from 2011.  The decrease in the first nine months of 2012 was primarily due to a smaller block of interest-sensitive life business in force due to lapses in recent periods.  The weighted average crediting rates for these products was 3.9 percent in both the first nine months of 2012 and 2011.

Amounts added to fixed index products generally fluctuate with the corresponding related investment income accounts described above.

Amortization related to operations includes amortization of insurance acquisition costs.  Insurance acquisition costs are generally amortized either: (i) in relation to the estimated gross profits for universal life and investment-type products; or (ii) in relation to actual and expected premium revenue for other products.  In addition, for universal life and investment-type products, we are required to adjust the total amortization recorded to date through the statement of operations if actual experience or other evidence suggests that earlier estimates of future gross profits should be revised.  Accordingly, amortization for universal life and investment-type products is dependent on the profits realized during the period and on our expectation of future profits.  For other products, we amortize insurance acquisition costs in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes.  The assumptions we use to estimate our future gross profits and premiums involve significant judgment.  A revision to our current assumptions could result in increases or decreases to amortization expense in future periods.  Earnings on our universal life products, which comprise a significant part of this block, are subject to volatility since our insurance acquisition costs are equal to the value of future estimated gross profits. Accordingly, the impact of adverse changes in our earlier estimates of future gross profits is generally reflected in earnings in the period such differences occur.

Interest expense on investment borrowings includes $5.0 million and $5.2 million of interest expense on collateralized borrowings in the third quarters of 2012 and 2011, respectively, and $15.1 million in both the nine months ended September 30, 2012 and 2011, as further described in the note to the consolidated financial statements entitled “Investment Borrowings”.

Other operating costs and expenses were $39.5 million in the third quarter of 2012, up 135 percent from 2011, and were $96.4 million in the first nine months of 2012, up 75 percent from 2011. In the three and nine months ended September 30, 2012, we recognized charges of $21 million and $41.5 million, respectively, related to tentative settlements of pending litigation as more fully described in the note to the consolidated financial statements entitled "Litigation and Other Legal Proceedings - Cost of Insurance Litigation".

Net realized investment gains (losses) fluctuate each period.  During the first nine months of 2012, net realized investment gains in this segment included $24.2 million of net gains from the sales of investments (primarily fixed maturities) and $15.4 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During the first nine months of 2011, net realized investment gains included $14.4 million of net gains from the sales of investments (primarily fixed maturities) and $11.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

Amortization related to net realized investment losses is the increase or decrease in the amortization of insurance acquisition costs which results from realized investment gains or losses.  When we sell securities which back our universal life and investment-type products at a gain (loss) and reinvest the proceeds at a different yield (or when we have the intent to sell the impaired investments before an anticipated recovery in value occurs), we increase (reduce) the amortization of insurance acquisition costs in order to reflect the change in estimated gross profits due to the gains (losses) realized and the resulting effect on estimated future yields.  Sales of fixed maturity investments resulted in an increase in the amortization of insurance acquisition costs of $.3 million and $.9 million in the third quarters of 2012 and 2011, respectively, and $1.9 million and $.2 million in the nine months ended September 30, 2012 and 2011, respectively.

Insurance policy benefits - fair value changes in embedded derivative liabilities represents fair value changes due to fluctuations in the interest rates used to discount embedded derivative liabilities related to our fixed index annuities. Prior to

79

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

June 30, 2011, we held certain trading securities to offset the income statement volatility caused by the interest rate fluctuations. In the second quarter of 2011, we sold this trading portfolio.

Amortization related to fair value changes in embedded derivative liabilities is the increase or decrease in the amortization of insurance acquisition costs which results from changes in interest rates used to discount embedded derivative liabilities related to our fixed index annuities.

Corporate Operations (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Corporate operations:
Interest expense on corporate debt	$	(16.3	)	$	(18.7	)	$	(50.4	)	$	(58.6	)
Net investment income (loss):
General account invested assets	1.0			1.1			2.9			2.0
Other special-purpose portfolios:
COLI	3.1			(11.5		)	5.4			(10.6		)
Investments held in a rabbi trust	—			(.2		)	4.1			1.8
Investments in certain hedge funds	(.1		)	(3.1		)	(1.9		)	(3.1		)
Other trading account activities	5.2			1.1			15.7			6.3
Fee revenue and other income	.3			.3			.9			.9
Net operating results of variable interest entities	4.7			3.8			9.8			6.0
Interest expense on investment borrowings	(.1		)	(.1		)	(.4		)	(.1		)
Other operating costs and expenses	(20.8		)	(18.9		)	(54.1		)	(42.5		)
Loss before net realized investment gains, loss on extinguishment of debt and income taxes	(23.0		)	(46.2		)	(68.0		)	(97.9		)
Net realized investment gains (losses)	.8			(4.0		)	1.8			(1.2		)
Loss on extinguishment of debt	(198.5		)	(1.1		)	(199.2		)	(3.1		)
Loss before income taxes	$	(220.7	)	$	(51.3	)	$	(265.4	)	$	(102.2	)

Interest expense on corporate debt has been primarily impacted by:  (i) prepayments of our Previous Senior Secured Credit Agreement in 2011 and 2012 and the amendment in May 2011 which reduced the interest rate payable on the Previous Senior Secured Credit Agreement; and (ii) repayments of the Senior Health Note.  Such transactions are further discussed in the note to the consolidated financial statements entitled “Notes Payable - Direct Corporate Obligations”. Our average corporate debt outstanding was $840.1 million and $973.4 million during the first nine months of 2012 and 2011, respectively.  The average interest rate on our debt was 7.3 percent and 7.5 percent during the first nine months of 2012 and 2011, respectively.

Net investment income on general account invested assets fluctuates based on the amount and type of invested assets in the corporate operations segment.

Net investment income on other special-purpose portfolios includes the income (loss) from:  (i) investments related to deferred compensation plans held in a rabbi trust (which is offset by amounts included in other operating costs and expenses as the investment results are allocated to participants’ account balances); (ii) trading account activities which commenced in the first quarter of 2011; (iii) income (loss) from COLI equal to the difference between the return on these investments and our overall portfolio yield; and (iv) investments in certain hedge funds which commenced in the third quarter of 2011.  COLI is utilized as an investment vehicle to fund Bankers’ agent deferred compensation plan.  For segment reporting, the Bankers Life segment is allocated a return on these investments equivalent to the yield on the Company’s overall portfolio, with any difference in the actual COLI return allocated to Corporate Operations.

Net operating results of variable interest entities represents the operating results of VIEs.  The VIEs are consolidated in accordance with GAAP.  These entities were established to issue securities and use the proceeds to invest in loans and other permitted assets.  Refer to the note to the consolidated financial statements entitled “Investments in Variable Interest Entities” for more information on the VIEs.

80

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Interest expense on investment borrowings represents interest expense on repurchase agreements as further discussed in the note to the consolidated financial statements entitled "Investment Borrowings".

Other operating costs and expenses include general corporate expenses, net of amounts charged to subsidiaries for services provided by the corporate operations.  These amounts fluctuate as a result of expenses such as consulting and legal costs which often vary from period to period. In the third quarters of 2012 and 2011, we recognized charges of $9.7 million and $8.9 million, respectively, related to changes in the underlying actuarial assumptions used to value our agent deferred compensation plan and certain retirement benefits. In the first quarter of 2012, we recognized a $6.8 million charge related to the relocation of Bankers Life's primary office.

Net realized investment gains (losses) often fluctuate each period.  During the first nine months of 2012, net realized investment gains included $2.2 million of net gains from the sales of investments (of which, $.3 million were net gains recognized by VIEs) and $.4 million of writedowns of investments (all of which were recognized by VIEs) due to other than temporary declines in fair value recognized through net income.  During the first nine months of 2011, net realized investment gains included $2.3 million of net gains from the sales of investments (of which, $3.3 million were net gains recognized by VIEs) and $3.5 million of writedowns of investments (all of which were recognized by VIEs) due to other than temporary declines in fair value recognized through net income.

Loss on extinguishment of debt in the first nine months of 2012 of $199.2 million represents: (i) $136.3 million (all of which was recognized in the third quarter of 2012) due to our repurchase of $200.0 million principal amount of 7.0% Debentures pursuant to the Debenture Repurchase Agreement and the write-off of unamortized discount and issuance costs associated with the 7.0% Debentures; (ii) $57.8 million (all of which was recognized in the third quarter of 2012) related to the tender offer and consent solicitation for the 9.0% Notes, the write-off of unamortized issuance costs related to the 9.0% Notes and other transactions; and (iii) $5.1 million ($4.4 million of which was recognized in the third quarter of 2012) representing the write-off of unamortized discount and issuance costs associated with repayments of our Previous Senior Secured Credit Agreement. Such transactions are further discussed in the note to the consolidated financial statements entitled “Notes Payable – Direct Corporate Obligations.” The loss on extinguishment of debt in the 2011 periods represents the write-off of unamortized discount and issuance costs associated with the prepayment of $105.7 million outstanding principal balance under the Previous Senior Secured Credit Agreement.

81

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

EBIT from Business Segments Summarized by In-Force and New Business

Management believes that an analysis of EBIT, separated between in-force and new business provides increased clarity around the value drivers of our business, particularly since the new business results are significantly impacted by the rate of sales, mix of business and the distribution channel through which new sales are made. EBIT from new business includes pre-tax revenues and expenses associated with new sales of our insurance products during the first year after the sale is completed. EBIT from in-force business includes all pre-tax revenues and expenses associated with sales of insurance products that were completed more than one year before the end of the reporting period. The allocation of certain revenues and expenses between new and in-force business is based on estimates, which we believe are reasonable.

The following summarizes our earnings, separated between in-force and new business on a consolidated basis and for each of our operating segments for the three and nine months ended September 30, 2012 and 2011:

Business segments - total (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
EBIT from In-Force Business
Revenues:
Insurance policy income	$	594.4		$	585.3		$	1,793.1		$	1,763.6
Net investment income and other	360.7			286.5			1,063.2			972.3
Total revenues	955.1			871.8			2,856.3			2,735.9
Benefits and expenses:
Insurance policy benefits	671.3			569.4			1,918.3			1,820.5
Amortization	54.1			55.5			191.8			202.7
Other expenses	125.3			98.5			363.0			296.3
Total benefits and expenses	850.7			723.4			2,473.1			2,319.5
EBIT from In-Force Business	$	104.4		$	148.4		$	383.2		$	416.4
EBIT from New Business
Revenues:
Insurance policy income	$	95.8		$	88.2		$	278.2		$	256.7
Net investment income and other	12.9			7.7			31.7			30.1
Total revenues	108.7			95.9			309.9			286.8
Benefits and expenses:
Insurance policy benefits	69.8			57.7			195.4			174.2
Amortization	6.7			13.3			22.1			31.8
Other expenses	78.3			71.2			221.7			207.4
Total benefits and expenses	154.8			142.2			439.2			413.4
EBIT from New Business	$	(46.1	)	$	(46.3	)	$	(129.3	)	$	(126.6	)
EBIT from In-Force and New Business
Revenues:
Insurance policy income	$	690.2		$	673.5		$	2,071.3		$	2,020.3
Net investment income and other	373.6			294.2			1,094.9			1,002.4
Total revenues	1,063.8			967.7			3,166.2			3,022.7
Benefits and expenses:
Insurance policy benefits	741.1			627.1			2,113.7			1,994.7
Amortization	60.8			68.8			213.9			234.5
Other expenses	203.6			169.7			584.7			503.7
Total benefits and expenses	1,005.5			865.6			2,912.3			2,732.9
EBIT from In-Force and New Business	$	58.3		$	102.1		$	253.9		$	289.8

82

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Bankers Life (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
EBIT from In-Force Business
Revenues:
Insurance policy income	$	345.7		$	339.0		$	1,039.1		$	1,024.1
Net investment income and other	212.7			153.9			620.6			543.6
Total revenues	558.4			492.9			1,659.7			1,567.7
Benefits and expenses:
Insurance policy benefits	377.0			313.7			1,093.1			1,031.9
Amortization	29.9			31.6			123.6			130.2
Other expenses	41.4			36.0			133.2			108.7
Total benefits and expenses	448.3			381.3			1,349.9			1,270.8
EBIT from In-Force Business	$	110.1		$	111.6		$	309.8		$	296.9
EBIT from New Business
Revenues:
Insurance policy income	$	70.4		$	65.6		$	202.5		$	190.1
Net investment income and other	12.9			7.7			31.7			30.1
Total revenues	83.3			73.3			234.2			220.2
Benefits and expenses:
Insurance policy benefits	57.6			46.9			159.1			142.4
Amortization	5.7			12.5			19.4			29.3
Other expenses	49.5			46.1			138.3			131.7
Total benefits and expenses	112.8			105.5			316.8			303.4
EBIT from New Business	$	(29.5	)	$	(32.2	)	$	(82.6	)	$	(83.2	)
EBIT from In-Force and New Business
Revenues:
Insurance policy income	$	416.1		$	404.6		$	1,241.6		$	1,214.2
Net investment income and other	225.6			161.6			652.3			573.7
Total revenues	641.7			566.2			1,893.9			1,787.9
Benefits and expenses:
Insurance policy benefits	434.6			360.6			1,252.2			1,174.3
Amortization	35.6			44.1			143.0			159.5
Other expenses	90.9			82.1			271.5			240.4
Total benefits and expenses	561.1			486.8			1,666.7			1,574.2
EBIT from In-Force and New Business	$	80.6		$	79.4		$	227.2		$	213.7

83

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Washington National (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
EBIT from In-Force Business
Revenues:
Insurance policy income	$	133.4		$	132.1		$	399.2		$	397.5
Net investment income and other	51.2			47.7			152.7			141.2
Total revenues	184.6			179.8			551.9			538.7
Benefits and expenses:
Insurance policy benefits	105.2			113.3			322.6			332.8
Amortization	10.5			10.2			32.5			33.5
Other expenses	32.6			33.9			98.9			97.9
Total benefits and expenses	148.3			157.4			454.0			464.2
EBIT from In-Force Business	$	36.3		$	22.4		$	97.9		$	74.5
EBIT from New Business
Revenues:
Insurance policy income	$	14.4		$	13.8		$	43.6		$	40.4
Net investment income and other	—			—			—			—
Total revenues	14.4			13.8			43.6			40.4
Benefits and expenses:
Insurance policy benefits	5.9			5.7			17.9			16.7
Amortization	.7			.6			2.2			2.1
Other expenses	10.2			8.7			28.9			28.8
Total benefits and expenses	16.8			15.0			49.0			47.6
EBIT from New Business	$	(2.4	)	$	(1.2	)	$	(5.4	)	$	(7.2	)
EBIT from In-Force and New Business
Revenues:
Insurance policy income	$	147.8		$	145.9		$	442.8		$	437.9
Net investment income and other	51.2			47.7			152.7			141.2
Total revenues	199.0			193.6			595.5			579.1
Benefits and expenses:
Insurance policy benefits	111.1			119.0			340.5			349.5
Amortization	11.2			10.8			34.7			35.6
Other expenses	42.8			42.6			127.8			126.7
Total benefits and expenses	165.1			172.4			503.0			511.8
EBIT from In-Force and New Business	$	33.9		$	21.2		$	92.5		$	67.3

84

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Colonial Penn (dollars in millions)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
EBIT from In-Force Business
Revenues:
Insurance policy income	$	43.5		$	42.0		$	130.4		$	125.8
Net investment income and other	10.1			10.3			30.7			31.5
Total revenues	53.6			52.3			161.1			157.3
Benefits and expenses:
Insurance policy benefits	32.0			30.9			101.6			97.6
Amortization	3.2			3.3			10.6			10.6
Other expenses	6.8			6.5			19.4			19.4
Total benefits and expenses	42.0			40.7			131.6			127.6
EBIT from In-Force Business	$	11.6		$	11.6		$	29.5		$	29.7
EBIT from New Business
Revenues:
Insurance policy income	$	11.0		$	8.8		$	32.1		$	26.2
Net investment income and other	—			—			—			—
Total revenues	11.0			8.8			32.1			26.2
Benefits and expenses:
Insurance policy benefits	6.3			5.1			18.4			15.1
Amortization	.3			.2			.5			.4
Other expenses	18.6			16.4			54.5			46.9
Total benefits and expenses	25.2			21.7			73.4			62.4
EBIT from New Business	$	(14.2	)	$	(12.9	)	$	(41.3	)	$	(36.2	)
EBIT from In-Force and New Business
Revenues:
Insurance policy income	$	54.5		$	50.8		$	162.5		$	152.0
Net investment income and other	10.1			10.3			30.7			31.5
Total revenues	64.6			61.1			193.2			183.5
Benefits and expenses:
Insurance policy benefits	38.3			36.0			120.0			112.7
Amortization	3.5			3.5			11.1			11.0
Other expenses	25.4			22.9			73.9			66.3
Total benefits and expenses	67.2			62.4			205.0			190.0
EBIT from In-Force and New Business	$	(2.6	)	$	(1.3	)	$	(11.8	)	$	(6.5	)

85

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Other CNO Business (dollars in millions)

	Three months ended					Nine months ended
	September 30,					September 30,
	2012			2011		2012			2011
EBIT from In-Force Business (a)
Revenues:
Insurance policy income	$	71.8		$	72.2	$	224.4		$	216.2
Net investment income and other	86.7			74.6		259.2			256.0
Total revenues	158.5			146.8		483.6			472.2
Benefits and expenses:
Insurance policy benefits	157.1			111.5		401.0			358.2
Amortization	10.5			10.4		25.1			28.4
Other expenses	44.5			22.1		111.5			70.3
Total benefits and expenses	212.1			144.0		537.6			456.9
EBIT from In-Force Business	$	(53.6	)	$	2.8	$	(54.0	)	$	15.3

_________________________

(a) All activity in the Other CNO Business segment relates to in-force business.

The above analysis of EBIT, separated between in-force and new business, illustrates how our segments are impacted by the rate of sales, mix of business and distribution channel through which new sales are made. In addition, when the impacts from new business are separated, the value drivers of our in-force business are more apparent.

The EBIT from in-force business in the Bankers Life segment grew in the first nine months of 2012 primarily due to the growth in this segment's in-force block reflecting prior period sales and improved persistency. Other expenses include a $10 million settlement with state regulators in the first quarter of 2012. EBIT from in-force business in the three months ended September 30, 2012 was comparable to the prior year. The increased earnings from the growth in this segment's in-force block was offset by higher incurred claims on life and long-term care policies.

The EBIT from in-force business in the Washington National segment grew in the 2012 periods primarily due to higher investment income on higher average balance of general account assets from the FHLB investment borrowing program that commenced in June 2011.

The EBIT from new business in the Colonial Penn segment in the 2012 periods reflects additional marketing costs. The vast majority of the costs to generate new business in this segment are not deferrable and EBIT will fluctuate based on management's decisions on how much marketing costs to incur in each period.

We are not investing in new business in the Other CNO Business segment.

86

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

PREMIUM COLLECTIONS

In accordance with GAAP, insurance policy income in our consolidated statement of operations consists of premiums earned for traditional insurance policies that have life contingencies or morbidity features.  For annuity and universal life contracts, premiums collected are not reported as revenues, but as deposits to insurance liabilities.  We recognize revenues for these products over time in the form of investment income and surrender or other charges.

Our insurance segments sell products through three primary distribution channels — career agents (our Bankers Life segment), direct marketing (our Colonial Penn segment) and independent producers (our Washington National segment).  Our career agency force in the Bankers Life segment sells primarily Medicare supplement and long-term care insurance policies, PDP contracts, life insurance and annuities.  These agents visit the customer’s home, which permits one-on-one contact with potential policyholders and promotes strong personal relationships with existing policyholders.  Our direct marketing distribution channel in the Colonial Penn segment is engaged primarily in the sale of graded benefit life and simplified issue life insurance policies which are sold directly to the policyholder.  Our Washington National segment sells primarily supplemental health and life insurance.  These products are marketed through PMA, a subsidiary that specializes in marketing and distributing health products, and through independent marketing organizations and insurance agencies, including worksite marketing.

Agents, insurance brokers and marketing companies who market our products and prospective purchasers of our products use the financial strength ratings of our insurance subsidiaries as an important factor in determining whether to market or purchase.  Ratings have the most impact on our annuity, interest-sensitive life insurance and long-term care products.  The current financial strength ratings of our primary insurance subsidiaries (except Conseco Life) from A.M. Best, S&P, Moody’s and Fitch Ratings (“Fitch”) are “B++”, “BB+”, “Baa3” and “BBB”, respectively.  The current financial strength ratings of Conseco Life from A.M. Best, S&P, Moody's and Fitch are “B-”, “B+”, “Ba1” and  “BB+”, respectively.  For a description of these ratings and additional information on our ratings, see “Financial Strength Ratings of our Insurance Subsidiaries.”

We set premium rates on our health insurance policies based on facts and circumstances known at the time we issue the policies using assumptions about numerous variables, including the actuarial probability of a policyholder incurring a claim, the probable size of the claim, and the interest rate earned on our investment of premiums.  We also consider historical claims information, industry statistics, the rates of our competitors and other factors.  If our actual claims experience is less favorable than we anticipated and we are unable to raise our premium rates, our financial results may be adversely affected.  We generally cannot raise our health insurance premiums in any state until we obtain the approval of the state insurance regulator.  We review the adequacy of our premium rates regularly and file for rate increases on our products when we believe such rates are too low.  It is likely that we will not be able to obtain approval for all requested premium rate increases.  If such requests are denied in one or more states, our net income may decrease.  If such requests are approved, increased premium rates may reduce the volume of our new sales and may cause existing policyholders to lapse their policies.  If the healthier policyholders allow their policies to lapse, this would reduce our premium income and profitability in the future.

87

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Total premium collections by segment were as follows:

Bankers Life (dollars in millions)

	Three months ended				Nine months ended
	September 30,				September 30,
	2012		2011		2012		2011
Premiums collected by product:
Annuities:
Fixed index (first-year)	$	114.5	$	208.0	$	369.6	$	520.1
Other fixed rate (first-year)	56.0		55.1		151.7		222.3
Other fixed rate (renewal)	1.2		1.0		4.6		3.0
Subtotal - other fixed rate annuities	57.2		56.1		156.3		225.3
Total annuities	171.7		264.1		525.9		745.4
Health:
Medicare supplement (first-year)	24.7		24.5		73.6		74.3
Medicare supplement (renewal)	153.0		146.8		453.9		444.8
Subtotal - Medicare supplement	177.7		171.3		527.5		519.1
Long-term care (first-year)	6.0		5.9		17.4		18.0
Long-term care (renewal)	130.1		131.9		394.2		407.6
Subtotal - long-term care	136.1		137.8		411.6		425.6
PDP and PFFS (first year)	.1		.6		.5		1.2
PDP and PFFS (renewal)	10.2		15.6		39.8		40.6
Subtotal – PDP and PFFS	10.3		16.2		40.3		41.8
Other health (first-year)	.9		.4		1.9		1.1
Other health (renewal)	2.3		2.3		6.8		7.1
Subtotal - other health	3.2		2.7		8.7		8.2
Total health	327.3		328.0		988.1		994.7
Life insurance:
First-year	38.9		30.9		107.4		85.0
Renewal	42.4		34.6		119.4		98.9
Total life insurance	81.3		65.5		226.8		183.9
Collections on insurance products:
Total first-year premium collections on insurance products	241.1		325.4		722.1		922.0
Total renewal premium collections on insurance products	339.2		332.2		1,018.7		1,002.0
Total collections on insurance products	$	580.3	$	657.6	$	1,740.8	$	1,924.0

Annuities in this segment include fixed index and other fixed rate annuities sold to the senior market.  Annuity collections in this segment decreased 35 percent, to $171.7 million, in the third quarter of 2012, and 29 percent, to $525.9 million, in the first nine months of 2012, as compared to the same periods in 2011.  Premium collections from our fixed index products have fluctuated due to volatility in the financial markets in recent periods. In addition, premium collections from Bankers Life's fixed annuity products have decreased in recent periods as low new money interest rates negatively impacted our sales and the overall sales in the fixed annuity market.

Health products include Medicare supplement, PDP contracts, long-term care and other insurance products. Our profits on health policies depend on the overall level of sales, the length of time the business remains inforce, investment yields, claims experience and expense management.

88

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Collected premiums on Medicare supplement policies in the Bankers Life segment increased 3.7 percent, to $177.7 million, in the third quarter of 2012, and 1.6 percent, to $527.5 million, in the first nine months of 2012, as compared to the same periods in the prior year.

Premiums collected on Bankers Life’s long-term care policies decreased 1.2 percent, to $136.1 million, in the third quarter of 2012, and 3.3 percent, to $411.6 million, in the first nine months of 2012, as compared to the same periods in 2011.  The decrease was primarily attributable to higher lapses following premium rate increases in recent periods.

Premiums collected on PDP and PFFS business relate to our quota-share reinsurance agreements with Coventry. Premiums collected on PFFS business were nil and $3.6 million in the three and nine months ended September 30, 2011, respectively. The PFFS premiums recognized in 2011 relate to adjustments to prior year contracts based on audits conducted by the Centers for Medicare and Medicaid Services, an agency of the United States government which, among other things, administers the Medicare program. Such audits can result in positive or negative adjustments to premium revenue in the period the results of the audits are reported to us.

Life products in this segment include traditional and interest-sensitive life products.  Life premiums collected in this segment increased 24 percent, to $81.3 million, in the third quarter of 2012, and 23 percent, to $226.8 million, in the first nine months of 2012, as compared to the same periods in 2011, reflecting higher sales in this segment (including increased sales of single premium whole life products).

Washington National (dollars in millions)

	Three months ended				Nine months ended
	September 30,				September 30,
	2012		2011		2012		2011
Premiums collected by product:
Health:
Medicare supplement (first-year)	$	.2	$	.4	$	.8	$	1.5
Medicare supplement (renewal)	28.2		31.5		84.8		98.8
Subtotal - Medicare supplement	28.4		31.9		85.6		100.3
Supplemental health (first-year)	14.7		13.2		43.9		40.1
Supplemental health (renewal)	99.8		95.2		298.9		284.1
Subtotal – supplemental health	114.5		108.4		342.8		324.2
Other health (all renewal)	.7		.9		2.0		2.7
Total health	143.6		141.2		430.4		427.2
Life insurance:
First-year	.3		.4		.8		1.1
Renewal	2.7		3.7		10.0		11.2
Total life insurance	3.0		4.1		10.8		12.3
Collections on insurance products:
Total first-year premium collections on insurance products	15.2		14.0		45.5		42.7
Total renewal premium collections on insurance products	131.4		131.3		395.7		396.8
Total collections on insurance products	$	146.6	$	145.3	$	441.2	$	439.5

Health products in the Washington National segment include Medicare supplement, supplemental health and other insurance products.  Our profits on health policies depend on the overall level of sales, the length of time the business remains inforce, investment yields, claim experience and expense management.

Collected premiums on Medicare supplement policies in the Washington National segment decreased 11 percent, to $28.4 million, in the third quarter of 2012, and 15 percent, to $85.6 million, in the first nine months of 2012, as compared to the same periods in 2011.  We have experienced lower sales of these products as we have increased our focus on supplemental health products in recent periods.

89

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Premiums collected on supplemental health products (including specified disease, accident and hospital indemnity insurance products) increased 5.6 percent, to $114.5 million, in the third quarter of 2012, and 5.7 percent, to $342.8 million, in the first nine months of 2012, as compared to the same periods in 2011.  Such increases are due to higher new sales in recent periods.

Life products in the Washington National segment are primarily traditional life products.  Life premiums collected in this segment have declined in recent periods.

Colonial Penn (dollars in millions)

	Three months ended				Nine months ended
	September 30,				September 30,
	2012		2011		2012		2011
Premiums collected by product:
Life insurance:
First-year	$	10.9	$	8.9	$	32.0	$	26.2
Renewal	42.1		40.3		126.1		120.9
Total life insurance	53.0		49.2		158.1		147.1
Health (all renewal):
Medicare supplement	1.1		1.3		3.4		4.0
Other health	.1		.1		.3		.4
Total health	1.2		1.4		3.7		4.4
Collections on insurance products:
Total first-year premium collections on insurance products	10.9		8.9		32.0		26.2
Total renewal premium collections on insurance products	43.3		41.7		129.8		125.3
Total collections on insurance products	$	54.2	$	50.6	$	161.8	$	151.5

Life products in this segment are primarily graded benefit and simplified issue life insurance products.  Life premiums collected in this segment increased 7.7 percent, to $53.0 million, in the third quarter of 2012, and 7.5 percent, to $158.1 million, in the first nine months of 2012, as compared to the same periods in 2011.  Graded benefit life products sold through our direct response marketing channel accounted for $52.4 million and $48.5 million of our total collected premiums in the third quarters of 2012 and 2011, respectively, and $156.0 million and $144.7 million in the first nine months of 2012 and 2011, respectively.

Health products include Medicare supplement and other insurance products.  Our profits on health policies depend on the overall level of sales, the length of time the business remains inforce, investment yields, claims experience and expense management. Premiums collected on these products have decreased as we do not currently market these products through this segment.

90

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Other CNO Business (dollars in millions)

	Three months ended				Nine months ended
	September 30,				September 30,
	2012		2011		2012		2011
Premiums collected by product:
Annuities:
Fixed index (first-year)	$	.1	$	2.2	$	.3	$	7.6
Fixed index (renewal)	.4		.8		1.9		3.1
Subtotal - fixed index annuities	.5		3.0		2.2		10.7
Other fixed rate (first-year)	—		.1		—		2.1
Other fixed rate (renewal)	.4		.2		.8		.6
Subtotal - other fixed rate annuities	.4		.3		.8		2.7
Total annuities	.9		3.3		3.0		13.4
Health:
Long-term care (all renewal)	6.0		6.5		19.0		20.9
Other health (all renewal)	.1		.2		.5		.6
Total health	6.1		6.7		19.5		21.5
Life insurance:
First-year	.9		.3		2.3		1.6
Renewal	39.4		43.7		124.2		137.7
Total life insurance	40.3		44.0		126.5		139.3
Collections on insurance products:
Total first-year premium collections on insurance products	1.0		2.6		2.6		11.3
Total renewal premium collections on insurance products	46.3		51.4		146.4		162.9
Total collections on insurance products	$	47.3	$	54.0	$	149.0	$	174.2

Annuities in this segment include fixed index and other fixed annuities.  We are no longer actively pursuing sales of annuity products in this segment.  

Health products in the Other CNO Business segment include long-term care and other health insurance products.  Our profits on health policies depend on the length of time the business remains inforce, investment yields, claim experience and expense management.

The long-term care premiums in this segment relate to blocks of business that we no longer market or underwrite.  As a result, we expect this segment’s long-term care premiums to continue to decline, reflecting additional policy lapses in the future.

Life products in the Other CNO Business segment include primarily universal life products.  Life premiums collected in this segment decreased 8.4 percent, to $40.3 million, in the third quarter of 2012, and 9.2 percent, to $126.5 million, in the first nine months of 2012, as compared to the same periods in 2011. We are not actively marketing life products in this segment and expect premiums to continue to decline.

91

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

LIQUIDITY AND CAPITAL RESOURCES

Our capital structure as of September 30, 2012, and December 31, 2011, was as follows (dollars in millions):

	September 30, 2012			December 31, 2011
	(Restated)
Total capital:
Corporate notes payable	$	1,035.1		$	857.9
Shareholders’ equity:
Common stock	2.3			2.4
Additional paid-in capital	4,251.2			4,361.9
Accumulated other comprehensive income	1,234.4			781.6
Accumulated deficit	(421.7		)	(532.1		)
Total shareholders’ equity	5,066.2			4,613.8
Total capital	$	6,101.3		$	5,471.7

The following table summarizes certain financial ratios as of and for the nine months ended September 30, 2012, and as of and for the year ended December 31, 2011:

	September 30, 2012			December 31, 2011
Book value per common share (Restated)	$	22.07		$	19.12
Book value per common share, excluding accumulated other comprehensive income (a)	16.70			15.88
Ratio of earnings to fixed charges	1.13X			1.75X
Debt to total capital ratios:
Corporate debt to total capital (Restated)	17.0		%	15.7		%
Corporate debt to total capital, excluding accumulated other comprehensive income (a)	21.3		%	18.3		%

____________________

(a) This non-GAAP measure differs from the corresponding GAAP measure presented immediately above, because accumulated other comprehensive income has been excluded from the value of capital used to determine this measure.  Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income.  Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management.  However, this measure does not replace the corresponding GAAP measure.

Liquidity for Insurance Operations

Our insurance companies generally receive adequate cash flows from premium collections and investment income to meet their obligations.  Life insurance, long-term care insurance and annuity liabilities are generally long-term in nature.  Life and annuity policyholders may, however, withdraw funds or surrender their policies, subject to any applicable penalty provisions; there are generally no withdrawal or surrender benefits for long-term care insurance.  We seek to balance the duration of our invested assets with the estimated duration of benefit payments arising from contract liabilities.

Three of the Company’s insurance subsidiaries (Conseco Life, Washington National Insurance Company and Bankers Life) are members of the FHLB.  As members of the FHLB, Conseco Life, Washington National Insurance Company and Bankers Life have the ability to borrow on a collateralized basis from the FHLB.  Conseco Life, Washington National Insurance Company and Bankers Life are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings.  At September 30, 2012, the carrying value of the FHLB common stock was $82.5 million.  As of September 30, 2012, collateralized borrowings from the

92

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

FHLB totaled $1.7 billion and the proceeds were used to purchase fixed maturity securities.  The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.  The borrowings are collateralized by investments with an estimated fair value of $2.0 billion at September 30, 2012, which are maintained in a custodial account for the benefit of the FHLB. The following summarizes the terms of the borrowings (dollars in millions):

Amount		Maturity	Interest rate at
borrowed		date	September 30, 2012
$	100.0	November 2013	Variable rate – 0.515%
67.0		February 2014	Fixed rate – 1.830%
50.0		August 2014	Variable rate – 0.565%
100.0		August 2014	Variable rate – 0.476%
50.0		September 2015	Variable rate – 0.747%
150.0		October 2015	Variable rate – 0.571%
146.0		November 2015	Fixed rate – 5.300%
100.0		December 2015	Fixed rate – 4.710%
100.0		June 2016	Variable rate – 0.657%
75.0		June 2016	Variable rate – 0.621%
100.0		October 2016	Variable rate – 0.641%
50.0		November 2016	Variable rate – 0.684%
50.0		November 2016	Variable rate – 0.687%
100.0		June 2017	Variable rate – 0.751%
100.0		July 2017	Fixed rate – 3.900%
50.0		August 2017	Variable rate – 0.635%
75.0		August 2017	Variable rate – 0.577%
100.0		October 2017	Variable rate – 0.885%
37.0		November 2017	Fixed rate – 3.750%
50.0		July 2018	Variable rate – 0.917%
$	1,650.0

State laws generally give state insurance regulatory agencies broad authority to protect policyholders in their jurisdictions. Regulators have used this authority in the past to restrict the ability of our insurance subsidiaries to pay any dividends or other amounts without prior approval.  We cannot be assured that the regulators will not seek to assert greater supervision and control over our insurance subsidiaries’ businesses and financial affairs.

Financial Strength Ratings of our Insurance Subsidiaries

Financial strength ratings provided by A.M. Best, S&P, Moody’s and Fitch are the rating agency’s opinions of the ability of our insurance subsidiaries to pay policyholder claims and obligations when due.

On September 4, 2012, A.M. Best upgraded the financial strength ratings of our primary insurance subsidiaries, except Conseco Life, to “B++” from “B+”.  A.M. Best also affirmed the financial strength rating of “B-” of Conseco Life. The outlook for all ratings is stable. A “stable” designation means that there is a low likelihood of a rating change due to stable financial market trends.  The “B++” rating is assigned to companies that have a good ability, in A.M. Best’s opinion, to meet their ongoing obligations to policyholders.  A “B-” rating is assigned to companies that have a fair ability, in A.M. Best’s opinion, to meet their current obligations to policyholders, but are financially vulnerable to adverse changes in underwriting and economic conditions.  A.M. Best ratings for the industry currently range from “A++ (Superior)” to “F (In Liquidation)” and some companies are not rated.  An “A++” rating indicates a superior ability to meet ongoing obligations to policyholders.  A.M. Best has sixteen possible ratings.  There are four ratings above the “B++” rating of our primary insurance subsidiaries, other than Conseco Life, and eleven ratings that are below that rating.  There are seven ratings above the “B-” rating of Conseco Life and eight ratings that are below that rating.

93

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

On August 3, 2012, S&P affirmed the financial strength ratings of "BB+" of our primary insurance subsidiaries, except Conseco Life, and revised the outlook for such ratings to positive from stable. S&P also downgraded the financial strength rating of Conseco Life to "B+" from "BB+" and the outlook for such rating is stable. On August 4, 2011, S&P upgraded the financial strength ratings of our primary insurance subsidiaries to “BB+” from “BB”. A "positive" outlook means that a rating may be raised. A “stable” outlook means that a rating is not likely to change.  S&P financial strength ratings range from “AAA” to “R” and some companies are not rated.  An insurer rated “BB” or lower is regarded as having vulnerable characteristics that may outweigh its strengths.  A “BB” rating indicates the least degree of vulnerability within the range; a “CC” rating indicates the highest degree of vulnerability.  Pluses and minuses show the relative standing within a category.  In S&P’s view, an insurer rated “BB” has marginal financial security characteristics and although positive attributes exist, adverse business conditions could lead to an insufficient ability to meet financial commitments.  In S&P's view, an insurer rated "B" has weak financial security characteristics and adverse business conditions will likely impair its ability to meet financial commitments. S&P has twenty-one possible ratings.  There are ten ratings above the “BB+” rating of our primary insurance subsidiaries, other than Conseco Life, and ten ratings that are below that rating. There are thirteen ratings above the "B+" rating of Conseco Life and seven ratings that are below that rating.

On August 29, 2012, Moody's upgraded the financial strength ratings of our primary insurance subsidiaries, except Conseco Life, to "Baa3" from "Ba1". Moody's also affirmed the financial strength rating of "Ba1" of Conseco Life. The outlook for all ratings is stable. A “stable” designation means that a rating is not likely to change.  Moody’s financial strength ratings range from “Aaa” to “C”.  These ratings may be supplemented with numbers “1”, “2”, or “3” to show relative standing within a category.  In Moody's view, an insurer rated "Baa" offers adequate financial security, however, certain protective elements may be lacking or may be characteristically unreliable over any great length of time. In Moody’s view, an insurer rated “Ba” offers questionable financial security and, often, the ability of these companies to meet policyholders’ obligations may be very moderate and thereby not well safeguarded in the future. Moody’s has twenty-one possible ratings.  There are nine ratings above the “Baa3” rating of our primary insurance subsidiaries, other than Conseco Life, and eleven ratings that are below the rating. There are ten ratings above the "Ba1" rating of Conseco Life and ten ratings that are below that rating.

On September 5, 2012, Fitch affirmed the financial strength ratings of "BBB" of our primary insurance subsidiaries as well as the "BB+" rating of Conseco Life and the outlook for all of these ratings is stable. On February 3, 2012, Fitch upgraded the financial strength ratings of our primary insurance subsidiaries, except Conseco Life, to “BBB” (from “BBB-” or “BB+” depending on the company). Fitch also affirmed the financial strength rating of “BB+” of Conseco Life. A “BBB” rating, in Fitch's opinion, indicates that there is currently a low expectation of ceased or interrupted payments. The capacity to meet policyholder and contract obligations on a timely basis is considered adequate, but adverse changes in circumstances and economic conditions are more likely to impact this capacity. A “BB” rating, in Fitch's opinion, indicates that there is an elevated vulnerability to ceased or interrupted payments, particularly as the result of adverse economic or market changes over time. However, business or financial alternatives may be available to allow for policyholder and contract obligations to be met in a timely manner. Fitch ratings for the industry range from “AAA Exceptionally Strong” to “C Distressed” and some companies are not rated. Pluses and minuses show the relative standing within a category. Fitch has nineteen possible ratings. There are eight ratings above the “BBB" rating of our primary insurance subsidiaries, other than Conseco Life, and ten ratings that are below that rating. There are ten ratings above the “BB+” rating of Conseco Life and eight ratings that are below that rating.

In light of the difficulties experienced recently by many financial institutions, including insurance companies, rating agencies have increased the frequency and scope of their credit reviews and requested additional information from the companies that they rate, including us.  They may also adjust upward the capital and other requirements employed in the rating agency models for maintenance of certain ratings levels.  We cannot predict what actions rating agencies may take, or what actions we may take in response.  Accordingly, downgrades and outlook revisions related to us or the life insurance industry may occur in the future at any time and without notice by any rating agency.  These could increase policy surrenders and withdrawals, adversely affect relationships with our distribution channels, reduce new sales, reduce our ability to borrow and increase our future borrowing costs.

Liquidity of the Holding Companies

Availability and Sources and Uses of Holding Company Liquidity; Limitations on Ability of Insurance Subsidiaries to Make Dividend and Surplus Debenture Interest Payments to the Holding Companies

At September 30, 2012, CNO, CDOC, Inc. (“CDOC”) (our wholly owned subsidiary and a guarantor under the New Senior Secured Credit Agreement) and our other non-insurance subsidiaries held: (i) unrestricted cash and cash equivalents of

94

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

$209.4 million; (ii) fixed income investments of $57.2 million; and (iii) equity securities and other invested assets totaling $47.0 million.  CNO and CDOC are holding companies with no business operations of their own; they depend on their operating subsidiaries for cash to make principal and interest payments on debt, and to pay administrative expenses and income taxes.  CNO and CDOC receive cash from insurance subsidiaries, consisting of dividends and distributions, interest payments on surplus debentures and tax-sharing payments, as well as cash from non-insurance subsidiaries consisting of dividends, distributions, loans and advances.  The principal non-insurance subsidiaries that provide cash to CNO and CDOC are 40|86 Advisors, Inc. (“40|86 Advisors”), which receives fees from the insurance subsidiaries for investment services, and CNO Services, LLC which receives fees from the insurance subsidiaries for providing administrative services.  The agreements between our insurance subsidiaries and CNO Services, LLC and 40|86 Advisors, respectively, were previously approved by the domestic insurance regulator for each insurance company, and any payments thereunder do not require further regulatory approval.

The following summarizes the current legal ownership structure of CNO’s primary subsidiaries:

The ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from GAAP.  These regulations generally permit dividends to be paid from statutory earned surplus of the insurance company for any 12-month period in amounts equal to the greater of (or in a few states, the lesser of):  (i) statutory net gain from operations or net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year (excluded from this calculation would be the $80.4 million of additional surplus recognized related to certain deferred tax assets). This type of dividend is referred to as an “ordinary dividend”. Any dividend in excess of these levels or from an insurance company that has negative earned surplus requires the approval of the director or commissioner of the applicable state insurance department and is referred to as an “extraordinary dividend”.  Each of the direct insurance subsidiaries of CDOC has significant negative earned surplus and any dividend payments from the subsidiaries of CDOC will therefore require the approval of the director or commissioner of the applicable state insurance department.  In the first nine months of 2012, our insurance subsidiaries paid extraordinary dividends to CDOC totaling $198.0 million. Based on our continued expectation to generate strong statutory earnings and excess capital, we anticipate total year dividend payments to the holding company of $250 million to $275 million during 2012. We expect to receive regulatory approval for future dividends from our subsidiaries, but there can be no assurance that such payments will be approved or that the financial condition of our insurance subsidiaries will not change, making future approvals less likely.

We generally maintain capital and surplus levels in our insurance subsidiaries in an amount that is sufficient to maintain a minimum consolidated RBC ratio of 350 percent and will typically cause our insurance subsidiaries to pay ordinary dividends or request regulatory approval for extraordinary dividends when the consolidated RBC ratio exceeds such level and we have concluded the capital level in each of our insurance subsidiaries is adequate to support their business and projected growth.  The consolidated RBC ratio of our insurance subsidiaries decreased 8 percentage points, to 361 percent, during the third quarter of 2012, reflecting consolidated statutory operating earnings of $60.3 million and the payment of dividends to the non-insurance holding companies of $95 million. Consolidated statutory operating earnings in the third quarter of 2012 were reduced by a $40 million charge recognized by Conseco Life relating to the tentative settlement of certain cases related to the

95

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Valulife/Valuterm litigation described in the note to the accompanying consolidated financial statements entitled "Litigation and Other Legal Proceedings."  Conseco Life also recognized a $29.5 million charge to statutory earnings in the quarter ended March 31, 2012 related to these cases.

CDOC holds surplus debentures from Conseco Life Insurance Company of Texas (“Conseco Life of Texas”) with an aggregate principal amount of $749.6 million.  Interest payments do not require additional approval provided the RBC ratio of Conseco Life of Texas exceeds 100 percent (but do require prior written notice to the Texas state insurance department).  The RBC ratio of Conseco Life of Texas was 301 percent at September 30, 2012.  CDOC also holds a surplus debenture from Colonial Penn Life Insurance Company with an outstanding principal balance of $160.0 million. Interest payments require prior approval by the Pennsylvania state insurance department. Dividends and other payments from our non-insurance subsidiaries, including 40|86 Advisors and CNO Services, LLC, to CNO or CDOC do not require approval by any regulatory authority or other third party.  However, insurance regulators may prohibit payments by our insurance subsidiaries to parent companies if they determine that such payments could be adverse to our policyholders or contractholders.

The insurance subsidiaries of CDOC receive funds to pay dividends primarily from:  (i) the earnings of their direct businesses; (ii) tax sharing payments received from subsidiaries (if applicable); and (iii) with respect to Conseco Life of Texas, dividends received from subsidiaries.  At September 30, 2012, the subsidiaries of Conseco Life of Texas had earned surplus (deficit) as summarized below (dollars in millions):

	Earned surplus
Subsidiary of CDOC	(deficit)			Additional information
Subsidiaries of Conseco Life of Texas:
Bankers Life	$	280.2		(a)
Colonial Penn Life Insurance Company	(246.5		)	(b)

___________

(a) Bankers Life paid ordinary dividends of $65.0 million to Conseco Life of Texas in the first nine months of 2012.

(b) The deficit is primarily due to transactions which occurred several years ago, including a tax planning transaction and the fee paid to recapture a block of business previously ceded to an unaffiliated insurer.

A significant deterioration in the financial condition, earnings or cash flow of the material subsidiaries of CNO or CDOC for any reason could hinder such subsidiaries’ ability to pay cash dividends or other disbursements to CNO and/or CDOC, which, in turn, could limit CNO’s ability to meet debt service requirements and satisfy other financial obligations.  In addition, we may choose to retain capital in our insurance subsidiaries or to contribute additional capital to our insurance subsidiaries to strengthen their surplus, and these decisions could limit the amount available at our top tier insurance subsidiaries to pay dividends to the holding companies.  In the past, we have made capital contributions to our insurance subsidiaries to meet debt covenants and minimum capital levels required by certain regulators and it is possible we will be required to do so in the future. We paid a capital contribution to our insurance subsidiaries of $26.0 million in the first nine months of 2012, which had been accrued at December 31, 2011.

96

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

In the third quarter of 2012, as further discussed in the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations", we completed a comprehensive recapitalization plan. The following table sets forth the sources and uses of cash from the recapitalization transactions (dollars in millions):

Sources:
	New Senior Secured Credit Agreement	$	669.5
	Issuance of 6.375% Notes	275.0
	Total sources	$	944.5
Uses:
	Cash on hand for general corporate purposes	$	19.9
	Repurchase of $200 million principal amount of 7.0% Debentures pursuant to Debenture Repurchase Agreement	355.1
	Repayment of Previous Senior Secured Credit Agreement	223.8
	Repayment of $273.8 million principal amount of 9.0% Notes, including redemption premium, pursuant to tender offer	322.7
	Debt issuance costs	16.9
	Accrued interest	6.1
	Total uses	$	944.5

The scheduled principal payments on our direct corporate obligations are as follows at September 30, 2012 (dollars in millions):

Year ending September 30,	Principal
2013	$	55.4
2014	54.3
2015	79.3
2016	79.3
2017	97.2
Thereafter	678.7
	$	1,044.2

In May 2011, the Company announced a common share repurchase program of up to $100.0 million of the Company's outstanding common stock. In February 2012 and June 2012, the Company's board of directors approved, in aggregate, an additional $200.0 million to repurchase the Company's outstanding common stock. The Company had remaining repurchase authority of $130.7 million as of September 30, 2012. We currently anticipate repurchasing common shares near the high end of the $150 million to $170 million range during 2012 ($99.5 million of which were repurchased in the first nine months of 2012, representing 12.9 million shares).

In May 2012, we initiated a common stock dividend program. In both the second and third quarters of 2012, dividends declared and paid on common stock were $0.02 per common share totaling $9.4 million.

Also, in the first nine months of 2012, as required under the terms of the Previous Senior Secured Credit Agreement, we made mandatory prepayments of $31.4 million due to repurchases of our common stock and payment of a common stock dividend.

In March 2012, we paid in full the remaining $50.0 million principal balance on the Senior Health Note, which had been scheduled to mature in November 2013. The repayment in full of the Senior Health Note removed the previous restriction on our ability to pay cash dividends on our common stock.

97

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

The New Senior Secured Credit Agreement requires the Company to maintain (each as calculated in accordance with the New Senior Secured Credit Agreement): (i) a debt to total capitalization ratio of not more than 27.5 percent (such ratio was 21.5 percent at September 30, 2012); (ii) an interest coverage ratio of not less than 2.50 to 1.00 for each rolling four quarters (or, if less, the number of full fiscal quarters commencing after the effective date of the New Senior Secured Credit Agreement) (such ratio was not applicable for the period ended September 30, 2012); (iii) an aggregate ratio of total adjusted capital to company action level risk-based capital for the Company's insurance subsidiaries of not less than 250 percent (such ratio was 361 percent at September 30, 2012); and (iv) a combined statutory capital and surplus for the Company's insurance subsidiaries of at least $1,300.0 million (combined statutory capital and surplus at September 30, 2012, was $1,766.8 million).

Mandatory prepayments of the New Senior Secured Credit Agreement will be required, subject to certain exceptions, in an amount equal to: (i) 100% of the net cash proceeds from certain asset sales or casualty events; (ii) 100% of the net cash proceeds received by the Company or any of its restricted subsidiaries from certain debt issuances; and (iii) 100% of the amount of certain restricted payments made (including any common stock dividends and share repurchases) as defined in the New Senior Secured Credit Agreement provided that if, as of the end of the fiscal quarter immediately preceding such restricted payment, the debt to total capitalization ratio is: (x) equal to or less than 22.5%, but greater than 17.5%, the prepayment requirement shall be reduced to 33.33%; or (y) equal to or less than 17.5%, the prepayment requirement shall not apply.

Notwithstanding the foregoing, no mandatory prepayments pursuant to item (i) in the preceding paragraph shall be required if: (x) the debt to total capitalization ratio is equal or less than 20% and (y) either (A) the financial strength rating of certain of the Company's insurance subsidiaries is equal or better than A- (stable) from A.M. Best or (B) the New Senior Secured Credit Agreement is rated equal or better than BBB- (stable) from S&P and Baa3 (stable) by Moody's.

The 6.375% Indenture contains covenants that, among other things, limit (subject to certain exceptions) the Company's ability and the ability of the Company's Restricted Subsidiaries (as defined in the 6.375% Indenture) to:

• incur or guarantee additional indebtedness or issue preferred stock;

• pay dividends or make other distributions to shareholders;

• purchase or redeem capital stock or subordinated indebtedness;

• make investments;

• create liens;

• incur restrictions on the Company's ability and the ability of its Restricted Subsidiaries to pay dividends or make other payments to the Company;

• sell assets, including capital stock of the Company's subsidiaries;

• consolidate or merge with or into other companies or transfer all or substantially all of the Company's assets; and

• engage in transactions with affiliates.

Under the 6.375% Indenture, the Company can make Restricted Payments (as such term is defined in the 6.375% Indenture) up to a calculated limit, provided that the Company's pro forma risk-based capital ratio exceeds 225% after giving effect to the Restricted Payment and certain other conditions are met. Restricted Payments include, among other items, repurchases of common stock and cash dividends on common stock (to the extent such dividends exceed $30 million in the aggregate in any calendar year). The limit of Restricted Payments permitted under the 6.375% Indenture is the sum of (x) 50% of the Company's “Net Excess Cash Flow” (as defined in the 6.375% Indenture) for the period (taken as one accounting period) from July 1, 2012 to the end of the Company's most recently ended fiscal quarter for which financial statements are available at the time of such Restricted Payment, (y) $175 million and (z) certain other amounts specified in the 6.375% Indenture. Based on the provisions set forth in the 6.375% Indenture and the Company's Net Excess Cash Flow for the period from July 1, 2012 through September 30, 2012, the Company could have made additional Restricted Payments under this 6.375% Indenture covenant of approximately $244 million as of September 30, 2012. This limitation on Restricted Payments does not apply if the Debt to Total Capitalization Ratio (as defined in the 6.375% Indenture) as of the last day of the Company's most recently ended fiscal quarter for which financial statements are available that immediately precedes the date of any Restricted Payment,

98

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

calculated immediately after giving effect to such Restricted Payment and any related transactions on a pro forma basis, is equal to or less than 17.5%.

As part of our investment strategy for the holding company, we may enter into repurchase agreements to increase our investment return. We account for these transactions as collateralized borrowings, where the amount borrowed is equal to the sales price of the underlying securities. Repurchase agreements involve a sale of securities and an agreement to repurchase the same securities at a later date at an agreed-upon price. We had no such borrowings outstanding at September 30, 2012. The primary risks associated with short-term collateralized borrowings are: (i) a substantial decline in the market value of the margined security; and (ii) that a counterparty will be unable to perform under the terms of the contract or be unwilling to extend such related financing in future periods especially if the liquidity or value of the margined security has declined. Exposure is limited to any depreciation in value of the related securities.

We believe that the existing cash available to the holding company, the cash flows to be generated from operations and other transactions will be sufficient to allow us to meet our debt service obligations, pay corporate expenses and satisfy other financial obligations.  However, our cash flow is affected by a variety of factors, many of which are outside of our control, including insurance regulatory issues, competition, financial markets and other general business conditions.  We cannot provide assurance that we will possess sufficient income and liquidity to meet all of our debt service requirements and other holding company obligations.

99

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

INVESTMENTS

At September 30, 2012, the amortized cost, gross unrealized gains and losses and estimated fair value of fixed maturities, available for sale, and equity securities were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
Investment grade (a):
Corporate securities	$	13,446.3	$	2,205.7	$	(16.1	)	$	15,635.9
United States Treasury securities and obligations of United States government corporations and agencies	164.2		6.9		—			171.1
States and political subdivisions	1,770.3		267.9		(4.6		)	2,033.6
Debt securities issued by foreign governments	.8		—		—			.8
Asset-backed securities	1,068.0		73.9		(3.6		)	1,138.3
Collateralized debt obligations	322.2		5.0		(.6		)	326.6
Commercial mortgage-backed securities	1,400.7		142.7		(.8		)	1,542.6
Mortgage pass-through securities	18.8		1.4		—			20.2
Collateralized mortgage obligations	1,223.9		109.1		(.9		)	1,332.1
Total investment grade fixed maturities, available for sale	19,415.2		2,812.6		(26.6		)	22,201.2
Below-investment grade (a):
Corporate securities	1,140.3		60.0		(12.7		)	1,187.6
States and political subdivisions	15.3		—		(.8		)	14.5
Asset-backed securities	323.3		18.1		(3.0		)	338.4
Collateralized debt obligations	5.4		.2		(.2		)	5.4
Collateralized mortgage obligations	926.2		69.0		—			995.2
Total below-investment grade fixed maturities, available for sale	2,410.5		147.3		(16.7		)	2,541.1
Total fixed maturities, available for sale	$	21,825.7	$	2,959.9	$	(43.3	)	$	24,742.3
Equity securities	$	174.0	$	6.1	$	(.1	)	$	180.0

_______________

(a) Investment ratings – Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody’s, S&P or Fitch), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC").  NAIC designations of “1” or “2” include fixed maturities generally rated investment grade (rated “Baa3” or higher by Moody’s or rated “BBB-” or higher by S&P and Fitch).  NAIC designations of “3” through “6” are referred to as below-investment grade (which generally are rated “Ba1” or lower by Moody’s or rated “BB+” or lower by S&P and Fitch).  References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.

100

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

The NAIC evaluates the fixed maturity investments of insurers for regulatory and capital assessment purposes and assigns securities to one of six credit quality categories called NAIC designations, which are used by insurers when preparing their annual statements based on statutory accounting principles. The NAIC designations are generally similar to the credit quality designations of the NRSROs for marketable fixed maturity securities, except for certain structured securities as described below. The following summarizes the NAIC designations and NRSRO equivalent ratings:

NAIC Designation	NRSRO Equivalent Rating
1	AAA/AA/A
2	BBB
3	BB
4	B
5	CCC and lower
6	In or near default

The NAIC adopted revised rating methodologies for non-agency residential mortgage-backed securities that became effective December 31, 2009 and for commercial mortgage-backed traded securities and other asset-backed securities that became effective December 31, 2010. The NAIC's objective with the revised ratings was to increase the accuracy in assessing potential losses, and to use the improved assessment to determine a more appropriate capital requirement for such structured securities. Accordingly, certain structured securities rated below investment grade by the NRSROs could be assigned as NAIC 1 or NAIC 2 securities dependent on the cost basis of the holder relative to estimated recoverable amounts as determined by the NAIC.

A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of September 30, 2012 is as follows (dollars in millions):

					Percentage
			Estimated		of total
NAIC	Amortized		fair		estimated
designation	cost		value		fair value
1	$	10,454.4	$	11,893.9	48.1	%
2	10,140.2		11,564.4		46.7
3	890.8		937.0		3.8
4	304.0		315.2		1.3
5	35.9		31.4		.1
6	.4		.4		—
	$	21,825.7	$	24,742.3	100.0	%

101

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Concentration of Fixed Maturity Securities, Available for Sale

The following table summarizes the carrying values and gross unrealized losses of our fixed maturity securities, available for sale, by category as of September 30, 2012 (dollars in millions):

	Carrying value		Percent of fixed maturities		Gross unrealized losses		Percent of gross unrealized losses
Energy/pipelines	$	2,538.7	10.3	%	$	.3	.8	%
Collateralized mortgage obligations	2,327.3		9.4		.9		2.1
Utilities	2,100.6		8.5		.7		1.6
States and political subdivisions	2,048.1		8.3		5.4		12.6
Commercial mortgage-backed securities	1,542.6		6.2		.8		1.7
Insurance	1,538.1		6.2		2.5		5.9
Asset-backed securities	1,476.7		6.0		6.6		15.2
Food/beverage	1,254.8		5.1		3.5		8.1
Healthcare/pharmaceuticals	1,208.3		4.9		.3		.8
Cable/media	987.9		4.0		3.5		8.0
Real estate/REITs	912.9		3.7		—		.1
Banks	805.6		3.2		2.4		5.6
Capital goods	690.1		2.8		.1		.3
Transportation	564.2		2.3		—		—
Telecom	532.9		2.1		9.1		20.9
Aerospace/defense	440.7		1.8		—		—
Chemicals	424.7		1.7		—		—
Building materials	382.3		1.5		4.8		11.1
Metals and mining	362.3		1.5		1.2		2.7
Paper	337.6		1.4		—		—
Consumer products	337.5		1.4		.1		.1
Collateralized debt obligations	332.0		1.3		.8		1.8
Brokerage	294.1		1.2		.1		.2
Other	1,302.3		5.2		.2		.4
Total fixed maturities, available for sale	$	24,742.3	100.0	%	$	43.3	100.0	%

Below-Investment Grade Securities

At September 30, 2012, the amortized cost of the Company’s below-investment grade fixed maturity securities was $2,410.5 million, or 11 percent of the Company’s fixed maturity portfolio.  The estimated fair value of the below-investment grade portfolio was $2,541.1 million, or 105 percent of the amortized cost.

Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities.  Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade corporate debt securities and in many cases severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer.  Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are generally more sensitive to adverse economic conditions.  The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

102

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Net Realized Investment Gains (Losses)

The following table sets forth the net realized investment gains (losses) for the periods indicated (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Fixed maturity securities, available for sale:
Realized gains on sale	$	35.1		$	74.3		$	103.4		$	141.2
Realized losses on sale	(7.5		)	(18.1		)	(15.3		)	(57.1		)
Impairments:
Total other-than-temporary impairment losses	—			—			(.9		)	(11.5		)
Other-than-temporary impairment losses recognized in accumulated other comprehensive income (loss)	—			—			—			—
Net impairment losses recognized	—			—			(.9		)	(11.5		)
Net realized investment gains from fixed maturities	27.6			56.2			87.2			72.6
Equity securities	—			(.4		)	.1			(.2		)
Commercial mortgage loans	(1.4		)	(21.5		)	(1.5		)	(22.2		)
Impairments of mortgage loans and other investments	(23.1		)	(2.9		)	(33.6		)	(14.8		)
Other	6.0			(.8		)	11.7			3.2
Net realized investment gains	$	9.1		$	30.6		$	63.9		$	38.6

During the first nine months of 2012, we recognized net realized investment gains of $63.9 million, which were comprised of $89.0 million of net gains from the sales of investments (primarily fixed maturities) with proceeds of $1.9 billion, the increase in fair value of certain fixed maturity investments with embedded derivatives of $9.4 million, and $34.5 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

During the first nine months of 2011, we recognized net realized investment gains of $38.6 million, which were comprised of $64.9 million of net gains from the sales of investments (primarily fixed maturities) and $26.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

At September 30, 2012, fixed maturity securities in default or considered nonperforming had an aggregate amortized cost of $.4 million and a carrying value of $.5 million.

During the first nine months of 2012, the $34.5 million of other-than-temporary impairments we recorded in earnings included: (i) $3.2 million of losses related to certain commercial mortgage loans; (ii) $29.9 million of losses on equity securities primarily related to investments obtained through the commutation of an investment made by our Predecessor (as further described below); and (iii) $1.4 million of additional losses following unforeseen issue-specific events or conditions.

During the first nine months of 2012, the $15.3 million of realized losses on sales of $393.8 million of fixed maturity securities, available for sale, included:  (i) $5.1 million of losses related to the sales of mortgage-backed securities and asset-backed securities; and (ii) $10.2 million of additional losses primarily related to various corporate securities.  Securities are generally sold at a loss following unforeseen issue-specific events or conditions or shifts in perceived risks.  These reasons include but are not limited to:  (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; or (v) related to structured securities, changes in expected cash flows.

As disclosed in the notes to the consolidated financial statements included in our 2011 Annual Report on Form 10-K, we completed the commutation of an investment made by our Predecessor in a guaranteed investment contract issued by a Bermuda insurance company in exchange for interests in certain underlying assets held by the insurance company.  During the first nine months of 2011, we completed the commutation of this investment, in a series of transactions, pursuant to which we received government agency securities as well as equity interests in certain corporate investments with an aggregate fair value of $197.5 million in exchange for our holdings with a book value of $201.5 million (resulting in a net realized loss of $4.0

103

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

million, of which, a realized gain of $4.9 million was recognized in the third quarter of 2011). During the first nine months of 2011, we recognized impairment charges of $11.5 million (none of which was recognized in the third quarter of 2011) on the underlying invested assets.

During the first nine months of 2011, the $26.3 million of other-than-temporary impairments we recorded in earnings included: (i) $11.5 million on an investment in a guaranteed investment contract as discussed above; (ii) $10.5 million of losses related to certain commercial mortgage loans; (iii) $3.5 million related to investments held by a VIE as a result of our intent to sell such investments; and (iv) $.8 million of additional losses following unforeseen issue-specific events or conditions.

During the first nine months of 2011, the $57.1 million of realized losses on sales of $.9 billion of fixed maturity securities, available for sale, included: (i) $20.6 million of losses related to the sales of mortgage-backed securities and asset-backed securities; (ii) $13.4 million related to sales of securities issued by states and political subdivisions; (iii) $8.9 million related to the commutation of the guaranteed investment contract as discussed above; and (iv) $14.2 million of additional losses primarily related to various corporate securities.

Our fixed maturity investments are generally purchased in the context of a long-term strategy to fund insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities.  In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities.

There were no investments sold at a loss during the first nine months of 2012 that had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis for more than 12 months prior to the sale of the investment.

We regularly evaluate all of our investments with unrealized losses for possible impairment.  Our assessment of whether unrealized losses are “other than temporary” requires significant judgment.  Factors considered include:  (i) the extent to which fair value is less than the cost basis; (ii) the length of time that the fair value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for specific events, developments or circumstances likely to affect the value of the investment; (v) the investment’s rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) whether we intend to sell the investment or it is more likely than not that circumstances will require us to sell the investment before recovery occurs; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values;  (ix) projections of, and unfavorable changes in, cash flows on structured securities including mortgage-backed and asset-backed securities; (x) our best estimate of the value of any collateral; and (xi) other objective and subjective factors.

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio.  Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

104

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

The following table sets forth the amortized cost and estimated fair value of those fixed maturities, available for sale, with unrealized losses at September 30, 2012, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.  Structured securities frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	10.0	$	10.0
Due after one year through five years	55.0		54.1
Due after five years through ten years	177.8		172.9
Due after ten years	478.9		450.5
Subtotal	721.7		687.5
Structured securities	375.7		366.6
Total	$	1,097.4	$	1,054.1

There were no investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis at September 30, 2012.

105

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

The following table summarizes the gross unrealized losses of our fixed maturity securities, available for sale, by category and ratings category as of September 30, 2012 (dollars in millions):

	Investment grade				Below investment grade
	AAA/AA/A		BBB		BB		B+ and below		Total gross unrealized losses
Telecom	$	—	$	8.5	$	.1	$	.4	$	9.0
Asset-backed securities	1.0		2.6		2.3		.7		6.6
States and political subdivisions	1.5		3.1		.8		—		5.4
Building materials	—		—		3.6		1.2		4.8
Food/beverage	—		3.5		—		—		3.5
Cable/media	—		—		1.1		2.4		3.5
Insurance	—		1.9		.6		—		2.5
Banks	—		.7		1.7		—		2.4
Metals and mining	—		.4		.8		—		1.2
Collateralized mortgage obligations	.8		.1		—		—		.9
Collateralized debt obligations	.6		—		—		.2		.8
Commercial mortgage-backed securities	.6		.2		—		—		.8
Utilities	—		.7		—		—		.7
Energy/pipelines	—		—		.2		.1		.3
Healthcare/pharmaceuticals	—		.1		.2		—		.3
Capital goods	—		—		.1		.1		.2
Brokerage	—		.1		—		—		.1
Consumer products	—		—		.1		—		.1
Real estate/REITs	—		.1		—		—		.1
Other	—		.1		—		—		.1
Total fixed maturities, available for sale	$	4.5	$	22.1	$	11.6	$	5.1	$	43.3

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active investment management. Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities.

106

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities had been in a continuous unrealized loss position, at September 30, 2012 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair  value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
States and political subdivisions	$	40.2	$	(2.0	)	68.7		$	(3.4	)	$	108.9	$	(5.4	)
Corporate securities	300.5		(9.2		)	278.1		(19.6		)	578.6		(28.8		)
Asset-backed securities	42.1		(.3		)	137.8		(6.3		)	179.9		(6.6		)
Collateralized debt obligations	12.7		(.1		)	47.2		(.7		)	59.9		(.8		)
Commercial mortgage-backed securities	16.0		(.1		)	14.3		(.7		)	30.3		(.8		)
Mortgage pass-through securities	—		—			2.0		—			2.0		—
Collateralized mortgage obligations	58.5		(.5		)	36.0		(.4		)	94.5		(.9		)
Total fixed maturities, available for sale	$	470.0	$	(12.2	)	$	584.1	$	(31.1	)	$	1,054.1	$	(43.3	)
Equity securities	$	2.1	$	(.1	)	$	—	$	—		$	2.1	$	(.1	)

Based on management’s current assessment of investments with unrealized losses at September 30, 2012, the Company believes the issuers of the securities will continue to meet their obligations (or with respect to equity-type securities, the investment value will recover to its cost basis).  While we do not have the intent to sell securities with unrealized losses and it is not more likely than not that we will be required to sell securities with unrealized losses prior to their anticipated recovery, our intent on an individual security may change, based upon market or other unforeseen developments.  In such instances, if a loss is recognized from a sale subsequent to a balance sheet date due to these unexpected developments, the loss is recognized in the period in which we had the intent to sell the security before its anticipated recovery.

Structured Securities

At September 30, 2012 fixed maturity investments included structured securities with an estimated fair value of $5.7 billion (or 23 percent of all fixed maturity securities).  The yield characteristics of structured securities differ in some respects from those of traditional corporate fixed-income securities or government securities.  For example, interest and principal payments on structured securities may occur more frequently, often monthly.  In many instances, we are subject to the risk that the amount and timing of principal and interest payments may vary from expectations.  For example, in many cases, partial prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including:  the relative sensitivity of the underlying assets backing the security to changes in interest rates; a variety of economic, geographic and other factors; the timing and pace of liquidations of defaulted collateral; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure).  In addition, the total amount of payments for non-agency structured securities may be affected by changes to cumulative default rates or loss severities of the related collateral.

107

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

The following table sets forth the par value, amortized cost and estimated fair value of structured securities, summarized by interest rates on the underlying collateral, at September 30, 2012 (dollars in millions):

	Par value		Amortized cost		Estimated fair value
Below 4 percent	$	632.9	$	582.2	$	598.0
4 percent – 5 percent	771.2		752.1		827.9
5 percent – 6 percent	2,880.6		2,732.6		2,965.7
6 percent – 7 percent	977.9		915.8		987.9
7 percent – 8 percent	168.2		173.8		185.1
8 percent and above	131.2		132.0		134.2
Total structured securities	$	5,562.0	$	5,288.5	$	5,698.8

The amortized cost and estimated fair value of structured securities at September 30, 2012, summarized by type of security, were as follows (dollars in millions):

			Estimated fair value
Type	Amortized cost		Amount		Percent of fixed maturities
Pass-throughs, sequential and equivalent securities	$	1,443.4	$	1,553.9	6.3	%
Planned amortization classes, target amortization classes and accretion-directed securities	697.0		763.0		3.1
Commercial mortgage-backed securities	1,400.7		1,542.6		6.2
Asset-backed securities	1,391.3		1,476.7		6.0
Collateralized debt obligations	327.6		332.0		1.3
Other	28.5		30.6		.1
Total structured securities	$	5,288.5	$	5,698.8	23.0	%

Pass-throughs, sequentials and equivalent securities have unique prepayment variability characteristics.  Pass-through securities typically return principal to the holders based on cash payments from the underlying collateral obligations. Sequential securities return principal to tranche holders in a detailed hierarchy.  Planned amortization classes, targeted amortization classes and accretion-directed securities adhere to fixed schedules of principal payments as long as the underlying mortgage loans experience prepayments within certain estimated ranges.  In most circumstances, changes in prepayment rates are first absorbed by support or companion classes insulating the timing of receipt of cash flows from the consequences of both faster prepayments (average life shortening) and slower prepayments (average life extension).

Commercial mortgage-backed securities are secured by commercial real estate mortgages, generally income producing properties that are managed for profit.  Property types include multi-family dwellings including apartments, retail centers, hotels, restaurants, hospitals, nursing homes, warehouses, and office buildings.  Most commercial mortgage-backed securities have call protection features whereby underlying borrowers may not prepay their mortgages for stated periods of time without incurring prepayment penalties.

108

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Commercial Mortgage Loans

The following table provides the carrying value and estimated fair value of our outstanding mortgage loans and the underlying collateral as of September 30, 2012, summarized by loan-to-value ratios (dollars in millions):

			Estimated fair value
Loan-to-value ratio (a)	Carrying value		Mortgage loans		Collateral
Less than 60%	$	778.1	$	866.5	$	2,214.6
60% to 70%	298.5		319.8		462.8
Greater than 70% to 80%	284.3		300.5		383.4
Greater than 80% to 90%	125.6		130.1		148.0
Greater than 90%	110.7		101.4		117.3
Total	$	1,597.2	$	1,718.3	$	3,326.1

________________

(a) Loan-to-value ratios are calculated as the ratio of:  (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.

INVESTMENT IN VARIABLE INTEREST ENTITIES

The following table provides supplemental information about the revenues and expenses of the VIEs which have been consolidated in accordance with authoritative guidance, after giving effect to the elimination of our investment in the VIEs and investment management fees earned by a subsidiary of the Company (dollars in millions):

	Three months ended					Nine months ended
	September 30,					September 30,
	2012		2011			2012			2011
Revenues:
Net investment income – policyholder and reinsurer accounts and other special-purpose portfolios	$	10.2	$	5.9		$	23.6		$	14.0
Fee revenue and other income	.4		.4			1.1			.9
Total revenues	10.6		6.3			24.7			14.9
Expenses:
Interest expense	5.8		2.4			14.5			8.4
Other operating expenses	.1		.1			.4			.5
Total expenses	5.9		2.5			14.9			8.9
Income before net realized investment gains (losses) and income taxes	4.7		3.8			9.8			6.0
Net realized investment gains (losses)	.1		(.6		)	(.1		)	(.2		)
Income before income taxes	$	4.8	$	3.2		$	9.7		$	5.8

During the first nine months of 2012, net realized investment losses included:  (i) $.3 million of net gains from the sales of investments; and (ii) $.4 million of writedowns of investments held by VIEs as a result of our intent not to hold such investments for a period of time that would be sufficient to allow for any anticipated recovery in value.  During the first nine months of 2011, net realized investment gains included:  (i) $3.3 million of net gains from the sales of investments; and (ii) $3.5 million of writedowns of investments held by VIEs as a result of our intent to sell such investments.

109

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Supplemental Information on Investments Held by VIEs

The following table summarizes the carrying values of the investments held by the VIEs by category as of September 30, 2012 (dollars in millions):

	Carrying value		Percent of fixed maturities		Gross unrealized losses		Percent of gross unrealized losses
Healthcare/pharmaceuticals	$	106.0	12.8	%	$	.9	27.0	%
Cable/media	95.9		11.6		.3		9.6
Technology	75.4		9.1		.2		6.7
Autos	65.4		7.9		.1		1.5
Food/beverage	57.2		6.9		.1		2.3
Brokerage	49.5		5.9		.6		18.7
Gaming	40.4		4.9		.1		2.0
Consumer products	28.5		3.4		.4		12.4
Insurance	26.4		3.2		—		.2
Telecom	26.1		3.2		.1		1.7
Entertainment/hotels	25.9		3.1		.2		6.5
Aerospace/defense	21.8		2.6		—		—
Utilities	20.8		2.5		.1		1.6
Chemicals	19.3		2.3		—		.8
Retail	18.9		2.3		—		.4
Building materials	18.7		2.3		—		.3
Metals and mining	16.0		1.9		—		—
Energy/pipelines	15.5		1.9		—		.9
Real estate/REITs	12.6		1.5		—		.4
Transportation	12.5		1.5		—		1.4
Capital goods	9.5		1.1		—		.3
Paper	5.0		.6		.1		2.0
Other	62.1		7.5		.1		3.3
Total	$	829.4	100.0	%	$	3.3	100.0	%

The following table sets forth the amortized cost and estimated fair value of those investments held by the VIEs with unrealized losses at September 30, 2012, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	1.2	$	1.2
Due after one year through five years	199.7		196.8
Due after five years through ten years	105.9		105.5
Total	$	306.8	$	303.5

There were no investments held by the VIEs rated below-investment grade which had been continuously in an unrealized loss position exceeding 20 percent of the cost basis as of September 30, 2012.

110

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

NEW ACCOUNTING STANDARDS

See “Recently Issued Accounting Standards” in the notes to consolidated financial statements for a discussion of recently issued accounting standards.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Our market risks, and the ways we manage them, are summarized in “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in our Annual Report on Form 10-K for the year ended December 31, 2011.  There have been no material changes in the first nine months of 2012 to such risks or our management of such risks.

ITEM 4.  CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures.  Prior to the filing of our original Form 10-Q for the quarterly period ended September 30, 2012 with the SEC on November 1, 2012, CNO’s management, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of CNO’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended).  Based on its evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2012, CNO’s disclosure controls and procedures were effective to ensure that information required to be disclosed by CNO in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.  Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

In connection with the correction of certain items in our consolidated financial statements as further described in the note to the consolidated financial statements entitled "Correction to Previously Issued Financial Statements" included in this Form 10-Q/A, management of the Company reevaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report and determined that the misstatement resulted from a material weakness in internal control over financial reporting. Specifically, controls in place to ensure the accurate calculation of shadow adjustments impacting accumulated other comprehensive income did not operate effectively. Therefore, management has subsequently concluded that the Company's disclosure controls and procedures were not effective as of the end of the period covered by this report.

Changes to Internal Control Over Financial Reporting.  Except for the material weakness in internal controls over financial reporting described above, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) during the nine months ended September 30, 2012, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Remediation of Material Weakness. As a result of the identification of the inadvertent error that led to the amendment of our Form 10-Q and the related reassessment of disclosure controls and procedures and internal control over financial reporting, we have emphasized the importance of performing and reviewing calculations consistent with the design of our internal control structure in an effort to ensure controls operate effectively. The Company believes this action has remediated the material weakness.

PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS.

Information required for Part II, Item 1 is incorporated by reference to the discussion under the heading “Litigation and Other Legal Proceedings” in the footnotes to our consolidated financial statements included in Part I, Item 1 of this Form 10-Q.

111

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

ITEM 1A.  RISK FACTORS.

CNO and its businesses are subject to a number of risks including general business and financial risk factors.  Any or all of such factors could have a material adverse effect on the business, financial condition or results of operations of CNO.  Refer to “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011, for further discussion of such risk factors.  There have been no material changes from such previously disclosed risk factors.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Issuer Purchases of Equity Securities

Period	Total number of shares (or units)	Average price paid per share (or unit)		Total number of shares (or units) purchased as part of publicly announced plans or programs	Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs(a)
					(dollars in millions)
July 1 through July 31	2,515,103	$	7.95	2,515,103	$	152.1
August 1 through August 31	852,330	8.28		852,330	145.0
September 1 through September 30	1,437,726	9.98		1,437,197	130.7
Total	4,805,159	8.62		4,804,630	130.7

____________

(a) In May 2011, the Company announced a common share repurchase program of up to $100.0 million. In both February 2012 and June 2012, the Company announced that its board of directors had approved an additional $100.0 million ($200.0 million in aggregate) to repurchase the Company's outstanding common stock.

Under the 6.375% Indenture, the Company can make Restricted Payments (as such term is defined in the 6.375% Indenture) up to a calculated limit, provided that the Company's pro forma risk-based capital ratio exceeds 225% after giving effect to the Restricted Payment and certain other conditions are met. Restricted Payments include, among other items, repurchases of common stock and cash dividends on common stock (to the extent such dividends exceed $30 million in the aggregate in any calendar year). The limit of Restricted Payments permitted under the 6.375% Indenture is the sum of (x) 50% of the Company's “Net Excess Cash Flow” (as defined in the 6.375% Indenture) for the period (taken as one accounting period) from July 1, 2012 to the end of the Company's most recently ended fiscal quarter for which financial statements are available at the time of such Restricted Payment, (y) $175 million and (z) certain other amounts specified in the 6.375% Indenture. Based on the provisions set forth in the 6.375% Indenture and the Company's Net Excess Cash Flow for the period from July 1, 2012 through September 30, 2012, the Company could have made additional Restricted Payments under this 6.375% Indenture covenant of approximately $244 million as of September 30, 2012. This limitation on Restricted Payments does not apply if the Debt to Total Capitalization Ratio (as defined in the 6.375% Indenture) as of the last day of the Company's most recently ended fiscal quarter for which financial statements are available that immediately precedes the date of any Restricted Payment, calculated immediately after giving effect to such Restricted Payment and any related transactions on a pro forma basis, is equal to or less than 17.5%.

ITEM 5.  OTHER INFORMATION.

None.

112

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

ITEM 6.  EXHIBITS.

3.2	Amended and Restated Bylaws of CNO Financial Group, Inc., incorporated by reference to Exhibit 3.2 of our Current Report on Form 8-K filed August 1, 2012.
4.1	Indenture, dated as of September 28, 2012, by and among CNO Financial Group, Inc., the subsidiary guarantors party thereto and Wilmington Trust, National Association, as trustee and as collateral agent, incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed October 1, 2012.
4.2	Form of 6.375% Senior Secured Note due 2020 (included in Exhibit 4.1), incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K filed October 1, 2012.
10.1	Security Agreement, dated as of September 28, 2012, by and among CNO Financial Group, Inc., the subsidiary guarantors party thereto and Wilmington Trust, National Association, as collateral agent, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed October 1, 2012.
10.2	Credit Agreement, dated as of September 28, 2012, by and among CNO Financial Group, Inc., JPMorgan Chase Bank, N.A., as agent, and the lenders from time to time party thereto, incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed October 1, 2012.
10.3	Guarantee and Security Agreement, dated as of September 28, 2012, by and among CNO Financial Group, Inc., the subsidiary guarantors party thereto and JPMorgan Chase Bank, N.A., as agent, incorporated by reference to Exhibit 10.3 of our Current Report on Form 8-K filed October 1, 2012.
10.4	Pari Passu Intercreditor Agreement, dated as of September 28, 2012, among JPMorgan Chase Bank, N.A., as administrative agent for the credit agreement secured parties and Wilmington Trust, National Association, as collateral agent and authorized representative with respect to the 6.375% Senior Secured Notes due 2020, incorporated by reference to Exhibit 10.4 of our Current Report on Form 8-K filed October 1, 2012.
10.5	First Supplemental Indenture, dated as of September 28, 2012, among CNO Financial Group, Inc., the subsidiary guarantors party thereto and Wilmington Trust, National Association, as trustee and as collateral agent with respect to the 9.00% Senior Secured Notes due 2018, incorporated by reference to Exhibit 10.5 of our Current Report on Form 8-K filed October 1, 2012.
10.6	Employment Agreement dated as of July 23, 2012 between CNO Services, LLC and Bruce Baude.
12.1	Computation of Ratio of Earnings to Fixed Charges.
31.1	Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

113

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CNO FINANCIAL GROUP, INC.

Dated:  February 1, 2013

By:	/s/ Frederick J. Crawford
	Frederick J. Crawford
	Executive Vice President and Chief Financial Officer
	(authorized officer and principal financial officer)

114

EX-10.6

Exhibit 10.6

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT, dated as of the 23rd day of July, 2012, is between CNO Services, LLC, an Indiana limited liability company (“Company”), and Bruce Baude (“Executive”).

WHEREAS, the Company desires to have the benefit and advantage of the services of Executive to assist the Company and CNO Financial Group, Inc. (“CNO”) upon the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.Employment. The Company hereby employs Executive and Executive hereby accepts employment upon the terms and conditions hereinafter set forth.

2.Term. The effective date of this agreement (the “Agreement”) shall be July 23, 2012 (the “Effective Date”). Subject to the provisions for termination as provided in Section 10 hereof, the term of Executive's employment under this Agreement shall be the period beginning on the Effective Date and ending on July 31, 2015 (the “Term"). The Term shall not be automatically renewed and shall end upon any earlier termination of Executive's employment with the Company.

3.Duties. During the Term, Executive shall be engaged by the Company in the capacity of Executive Vice President, Chief Operations and Technology Officer of the Company, or in such other senior executive capacity as the Chief Executive Officer of CNO shall specify. Executive shall report to the Chief Executive Officer of CNO or such other senior executive officer as the Chief Executive Officer of CNO may specify regarding the performance of his duties.

4.Extent of Services. During the Term, subject to the direction and control of the Chief Executive Officer of CNO, Executive shall have the power and authority commensurate with his executive status and necessary to perform his duties hereunder. Executive shall devote his entire employable time, attention and best efforts to the business of the Company and, during the Term, shall not, without the consent of the Company, be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage; provided, however, that this shall not be construed as preventing Executive from serving on boards of professional, community, civic, education, charitable and corporate organizations on which he presently serves or may choose to serve or investing his assets in such form or manner as will not require any services on the part of Executive in the operation of the affairs of the companies in which such investments are made (to the extent not in violation of the non-solicitation provisions of Section 9 hereof); provided, however, that corporate organizations shall be limited to those mutually agreed upon by Executive and the Company.

1

5.Compensation. During the Term:

(a)As compensation for services hereunder rendered during the Term hereof, Executive shall receive a base salary (“Base Salary”) of Four Hundred Seventy-Five Thousand Dollars ($475,000) per year payable in equal installments in accordance with the Company's payroll procedure for its salaried executives. Salary payments and other payments under this Agreement shall be subject to withholding of taxes and other appropriate and customary amounts. Executive may receive increases in his Base Salary from time to time, based upon his performance, subject to approval of the Company.

(b)In addition to Base Salary, Executive will have an opportunity to earn a bonus each year, as determined by the Company, with a target annual bonus equal to 100% of Executive's Base Salary (the “Target Bonus”) and a maximum annual bonus of 200% of Executive's Base Salary with respect to any calendar year, with such bonus payable at such time that other similar payments are made to other Company executives but in no event later than March 15 of the year following the year with respect to which such bonus was payable, unless the bonus amounts to be paid cannot be confirmed and paid on or before March 15, in which event the bonuses will be paid within 15 days after the bonus amounts have been confirmed by the Company. For purposes of clarification, annual executive bonuses are payable on or before March 15 of the year following the year with respect to which such bonuses are payable, if Executive remains employed with the Company through such date or as otherwise payable under Section 11 of this Agreement. Notwithstanding the above, a pro-rata portion of the 2015 bonus will be paid at the same time that similar payments are made to other Company executives if Executive remains employed through the end of the Term. The bonus for 2012 will be prorated for the period of the year in which Executive is employed by the Company and shall not be less than Three Hundred Thousand Dollars ($300,000). The performance requirements for Target Bonuses will be based on financial and other objective targets that the CNO Board of Directors (the “Board”) or the Human Resources and Compensation Committee of the Board (the “Compensation Committee”) believes are reasonably attainable at the time that they are set.

(c)Executive shall be entitled to receive a grant of shares of restricted stock, with a value of approximately One Hundred Fifty Thousand Dollars ($150,000). The restricted stock will vest in three equal annual installments beginning one year after the date of grant. The restricted stock will be governed by the terms and conditions of the award agreement between the Company and Executive.

(d)Executive shall be entitled to receive a grant of options to purchase shares of common stock, with a value of approximately Two Hundred Fifty Thousand Dollars ($250,000). One-half of the options will vest on the second anniversary of the date of grant and one-half will vest on the third anniversary of the date of grant. The options will expire seven years from the date of grant. The option grant will be governed by the terms and conditions of the award agreement between the Company and Executive.

(e) Executive shall be eligible to participate in and receive future grants under any CNO stock or equity-based program offered to senior executives, subject to the discretion of the Board or the Compensation Committee.

2

6.Additional Benefits. During the Term:

(a)Executive shall be entitled to participate in such existing executive benefit plans and insurance programs offered by the Company, or which it may adopt from time to time, for its executive management or supervisory personnel generally, in accordance with the eligibility requirements for participation therein. Nothing herein shall be construed so as to prevent the Company from modifying or terminating any executive benefit plans or programs, or additional benefits, that it may adopt from time to time.

(b)Executive shall be entitled to four weeks of vacation with pay each year.

(c)Executive may incur reasonable expenses for promoting the Company's business, including expenses for entertainment, travel, and similar items. The Company shall reimburse Executive for all such reasonable expenses upon Executive's periodic presentation of an itemized account of such expenditures in accordance with the Company's policies and procedures and Section 21 hereof; provided, however, that any such reimbursement will be made no later than March 15 of the year following the year in which the expense was incurred. The Company agrees to pay Executive an additional amount to cover the incremental additional income taxes incurred by Executive, if any, with respect to payment or reimbursement of any reasonable business expenses pursuant to this subsection (c); provided, however, that any such payment will be made no later than March 15 of the year following the year in which the income tax was incurred.

(d) Executive shall be entitled to reimbursement of reasonable relocation expenses for moving his family to the Carmel, Indiana area in accordance with the Company's current executive relocation policy, provided that these expenses shall be capped at $50,000 and there shall be no reimbursement for any moving expenses incurred on or after July 23, 2014. All expenses must be appropriately documented by Executive to the Company. In the event that Executive's employment is terminated for Just Cause or if he terminates his employment other than With Reason prior to July 23, 2014, Executive agrees to repay such expenses to the Company.

(e)Executive shall be permitted to make elective contributions to any Company-sponsored, non-qualified deferred compensation plan in accordance with the terms of such plan.

7.Disability.

(a) If Executive shall become physically or mentally disabled during the Term to the extent that his ability to perform his duties and services hereunder is materially and adversely impaired (any such incapacity, a “Disability”), his Base Salary, bonus and other compensation provided herein shall continue while he remains employed by the Company; provided, that if such Disability (as determined in the Company's reasonable judgment, exercised in good faith) continues for at least three (3) consecutive months, the Company may terminate Executive's employment hereunder, in which case the Company within 10 business days shall pay Executive a cash payment equal to (i) his annual Base Salary as provided in Section 5(a) hereof to the extent earned but unpaid as of the date of

3

termination (“Unpaid Salary”), (ii) the bonus payable pursuant to Section 5(b) for the fiscal year of the Company ending prior to the date of termination (to the extent earned based on performance under the goals and objectives of the applicable plan but not previously paid) (“Unpaid Bonus”) and (iii) Executive's then accrued but unused vacation (“Unpaid Vacation”) (the Unpaid Salary, Unpaid Bonus and Unpaid Vacation referred to sometimes together as the “Accrued Amounts”). Additionally, in the event of a termination of employment due to Disability, the Company shall pay to Executive a pro-rata portion of the Target Bonus for the year in which the termination for Disability occurred. All options, restricted stock and/or other awards held by Executive on the date of termination for Disability shall vest only through the date of termination according to the normal vesting schedule applicable to such options, restricted stock and/or other awards and shall be treated in accordance with the applicable award agreements.

(b) No payments or vesting under this Section 7 will be made if such Disability arose primarily from (a) chronic use of intoxicants, drugs or narcotics (other than drugs prescribed to Executive by a physician and used by Executive for their intended purpose for which they had been prescribed) or (b) intentionally self-inflicted injury or intentionally self-induced illness.

8.Disclosure of Information. Executive acknowledges that, in and as a result of his employment with the Company, he has been and will be making use of, acquiring and/or adding to confidential information of the Company and its affiliates of a special and unique nature and value. As a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5, as well as any additional benefits stated herein, Executive covenants and agrees that he shall not, at any time while he is employed by the Company or at any time thereafter, directly or indirectly, divulge or disclose for any purpose whatsoever, any confidential information (whether or not specifically labeled or identified as “confidential information”), in any form or medium, that has been obtained by or disclosed to him as a result of his employment with the Company and which the Company or any of its affiliates has taken appropriate steps to safeguard, except to the extent that such confidential information (a) becomes a matter of public record or is otherwise available to the general public, other than as a result of any act or omission of Executive, (b) is required to be disclosed by any law, regulation or order of any court or regulatory commission, department or agency, in which event Executive shall give prompt notice of such requirement to the Company to enable the Company to seek an appropriate protective order or confidential treatment, (c) must be disclosed to enable Executive properly to perform his duties under this Agreement or (d) was developed by Executive prior to his employment by the Company. Upon the termination of Executive's employment, Executive shall return such information (in whatever form) obtained from or belonging to the Company or any of its affiliates which he may have in his possession or control.

9.Covenants against Solicitation. Executive acknowledges that the services he is to render to the Company and its affiliates are of a special and unusual character, with a unique value to the Company and its affiliates, the loss of which cannot adequately be compensated by damages or an action at law. In view of the unique value to the Company and its affiliates of the services of Executive for which the Company has contracted hereunder, because of the confidential information to be obtained by, or disclosed to, Executive as set forth in Section 8

4

above, and as a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5 hereof, as well as any additional benefits stated herein, and other good and valuable consideration, Executive covenants and agrees that throughout the period Executive remains employed or compensated hereunder and for one year thereafter, Executive shall not, directly or indirectly, anywhere in the United States of America (i) solicit or attempt to convert to other insurance carriers or other corporations, persons or other entities providing these same or similar products or services provided by the Company and its affiliates, any customers or policyholders of the Company or any of its affiliates; or (ii) solicit for employment or employ any individual who was employed by the Company or any of its affiliates during the term of Executive's employment with the Company. Should any particular covenant or provision of this Section 9 be held unreasonable or contrary to public policy for any reason, including, without limitation, the time period, geographical area, or scope of activity covered by any restrictive covenant or provision, the Company and Executive acknowledge and agree that such covenant or provision shall automatically be deemed modified such that the contested covenant or provision shall have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so modified to whatever extent would be reasonable and enforceable under applicable law.

10.Termination. During the Term:

(a)Either the Company or Executive may terminate his employment at any time for any reason upon written notice to the other. The Company may terminate Executive's employment for Just Cause pursuant to Section 10(b) below or in a Control Termination pursuant to Section 10(c) below. Executive's employment shall also terminate (i) upon the death of Executive or (ii) after Disability of Executive pursuant to Section 7 hereof.

(b)The Company may terminate Executive's employment at any time for Just Cause. For purposes of this Agreement, “Just Cause” shall mean:

(i) (A) material breach by Executive of this Agreement not cured within 15 days after written notice to Executive by the Company, (B) a material breach of Executive's duty of loyalty to the Company or its affiliates not cured within 15 days after written notice to Executive by the Company, or (C) willful malfeasance or fraud or dishonesty of a substantial nature in performing Executive's services on behalf of the Company or its affiliates, which in each case is willful and deliberate on Executive's part and committed in bad faith or without reasonable belief that such breach or action is in the best interests of the Company or its affiliates;

(ii) Executive's use of alcohol or drugs (other than drugs prescribed to Executive by a physician and used by Executive for their intended purposes for which they had been prescribed) or other repeated conduct which materially and repeatedly interferes with the performance of his duties hereunder, which materially compromises the integrity or the reputation of the Company or its

5

affiliates, or which results in other substantial economic harm to the Company or its affiliates;

(iii) Executive's conviction by a court of law, admission that he is guilty, or entry of a plea of nolo contendere with regard to a felony or other crime involving moral turpitude;

(iv) Executive's unscheduled absence from his employment duties other than as a result of illness or disability, for whatever cause, for a period of more than three (3) consecutive days, without consent from the Company prior to the expiration of the three (3) day period;

(v) Executive's failure to take action or to abstain from taking action, as directed in writing by a member of the Board or a higher ranking executive of the Company or CNO, where such failure continues after Executive has been given written notice of such failure and at least five (5) business days thereafter to cure such failure; or

(vi) Any intentional wrongful act or omission by Executive that results in the restatement of CNO's financial statements due to a violation of the Sarbanes-Oxley Act of 2002.

No termination shall be deemed to be a termination by the Company for Just Cause if the termination is as a result of Executive refusing to act in a manner that would be a violation of applicable law or where Executive acts (or refrains from taking action) in good faith in accordance with directions of a member of the Board or higher ranking executive but was unable to attain the desired results because such results were inherently unreasonable or unattainable.

(c)The Company may terminate Executive's employment in a Control Termination. A "Control Termination" shall mean any termination by the Company (or its successor) of Executive's employment for any reason within six months in anticipation of or within two years following a Change in Control.

The term "Change in Control" shall mean the occurrence of any of the following:

(i) the acquisition (other than an acquisition in connection with a “Non-Control Transaction”) by any "person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the "1934 Act")) of "beneficial ownership" (as such term is defined in Rule 13d-3 promulgated under the 1934 Act), directly or indirectly, of securities of CNO or its Ultimate Parent representing 51% or more of the combined voting power of the then outstanding securities of CNO or its Ultimate Parent entitled to vote generally with respect to the election of the Board or the board of directors of CNO's Ultimate Parent; or

(ii) as a result of or in connection with a tender or exchange offer or contest for election of directors, individual board members of CNO (identified as

6

of the date of commencement of such tender or exchange offer, or the commencement of such election contest, as the case may be) cease to constitute at least a majority of the Board; or

(iii) the consummation of a merger, consolidation or reorganization with or into CNO unless (x) the stockholders of CNO immediately before such transaction beneficially own, directly or indirectly, immediately following such transaction securities representing 51% or more of the combined voting power of the then outstanding securities entitled to vote generally with respect to the election of the board of directors of CNO (or its successor) or, if applicable, the Ultimate Parent and (y) individual board members of CNO (identified as of the date that a binding agreement providing for such transaction is signed) constitute at least a majority of the board of directors of CNO (or its successor) or, if applicable, the Ultimate Parent (a transaction to which clauses (x) and (y) apply, a “Non-Control Transaction”).

For purposes of this Agreement, “Ultimate Parent” shall mean the parent corporation (or if there is more than one parent corporation, the ultimate parent corporation) that, following a transaction, directly or indirectly beneficially owns a majority of the voting power of the outstanding securities entitled to vote with respect to the election of the board of directors of CNO (or its successor).

(d)At Executive's option, he may terminate employment with the Company "With Reason" provided one or more of the following conditions are met: (i) any reduction in Executive's Base Salary or Target Bonus without his consent, or (ii) there is a "Change in Control" as defined in Section 10(c) and, following Executive's written request made prior to the Change in Control, the ultimate parent entity or entities directly or indirectly gaining control of a majority of the Board or outstanding securities entitled to vote with respect to the Board fails to affirm and guarantee the Company's current and future obligations under this Agreement; provided that the events described in clauses (i) and (ii) above shall constitute With Reason only if the Company fails to cure such event (if capable of being cured) within 30 days after receipt from Executive of written notice of the event which constitutes With Reason; provided, further, that With Reason shall cease to exist for an event on the 60^th day following the later of its occurrence or Executive's knowledge thereof, unless Executive has given the Company written notice thereof prior to such date.

(e)Upon termination of Executive's employment with the Company for any reason (whether voluntary or involuntary), Executive shall be deemed to have voluntarily resigned from all positions that Executive may then hold with the Company and any of its affiliates; provided that such deemed resignation shall not adversely affect Executive's rights to compensation or benefits under this Agreement and shall not affect the determination of whether Executive's termination was for Just Cause or With Reason.

11. Payments Following Termination.

7

(a)In the event that Executive's employment is terminated by the Company for Just Cause or if Executive voluntarily resigns, then (i) the Company within 10 business days shall pay Executive a cash payment of his Base Salary as provided in Section 5(a) hereof that was earned but unpaid as of the date of termination (the “Termination Date”) and (ii) no bonus for the year of termination will be earned or paid to Executive. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(b)In the event Executive's employment is terminated by the death of Executive, then the Company shall pay Executive's estate within 30 days (i) the Accrued Amounts and (ii) a pro-rata portion of the Target Bonus for the year in which his death occurs. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(c)     In the event that Executive is terminated by the Company without Just Cause (and other than a termination due to expiration of the Term, death, disability or a Control Termination) or by Executive With Reason, then the Company shall pay Executive within 30 days of the Termination Date the Accrued Amounts. Additionally, following such a termination, Executive shall be entitled to receive (i) a bonus pursuant to Section 5(b) based on CNO's actual performance for the year in which Executive is terminated (prorated for the partial year period ending on the Termination Date), payable at the same time when such bonus amount normally would have been paid pursuant to Section 5(b), and (ii) a cash lump sum equal to the sum of his annual Base Salary and Target Bonus. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(d)     In the event that Executive is terminated by the Company (or its successor) in a Control Termination as so defined, then the Company shall pay Executive within 30 days of the Termination Date the Accrued Amounts. Additionally, following such a termination, Executive shall be entitled to receive (i) a bonus pursuant to Section 5(b) based on CNO's actual performance for the year during which Executive is terminated (prorated for the partial year period ending on the Termination Date), payable at the same time as such bonus payment would have been paid pursuant to Section 5(b), and (ii) a cash lump sum equal to the sum of (A) his Target Bonus and (B) one and one-half times his annual Base Salary. All stock options, restricted stock and/or other awards held by Executive upon the occurrence of a Change in Control shall be treated in accordance with the applicable award agreements.

(e)Notwithstanding anything to the contrary, payment of any severance under this Agreement is conditioned upon the execution by Executive of a separation and release agreement in a form acceptable to the Company and the observation of such waiting or revocation periods, if any, before and after execution of the agreement by Executive as are required by law, such as, for example, the waiting or revocation periods required for a waiver and release to be effective with respect to claims under the Age

8

Discrimination in Employment Act, provided that the Company delivers to Executive such agreement within seven days of the Termination Date.

12.Character of Termination Payments. The amounts payable to Executive upon any termination of his employment shall be considered severance pay in consideration of past services rendered on behalf of the Company and his continued service from the date hereof to the date he becomes entitled to such payments and shall be the sole amount of severance pay to which Executive is entitled from the Company and its affiliates upon termination of his employment during the Term. Executive shall have no duty to mitigate his damages by seeking other employment and, should Executive actually receive compensation from any such other employment, the payments required hereunder shall not be reduced or offset by any such other compensation.

13.Representations of the Parties.

(a)The Company represents and warrants to Executive that (i) this Agreement has been duly authorized, executed and delivered by the Company and constitutes valid and binding obligations of the Company; and (ii) the employment of Executive on the terms and conditions contained in this Agreement will not conflict with, result in a breach or violation of, constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to: (A) the certificate of formation, (B) the terms of any indenture, contract, lease, mortgage, deed of trust, note, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party or bound or to which its property is subject, or (C) any statute, law, rule, regulation, judgment, order or decree applicable to the Company, or any regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company.

(b)Executive represents and warrants to the Company that: (i) this Agreement has been duly executed and delivered by Executive and constitutes a valid and binding obligation of Executive; and (ii) neither the execution of this Agreement by Executive nor his employment by the Company on the terms and conditions contained herein will conflict with, result in a breach or violation of, or constitute a default under any agreement, obligation, condition, covenant or instrument to which Executive is a party or bound or to which his property is subject, or any statute, law, rule, regulation, judgment, order or decree applicable to Executive of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over Executive or any of his property.

14.Arbitration of Disputes; Injunctive Relief.

(a)Arbitration. Except as provided in subsection (b) below, any controversy or claim arising out of or relating to this Agreement or the breach thereof shall be settled by binding arbitration in the City of Indianapolis, Indiana, in accordance with the laws of the State of Indiana by three arbitrators, one of whom shall be appointed by the Company, one by Executive, and the third of whom shall be appointed by the first two arbitrators. If the first two arbitrators cannot agree on the appointment of a third

9

arbitrator, then the third arbitrator shall be appointed by the Chief Judge of the United States District Court for the Southern District of Indiana. The arbitration shall be conducted in accordance with the rules of the American Arbitration Association, except with respect to the selection of arbitrators, which shall be as provided in this Section. Judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. All reasonable costs and expenses (including fees and disbursements of counsel) incurred by Executive pursuant to this Section 14 shall be paid on behalf of or reimbursed to Executive promptly by the Company; provided, however, that in the event the Company prevails in such proceedings, Executive shall immediately repay all such amounts to the Company.

(b)Executive acknowledges that a breach or threatened breach by Executive of Sections 8 or 9 of this Agreement will give rise to irreparable injury to the Company and that money damages will not be adequate relief for such injury. Notwithstanding paragraph (a) above, the Company and Executive agree that the Company may seek and obtain injunctive relief, including, without limitation, temporary restraining orders, preliminary injunctions and/or permanent injunctions, in a court of proper jurisdiction to restrain or prohibit a breach or threatened breach of Section 8 or 9 of this Agreement. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies available to the Company for such breach or threatened breach, including the recovery of damages from Executive.

15.Notices. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered mail to his residence, in the case of Executive, or to the business office of its General Counsel, in the case of the Company.

16.Waiver of Breach and Severability. The waiver by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by either party. In the event any provision of this Agreement is found to be invalid or unenforceable, it may be severed from the Agreement, and the remaining provisions of the Agreement shall continue to be binding and effective.

17.Entire Agreement. Other than any equity award agreements entered into pursuant to the CNO Financial Group, Inc. Amended and Restated Long-Term Incentive Plan or any subsequent incentive plan, this instrument contains the entire agreement of the parties and, as of the Effective Date, supersedes all other obligations of the Company and its affiliates under other agreements or otherwise. The compensation and benefits to be paid under the terms of this Agreement are in lieu of all other compensation or benefits to which Executive is entitled from CNO, the Company, and its affiliates, and upon termination of Executive's employment with the Company Executive will not be entitled to receive any severance or other payments beyond those specified in this Agreement. This Agreement may not be changed orally, but only by an instrument in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

18.Binding Agreement and Governing Law; Assignment Limited. This Agreement shall be binding upon and shall inure to the benefit of the parties and their lawful successors in interest (including, without limitation, Executive's estate, heirs and personal representatives) and, except for issues or matters as to which federal law is applicable, shall be construed in

10

accordance with and governed by the laws of the State of Indiana. This Agreement is personal to each of the parties hereto, and neither party may assign or delegate any of its rights or obligations hereunder without the prior written consent of the other.

19.Indemnification. If Executive was or is made a party or is threatened to be made a party to or is otherwise involved (including involvement as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that he is or was an officer or employee of the Company or any of its affiliates, Executive shall be indemnified and held harmless by the Company to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than permitted prior thereto), against all expense, liability and loss (including attorneys' fees, judgments, fines, excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by Executive in connection therewith and such indemnification shall continue as to Executive if he ceases to be an officer or employee and shall inure to the benefit of Executive's heirs, executors and administrators; provided, however, that the Company shall indemnify Executive in connection with a Proceeding (or part thereof) initiated by Executive only if such Proceeding (or part thereof) was authorized by the managing member of the Company. The right to indemnification conferred in this paragraph shall include the obligation of the Company to pay the expenses incurred in defending any such Proceeding in advance of its final disposition (an “Advance of Expenses”); provided, however, that, if and to the extent that the Delaware General Corporation Law requires, an Advance of Expenses incurred by Executive in his capacity as an officer or employee shall be made only upon delivery to the Company of an undertaking, by or on behalf of Executive, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that Executive is not entitled to be indemnified for such expenses under this paragraph or otherwise.

20. No Third Party Beneficiaries. The terms and provisions of this Agreement are intended solely for the benefit of each party hereto and their respective successors or permitted assigns, and it is not intended to confer third-party beneficiary rights upon any other person.

21.Section 409A. This Agreement is intended to comply with Section 409A of the Code and will be interpreted accordingly. References under this Agreement to Executive's termination of employment shall be deemed to refer to the date upon which Executive has experienced a “separation from service” within the meaning of Section 409A of the Code. Notwithstanding anything herein to the contrary, (i) if at the time of Executive's separation from service with the Company Executive is a “specified employee” as defined in Section 409A of the Code (and any related regulations or announcements thereunder) and the deferral of the commencement of any payments or benefits otherwise payable hereunder or payable under any other compensatory arrangement between Executive and the Company or any of its affiliates as a result of such separation from service is necessary in order to prevent any accelerated or additional tax under Section 409A of the Code, then the Company will defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive's separation from service (or the earliest date as is permitted under Section 409A of the Code), at which point all payments deferred pursuant to this Section 21 shall be paid to Executive in a lump sum and (ii) if any payments of money or other benefits due to Executive

11

hereunder could cause the application of an accelerated or additional tax under Section 409A of the Code, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner that does not cause such an accelerated or additional tax. To the extent any reimbursements or in-kind benefits due to Executive under this Agreement constitute “deferred compensation” under Section 409A of the Code, any such reimbursements or in-kind benefits shall be paid to Executive in a manner consistent with Treas. Reg. Section 1.409A-3(i)(l)(iv). Additionally, to the extent that Executive's receipt of any in-kind benefits from the Company or its affiliates must be delayed pursuant to this Section 21 due to his status as a “specified employee,” Executive may elect to instead purchase and receive such benefits during the period in which the provision of benefits would otherwise be delayed by paying the Company (or its affiliates) for the fair market value of such benefits (as determined by the Company in good faith) during such period. Any amounts paid by Executive pursuant to the preceding sentence shall be reimbursed to Executive as described above on the date that is six months following his separation from service. Each payment made under this Agreement shall be designated as a “separate payment” within the meaning of Section 409A of the Code. The Company shall consult with Executive in good faith regarding the implementation of the provisions of this Section 21, provided that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect thereto.

22. Counterparts: This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written, effective as of the Effective Date.

COMPANY:

CNO SERVICES, LLC

/s/ Edward J. Bonach        

Edward J. Bonach

President

EXECUTIVE:

/s/ Bruce Baude            

Bruce Baude

12

EX-12.1

Exhibit 12.1

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Computation of Ratio of Earnings to Fixed Charges

(Dollars in millions)

	Nine months ended September 30, 2012			Year ended December 31, 2011
Pretax income from operations:
Net income	$	119.8		$	335.7
Add income tax benefit	(81.8		)	(29.5		)
Pretax income from operations	38.0			306.2
Add fixed charges:
Interest expense on corporate debt	50.4			76.3
Interest expense on investment borrowings and borrowings related to variable interest entities	36.3			37.8
Interest added to policyholder account balances	199.2			282.5
Portion of rental (a)	10.5			13.1
Fixed charges	296.4			409.7
Adjusted earnings	$	334.4		$	715.9
Ratio of earnings to fixed charges	1.13X			1.75X

____________________

(a) Interest portion of rental is estimated to be 33 percent.

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Edward J. Bonach, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of CNO Financial Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  February 1, 2013

/s/ Edward J. Bonach    

Edward J. Bonach

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Frederick J. Crawford, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of CNO Financial Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  February 1, 2013

/s/ Frederick J. Crawford    

Frederick J. Crawford

Executive Vice President

and Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CNO Financial Group, Inc. (the “Company”) on Form 10-Q/A for the period ending September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Edward J. Bonach, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my actual knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Edward J. Bonach    

Edward J. Bonach

Chief Executive Officer

February 1, 2013

A signed original of this written statement required by Section 906 has been provided to CNO Financial Group, Inc. and will be retained by CNO Financial Group, Inc. and furnished to the Securities and Exchange Commission upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CNO Financial Group, Inc. (the “Company”) on Form 10-Q/A for the period ending September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frederick J. Crawford, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my actual knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Frederick J. Crawford    

Frederick J. Crawford

Executive Vice President

and Chief Financial Officer

February 1, 2013

A signed original of this written statement required by Section 906 has been provided to CNO Financial Group, Inc. and will be retained by CNO Financial Group, Inc. and furnished to the Securities and Exchange Commission upon request.

XML

INVESTMENTS - AVAILABLE FOR SALE SECURITIES (DETAILS) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012		Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]
Trading securities	$ 199.4		$ 91.6
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	9.6		(4.4)
Net unrealized gains (losses) on all other investments	2,914.8		1,733.2
Adjustment to present value of future profits (a)	(200.7)	[1]	(214.8)	[1]
Adjustment to deferred acquisition costs	(458.0)		(289.3)
Adjustment to insurance liabilities	(334.4)		0
Unrecognized net loss related to deferred compensation plan	(8.8)		(8.3)
Deferred income tax liabilities	(688.1)		(434.8)
Accumulated other comprehensive income	1,234.4		781.6
Reduction to Present Value of Future Profits Due to Unrealized Gains That Would Result in Premium Deficiency if Unrealized Gains Were Realized	(166.5)
Reduction to Deferred Acquisition Costs Due to Unrealized Gains That Would Result in Premium Deficiency if Unrealized Gains Were Realized	(150.8)
Increase to insurance liabilities due to unrealized gains that would result in premium deficiency if unrealized gains were realized	(334.4)		0
Increase to Deferred Tax Assets Due to Unrealized Gains That Would Result in Premium Deficiency if Unrealized Gains Were Realized	234.6
Available-for-sale Debt Securities Amortized Cost Basis	21,825.7
Available-for-sale Securities, Gross Unrealized Gains	2,959.9
Available-for-sale Securities, Gross Unrealized Losses	(43.3)
Available-for-sale Securities, Fair Value Disclosure	24,742.3
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	(7.3)
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale Securities, Debt Maturities, within One Year, Amortized Cost Basis	178.3
Available-for-sale Securities, Debt Maturities, within One Year, Fair Value	180.7
Available-for-sale Securities, Debt Maturities, after One Through Five Years, Amortized Cost Basis	1,558.1
Available-for-sale Securities, Debt Maturities, after One Through Five Years, Fair Value	1,697.5
Available-for-sale Securities, Debt Maturities, after Five Through Ten Years, Amortized Cost Basis	4,491.1
Available-for-sale Securities, Debt Maturities, after Five Through Ten Years, Fair Value	5,038.7
Available-for-sale Securities, Debt Maturities, after Ten Years, Amortized Cost Basis	10,309.7
Available-for-sale Securities, Debt Maturities, after Ten Years, Fair Value	12,126.6
Available For Sale Securities, Debt Maturities, Amortized Cost, Subtotal	16,537.2
Available For Sale Securities, Debt Maturities, Fair Value, Subtotal	19,043.5
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Amortized Cost Basis	5,288.5
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value	5,698.8
Available-for-sale Securities, Debt Maturities, Amortized Cost Basis	21,825.7		21,779.1
Available-for-sale Securities, Debt Securities	24,742.3		23,516.0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	470.0		2,932.6
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	(12.2)		(104.0)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	584.1		835.9
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	(31.1)		(118.9)
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	1,054.1		3,768.5
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	(43.3)		(222.9)
Corporate securities [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	14,586.6
Available-for-sale Securities, Gross Unrealized Gains	2,265.7
Available-for-sale Securities, Gross Unrealized Losses	(28.8)
Available-for-sale Securities, Fair Value Disclosure	16,823.5
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	300.5		1,394.7
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	(9.2)		(57.0)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	278.1		466.2
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	(19.6)		(79.9)
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	578.6		1,860.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	(28.8)		(136.9)
US Treasury and Government [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	164.2
Available-for-sale Securities, Gross Unrealized Gains	6.9
Available-for-sale Securities, Gross Unrealized Losses	0
Available-for-sale Securities, Fair Value Disclosure	171.1
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value			9.1
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses			0
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value			0.2
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses			0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value			9.3
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses			0
US States and Political Subdivisions Debt Securities [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	1,785.6
Available-for-sale Securities, Gross Unrealized Gains	267.9
Available-for-sale Securities, Gross Unrealized Losses	(5.4)
Available-for-sale Securities, Fair Value Disclosure	2,048.1
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	40.2		6.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	(2.0)		(0.2)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	68.7		155.4
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	(3.4)		(13.4)
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	108.9		162.3
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	(5.4)		(13.6)
Foreign Government Debt Securities [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	0.8
Available-for-sale Securities, Gross Unrealized Gains	0
Available-for-sale Securities, Gross Unrealized Losses	0
Available-for-sale Securities, Fair Value Disclosure	0.8
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value			0.5
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses			0
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value			0
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses			0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value			0.5
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses			0
Asset-backed Securities [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	1,391.3
Available-for-sale Securities, Gross Unrealized Gains	92.0
Available-for-sale Securities, Gross Unrealized Losses	(6.6)
Available-for-sale Securities, Fair Value Disclosure	1,476.7
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	42.1		437.6
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	(0.3)		(14.5)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	137.8		147.5
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	(6.3)		(22.2)
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	179.9		585.1
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	(6.6)		(36.7)
Collateralized Debt Obligations [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	327.6
Available-for-sale Securities, Gross Unrealized Gains	5.2
Available-for-sale Securities, Gross Unrealized Losses	(0.8)
Available-for-sale Securities, Fair Value Disclosure	332.0
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	12.7		268.8
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	(0.1)		(6.3)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	47.2		1.7
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	(0.7)		0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	59.9		270.5
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	(0.8)		(6.3)
Commercial Mortgage Backed Securities [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	1,400.7
Available-for-sale Securities, Gross Unrealized Gains	142.7
Available-for-sale Securities, Gross Unrealized Losses	(0.8)
Available-for-sale Securities, Fair Value Disclosure	1,542.6
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	16.0		168.8
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	(0.1)		(5.2)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	14.3		33.0
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	(0.7)		(2.7)
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	30.3		201.8
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	(0.8)		(7.9)
Mortgage Pass Through Securities [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	18.8
Available-for-sale Securities, Gross Unrealized Gains	1.4
Available-for-sale Securities, Gross Unrealized Losses	0
Available-for-sale Securities, Fair Value Disclosure	20.2
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	0		1.2
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	0		0
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	2.0		2.2
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	0		(0.1)
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	2.0		3.4
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	0		(0.1)
Collateralized Mortgage Backed Securities [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Available-for-sale Debt Securities Amortized Cost Basis	2,150.1
Available-for-sale Securities, Gross Unrealized Gains	178.1
Available-for-sale Securities, Gross Unrealized Losses	(0.9)
Available-for-sale Securities, Fair Value Disclosure	2,327.3
Other than Temporary Impairment Losses, Investments, Available-for-sale Securities	(7.3)
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	58.5		645.0
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	(0.5)		(20.8)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	36.0		29.7
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	(0.4)		(0.6)
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	94.5		674.7
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	(0.9)		(21.4)
Equity Securities [Member]
Available-for-sale Securities, Continuous Unrealized Loss Position [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	2.1		41.6
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses	(0.1)		(3.0)
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	0		0.4
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Losses	0		0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	2.1		42.0
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	$ (0.1)		$ (3.0)

[1] The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003 (the date our Predecessor emerged from bankruptcy).

XML

SALES INDUCEMENTS (DETAILS) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Deferred Sales Inducements [Abstract]
Deferred Sales Inducements, Additions	$ 3.1	$ 9.7
Deferred Sales Inducements, Amortization Expense	20.5	21.2
Deferred Sales Inducements, Net	131.8		149.2
Persistency Bonus Benefits Included in Insurance Liabilities	$ 36.6		$ 50.0

XML

INCOME TAXES - OPERATING LOSS CARRYFORWARDS (DETAILS) (USD $)	1 Months Ended	9 Months Ended		12 Months Ended
	Jul. 31, 2006	Sep. 30, 2012		Dec. 31, 2008	Dec. 31, 2011
Operating Loss Carryforwards [Line Items]
Other Tax Carryforward, Gross Amount		$ 872,500,000
Total loss carryforwards		4,776,000,000
Net operating loss carryforward to be reclassified as non life net operating loss carryforwards		631,000,000
Loss on Investment in Senior Health				742,000,000
Net state operating loss carryforwards		16,300,000			16,800,000
Cancellation of Debt Income Realized	2,500,000,000
Valuation Allowance, Deferred Tax Asset, Change in Amount Due to Classifying Loss as Ordinary		140,000,000
Carryforward Expiration 2013 [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Carryforward, Expiration Dates		2013
Other Tax Carryforward, Gross Amount		836,700,000
Total loss carryforwards		836,700,000
Carryforward Expiration 2014 [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Carryforward, Expiration Dates		2014
Other Tax Carryforward, Gross Amount		28,600,000
Total loss carryforwards		28,600,000
Carryforward Expiration 2015 [Member]
Operating Loss Carryforwards [Line Items]
Other Tax Carryforward, Expiration Dates		2015
Other Tax Carryforward, Gross Amount		7,200,000
Total loss carryforwards		7,200,000
Carryforward Expiration 2018 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2018
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		550,900,000
Carryforward Expiration 2021 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2021
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		29,500,000
Carryforward Expiration 2022 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2022
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		204,100,000
Carryforward Expiration 2023 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2023
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		2,602,800,000
Carryforward Expiration 2024 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2024
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		3,200,000
Carryforward Expiration 2025 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2025
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		118,800,000
Carryforward Expiration 2027 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2027
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		216,800,000
Carryforward Expiration 2028 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2028
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		500,000
Carryforward Expiration 2029 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2029
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		148,900,000
Carryforward Expiration 2031 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates		2031
Other Tax Carryforward, Gross Amount		0
Total loss carryforwards		28,000,000
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		3,900,000,000
Non Life Insurance Companies [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		3,119,000,000
Valuation Allowance, Deferred Tax Asset, Change in Amount Due to Cancellation of Debt Income Issue		140,000,000
Amount of Tax Losses on Investment in Conseco Finance Corp	3,800,000,000
Non Life Insurance Companies [Member] | Carryforward Expiration 2013 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Non Life Insurance Companies [Member] | Carryforward Expiration 2014 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Non Life Insurance Companies [Member] | Carryforward Expiration 2015 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Non Life Insurance Companies [Member] | Carryforward Expiration 2018 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Non Life Insurance Companies [Member] | Carryforward Expiration 2021 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Non Life Insurance Companies [Member] | Carryforward Expiration 2022 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Non Life Insurance Companies [Member] | Carryforward Expiration 2023 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		2,602,800,000	[1]
Non Life Insurance Companies [Member] | Carryforward Expiration 2024 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		3,200,000
Non Life Insurance Companies [Member] | Carryforward Expiration 2025 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		118,800,000
Non Life Insurance Companies [Member] | Carryforward Expiration 2027 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		216,800,000
Non Life Insurance Companies [Member] | Carryforward Expiration 2028 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		500,000
Non Life Insurance Companies [Member] | Carryforward Expiration 2029 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		148,900,000
Non Life Insurance Companies [Member] | Carryforward Expiration 2031 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		28,000,000
Life Insurance Companies [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		784,500,000
Amount of Tax Losses on Investment in Conseco Finance Corp	2,100,000,000
Life Insurance Companies [Member] | Carryforward Expiration 2013 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Life Insurance Companies [Member] | Carryforward Expiration 2014 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Life Insurance Companies [Member] | Carryforward Expiration 2015 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Life Insurance Companies [Member] | Carryforward Expiration 2018 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		550,900,000	[1]
Life Insurance Companies [Member] | Carryforward Expiration 2021 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		29,500,000
Life Insurance Companies [Member] | Carryforward Expiration 2022 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		204,100,000
Life Insurance Companies [Member] | Carryforward Expiration 2023 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0	[2]
Life Insurance Companies [Member] | Carryforward Expiration 2024 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Life Insurance Companies [Member] | Carryforward Expiration 2025 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Life Insurance Companies [Member] | Carryforward Expiration 2027 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Life Insurance Companies [Member] | Carryforward Expiration 2028 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Life Insurance Companies [Member] | Carryforward Expiration 2029 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		0
Life Insurance Companies [Member] | Carryforward Expiration 2031 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		$ 0

[1] The life/non-life allocation summarized above assumes the IRS does not ultimately agree with the tax position we have taken in our tax returns with respect to the allocation of CODI. If the IRS ultimately agrees with our tax position, approximately $631 million of the non-life NOLs expiring in 2023 would be characterized as life NOLs expiring in 2018.

[2] The allocation of the capital loss carryforwards summarized above assumes the IRS does not ultimately agree with the tax position we have taken with respect to our investment in Senior Health, which was worthless when it was transferred to the Independent Trust in 2008. If the IRS ultimately agrees with our tax position of classifying this loss as ordinary, capital loss carryforwards expiring in 2013 would decrease and life NOLs expiring in 2023 would increase by $742 million.

XML

RECENTLY ISSUED ACCOUNTING STANDARDS (DETAILS) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Changes from Adoption of New Accounting Standard, Statement of Operations [Abstract]
Amortization	$ 60.9	$ 58.6	$ 215.8	$ 224.1
Other operating costs and expenses	217.5	182.0	617.8	527.8
Total benefits and expenses	1,251.8	930.6	3,243.9	2,869.6
Income before income taxes	(158.8)	61.7	38.0	203.9
Tax expense on period income	(10.8)	25.2	61.2	75.6
Net income (loss)	(5.0)	179.5	119.8	271.3
Earnings Per Share, Basic	$ (0.02)	$ 0.73	$ 0.51	$ 1.09
Earnings Per Share, Diluted	$ (0.02)	$ 0.61	$ 0.45	$ 0.92
Changes from Adoption of New Accounting Standard, Statements of Cash Flows [Abstract]
Policy acquisition costs			(141.4)	(164.9)
Other operating costs			(558.6)	(513.6)
Net cash provided by operating activities			424.6	562.2
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Balance, beginning of period	653.5	975.5	797.1	999.6
Deferred Policy Acquisition Costs, Additions	46.7	58.3	141.4	164.9
Deferred Policy Acquisition Cost, Amortization Expense	(44.5)	(35.5)	(146.4)	(134.7)
Deferred Policy Acquisition Cost, Related to Fair Value Adjustment of Fixed Maturities	(32.3)	(163.8)	(168.7)	(195.3)
Balance, end of period	623.4	834.5	623.4	834.5
As originally reported [Member]
Changes from Adoption of New Accounting Standard, Statement of Operations [Abstract]
Amortization		87.2		325.4
Other operating costs and expenses		127.6		367.1
Total benefits and expenses		904.8		2,810.2
Income before income taxes		87.5		263.3
Tax expense on period income		34.5		96.9
Net income (loss)		196.0		309.4
Earnings Per Share, Basic		$ 0.79		$ 1.24
Earnings Per Share, Diluted		$ 0.66		$ 1.05
Changes from Adoption of New Accounting Standard, Statements of Cash Flows [Abstract]
Policy acquisition costs				328.6
Other operating costs				349.9
Net cash provided by operating activities				562.2
Effect of adoption of ASU 2010-26 [Member]
Changes from Adoption of New Accounting Standard, Statement of Operations [Abstract]
Amortization		(28.6)		(101.3)
Other operating costs and expenses		54.4		160.7
Total benefits and expenses		25.8		59.4
Income before income taxes		(25.8)		(59.4)
Tax expense on period income		(9.3)		(21.3)
Net income (loss)		(16.5)		(38.1)
Earnings Per Share, Basic		$ (0.06)		$ (0.15)
Earnings Per Share, Diluted		$ (0.05)		$ (0.13)
Changes from Adoption of New Accounting Standard, Statements of Cash Flows [Abstract]
Policy acquisition costs				(163.7)
Other operating costs				163.7
Net cash provided by operating activities				0
As adjusted [Member]
Changes from Adoption of New Accounting Standard, Statement of Operations [Abstract]
Amortization		58.6		224.1
Other operating costs and expenses		182.0		527.8
Total benefits and expenses		930.6		2,869.6
Income before income taxes		61.7		203.9
Tax expense on period income		25.2		75.6
Net income (loss)		179.5		271.3
Earnings Per Share, Basic		$ 0.73		$ 1.09
Earnings Per Share, Diluted		$ 0.61		$ 0.92
Changes from Adoption of New Accounting Standard, Statements of Cash Flows [Abstract]
Policy acquisition costs				164.9
Other operating costs				513.6
Net cash provided by operating activities				$ 562.2

XML

REINSURANCE (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Ceded Premiums Written	$ 48.0	$ 58.3	$ 164.5	$ 176.3
Reinsurance Effect on Claims and Benefits Incurred, Amount Ceded	56.4	45.4	172.2	160.2
Assumed Premiums Written	15.9	18.1	54.7	64.6
Coventry Health Care Marketing and Quota Share Agreements [Member]
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Assumed Premiums Written	$ 11.4	$ 12.8	$ 39.9	$ 47.6

XML

CHANGES IN COMMON STOCK (TABLES)

9 Months Ended

Sep. 30, 2012

Equity [Abstract]

Schedule of Stock by Class

Changes in the number of shares of common stock outstanding were as follows (shares in thousands):

Balance, December 31, 2011	241,305
Treasury stock purchased and retired	(12,894	)
Stock options exercised	692
Restricted stock vested	404		(a)
Balance, September 30, 2012	229,507

________

(a) Such amount was reduced by 143 thousand shares which were tendered to the Company for the payment of federal and state taxes owed on the vesting of restricted stock.

XML

CONSOLIDATED STATEMENT CASH FLOWS (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net income (loss)	$ (5.0)	$ 179.5	$ 119.8	$ 271.3
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization and depreciation			235.2	243.6
Income taxes			(87.3)	(69.8)
Insurance liabilities			242.8	244.4
Accrual and amortization of investment income			(123.1)	62.9
Deferral of policy acquisition costs			(141.4)	(164.9)
Net realized investment (gains) losses	(9.1)	(30.6)	(63.9)	(38.6)
Loss on extinguishment of debt	198.5	1.1	199.2	3.1
Other			43.3	10.2
Net cash provided by operating activities			424.6	562.2
Other Noncash Investing and Financing Items [Abstract]
Stock option and restricted stock plans			$ 10.7	$ 10.2

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2012

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price.  We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, cash and cash equivalents, separate account assets and embedded derivatives.  We carry our company-owned life insurance policy, which is backed by a series of mutual funds, at its cash surrender value and our hedge fund investments at their net asset values; in both cases, we believe these values approximate their fair values. In addition, we disclose fair value for certain financial instruments, including mortgage loans and policy loans, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs.

The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information.  Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value.  Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value.

Valuation Hierarchy

There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable.

• Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities.  Our Level 1 assets primarily include cash and exchange traded securities.

• Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data.  Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies.  These models are primarily industry-standard models that consider various inputs such as interest rate, credit spread, reported trades, broker/dealer quotes, issuer spreads and other inputs that are observable or derived from observable information in the marketplace or are supported by observable levels at which transactions are executed in the marketplace.  Financial assets in this category primarily include:  certain public and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund and hedge fund investments; and most short-term investments; and non-exchange-traded derivatives such as call options to hedge liabilities related to our fixed index annuity products. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.

• Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions.  Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on non-binding broker prices or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information.  Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities.  Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.

At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value.  This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions.  Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. Any transfers between levels are reported as having occurred at the beginning of the period. There were no significant transfers between Level 1 and Level 2 in the first nine months of 2012.

The vast majority of our fixed maturity and equity securities, including those held in trading portfolios and those held by consolidated VIEs, short-term and separate account assets use Level 2 inputs for the determination of fair value.  These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value.  Substantially all of our Level 2 fixed maturity securities and separate account assets were valued from independent pricing services.  Third party pricing services normally derive the security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information.  If there are no recently reported trades, the third party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are developed and discounted at an estimated risk-adjusted market rate.  The number of prices obtained for a given security is dependent on the Company’s analysis of such prices as further described below.

For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes.  These broker quotes are non-binding andrepresent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs.  Approximately 22 percent of our Level 3 fixed maturity securities were valued using unadjusted broker quotes or broker-provided valuation inputs.  The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs.  For these securities, we use internally developed valuations.  Key assumptions used to determine fair value for these securities may include risk-free rates, risk premiums, performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market.  For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are developed and discounted at an estimated market rate.  The pricing matrix utilizes a spread level to determine the market price for a security.  The credit spread generally incorporates the issuer’s credit rating and other factors relating to the issuer’s industry and the security’s maturity.  In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity.

As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value.  The Company’s analysis includes:  (i) a review of the methodology used by third party pricing services; (ii) where available, a comparison of multiple pricing services’ valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably stale; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties.  As a result of such procedures, the Company may conclude the prices received from third parties are not reflective of current market conditions.  In those instances, we may request additional pricing quotes or apply internally developed valuations.  However, the number of instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received.

The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company’s judgment of the inputs or methodologies used by the independent pricing services to value different asset classes.  Such inputs include:  benchmark yields, reported trades, broker dealer quotes, issuer spreads, benchmark securities, bids, offers and reference data.  The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments.

Except for exchange traded derivatives which are classified as Level 1, the fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotations; time value and volatility factors underlying options; market interest rates; and non-performance risk.  For certain embedded derivatives, we may use actuarial assumptions in the determination of fair value.

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at September 30, 2012 is as follows (dollars in millions):

	Quoted prices in active markets  for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	16,506.2	$	317.3	$	16,823.5
United States Treasury securities and obligations of United States government corporations and agencies	—		171.1		—		171.1
States and political subdivisions	—		2,048.1		—		2,048.1
Debt securities issued by foreign governments	—		.8		—		.8
Asset-backed securities	—		1,433.9		42.8		1,476.7
Collateralized debt obligations	—		—		332.0		332.0
Commercial mortgage-backed securities	—		1,540.3		2.3		1,542.6
Mortgage pass-through securities	—		18.2		2.0		20.2
Collateralized mortgage obligations	—		2,284.2		43.1		2,327.3
Total fixed maturities, available for sale	—		24,002.8		739.5		24,742.3
Equity securities:
Corporate securities	20.5		119.2		2.2		141.9
Venture capital investments	—		—		38.1		38.1
Total equity securities	20.5		119.2		40.3		180.0
Trading securities:
Corporate securities	—		49.3		.6		49.9
United States Treasury securities and obligations of United States government corporations and agencies	—		4.9		—		4.9
States and political subdivisions	—		17.1		—		17.1
Asset-backed securities	—		50.3		—		50.3
Collateralized debt obligations	—		—		7.0		7.0
Commercial mortgage-backed securities	—		43.6		—		43.6
Mortgage pass-through securities	—		.2		—		.2
Collateralized mortgage obligations	—		24.1		—		24.1
Equity securities	.9		1.4		—		2.3
Total trading securities	.9		190.9		7.6		199.4
Investments held by variable interest entities - corporate securities	—		829.4		—		829.4
Other invested assets:
Company-owned life insurance	—		112.3		—		112.3
Hedge funds	—		16.3		—		16.3
Derivatives	—		81.8		—		81.8
Total other invested assets	—		210.4		—		210.4
Cash and cash equivalents - unrestricted:
Cash	202.0		—		—		202.0
Cash equivalents and short-term investments	—		213.3		—		213.3
Total cash and cash equivalents - unrestricted	202.0		213.3		—		415.3
Cash and cash equivalents held by variable interest entities	48.2		—		—		48.2
Assets held in separate accounts	—		15.7		—		15.7
Total assets carried at fair value by category	$	271.6	$	25,581.7	$	787.4	$	26,640.7
Liabilities:
Liabilities for insurance products:
Interest-sensitive products - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	737.9	$	737.9
Interest-sensitive products - embedded derivatives associated with modified coinsurance agreement	—		—		6.0		6.0
Total liabilities for insurance products	—		—		743.9		743.9
Total liabilities carried at fair value by category	$	—	$	—	$	743.9	$	743.9

For those financial instruments disclosed at fair value, we use the following methods and assumptions to determine the estimated fair values:

Mortgage loans and policy loans.  We discount future expected cash flows for loans included in our investment portfolio based on interest rates currently being offered for similar loans to borrowers with similar credit ratings.  We aggregate loans with similar characteristics in our calculations.  The fair value of policy loans approximates their carrying value.

Insurance liabilities for interest-sensitive products.  We discount future expected cash flows based on interest rates currently being offered for similar contracts with similar maturities.

Investment borrowings, notes payable and borrowings related to variable interest entities.  For publicly traded debt, we use current fair values.  For other notes, we use discounted cash flow analyses based on our current incremental borrowing rates for similar types of borrowing arrangements.

The fair value measurements for our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions):

	September 30, 2012										December 31, 2011
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,718.3	$	1,718.3	$	1,597.2	$	1,735.4	$	1,602.8
Policy loans	—		274.1		—		274.1		274.1		279.7		279.7
Liabilities:
Insurance liabilities for interest-sensitive products excluding embedded derivatives (a)	—		—		12,186.4		12,186.4		12,186.4		13,165.5		13,165.5
Investment borrowings	—		1,702.5		—		1,702.5		1,650.9		1,735.7		1,676.5
Borrowings related to variable interest entities	—		748.3		—		748.3		766.9		485.1		519.9
Notes payable – direct corporate obligations	—		1,114.4		—		1,114.4		1,035.1		978.3		857.9

____________________

(a) The estimated fair value of insurance liabilities for interest-sensitive products was approximately equal to its carrying value at September 30, 2012.  This was because interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.

The categorization of fair value measurements, by input level, for our fixed maturity securities, equity securities, trading securities, certain other invested assets, assets held in separate accounts and embedded derivative instruments included in liabilities for insurance products at December 31, 2011 is as follows (dollars in millions):

	Quoted prices in active markets  for identical assets or liabilities  (Level 1)		Significant other observable inputs (Level 2) (a)			Significant unobservable inputs  (Level 3) (a)			Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	15,594.4		$	278.1		$	15,872.5
United States Treasury securities and obligations of United States government corporations and agencies	—		303.8			1.6			305.4
States and political subdivisions	—		1,952.3			2.1			1,954.4
Debt securities issued by foreign governments	—		1.4			—			1.4
Asset-backed securities	—		1,334.3			79.7			1,414.0
Collateralized debt obligations	—		—			327.3			327.3
Commercial mortgage-backed securities	—		1,415.7			17.3			1,433.0
Mortgage pass-through securities	—		29.8			2.2			32.0
Collateralized mortgage obligations	—		2,051.2			124.8			2,176.0
Total fixed maturities, available for sale	—		22,682.9			833.1			23,516.0
Equity securities	17.9		87.3			69.9			175.1
Trading securities:
Corporate securities	—		67.6			—			67.6
United States Treasury securities and obligations of United States government corporations and agencies	—		4.9			—			4.9
States and political subdivisions	—		15.6			—			15.6
Asset-backed securities	—		.1			—			.1
Commercial mortgage-backed securities	—		—			.4			.4
Mortgage pass-through securities	—		.2			—			.2
Collateralized mortgage obligations	—		.7			—			.7
Equity securities	.7		1.4			—			2.1
Total trading securities	.7		90.5			.4			91.6
Investments held by variable interest entities	—		496.3			—			496.3
Other invested assets	—		159.9		(b)	—			159.9
Assets held in separate accounts	—		15.0			—			15.0
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	—		—			669.8		(c)	669.8

_____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) Includes company-owned life insurance and derivatives.

(c) Includes $666.3 million of embedded derivatives associated with our fixed index annuity products and $3.5 million of embedded derivatives associated with a modified coinsurance agreement.

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended September 30, 2012 (dollars in millions):

	September 30, 2012
	Beginning balance as of June 30, 2012 (a)			Purchases, sales, issuances and settlements, net (c)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		Transfers into Level 3		Transfers out of Level 3 (b)			Ending balance as of September 30, 2012			Amount of total gains (losses) for the three months ended September 30, 2012 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	321.0		$	14.0		$	—		$	7.3	$	12.5	$	(37.5	)	$	317.3		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.5			(1.5		)	—			—		—		—			—			—
States and political subdivisions	16.0			—			—			—		—		(16.0		)	—			—
Asset-backed securities	23.0			15.0			—			5.5		—		(.7		)	42.8			—
Collateralized debt obligations	330.1			(6.3		)	—			8.2		—		—			332.0			—
Commercial mortgage-backed securities	—			—			—			—		2.3		—			2.3			—
Mortgage pass-through securities	2.1			(.1		)	—			—		—		—			2.0			—
Collateralized mortgage obligations	4.5			(2.8		)	.1			1.0		44.6		(4.3		)	43.1			—
Total fixed maturities, available for sale	698.2			18.3			.1			22.0		59.4		(58.5		)	739.5			—
Equity securities:
Corporate securities	3.2			(1.0		)	—			—		—		—			2.2			—
Venture capital investments	58.0			—			(23.1		)	3.2		—		—			38.1			(23.1		)
Total equity securities	61.2			(1.0		)	(23.1		)	3.2		—		—			40.3			(23.1		)
Trading securities:
Corporate securities	—			—			—			—		.6		—			.6			—
States and political subdivisions	.5			—			—			—		—		(.5		)	—			—
Collateralized debt obligations	3.4			2.8			—			.8		—		—			7.0			.8
Total trading securities	3.9			2.8			—			.8		.6		(.5		)	7.6			.8
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(705.9		)	(22.7		)	(15.3		)	—		—		—			(743.9		)	(15.3		)

____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.

(c) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the three months ended September 30, 2012 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	27.0		$	(13.0	)	$	—		$	—	$	14.0
United States Treasury securities and obligations of United States government corporations and agencies	—			(1.5		)	—			—		(1.5		)
Asset-backed securities	15.0			—			—			—		15.0
Collateralized debt obligations	—			(6.3		)	—			—		(6.3		)
Mortgage pass-through securities	—			(.1		)	—			—		(.1		)
Collateralized mortgage obligations	11.0			(13.8		)	—			—		(2.8		)
Total fixed maturities, available for sale	53.0			(34.7		)	—			—		18.3
Equity securities - corporate securities	—			(1.0		)	—			—		(1.0		)
Trading securities - collateralized debt obligations	2.8			—			—			—		2.8
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(23.5		)	.2			(10.2		)	10.8		(22.7		)

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the nine months ended September 30, 2012 (dollars in millions):

	September 30, 2012
	Beginning balance as of December 31, 2011 (a)			Purchases, sales, issuances and settlements, net (c)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		Transfers into Level 3		Transfers out of Level 3 (b)			Ending balance as of September 30, 2012			Amount of total gains (losses) for the nine months ended September 30, 2012 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	278.1		$	54.9		$	—		$	9.4	$	67.5	$	(92.6	)	$	317.3		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.6			(1.6		)	—			—		—		—			—			—
States and political subdivisions	2.1			—			—			—		—		(2.1		)	—			—
Asset-backed securities	79.7			11.4			(.2		)	5.8		.5		(54.4		)	42.8			—
Collateralized debt obligations	327.3			(11.6		)	—			16.3		—		—			332.0			—
Commercial mortgage-backed securities	17.3			—			—			.1		—		(15.1		)	2.3			—
Mortgage pass-through securities	2.2			(.2		)	—			—		—		—			2.0			—
Collateralized mortgage obligations	124.8			30.0			(.1		)	1.4		—		(113.0		)	43.1			—
Total fixed maturities, available for sale	833.1			82.9			(.3		)	33.0		68.0		(277.2		)	739.5			—
Equity securities:
Corporate securities	6.4			(1.0		)	(3.8		)	.6		—		—			2.2			(3.8		)
Venture capital investments	63.5			—			(26.0		)	.6		—		—			38.1			(26.0		)
Total equity securities	69.9			(1.0		)	(29.8		)	1.2		—		—			40.3			(29.8		)
Trading securities:
Corporate securities	—			—			—			.1		.5		—			.6			.1
States and political subdivisions	—			—			—			—		—		—			—			—
Collateralized debt obligations	—			7.0			—			—		—		—			7.0			—
Commercial mortgage-backed securities	.4			—			—			—		—		(.4		)	—			—
Total trading securities	.4			7.0			—			.1		.5		(.4		)	7.6			.1
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(669.8		)	(52.1		)	(22.0		)	—		—		—			(743.9		)	(22.0		)

____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.

(c) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the nine months ended September 30, 2012 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	70.3		$	(15.4	)	$	—		$	—	$	54.9
United States Treasury securities and obligations of United States government corporations and agencies	—			(1.6		)	—			—		(1.6		)
Asset-backed securities	15.0			(3.6		)	—			—		11.4
Collateralized debt obligations	30.1			(41.7		)	—			—		(11.6		)
Mortgage pass-through securities	—			(.2		)	—			—		(.2		)
Collateralized mortgage obligations	45.3			(15.3		)	—			—		30.0
Total fixed maturities, available for sale	160.7			(77.8		)	—			—		82.9
Equity securities - corporate securities	—			(1.0		)	—			—		(1.0		)
Trading securities - collateralized debt obligations	7.0			—			—			—		7.0
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(75.3		)	41.9			(50.6		)	31.9		(52.1		)

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended September 30, 2011 (dollars in millions):

	September 30, 2011
	Beginning balance as of June 30, 2011			Purchases, sales, issuances and settlements, net (a)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in other comprehensive income (loss)			Transfers into Level 3		Transfers out of Level 3			Ending balance as of September 30, 2011			Amount of total gains (losses) for the three months ended September 30, 2011 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	361.8		$	(111.2	)	$	4.9		$	5.4		$	.5	$	(17.6	)	$	243.8		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.7			—			—			—			—		—			1.7			—
States and political subdivisions	—			—			—			.1			2.0		—			2.1			—
Asset-backed securities	170.7			1.2			—			—			4.1		(113.4		)	62.6			—
Collateralized debt obligations	193.5			72.7			—			(6.1		)	—		—			260.1			—
Mortgage pass-through securities	3.2			(.2		)	—			—			—		—			3.0			—
Collateralized mortgage obligations	204.1			3.6			—			.7			—		(30.2		)	178.2			—
Total fixed maturities, available for sale	935.0			(33.9		)	4.9			0.1			6.6		(161.2		)	751.5			—
Equity securities	44.6			27.3			—			(.3		)	—		—			71.6			—
Trading securities:
Collateralized mortgage obligations	—			—			—			—			—		—			—			—
Total trading securities	—			—			—			—			—		—			—			—
Investments held by variable interest entities:
Corporate securities	—			—			—			—			—		—			—			—
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(613.4		)	16.3			(44.8		)	—			—		—			(641.9		)	(44.8		)

____________

(a) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the three months ended September 30, 2011 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1.8		$	(113.0	)	$	—		$	—	$	(111.2	)
Asset-backed securities	4.2			(3.0		)	—			—		1.2
Collateralized debt obligations	84.2			(11.5		)	—			—		72.7
Mortgage pass-through securities	—			(.2		)	—			—		(.2		)
Collateralized mortgage obligations	20.5			(16.9		)	—			—		3.6
Total fixed maturities, available for sale	110.7			(144.6		)	—			—		(33.9		)
Equity securities	27.3			—			—			—		27.3
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(33.1		)	41.7			(2.6		)	10.3		16.3

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the nine months ended September 30, 2011 (dollars in millions):

	September 30, 2011
	Beginning balance as of December 31, 2010			Purchases, sales, issuances and settlements, net (a)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in other comprehensive income (loss)			Transfers into Level 3		Transfers out of Level 3			Ending balance as of September 30, 2011			Amount of total gains (losses) for the nine months ended September 30, 2011 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1,907.8		$	(289.0	)	$	(16.1	)	$	12.7		$	39.0	$	(1,410.6	)	$	243.8		$	(11.5	)
United States Treasury securities and obligations of United States government corporations and agencies	2.0			—			—			(.3		)	—		—			1.7			—
States and political subdivisions	2.5			(2.8		)	(.1		)	.5			2.0		—			2.1			—
Asset-backed securities	182.3			(.6		)	—			2.5			15.1		(136.7		)	62.6			—
Collateralized debt obligations	256.5			3.5			1.8			(1.7		)	—		—			260.1			—
Mortgage pass-through securities	3.5			(.5		)	—			—			—		—			3.0			—
Collateralized mortgage obligations	197.1			48.5			(2.1		)	3.2			5.9		(74.4		)	178.2			—
Total fixed maturities, available for sale	2,551.7			(240.9		)	(16.5		)	16.9			62.0		(1,621.7		)	751.5			(11.5		)
Equity securities	6.9			64.0			—			.7			—		—			71.6			—
Trading securities:
Collateralized mortgage obligations	.4			(.4		)	—			—			—		—			—			—
Total trading securities	.4			(.4		)	—			—			—		—			—			—
Investments held by variable interest entities:
Corporate securities	6.7			(7.9		)	1.5			(.3		)	—		—			—			—
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(553.2		)	(35.0		)	(53.7		)	—			—		—			(641.9		)	(53.7		)

____________

(a) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the nine months ended September 30, 2011 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1.8		$	(290.8	)	$	—		$	—	$	(289.0	)
States and political subdivisions	—			(2.8		)	—			—		(2.8		)
Asset-backed securities	4.1			(4.7		)	—			—		(.6		)
Collateralized debt obligations	106.6			(103.1		)	—			—		3.5
Mortgage pass-through securities	—			(.5		)	—			—		(.5		)
Collateralized mortgage obligations	94.5			(46.0		)	—			—		48.5
Total fixed maturities, available for sale	207.0			(447.9		)	—			—		(240.9		)
Equity securities	64.0			—			—			—		64.0
Trading securities:
Collateralized mortgage obligations	—			(.4		)	—			—		(.4		)
Investments held by variable interest entities:
Corporate securities	—			(7.9		)	—			—		(7.9		)
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(85.5		)	51.8			(28.4		)	27.1		(35.0		)

At September 30, 2012, 89 percent of our Level 3 fixed maturities, available for sale, were investment grade and 45 percent and 43 percent of our Level 3 fixed maturities, available for sale, consisted of collateralized debt obligations and corporate securities, respectively.

Realized and unrealized investment gains and losses presented in the preceding tables represent gains and losses during the time the applicable financial instruments were classified as Level 3.

Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and reinsurer accounts and other special-purpose portfolios, net realized investment gains (losses) or insurance policy benefits within the consolidated statement of operations or accumulated other comprehensive income within shareholders’ equity based on the appropriate accounting treatment for the instrument.

The amount presented for gains (losses) included in our net loss for assets and liabilities still held as of the reporting date primarily represents impairments for fixed maturities, available for sale, changes in fair value of trading securities and certain derivatives and changes in fair value of embedded derivative instruments included in liabilities for insurance products that exist as of the reporting date.

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at September 30, 2012 (dollars in millions):

	Fair value at September 30, 2012		Valuation technique(s)	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	212.4	Discounted cash flow analysis	Discount margins	1.95% - 3.27% (2.78%)
Asset-backed securities (b)	33.0		Discounted cash flow analysis	Discount margins	2.96% - 3.28% (3.15%)
Collateralized debt obligations (c)	339.0		Discounted cash flow analysis	Recoveries	61% - 66% (ramp over 24 months)
				Constant prepayment rate	20%
				Discount margins	1.30% - 10.00% (2.39%)
				Annual default rate	1.32% - 5.81% (3.27%)
				Portfolio CCC %	1.90% - 22.17% (12.78%)
Equity securities (d)	2.2		Discounted cash flow analysis	Recoveries	21%
Venture capital investments (e)	38.1		Market multiples	EBITDA multiple	4.8 - 29.0 (11.46)
				Revenue multiple	0.9 - 7.0 (4.2)
				Book equity multiple	0.8 - 3.8 (2.3)
Other assets categorized as Level 3 (f)	162.7		Unadjusted third-party price source	Not applicable	Not applicable
Total	787.4
Liabilities:
Interest sensitive products (g)	743.9		Discounted projected embedded derivatives	Projected portfolio yields	5.35% - 5.61% (5.55%)
				Discount rates	0.0 - 3.5% (1.3%)
				Surrender rates	4% - 43% (19%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Asset-backed securities - The significant unobservable input used in the fair value measurement of our asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(c) Collateralized debt obligations - The significant unobservable inputs used in the fair value measurement of our collateralized debt obligations relate to collateral performance, including default rate, recoveries and constant prepayment rate, as well as discount margins of the underlying collateral. Significant increases (decreases) in default rate in isolation would result in a significantly lower (higher) fair value measurement. Generally, a significant increase (decrease) in the constant prepayment rate and recoveries in isolation would result in a significantly higher (lower) fair value measurement. Generally a significant increase (decrease) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the annual default rate is accompanied by a directionally similar change in the assumption used for discount margins and portfolio CCC % and a directionally opposite change in the assumption used for constant prepayment rate and recoveries. A tranche's payment priority and investment cost basis could alter generalized fair value outcomes.

(d) Equity securities - The significant unobservable input used in the fair value measurement of our equity securities is the anticipated cash recovery. Significant increases (decreases) in the anticipated recovery would result in a significantly higher (lower) fair value measurement.

(e) Venture capital investments - The significant unobservable inputs used in the fair value measurement of our venture capital investments are the EBITDA multiple and revenue multiple. Generally, a significant increase (decrease) in the EBITDA or revenue multiples in isolation would result in a significantly higher (lower) fair value measurement.

(f) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(g) Interest sensitive products - The significant unobservable inputs used in the fair value measurement of our interest sensitive products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended							3 Months Ended	9 Months Ended				3 Months Ended		3 Months Ended				3 Months Ended	0 Months Ended			1 Months Ended	9 Months Ended	1 Months Ended			0 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2012 New Senior Secured Credit Agreement [Member]	Dec. 31, 2011 New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Senior Secured Note 6.375% [Member]	Dec. 31, 2011 Senior Secured Note 6.375% [Member]	Sep. 30, 2012 Previous Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Previous Senior Secured Credit Agreement [Member]	Dec. 31, 2011 Previous Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Other Notes Payable [Member]	Dec. 31, 2011 Other Notes Payable [Member]	Sep. 30, 2012 Senior Secured Notes 9 Percent [Member]	Dec. 31, 2011 Senior Secured Notes 9 Percent [Member]	Sep. 30, 2012 Convertible Subordinated Debt [Member]	Dec. 31, 2011 Convertible Subordinated Debt [Member]	Sep. 28, 2012 Senior Notes [Member] Pari Passu Intercreditor Agreement [Member]	Sep. 30, 2012 Senior Notes [Member] Senior Secured Note 6.375% [Member]	Sep. 30, 2012 Senior Notes [Member] Other Notes Payable [Member]	Sep. 28, 2012 Senior Notes [Member] Senior Secured Notes 9 Percent [Member]	Sep. 30, 2012 Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Notes Payable to Banks [Member] Previous Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Notes Payable to Banks [Member] Previous Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Notes Payable, Other Payables [Member] Convertible Subordinated Debt [Member]	Sep. 28, 2012 Maximum [Member] Senior Notes [Member] Pari Passu Intercreditor Agreement [Member]	Sep. 30, 2012 Maximum [Member] Senior Notes [Member] Senior Secured Note 6.375% [Member]	Sep. 28, 2012 Maximum [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Minimum [Member] Senior Notes [Member] Senior Secured Note 6.375% [Member]	Sep. 28, 2012 Minimum [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Term Loan Facility, Six-Year [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Term Loan Facility, Six-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Term Loan Facility, Four-Year [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Term Loan Facility, Four-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Revolving Credit Facility [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Revolving Credit Facility [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Uncommitted Subfacility [Member] Maximum [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Letter of Credit [Member] Maximum [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Eurodollar Rate [Member] Term Loan Facility, Six-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Eurodollar Rate [Member] Term Loan Facility, Four-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Base Rate [Member] Term Loan Facility, Six-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Base Rate [Member] Term Loan Facility, Four-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Base Rate [Member] Revolving Credit Facility [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Base Rate Subject to Eurodollar Floor [Member] Term Loan Facility, Six-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Base Rate Subject to Eurodollar Floor [Member] Term Loan Facility, Four-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Base Rate Floor [Member] Term Loan Facility, Six-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Base Rate Floor [Member] Term Loan Facility, Six-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Base Rate Floor [Member] Term Loan Facility, Four-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 28, 2012 Base Rate Floor [Member] Term Loan Facility, Four-Year [Member] Notes Payable to Banks [Member] New Senior Secured Credit Agreement [Member]	Sep. 30, 2012 Paulson & Co. Inc. [Member] Notes Payable, Other Payables [Member] Convertible Subordinated Debt [Member]
Debt Instrument [Line Items]
Notes Payable	$ 1,035.1		$ 1,035.1		$ 857.9	$ 675.0	$ 0		$ 0	$ 0	$ 0	$ 255.2	$ 0	$ 50.0	$ 1.2	$ 275.0	$ 93.0	$ 293.0		$ 275.0		$ 1.2												$ 425.0		$ 250.0																$ 200.0
Debt Instrument, Interest Rate, Stated Percentage	7.00%		7.00%					6.375%							9.00%		7.00%			6.375%		9.00%
Debt Instrument, Redemption Percentage of Aggregate Principal Amount																				100.00%
Debt Instrument, Redemption Percentage of Aggregate Principal Amount with Cash from Equity Offerings																													35.00%
Debt Instrument, Price Percentage of Aggregate Principal Amount																				106.375%
Debt Instrument, Terms, Mandatory Accelerated Repurchase, Percentage of Aggregate Principal Amount																				101.00%
Debt Instrument, Terms, Percentage of Trustees or Holders																				25.00%
Debt Instrument, Terms, Risk-Based Capital Ratio																															225.00%
Debt Instrument, Limit of Restricted Payments Permitted, Cash Dividends on Common Stock																															30
Debt Instrument, Limit of Restricted Payments Permitted, Percent of Net Excess Cash Flow																				50.00%
Debt Instrument, Limit of Restricted Payments Permitted, Amount																				175.0
Debt Instrument, Limit of Restricted Payments Permitted, Amount of Allowed Additional Payments																				244
Debt Instrument, Limit of Restricted Payments Permitted, Debt to Total Capitalization Ratio Value																													17.50%
Debt Instrument, Term of Agreement																																	6 years		4 years		3 years
Line of Credit Facility, Maximum Borrowing Capacity																																						50.0	5.0	5.0
Debt Instrument, Annual Amortization Percentage of Loan																																		1.00%
Debt Instrument, Annual Amortization Percentage of Loan in First and Second Year																																				20.00%
Debt Instrument, Annual Amortization Percentage of Loan in Third and Fourth Year																																				30.00%
Debt Instrument, Increase, Additional Borrowings																														250.0
Debt Instrument, Terms, Mandatory Prepayments, Percentage of Net Cash Proceeds from Asset Sales and Casualty Events																								100.00%
Debt Instrument, Terms, Mandatory Prepayments, Percentage of Net Cash Proceeds Received for Restricted Subsidiaries from Debt Issuances																								100.00%
Debt Instrument, Terms, Mandatory Prepayments, Percentage of Restricted Payments																								100.00%
Debt to Capitalization Ratio, Threshold Requiring Equal Debt Repayment																														22.50%		17.50%
Debt Instrument, Terms, Mandatory Prepayments, Reduced Percentage																								33.33%
Debt to Capitalization Ratio, Maximum Threshold for Repayment Requirement																							17.50%
Debt Instrument, Debt to Capitalization Ratio, Percentage Required No Mandatory Prepayment																														20.00%
Debt Instrument, Basis Spread on Variable Rate																																						3.50%			3.75%	3.25%	2.75%	2.25%	2.50%	1.25%	1.00%	5.00%	2.25%	4.25%	2.00%
Debt to Capitalization Ratio Required																														27.50%
Debt to Capitalization Ratio at Period End																							21.50%
Interest Coverage Ratio Required																																2.50
Aggregate Adjusted Capital to Company Action Level Risk-Based Capital Ratio, After Stated Date																																250.00%
Aggregate Adjusted Capital to Company Action Level Risk Based Capital Ratio at Period End																							361.00%
Minimum Combined Statutory Capital and Surplus																																1,300.0
Combined Statutory Capital and Surplus at Period End																							1,766.8
Mandatory Debt Repayment																										31.4
Debt Instrument, Terms, Removal of Collateral Restrictions, Amount of Outstanding Borrowings																												25.0
Debt Instrument, Terms, Removal of Collateral Restrictions, Period of Time After Default and Holders Make Certain Representations																			180 days
Debt Instrument, Cash Tender Offer to Repay Long-term Debt																						273.8
Repayments of Long-term Debt																						326.3			223.8		355.1
Debt Instrument, Discount Rate																											2.80%
Repayments of Long-term Debt, Portion Related to Tender Offer																						313.1
Repayments of Long-term Debt, Portion Related to Consent Payments																						8.2
Repayments of Long-term Debt, Portion Related to Accrued and Unpaid Interest																						5.0
Repayments of Notes Payable			779.0	130.7																	50.0
Gains (Losses) on Extinguishment of Debt	(198.5)	(1.1)	(199.2)	(3.1)							(5.1)				(57.8)		(136.3)
Gains (Losses) on Extinguishment of Debt, Portion Related to Unamortized Discount										$ (4.4)

XML

EARNINGS PER SHARE (SCHEDULE OF BASIC AND DILUTED EPS CALCULATIONS) (DETAILS) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]
Net income (loss) for basic earnings per share	$ (5.0)	$ 179.5	$ 119.8	$ 271.3
Add: interest expense on 7.0% Convertible Senior Debentures due 2016 (the “7.0% Debentures”), net of income taxes	0	3.7	11.1	11.1
Net income for diluted earnings per share	$ (5.0)	$ 183.2	$ 130.9	$ 282.4
Shares:
Weighted average shares outstanding for basic earnings per share	231,481,000	246,965,000	236,555,000	249,673,000
Effect of dilutive securities on weighted average shares:
7% Debentures	0	53,367,000	53,037,000	53,367,000
Stock option and restricted stock plans	0	2,353,000	2,639,000	2,712,000
Warrants	0	23,000	752,000	333,000
Dilutive potential common shares	0	55,743,000	56,428,000	56,412,000
Weighted average shares outstanding for diluted earnings per share	231,481,000	302,708,000	292,983,000	306,085,000

XML

FAIR VALUE MEASUREMENTS (TABLES)

9 Months Ended

Sep. 30, 2012

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

The fair value measurements for our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions):

	September 30, 2012										December 31, 2011
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,718.3	$	1,718.3	$	1,597.2	$	1,735.4	$	1,602.8
Policy loans	—		274.1		—		274.1		274.1		279.7		279.7
Liabilities:
Insurance liabilities for interest-sensitive products excluding embedded derivatives (a)	—		—		12,186.4		12,186.4		12,186.4		13,165.5		13,165.5
Investment borrowings	—		1,702.5		—		1,702.5		1,650.9		1,735.7		1,676.5
Borrowings related to variable interest entities	—		748.3		—		748.3		766.9		485.1		519.9
Notes payable – direct corporate obligations	—		1,114.4		—		1,114.4		1,035.1		978.3		857.9

____________________

(a) The estimated fair value of insurance liabilities for interest-sensitive products was approximately equal to its carrying value at September 30, 2012.  This was because interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.

The categorization of fair value measurements, by input level, for our fixed maturity securities, equity securities, trading securities, certain other invested assets, assets held in separate accounts and embedded derivative instruments included in liabilities for insurance products at December 31, 2011 is as follows (dollars in millions):

	Quoted prices in active markets  for identical assets or liabilities  (Level 1)		Significant other observable inputs (Level 2) (a)			Significant unobservable inputs  (Level 3) (a)			Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	15,594.4		$	278.1		$	15,872.5
United States Treasury securities and obligations of United States government corporations and agencies	—		303.8			1.6			305.4
States and political subdivisions	—		1,952.3			2.1			1,954.4
Debt securities issued by foreign governments	—		1.4			—			1.4
Asset-backed securities	—		1,334.3			79.7			1,414.0
Collateralized debt obligations	—		—			327.3			327.3
Commercial mortgage-backed securities	—		1,415.7			17.3			1,433.0
Mortgage pass-through securities	—		29.8			2.2			32.0
Collateralized mortgage obligations	—		2,051.2			124.8			2,176.0
Total fixed maturities, available for sale	—		22,682.9			833.1			23,516.0
Equity securities	17.9		87.3			69.9			175.1
Trading securities:
Corporate securities	—		67.6			—			67.6
United States Treasury securities and obligations of United States government corporations and agencies	—		4.9			—			4.9
States and political subdivisions	—		15.6			—			15.6
Asset-backed securities	—		.1			—			.1
Commercial mortgage-backed securities	—		—			.4			.4
Mortgage pass-through securities	—		.2			—			.2
Collateralized mortgage obligations	—		.7			—			.7
Equity securities	.7		1.4			—			2.1
Total trading securities	.7		90.5			.4			91.6
Investments held by variable interest entities	—		496.3			—			496.3
Other invested assets	—		159.9		(b)	—			159.9
Assets held in separate accounts	—		15.0			—			15.0
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	—		—			669.8		(c)	669.8

_____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) Includes company-owned life insurance and derivatives.

(c) Includes $666.3 million of embedded derivatives associated with our fixed index annuity products and $3.5 million of embedded derivatives associated with a modified coinsurance agreement.

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at September 30, 2012 is as follows (dollars in millions):

	Quoted prices in active markets  for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	16,506.2	$	317.3	$	16,823.5
United States Treasury securities and obligations of United States government corporations and agencies	—		171.1		—		171.1
States and political subdivisions	—		2,048.1		—		2,048.1
Debt securities issued by foreign governments	—		.8		—		.8
Asset-backed securities	—		1,433.9		42.8		1,476.7
Collateralized debt obligations	—		—		332.0		332.0
Commercial mortgage-backed securities	—		1,540.3		2.3		1,542.6
Mortgage pass-through securities	—		18.2		2.0		20.2
Collateralized mortgage obligations	—		2,284.2		43.1		2,327.3
Total fixed maturities, available for sale	—		24,002.8		739.5		24,742.3
Equity securities:
Corporate securities	20.5		119.2		2.2		141.9
Venture capital investments	—		—		38.1		38.1
Total equity securities	20.5		119.2		40.3		180.0
Trading securities:
Corporate securities	—		49.3		.6		49.9
United States Treasury securities and obligations of United States government corporations and agencies	—		4.9		—		4.9
States and political subdivisions	—		17.1		—		17.1
Asset-backed securities	—		50.3		—		50.3
Collateralized debt obligations	—		—		7.0		7.0
Commercial mortgage-backed securities	—		43.6		—		43.6
Mortgage pass-through securities	—		.2		—		.2
Collateralized mortgage obligations	—		24.1		—		24.1
Equity securities	.9		1.4		—		2.3
Total trading securities	.9		190.9		7.6		199.4
Investments held by variable interest entities - corporate securities	—		829.4		—		829.4
Other invested assets:
Company-owned life insurance	—		112.3		—		112.3
Hedge funds	—		16.3		—		16.3
Derivatives	—		81.8		—		81.8
Total other invested assets	—		210.4		—		210.4
Cash and cash equivalents - unrestricted:
Cash	202.0		—		—		202.0
Cash equivalents and short-term investments	—		213.3		—		213.3
Total cash and cash equivalents - unrestricted	202.0		213.3		—		415.3
Cash and cash equivalents held by variable interest entities	48.2		—		—		48.2
Assets held in separate accounts	—		15.7		—		15.7
Total assets carried at fair value by category	$	271.6	$	25,581.7	$	787.4	$	26,640.7
Liabilities:
Liabilities for insurance products:
Interest-sensitive products - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	737.9	$	737.9
Interest-sensitive products - embedded derivatives associated with modified coinsurance agreement	—		—		6.0		6.0
Total liabilities for insurance products	—		—		743.9		743.9
Total liabilities carried at fair value by category	$	—	$	—	$	743.9	$	743.9

Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended September 30, 2012 (dollars in millions):

	September 30, 2012
	Beginning balance as of June 30, 2012 (a)			Purchases, sales, issuances and settlements, net (c)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		Transfers into Level 3		Transfers out of Level 3 (b)			Ending balance as of September 30, 2012			Amount of total gains (losses) for the three months ended September 30, 2012 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	321.0		$	14.0		$	—		$	7.3	$	12.5	$	(37.5	)	$	317.3		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.5			(1.5		)	—			—		—		—			—			—
States and political subdivisions	16.0			—			—			—		—		(16.0		)	—			—
Asset-backed securities	23.0			15.0			—			5.5		—		(.7		)	42.8			—
Collateralized debt obligations	330.1			(6.3		)	—			8.2		—		—			332.0			—
Commercial mortgage-backed securities	—			—			—			—		2.3		—			2.3			—
Mortgage pass-through securities	2.1			(.1		)	—			—		—		—			2.0			—
Collateralized mortgage obligations	4.5			(2.8		)	.1			1.0		44.6		(4.3		)	43.1			—
Total fixed maturities, available for sale	698.2			18.3			.1			22.0		59.4		(58.5		)	739.5			—
Equity securities:
Corporate securities	3.2			(1.0		)	—			—		—		—			2.2			—
Venture capital investments	58.0			—			(23.1		)	3.2		—		—			38.1			(23.1		)
Total equity securities	61.2			(1.0		)	(23.1		)	3.2		—		—			40.3			(23.1		)
Trading securities:
Corporate securities	—			—			—			—		.6		—			.6			—
States and political subdivisions	.5			—			—			—		—		(.5		)	—			—
Collateralized debt obligations	3.4			2.8			—			.8		—		—			7.0			.8
Total trading securities	3.9			2.8			—			.8		.6		(.5		)	7.6			.8
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(705.9		)	(22.7		)	(15.3		)	—		—		—			(743.9		)	(15.3		)

____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.

(c) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the three months ended September 30, 2012 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	27.0		$	(13.0	)	$	—		$	—	$	14.0
United States Treasury securities and obligations of United States government corporations and agencies	—			(1.5		)	—			—		(1.5		)
Asset-backed securities	15.0			—			—			—		15.0
Collateralized debt obligations	—			(6.3		)	—			—		(6.3		)
Mortgage pass-through securities	—			(.1		)	—			—		(.1		)
Collateralized mortgage obligations	11.0			(13.8		)	—			—		(2.8		)
Total fixed maturities, available for sale	53.0			(34.7		)	—			—		18.3
Equity securities - corporate securities	—			(1.0		)	—			—		(1.0		)
Trading securities - collateralized debt obligations	2.8			—			—			—		2.8
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(23.5		)	.2			(10.2		)	10.8		(22.7		)

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the nine months ended September 30, 2012 (dollars in millions):

	September 30, 2012
	Beginning balance as of December 31, 2011 (a)			Purchases, sales, issuances and settlements, net (c)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		Transfers into Level 3		Transfers out of Level 3 (b)			Ending balance as of September 30, 2012			Amount of total gains (losses) for the nine months ended September 30, 2012 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	278.1		$	54.9		$	—		$	9.4	$	67.5	$	(92.6	)	$	317.3		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.6			(1.6		)	—			—		—		—			—			—
States and political subdivisions	2.1			—			—			—		—		(2.1		)	—			—
Asset-backed securities	79.7			11.4			(.2		)	5.8		.5		(54.4		)	42.8			—
Collateralized debt obligations	327.3			(11.6		)	—			16.3		—		—			332.0			—
Commercial mortgage-backed securities	17.3			—			—			.1		—		(15.1		)	2.3			—
Mortgage pass-through securities	2.2			(.2		)	—			—		—		—			2.0			—
Collateralized mortgage obligations	124.8			30.0			(.1		)	1.4		—		(113.0		)	43.1			—
Total fixed maturities, available for sale	833.1			82.9			(.3		)	33.0		68.0		(277.2		)	739.5			—
Equity securities:
Corporate securities	6.4			(1.0		)	(3.8		)	.6		—		—			2.2			(3.8		)
Venture capital investments	63.5			—			(26.0		)	.6		—		—			38.1			(26.0		)
Total equity securities	69.9			(1.0		)	(29.8		)	1.2		—		—			40.3			(29.8		)
Trading securities:
Corporate securities	—			—			—			.1		.5		—			.6			.1
States and political subdivisions	—			—			—			—		—		—			—			—
Collateralized debt obligations	—			7.0			—			—		—		—			7.0			—
Commercial mortgage-backed securities	.4			—			—			—		—		(.4		)	—			—
Total trading securities	.4			7.0			—			.1		.5		(.4		)	7.6			.1
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(669.8		)	(52.1		)	(22.0		)	—		—		—			(743.9		)	(22.0		)

____________

(a) We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

(b) For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.

(c) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the nine months ended September 30, 2012 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	70.3		$	(15.4	)	$	—		$	—	$	54.9
United States Treasury securities and obligations of United States government corporations and agencies	—			(1.6		)	—			—		(1.6		)
Asset-backed securities	15.0			(3.6		)	—			—		11.4
Collateralized debt obligations	30.1			(41.7		)	—			—		(11.6		)
Mortgage pass-through securities	—			(.2		)	—			—		(.2		)
Collateralized mortgage obligations	45.3			(15.3		)	—			—		30.0
Total fixed maturities, available for sale	160.7			(77.8		)	—			—		82.9
Equity securities - corporate securities	—			(1.0		)	—			—		(1.0		)
Trading securities - collateralized debt obligations	7.0			—			—			—		7.0
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(75.3		)	41.9			(50.6		)	31.9		(52.1		)

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the three months ended September 30, 2011 (dollars in millions):

	September 30, 2011
	Beginning balance as of June 30, 2011			Purchases, sales, issuances and settlements, net (a)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in other comprehensive income (loss)			Transfers into Level 3		Transfers out of Level 3			Ending balance as of September 30, 2011			Amount of total gains (losses) for the three months ended September 30, 2011 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	361.8		$	(111.2	)	$	4.9		$	5.4		$	.5	$	(17.6	)	$	243.8		$	—
United States Treasury securities and obligations of United States government corporations and agencies	1.7			—			—			—			—		—			1.7			—
States and political subdivisions	—			—			—			.1			2.0		—			2.1			—
Asset-backed securities	170.7			1.2			—			—			4.1		(113.4		)	62.6			—
Collateralized debt obligations	193.5			72.7			—			(6.1		)	—		—			260.1			—
Mortgage pass-through securities	3.2			(.2		)	—			—			—		—			3.0			—
Collateralized mortgage obligations	204.1			3.6			—			.7			—		(30.2		)	178.2			—
Total fixed maturities, available for sale	935.0			(33.9		)	4.9			0.1			6.6		(161.2		)	751.5			—
Equity securities	44.6			27.3			—			(.3		)	—		—			71.6			—
Trading securities:
Collateralized mortgage obligations	—			—			—			—			—		—			—			—
Total trading securities	—			—			—			—			—		—			—			—
Investments held by variable interest entities:
Corporate securities	—			—			—			—			—		—			—			—
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(613.4		)	16.3			(44.8		)	—			—		—			(641.9		)	(44.8		)

____________

(a) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the three months ended September 30, 2011 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1.8		$	(113.0	)	$	—		$	—	$	(111.2	)
Asset-backed securities	4.2			(3.0		)	—			—		1.2
Collateralized debt obligations	84.2			(11.5		)	—			—		72.7
Mortgage pass-through securities	—			(.2		)	—			—		(.2		)
Collateralized mortgage obligations	20.5			(16.9		)	—			—		3.6
Total fixed maturities, available for sale	110.7			(144.6		)	—			—		(33.9		)
Equity securities	27.3			—			—			—		27.3
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(33.1		)	41.7			(2.6		)	10.3		16.3

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the nine months ended September 30, 2011 (dollars in millions):

	September 30, 2011
	Beginning balance as of December 31, 2010			Purchases, sales, issuances and settlements, net (a)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in other comprehensive income (loss)			Transfers into Level 3		Transfers out of Level 3			Ending balance as of September 30, 2011			Amount of total gains (losses) for the nine months ended September 30, 2011 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1,907.8		$	(289.0	)	$	(16.1	)	$	12.7		$	39.0	$	(1,410.6	)	$	243.8		$	(11.5	)
United States Treasury securities and obligations of United States government corporations and agencies	2.0			—			—			(.3		)	—		—			1.7			—
States and political subdivisions	2.5			(2.8		)	(.1		)	.5			2.0		—			2.1			—
Asset-backed securities	182.3			(.6		)	—			2.5			15.1		(136.7		)	62.6			—
Collateralized debt obligations	256.5			3.5			1.8			(1.7		)	—		—			260.1			—
Mortgage pass-through securities	3.5			(.5		)	—			—			—		—			3.0			—
Collateralized mortgage obligations	197.1			48.5			(2.1		)	3.2			5.9		(74.4		)	178.2			—
Total fixed maturities, available for sale	2,551.7			(240.9		)	(16.5		)	16.9			62.0		(1,621.7		)	751.5			(11.5		)
Equity securities	6.9			64.0			—			.7			—		—			71.6			—
Trading securities:
Collateralized mortgage obligations	.4			(.4		)	—			—			—		—			—			—
Total trading securities	.4			(.4		)	—			—			—		—			—			—
Investments held by variable interest entities:
Corporate securities	6.7			(7.9		)	1.5			(.3		)	—		—			—			—
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(553.2		)	(35.0		)	(53.7		)	—			—		—			(641.9		)	(53.7		)

____________

(a) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the nine months ended September 30, 2011 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	1.8		$	(290.8	)	$	—		$	—	$	(289.0	)
States and political subdivisions	—			(2.8		)	—			—		(2.8		)
Asset-backed securities	4.1			(4.7		)	—			—		(.6		)
Collateralized debt obligations	106.6			(103.1		)	—			—		3.5
Mortgage pass-through securities	—			(.5		)	—			—		(.5		)
Collateralized mortgage obligations	94.5			(46.0		)	—			—		48.5
Total fixed maturities, available for sale	207.0			(447.9		)	—			—		(240.9		)
Equity securities	64.0			—			—			—		64.0
Trading securities:
Collateralized mortgage obligations	—			(.4		)	—			—		(.4		)
Investments held by variable interest entities:
Corporate securities	—			(7.9		)	—			—		(7.9		)
Liabilities:
Liabilities for insurance products:
Interest-sensitive products	(85.5		)	51.8			(28.4		)	27.1		(35.0		)

Fair Value, Measurement Inputs, Disclosure [Table Text Block]

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at September 30, 2012 (dollars in millions):

	Fair value at September 30, 2012		Valuation technique(s)	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	212.4	Discounted cash flow analysis	Discount margins	1.95% - 3.27% (2.78%)
Asset-backed securities (b)	33.0		Discounted cash flow analysis	Discount margins	2.96% - 3.28% (3.15%)
Collateralized debt obligations (c)	339.0		Discounted cash flow analysis	Recoveries	61% - 66% (ramp over 24 months)
				Constant prepayment rate	20%
				Discount margins	1.30% - 10.00% (2.39%)
				Annual default rate	1.32% - 5.81% (3.27%)
				Portfolio CCC %	1.90% - 22.17% (12.78%)
Equity securities (d)	2.2		Discounted cash flow analysis	Recoveries	21%
Venture capital investments (e)	38.1		Market multiples	EBITDA multiple	4.8 - 29.0 (11.46)
				Revenue multiple	0.9 - 7.0 (4.2)
				Book equity multiple	0.8 - 3.8 (2.3)
Other assets categorized as Level 3 (f)	162.7		Unadjusted third-party price source	Not applicable	Not applicable
Total	787.4
Liabilities:
Interest sensitive products (g)	743.9		Discounted projected embedded derivatives	Projected portfolio yields	5.35% - 5.61% (5.55%)
				Discount rates	0.0 - 3.5% (1.3%)
				Surrender rates	4% - 43% (19%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Asset-backed securities - The significant unobservable input used in the fair value measurement of our asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(c) Collateralized debt obligations - The significant unobservable inputs used in the fair value measurement of our collateralized debt obligations relate to collateral performance, including default rate, recoveries and constant prepayment rate, as well as discount margins of the underlying collateral. Significant increases (decreases) in default rate in isolation would result in a significantly lower (higher) fair value measurement. Generally, a significant increase (decrease) in the constant prepayment rate and recoveries in isolation would result in a significantly higher (lower) fair value measurement. Generally a significant increase (decrease) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the annual default rate is accompanied by a directionally similar change in the assumption used for discount margins and portfolio CCC % and a directionally opposite change in the assumption used for constant prepayment rate and recoveries. A tranche's payment priority and investment cost basis could alter generalized fair value outcomes.

(d) Equity securities - The significant unobservable input used in the fair value measurement of our equity securities is the anticipated cash recovery. Significant increases (decreases) in the anticipated recovery would result in a significantly higher (lower) fair value measurement.

(e) Venture capital investments - The significant unobservable inputs used in the fair value measurement of our venture capital investments are the EBITDA multiple and revenue multiple. Generally, a significant increase (decrease) in the EBITDA or revenue multiples in isolation would result in a significantly higher (lower) fair value measurement.

(f) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(g) Interest sensitive products - The significant unobservable inputs used in the fair value measurement of our interest sensitive products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

XML

INVESTMENT BORROWINGS (DETAILS) (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	$ 1,650,900,000		$ 1,676,500,000
Interest rate	7.00%
Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Carrying value of FHLB common stock	82,500,000
Investment borrowings	1,650,000,000		1,650,000,000
Estimated fair value of collateralized investments for FHLB borrowings	2,000,000,000
Interest expense on FHLB borrowings	21,300,000	18,900,000
Aggregate fee to prepay all fixed rate FHLB borrowings	51,600,000
Repurchase Agreements [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Assets sold under agreements to repurchase	0		24,800,000
Other Borrowings [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	900,000		1,700,000
Borrowings Due November 2013 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	100,000,000
Maturity date	Nov. 30, 2013
Interest rate	0.515%
Borrowings Due February 2014 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	67,000,000
Maturity date	Feb. 28, 2014
Interest rate	1.83%
Borrowings Due August 2014 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	50,000,000
Maturity date	Aug. 31, 2014
Interest rate	0.565%
Borrowings Due August 2014 Rate 2 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	100,000,000
Maturity date	Aug. 31, 2014
Interest rate	0.476%
Borrowings Due September 2015 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	50,000,000
Maturity date	Sep. 30, 2015
Interest rate	0.747%
Borrowings Due October 2015 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	150,000,000
Maturity date	Oct. 31, 2015
Interest rate	0.571%
Borrowings Due November 2015 Rate Two [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	146,000,000
Maturity date	Nov. 30, 2015
Interest rate	5.30%
Borrowings Due December 2015 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	100,000,000
Maturity date	Dec. 31, 2015
Interest rate	4.71%
Borrowings Due June 2016 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	100,000,000
Maturity date	Jun. 30, 2016
Interest rate	0.657%
Borrowings Due June 2016 Rate Two [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	75,000,000
Maturity date	Jun. 30, 2016
Interest rate	0.621%
Borrowings Due October 2016 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	100,000,000
Maturity date	Oct. 31, 2016
Interest rate	0.641%
Borrowings Due November 2016 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	50,000,000
Maturity date	Nov. 30, 2016
Interest rate	0.684%
Borrowings Due November 2016 Rate Two [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	50,000,000
Maturity date	Nov. 30, 2016
Interest rate	0.687%
Borrowings Due June 2017 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	100,000,000
Maturity date	Jun. 30, 2017
Interest rate	0.751%
Borrowings Due July 2017 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	100,000,000
Maturity date	Jul. 31, 2017
Interest rate	3.90%
Borrowings Due August 2017 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	50,000,000
Maturity date	Aug. 31, 2017
Interest rate	0.635%
Borrowings Due August 2017 Rate 2 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	75,000,000
Maturity date	Aug. 31, 2017
Interest rate	0.577%
Borrowings Due October 2017 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	100,000,000
Maturity date	Oct. 31, 2017
Interest rate	0.885%
Borrowings Due November 2017 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	37,000,000
Maturity date	Nov. 30, 2017
Interest rate	3.75%
Borrowings Due July 2018 [Member] | Federal Home Loan Bank Advances [Member]
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings	$ 50,000,000
Maturity date	Jul. 31, 2018
Interest rate	0.917%

XML

FAIR VALUE MEASUREMENTS - CATEGORIZATION OF FAIR VALUE MEASUREMENTS (DETAILS) (USD $) In Millions, unless otherwise specified	Sep. 30, 2012		Dec. 31, 2011
Fair Value, Assets and Liabilities Meaured on Recurring Basis with Carrying Amount [Abstract]
Mortgage loans	$ 1,597.2		$ 1,602.8
Policy loans	274.1		279.7
Fair Value, Measurements, Recurring [Member]
Assets, Fair Value Disclosure [Abstract]
Mortgage loans	1,597.2		1,602.8
Policy loans	274.1		279.7
Fair Value, Assets and Liabilities Meaured on Recurring Basis with Carrying Amount [Abstract]
Insurance liabilities for interest-sensitive products excluding embedded derivatives	12,186.4	[1]	13,165.5	[1]
Investment borrowings	1,650.9		1,676.5
Borrowings related to variable interest entities	766.9		519.9
Notes Payable, Fair Value Disclosure	1,035.1		857.9
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Equity securities	20.5		17.9
Mortgage loans	0
Policy loans	0
Trading securities	0.9		0.7
Investments held by variable interest entities			0
Other invested assets	0		0
Cash and cash equivalents - unrestricted	202.0
Cash and cash equivalents held by variable interest entities	48.2
Assets held in separate accounts	0		0
Total assets carried at fair value by category	271.6
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	0		0
Total liabilities carried at fair value by category	0
Fair Value, Assets and Liabilities Meaured on Recurring Basis with Carrying Amount [Abstract]
Insurance liabilities for interest-sensitive products excluding embedded derivatives	0	[1]
Investment borrowings	0
Borrowings related to variable interest entities	0
Notes Payable, Fair Value Disclosure	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	24,002.8		22,682.9	[2]
Equity securities	119.2		87.3	[2]
Mortgage loans	0
Policy loans	274.1
Trading securities	190.9		90.5	[2]
Investments held by variable interest entities			496.3	[2]
Other invested assets	210.4		159.9	[2],[3]
Cash and cash equivalents - unrestricted	213.3
Cash and cash equivalents held by variable interest entities	0
Assets held in separate accounts	15.7		15.0	[2]
Total assets carried at fair value by category	25,581.7
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	0		0	[2]
Total liabilities carried at fair value by category	0
Fair Value, Assets and Liabilities Meaured on Recurring Basis with Carrying Amount [Abstract]
Insurance liabilities for interest-sensitive products excluding embedded derivatives	0	[1]
Investment borrowings	1,702.5
Borrowings related to variable interest entities	748.3
Notes Payable, Fair Value Disclosure	1,114.4
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	739.5		833.1	[2]
Equity securities	40.3		69.9	[2]
Mortgage loans	1,718.3
Policy loans	0
Trading securities	7.6		0.4	[2]
Investments held by variable interest entities			0	[2]
Other invested assets	0		0	[2]
Cash and cash equivalents - unrestricted	0
Cash and cash equivalents held by variable interest entities	0
Assets held in separate accounts	0		0	[2]
Total assets carried at fair value by category	787.4
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	743.9		669.8	[2],[4]
Total liabilities carried at fair value by category	743.9
Fair Value, Assets and Liabilities Meaured on Recurring Basis with Carrying Amount [Abstract]
Insurance liabilities for interest-sensitive products excluding embedded derivatives	12,186.4	[1]
Investment borrowings	0
Borrowings related to variable interest entities	0
Notes Payable, Fair Value Disclosure	0
Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	24,742.3		23,516.0
Equity securities	180.0		175.1
Mortgage loans	1,718.3		1,735.4
Policy loans	274.1		279.7
Trading securities	199.4		91.6
Investments held by variable interest entities			496.3
Other invested assets	210.4		159.9
Cash and cash equivalents - unrestricted	415.3
Cash and cash equivalents held by variable interest entities	48.2
Assets held in separate accounts	15.7		15.0
Total assets carried at fair value by category	26,640.7
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	743.9		669.8
Total liabilities carried at fair value by category	743.9
Fair Value, Assets and Liabilities Meaured on Recurring Basis with Carrying Amount [Abstract]
Insurance liabilities for interest-sensitive products excluding embedded derivatives	12,186.4	[1]	13,165.5	[1]
Investment borrowings	1,702.5		1,735.7
Borrowings related to variable interest entities	748.3		485.1
Notes Payable, Fair Value Disclosure	1,114.4		978.3
Venture Capital Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Equity securities	0
Venture Capital Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Equity securities	0
Venture Capital Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Equity securities	38.1
Venture Capital Funds [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Equity securities	38.1
Foreign Government Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Foreign Government Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0.8		1.4	[2]
Foreign Government Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0	[2]
Foreign Government Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0.8		1.4
Corporate securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Equity securities	20.5
Trading securities	0		0
Corporate securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	16,506.2		15,594.4	[2]
Equity securities	119.2
Trading securities	49.3		67.6	[2]
Corporate securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	317.3		278.1	[2]
Equity securities	2.2
Trading securities	0.6		0	[2]
Corporate securities [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	16,823.5		15,872.5
Equity securities	141.9
Trading securities	49.9		67.6
US Treasury and Government [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Trading securities	0		0
US Treasury and Government [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	171.1		303.8	[2]
Trading securities	4.9		4.9	[2]
US Treasury and Government [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		1.6	[2]
Trading securities	0		0	[2]
US Treasury and Government [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	171.1		305.4
Trading securities	4.9		4.9
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Trading securities	0		0
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	2,048.1		1,952.3	[2]
Trading securities	17.1		15.6	[2]
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		2.1	[2]
Trading securities	0		0	[2]
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	2,048.1		1,954.4
Trading securities	17.1		15.6
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Trading securities	0		0
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	1,433.9		1,334.3	[2]
Trading securities	50.3		0.1	[2]
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	42.8		79.7	[2]
Trading securities	0		0	[2]
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	1,476.7		1,414.0
Trading securities	50.3		0.1
Collateralized Debt Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Trading securities	0
Collateralized Debt Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0	[2]
Trading securities	0
Collateralized Debt Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	332.0		327.3	[2]
Trading securities	7.0
Collateralized Debt Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	332.0		327.3
Trading securities	7.0
Commercial Mortgage Backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Trading securities	0		0
Commercial Mortgage Backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	1,540.3		1,415.7	[2]
Trading securities	43.6		0	[2]
Commercial Mortgage Backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	2.3		17.3	[2]
Trading securities	0		0.4	[2]
Commercial Mortgage Backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	1,542.6		1,433.0
Trading securities	43.6		0.4
Mortgage Pass Through Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Trading securities	0		0
Mortgage Pass Through Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	18.2		29.8	[2]
Trading securities	0.2		0.2	[2]
Mortgage Pass Through Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	2.0		2.2	[2]
Trading securities	0		0	[2]
Mortgage Pass Through Securities [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	20.2		32.0
Trading securities	0.2		0.2
Collateralized Mortgage Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	0		0
Trading securities	0		0
Collateralized Mortgage Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	2,284.2		2,051.2	[2]
Trading securities	24.1		0.7	[2]
Collateralized Mortgage Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	43.1		124.8	[2]
Trading securities	0		0	[2]
Collateralized Mortgage Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Fixed maturities, available for sale	2,327.3		2,176.0
Trading securities	24.1		0.7
Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Trading securities	0.9		0.7
Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Trading securities	1.4		1.4	[2]
Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Trading securities	0		0	[2]
Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Trading securities	2.3		2.1
Embedded Derivatives Associated with Fixed Index Annuity Products [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	0
Embedded Derivatives Associated with Fixed Index Annuity Products [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	0
Embedded Derivatives Associated with Fixed Index Annuity Products [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	737.9
Embedded Derivatives Associated with Fixed Index Annuity Products [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	737.9
Embedded Derivative Associated With Modified Coinsurance Agreement [Member]
Fair Value, Assets and Liabilities Meaured on Recurring Basis with Carrying Amount [Abstract]
Embedded derivatives	6.0		3.5
Embedded Derivative Associated With Modified Coinsurance Agreement [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	0
Embedded Derivative Associated With Modified Coinsurance Agreement [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	0
Embedded Derivative Associated With Modified Coinsurance Agreement [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	6.0
Embedded Derivative Associated With Modified Coinsurance Agreement [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Liabilities, Fair Value Disclosure [Abstract]
Liabilities For Interest Sensitive Products, Fair Value Disclosure	6.0
Embedded Derivative Financial Instruments [Member]
Fair Value, Assets and Liabilities Meaured on Recurring Basis with Carrying Amount [Abstract]
Embedded derivatives	737.9		666.3
Company-Owned Life Insurance [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	0
Company-Owned Life Insurance [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	112.3
Company-Owned Life Insurance [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	0
Company-Owned Life Insurance [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	112.3
Hedge Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	0
Hedge Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	16.3
Hedge Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	0
Hedge Funds [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	16.3
Derivatives [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	0
Derivatives [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	81.8
Derivatives [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	0
Derivatives [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Other invested assets	81.8
Cash [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents - unrestricted	202.0
Cash [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents - unrestricted	0
Cash [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents - unrestricted	0
Cash [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents - unrestricted	202.0
Cash Equivalents and Short-Term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents - unrestricted	0
Cash Equivalents and Short-Term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents - unrestricted	213.3
Cash Equivalents and Short-Term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents - unrestricted	0
Cash Equivalents and Short-Term Investments [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalents - unrestricted	213.3
Corporate Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments held by variable interest entities	0
Corporate Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments held by variable interest entities	829.4
Corporate Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Investments held by variable interest entities	0
Corporate Securities [Member] | Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Assets, Fair Value Disclosure [Abstract]
Investments held by variable interest entities	$ 829.4

[1] The estimated fair value of insurance liabilities for interest-sensitive products was approximately equal to its carrying value at September 30, 2012. This was because interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.

[2] We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

[3] Includes company-owned life insurance and derivatives.

[4] Includes $666.3 million of embedded derivatives associated with our fixed index annuity products and $3.5 million of embedded derivatives associated with a modified coinsurance agreement.

XML

INCOME TAXES (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Income Tax Disclosure [Abstract]
Loss on extinguishment of debt	$ 198.5	$ 1.1	$ 199.2	$ 3.1
Income Tax Expense (Benefit) [Abstract]
Current tax expense	2.4	2.3	9.1	7.2
Deferred tax expense (benefit)	11.1	22.9	76.4	68.4
Valuation allowance applicable to current year income	(31.8)	0	(31.8)	0
Income tax expense (benefit) calculated based on estimated annual effective tax rate	(18.3)	25.2	53.7	75.6
Valuation allowance reduction impacting income in future years	(111.2)	(143.0)	(111.2)	(143.0)
Deferred tax benefit related to loss on extinguishment of debt and other items	(24.3)	0	(24.3)	0
Total income tax benefit	(153.8)	(117.8)	(81.8)	(67.4)
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
U.S. statutory corporate rate			35.00%	35.00%
Valuation allowance reduction applicable to current year income			(13.80%)	0.00%
Nondeductible amounts			0.50%	1.80%
State taxes			1.00%	1.00%
Provision for tax issues, tax credits and other			0.00%	(0.80%)
Estimated annual effective tax rate			22.70%	37.00%
Components of Deferred Tax Assets [Abstract]
Net federal operating loss carryforwards	1,366.2		1,366.2		1,445.2
Net state operating loss carryforwards	16.3		16.3		16.8
Tax credits	37.7		37.7		32.6
Capital loss carryforwards	305.4		305.4		342.3
Insurance liabilities	754.8		754.8		744.4
Other	81.7		81.7		64.8
Gross deferred tax assets	2,562.1		2,562.1		2,646.1
Deferred tax liabilities:
Investments	(21.9)		(21.9)		(24.2)
Present value of future profits and deferred acquisition costs	(333.7)		(333.7)		(363.7)
Accumulated other comprehensive income	(688.1)		(688.1)		(434.8)
Gross deferred tax liabilities	(1,043.7)		(1,043.7)		(822.7)
Net deferred tax assets before valuation allowance	1,518.4		1,518.4		1,823.4
Valuation allowance	(795.4)		(795.4)		(938.4)
Net deferred tax assets	723.0		723.0		885.0
Current income taxes accrued	(23.5)		(23.5)		(19.6)
Income tax assets, net	699.5		699.5		865.4
Estimated deferred tax assets realized through future taxable earnings			893
Identified reductions in deferred tax valuation allowance to be recognized in 2012	155.0
Decrease in valuation allowance for deferred tax assets	(143.0)	(143.0)	(143.0)	(143.0)
Identified reductions in deferred tax allowance to be recognized in future period	12.0
Reduction valuation allowance due to increase in taxable income	43.8
Change in valuation allowance, amount to be recognized in current period	31.8
Reduction in valuation allowance for deferred tax assets	111.2
Deferred tax valuation assumption for annual taxable income growth (percent)	5.00%		5.00%
Normalized average annual taxable income for last three years			293
Normalized average annual taxable income for last three years in prior projection			$ 260
Loss limitation based on income of life insurance company (percent)	35.00%		35.00%
Loss limitation based on loss of non-life entities (percent)	35.00%		35.00%
Debenture interest rate	7.00%		7.00%
Federal long term tax exempt rate (percent)	3.02%		3.02%
Ownership change threshold restricting NOL usage (percent)	50.00%		50.00%

XML

BUSINESS AND BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2012

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BUSINESS AND BASIS OF PRESENTATION

BUSINESS AND BASIS OF PRESENTATION

The following notes should be read together with the notes to the consolidated financial statements included in our 2011 Annual Report on Form 10-K as retrospectively updated by the Current Report on Form 8-K filed on September 4, 2012 in connection with a change in accounting principle.

CNO Financial Group, Inc., a Delaware corporation (“CNO”), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products.  CNO became the successor to Conseco, Inc., an Indiana corporation (our “Predecessor”), in connection with our bankruptcy reorganization which became effective on September 10, 2003.  The terms “CNO Financial Group, Inc.”, the “Company”, “we”, “us”, and “our” as used in these financial statements refer to CNO and its subsidiaries or, when the context requires otherwise, our Predecessor and its subsidiaries.  We focus on serving the senior and middle-income markets, which we believe are attractive, underserved, high growth markets.  We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

Our unaudited consolidated financial statements reflect normal recurring adjustments that, in the opinion of management, are necessary for a fair statement of our financial position, results of operations and cash flows for the periods presented.  As permitted by rules and regulations of the Securities and Exchange Commission (the “SEC”) applicable to quarterly reports on Form 10-Q, we have condensed or omitted certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).  We have reclassified certain amounts from the prior periods to conform to the 2012 presentation.  These reclassifications have no effect on net income or shareholders’ equity.  Results for interim periods are not necessarily indicative of the results that may be expected for a full year.

As discussed in the note to the consolidated financial statements entitled "Recently Issued Accounting Standards", we have adopted the provisions of Financial Accounting Standards Update No. 2010-26 (“ASU 2010-26”), effective January 1, 2012, which modified the definition of the types of costs incurred by insurance entities that could be capitalized in the acquisition of new and renewal contracts. Pursuant to the guidance, we elected to adopt the provisions on a retrospective basis. Accordingly, all prior periods presented have been retrospectively adjusted.

The balance sheet at December 31, 2011, presented herein, has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.

When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods.  For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals.  If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.

Our consolidated financial statements exclude the results of transactions between us and our consolidated affiliates, or among our consolidated affiliates.

XML

FAIR VALUE MEASUREMENTS - UNOBSERVABLE INPUT RECONCILIATION (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011
Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	$ 698.2	[1]	$ 935.0		$ 833.1		$ 2,551.7
Purchases, sales, issuances and settlements, net	18.3	[2]	(33.9)	[3]	82.9	[4]	(240.9)	[5]
Total realized and unrealized gains (losses) included in net income	0.1		4.9		(0.3)		(16.5)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	22.0		0.1		33.0		16.9
Transfers into level 3	59.4		6.6		68.0		62.0
Transfers out of level 3	(58.5)	[4]	(161.2)		(277.2)	[1]	(1,621.7)
Fair value, measurement with unobservable inputs reconciliation, ending balance	739.5		751.5		739.5		751.5
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0		0		0		(11.5)
Equity Securities Classification [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Purchases, sales, issuances and settlements, net	(1.0)
Trading Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	3.9	[1]	0		0.4		0.4
Purchases, sales, issuances and settlements, net	2.8	[2]	0	[3]	7.0	[4]	(0.4)	[5]
Total realized and unrealized gains (losses) included in net income	0		0		0		0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.8		0		0.1		0
Transfers into level 3	0.6		0		0.5		0
Transfers out of level 3	(0.5)	[4]	0		(0.4)	[1]	0
Fair value, measurement with unobservable inputs reconciliation, ending balance	7.6		0		7.6		0
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0.8		0		0.1		0
Corporate securities [Member] | Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	321.0	[1]	361.8		278.1		1,907.8
Purchases, sales, issuances and settlements, net	14.0	[2]	(111.2)	[3]	54.9	[4]	(289.0)	[5]
Total realized and unrealized gains (losses) included in net income	0		4.9		0		(16.1)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	7.3		5.4		9.4		12.7
Transfers into level 3	12.5		0.5		67.5		39.0
Transfers out of level 3	(37.5)	[4]	(17.6)		(92.6)	[1]	(1,410.6)
Fair value, measurement with unobservable inputs reconciliation, ending balance	317.3		243.8		317.3		243.8
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0		0		0		(11.5)
Corporate securities [Member] | Equity Securities Classification [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	3.2	[1]			6.4
Purchases, sales, issuances and settlements, net	(1.0)	[2]			(1.0)	[4]
Total realized and unrealized gains (losses) included in net income	0				(3.8)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0				0.6
Transfers into level 3	0				0
Transfers out of level 3	0	[4]			0	[1]
Fair value, measurement with unobservable inputs reconciliation, ending balance	2.2				2.2
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0				(3.8)
US Treasury and Government [Member] | Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	1.5	[1]	1.7		1.6		2.0
Purchases, sales, issuances and settlements, net	(1.5)	[2]	0	[3]	(1.6)	[4]	0	[5]
Total realized and unrealized gains (losses) included in net income	0		0		0		0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0		0		0		(0.3)
Transfers into level 3	0		0		0		0
Transfers out of level 3	0	[4]	0		0	[1]	0
Fair value, measurement with unobservable inputs reconciliation, ending balance	0		1.7		0		1.7
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0		0		0		0
US States and Political Subdivisions Debt Securities [Member] | Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	16.0	[1]	0		2.1		2.5
Purchases, sales, issuances and settlements, net	0	[2]	0	[3]	0	[4]	(2.8)	[5]
Total realized and unrealized gains (losses) included in net income	0		0		0		(0.1)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0		0.1		0		0.5
Transfers into level 3	0		2.0		0		2.0
Transfers out of level 3	(16.0)	[4]	0		(2.1)	[1]	0
Fair value, measurement with unobservable inputs reconciliation, ending balance	0		2.1		0		2.1
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0		0		0		0
Asset-backed Securities [Member] | Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	23.0	[1]	170.7		79.7		182.3
Purchases, sales, issuances and settlements, net	15.0	[2]	1.2	[3]	11.4	[4]	(0.6)	[5]
Total realized and unrealized gains (losses) included in net income	0		0		(0.2)		0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	5.5		0		5.8		2.5
Transfers into level 3	0		4.1		0.5		15.1
Transfers out of level 3	(0.7)	[4]	(113.4)		(54.4)	[1]	(136.7)
Fair value, measurement with unobservable inputs reconciliation, ending balance	42.8		62.6		42.8		62.6
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0		0		0		0
Collateralized debt obligations [Member] | Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	330.1	[1]	193.5		327.3		256.5
Purchases, sales, issuances and settlements, net	(6.3)	[2]	72.7	[3]	(11.6)	[4]	3.5	[5]
Total realized and unrealized gains (losses) included in net income	0		0		0		1.8
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	8.2		(6.1)		16.3		(1.7)
Transfers into level 3	0		0		0		0
Transfers out of level 3	0	[4]	0		0	[1]	0
Fair value, measurement with unobservable inputs reconciliation, ending balance	332.0		260.1		332.0		260.1
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0		0		0		0
Mortgage Pass Through Securities [Member] | Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	2.1	[1]	3.2		2.2		3.5
Purchases, sales, issuances and settlements, net	(0.1)	[2]	(0.2)	[3]	(0.2)	[4]	(0.5)	[5]
Total realized and unrealized gains (losses) included in net income	0		0		0		0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0		0		0		0
Transfers into level 3	0		0		0		0
Transfers out of level 3	0	[4]	0		0	[1]	0
Fair value, measurement with unobservable inputs reconciliation, ending balance	2.0		3.0		2.0		3.0
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0		0		0		0
Collateralized Mortgage Obligations [Member] | Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	4.5	[1]	204.1		124.8		197.1
Purchases, sales, issuances and settlements, net	(2.8)	[2]	3.6	[3]	30.0	[4]	48.5	[5]
Total realized and unrealized gains (losses) included in net income	0.1		0		(0.1)		(2.1)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	1.0		0.7		1.4		3.2
Transfers into level 3	44.6		0		0		5.9
Transfers out of level 3	(4.3)	[4]	(30.2)		(113.0)	[1]	(74.4)
Fair value, measurement with unobservable inputs reconciliation, ending balance	43.1		178.2		43.1		178.2
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0		0		0		0
Equity Securities [Member] | Equity Securities Classification [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	61.2	[1]	44.6		69.9		6.9
Purchases, sales, issuances and settlements, net	(1.0)	[2]	27.3	[3]	(1.0)	[4]	64.0	[5]
Total realized and unrealized gains (losses) included in net income	(23.1)		0		(29.8)		0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	3.2		(0.3)		1.2		0.7
Transfers into level 3	0		0		0		0
Transfers out of level 3	0	[4]	0		0	[1]	0
Fair value, measurement with unobservable inputs reconciliation, ending balance	40.3		71.6		40.3		71.6
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	(23.1)		0		(29.8)		0
Venture Capital Funds [Member] | Equity Securities Classification [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	58.0	[1]			63.5
Purchases, sales, issuances and settlements, net	0	[2]			0	[4]
Total realized and unrealized gains (losses) included in net income	(23.1)				(26.0)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	3.2				0.6
Transfers into level 3	0				0
Transfers out of level 3	0	[4]			0	[1]
Fair value, measurement with unobservable inputs reconciliation, ending balance	38.1				38.1
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	(23.1)				(26.0)
Commercial Mortgage Backed Securities [Member] | Fixed maturities, available for sale [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	0				17.3
Purchases, sales, issuances and settlements, net	0	[4]			0
Total realized and unrealized gains (losses) included in net income	0				0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0				0.1
Transfers into level 3	2.3				0
Transfers out of level 3	0	[1]			(15.1)
Fair value, measurement with unobservable inputs reconciliation, ending balance	2.3				2.3
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0				0
Interest Sensitive Products [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	(15.3)		(44.8)		(22.0)		(53.7)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliations, liability value, beginning balance	(705.9)	[1]	(613.4)		(669.8)		(553.2)
Purchases, sales, issuances and settlements, net	(22.7)	[2]	16.3	[3]	(52.1)	[4]	(35.0)	[5]
Total realized and unrealized gains (losses) included in net income	(15.3)		(44.8)		(22.0)		(53.7)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0		0		0		0
Transfers into level 3	0		0		0		0
Transfers out of level 3	0	[4]	0		0	[1]	0
Fair value, measurement with unobservable inputs reconciliations, liability value, ending balance	(743.9)		(641.9)		(743.9)		(641.9)
US States and Political Subdivisions Debt Securities [Member] | Trading Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	0.5	[1]			0
Purchases, sales, issuances and settlements, net	0	[2]			0	[4]
Total realized and unrealized gains (losses) included in net income	0				0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0				0
Transfers into level 3	0				0
Transfers out of level 3	(0.5)	[4]			0	[1]
Fair value, measurement with unobservable inputs reconciliation, ending balance	0				0
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0				0
Collateralized Debt Obligations [Member] | Trading Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	3.4	[1]			0
Purchases, sales, issuances and settlements, net	2.8	[2]			7.0	[4]
Total realized and unrealized gains (losses) included in net income	0				0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.8				0
Transfers into level 3	0				0
Transfers out of level 3	0	[4]			0	[1]
Fair value, measurement with unobservable inputs reconciliation, ending balance	7.0				7.0
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0.8				0
Corporate securities [Member] | Equity Securities Classification [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Purchases, sales, issuances and settlements, net					(1.0)
Corporate securities [Member] | Trading Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance	0	[1]			0
Purchases, sales, issuances and settlements, net	0	[4]			0
Total realized and unrealized gains (losses) included in net income	0				0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0				0.1
Transfers into level 3	0.6				0.5
Transfers out of level 3	0	[1]			0
Fair value, measurement with unobservable inputs reconciliation, ending balance	0.6				0.6
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date	0				0.1
Collateralized Mortgage Obligations [Member] | Trading Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance			0		0.4		0.4
Purchases, sales, issuances and settlements, net			0	[3]	0	[4]	(0.4)	[5]
Total realized and unrealized gains (losses) included in net income			0		0		0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			0		0		0
Transfers into level 3			0		0		0
Transfers out of level 3			0		(0.4)	[1]	0
Fair value, measurement with unobservable inputs reconciliation, ending balance	0		0		0		0
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date			0		0		0
Corporate Securities [Member] | Corporate Securities Held By Variable Interest Entities [Member] | Investments Held By Variable Interest Entities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, measurement with unobservable inputs reconciliation, beginning balance			0				6.7
Purchases, sales, issuances and settlements, net			0	[3]			(7.9)	[5]
Total realized and unrealized gains (losses) included in net income			0				1.5
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			0				(0.3)
Transfers into level 3			0				0
Transfers out of level 3			0				0
Fair value, measurement with unobservable inputs reconciliation, ending balance			0				0
Amount of total gains (losses) included in net income related to assets and liabilities still held at the reporting date			0				0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Purchases, sales, issuances and settlements, net							$ (7.9)

[1] We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.

[2] Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the three months ended September 30, 2012 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, netAssets: Fixed maturities, available for sale: Corporate securities$27.0 $(13.0) $— $— $14.0United States Treasury securities and obligations of United States government corporations and agencies— (1.5) — — (1.5)Asset-backed securities15.0 — — — 15.0Collateralized debt obligations— (6.3) — — (6.3)Mortgage pass-through securities— (.1) — — (.1)Collateralized mortgage obligations11.0 (13.8) — — (2.8)Total fixed maturities, available for sale53.0 (34.7) — — 18.3Equity securities - corporate securities— (1.0) — — (1.0)Trading securities - collateralized debt obligations2.8 — — — 2.8Liabilities: Liabilities for insurance products: Interest-sensitive products(23.5) .2 (10.2) 10.8 (22.7)

[3] Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the three months ended September 30, 2011 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, netAssets: Fixed maturities, available for sale: Corporate securities$1.8 $(113.0) $— $— $(111.2)Asset-backed securities4.2 (3.0) — — 1.2Collateralized debt obligations84.2 (11.5) — — 72.7Mortgage pass-through securities— (.2) — — (.2)Collateralized mortgage obligations20.5 (16.9) — — 3.6Total fixed maturities, available for sale110.7 (144.6) — — (33.9)Equity securities27.3 — — — 27.3Liabilities: Liabilities for insurance products: Interest-sensitive products(33.1) 41.7 (2.6) 10.3 16.3

[4] For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.

[5] Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the nine months ended September 30, 2011 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, netAssets: Fixed maturities, available for sale: Corporate securities$1.8 $(290.8) $— $— $(289.0)States and political subdivisions— (2.8) — — (2.8)Asset-backed securities4.1 (4.7) — — (.6)Collateralized debt obligations106.6 (103.1) — — 3.5Mortgage pass-through securities— (.5) — — (.5)Collateralized mortgage obligations94.5 (46.0) — — 48.5Total fixed maturities, available for sale207.0 (447.9) — — (240.9)Equity securities64.0 — — — 64.0Trading securities: Collateralized mortgage obligations— (.4) — — (.4)Investments held by variable interest entities: Corporate securities— (7.9) — — (7.9)Liabilities: Liabilities for insurance products: Interest-sensitive products(85.5) 51.8 (28.4) 27.1 (35.0)

XML

EARNINGS PER SHARE (DETAILS) (USD $)	3 Months Ended
	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest on Convertible Debt, Net of Tax	$ 3,700,000
Incremental Common Shares Attributable to Conversion of Debt Securities	56,651,000
Antidilutive Securities Excluded From Computation Of Earnings Per Share Related to Debt, Amount	52,366,000
Antidilutive Securities Excluded From Computation Of Earnings Per Share Related to Share-based Compensation, Amount	2,968,000
Antidilutive Securities Excluded From Computation Of Earnings Per Share Related to Warrants, Amount	1,317,000
Debt Instrument, Interest Rate, Stated Percentage	7.00%
Conversion Price for Convertible Senior Debentures	$ 5.49
Conversion Rate for Convertible Senior Debentures	182.1494
Par Value of Each Convertible Senior Debenture	$ 1,000
Convertible Subordinated Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	7.00%

XML

BUSINESS SEGMENTS (TABLES)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Operating information by segment was as follows (dollars in millions):

	Three months ended					Nine months ended
	September 30,					September 30,
	2012		2011			2012		2011
Revenues:
Bankers Life:
Insurance policy income:
Annuities	$	6.8	$	9.6		$	21.9	$	26.7
Health	335.1		334.0			1,010.6		1,017.1
Life	74.2		61.0			209.1		170.4
Net investment income (a)	221.6		158.0			642.1		564.5
Fee revenue and other income (a)	4.0		3.6			10.2		9.2
Total Bankers Life revenues	641.7		566.2			1,893.9		1,787.9
Washington National:
Insurance policy income:
Health	143.4		141.2			429.0		423.1
Life	3.6		3.9			11.6		11.8
Other	.8		.8			2.2		3.0
Net investment income (a)	50.9		47.3			151.9		140.3
Fee revenue and other income (a)	.3		.4			.8		.9
Total Washington National revenues	199.0		193.6			595.5		579.1
Colonial Penn:
Insurance policy income:
Health	1.3		1.4			4.0		4.5
Life	53.2		49.4			158.5		147.5
Net investment income (a)	9.9		10.1			30.1		30.9
Fee revenue and other income (a)	.2		.2			.6		.6
Total Colonial Penn revenues	64.6		61.1			193.2		183.5
Other CNO Business:
Insurance policy income:
Annuities	2.5		3.4			8.3		8.6
Health	6.2		6.9			19.3		21.3
Life	62.9		61.7			196.2		184.9
Other	.2		.2			.6		1.4
Net investment income (a)	86.7		74.6			259.2		256.0
Total Other CNO Business revenues	158.5		146.8			483.6		472.2
Corporate operations:
Net investment income	19.4		(6.7		)	49.8		10.4
Fee and other income	.7		.7			2.0		1.8
Total corporate revenues	20.1		(6.0		)	51.8		12.2
Total revenues	1,083.9		961.7			3,218.0		3,034.9

(continued on next page)

(continued from previous page)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Expenses:
Bankers Life:
Insurance policy benefits	$	434.6		$	360.6		$	1,252.2		$	1,174.3
Amortization	35.6			44.1			143.0			159.5
Interest expense on investment borrowings	1.3			1.2			4.1			3.5
Other operating costs and expenses	89.6			80.9			267.4			236.9
Total Bankers Life expenses	561.1			486.8			1,666.7			1,574.2
Washington National:
Insurance policy benefits	111.1			119.0			340.5			349.5
Amortization	11.2			10.8			34.7			35.6
Interest expense on investment borrowings	.7			.2			2.2			.2
Other operating costs and expenses	42.1			42.4			125.6			126.5
Total Washington National expenses	165.1			172.4			503.0			511.8
Colonial Penn:
Insurance policy benefits	38.3			36.0			120.0			112.7
Amortization	3.5			3.5			11.1			11.0
Other operating costs and expenses	25.4			22.9			73.9			66.3
Total Colonial Penn expenses	67.2			62.4			205.0			190.0
Other CNO Business:
Insurance policy benefits	157.1			111.5			401.0			358.2
Amortization	10.5			10.4			25.1			28.4
Interest expense on investment borrowings	5.0			5.3			15.1			15.2
Other operating costs and expenses	39.5			16.8			96.4			55.1
Total Other CNO Business expenses	212.1			144.0			537.6			456.9
Corporate operations:
Interest expense on corporate debt	16.3			18.7			50.4			58.6
Interest expense on borrowings of variable interest entities	5.8			2.4			14.5			8.4
Interest expense on investment borrowings	.1			.1			.4			.1
Loss on extinguishment of debt	198.5			1.1			199.2			3.1
Other operating costs and expenses	20.9			19.0			54.5			43.0
Total corporate expenses	241.6			41.3			319.0			113.2
Total expenses	1,247.1			906.9			3,231.3			2,846.1
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes:
Bankers Life	80.6			79.4			227.2			213.7
Washington National	33.9			21.2			92.5			67.3
Colonial Penn	(2.6		)	(1.3		)	(11.8		)	(6.5		)
Other CNO Business	(53.6		)	2.8			(54.0		)	15.3
Corporate operations	(221.5		)	(47.3		)	(267.2		)	(101.0		)
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	$	(163.2	)	$	54.8		$	(13.3	)	$	188.8

___________________

(a) It is not practicable to provide additional components of revenue by product or services.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

A reconciliation of segment revenues and expenses to consolidated revenues and expenses is as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Total segment revenues	$	1,083.9		$	961.7		$	3,218.0		$	3,034.9
Net realized investment gains	9.1			30.6			63.9			38.6
Consolidated revenues	$	1,093.0		$	992.3		$	3,281.9		$	3,073.5
Total segment expenses	$	1,247.1		$	906.9		$	3,231.3		$	2,846.1
Insurance policy benefits - fair value changes in embedded derivative liabilities	4.6			33.9			10.7			33.9
Amortization related to fair value changes in embedded derivative liabilities	(1.6		)	(14.1		)	(4.0		)	(14.1		)
Amortization related to net realized investment gains	1.7			3.9			5.9			3.7
Consolidated expenses	$	1,251.8		$	930.6		$	3,243.9		$	2,869.6

XML

EARNINGS PER SHARE (TABLES)

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

A reconciliation of net income and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands):

	Three months ended					Nine months ended
	September 30,					September 30,
	2012			2011		2012		2011
Net income (loss) for basic earnings per share	$	(5.0	)	$	179.5	$	119.8	$	271.3
Add:  interest expense on 7.0% Convertible Senior Debentures due 2016 (the “7.0% Debentures”), net of income taxes	—			3.7		11.1		11.1
Net income for diluted earnings per share	$	(5.0	)	$	183.2	$	130.9	$	282.4
Shares:
Weighted average shares outstanding for basic earnings per share	231,481			246,965		236,555		249,673
Effect of dilutive securities on weighted average shares:
7% Debentures	—			53,367		53,037		53,367
Stock option and restricted stock plans	—			2,353		2,639		2,712
Warrants	—			23		752		333
Dilutive potential common shares	—			55,743		56,428		56,412
Weighted average shares outstanding for diluted earnings per share	231,481			302,708		292,983		306,085

XML

LITIGATION AND OTHER LEGAL PROCEEDINGS (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended			9 Months Ended				3 Months Ended	9 Months Ended	0 Months Ended
	Sep. 30, 2012	Sep. 30, 2012 Conseco Life Insurance Company Litigation [Member]	Mar. 31, 2012 Conseco Life Insurance Company Litigation [Member]	Sep. 30, 2012 Multistate Examination, Senior Health and Bankers Life [Member]	Sep. 30, 2012 Regulatory Settlement For Certain Lifetrend Life Insurance Products [Member]	Oct. 31, 2008 Regulatory Settlement For Certain Lifetrend Life Insurance Products [Member]	Dec. 31, 2008 CIUL Universal Life Member [Member]	Sep. 30, 2012 Settlement with State Securities Regulators [Member]	Sep. 30, 2012 Minimum [Member] Multistate Examination, Senior Health and Bankers Life [Member]	Apr. 05, 2012 Pending Litigation [Member] Settlement with State Securities Regulators [Member]
Loss Contingencies [Line Items]
Pre-tax charge related to recorded loss contingency		$ 21	$ 20					$ 10
Number of States Involved In Multistate Examination									40
Loss Contingency, Maximum Senior Health				2.3
Potential Additional Amount Payable If Improvement Benchmarks Are Not Met				10
Lifetrend Policy Holders That Were Mailed a Notice						12,000
CIUL Universal Life Policy Holders Which Were Mailed a Notice							16,000
Fund Established For Certain Lifetrend Life Insurance Product Owners					10
Assesment To Be Paid To Participating Lifetrend Jurisdictions					1
Percentage of Lifetrend Policy Holders Represented by Jurisdictions That Have Signed Agreement					98.00%
Number of States Participating in Examination of Compliance with Unclaimed Property Laws	34
Settlement payment by Bankers to state securities regulators										$ 9.9

XML

BUSINESS SEGMENTS (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011
Revenues:
Fee revenue and other income	$ 5.2		$ 4.9		$ 13.6		$ 12.5
Revenues	1,083.9		961.7		3,218.0		3,034.9
Benefits and expenses:
Insurance policy benefits	745.7		661.0		2,124.4		2,028.6
Loss on extinguishment of debt	198.5		1.1		199.2		3.1
Other operating costs and expenses	217.5		182.0		617.8		527.8
Total expenses	1,247.1		906.9		3,231.3		2,846.1
Income before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	(163.2)		54.8		(13.3)		188.8
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Total segment revenues	1,083.9		961.7		3,218.0		3,034.9
Net realized investment gains (losses)	9.1		30.6		63.9		38.6
Consolidated revenues	1,093.0		992.3		3,281.9		3,073.5
Total segment expenses	1,247.1		906.9		3,231.3		2,846.1
Insurance policy benefits - fair value changes in embedded derivative liabilities	4.6		33.9		10.7		33.9
Amortization related to fair value changes in embedded derivative liabilities	(1.6)		(14.1)		(4.0)		(14.1)
Amortization related to net realized investment gains (losses)	1.7		3.9		5.9		3.7
Consolidated expenses	1,251.8		930.6		3,243.9		2,869.6
Bankers Life [Member]
Revenues:
Annuities	6.8		9.6		21.9		26.7
Health	335.1		334.0		1,010.6		1,017.1
Life	74.2		61.0		209.1		170.4
Net investment income	221.6	[1]	158.0	[1]	642.1	[1]	564.5	[1]
Fee revenue and other income	4.0	[1]	3.6	[1]	10.2	[1]	9.2	[1]
Revenues	641.7		566.2		1,893.9		1,787.9
Benefits and expenses:
Insurance policy benefits	434.6		360.6		1,252.2		1,174.3
Amortization	35.6		44.1		143.0		159.5
Interest expense on investment borrowings	1.3		1.2		4.1		3.5
Other operating costs and expenses	89.6		80.9		267.4		236.9
Total expenses	561.1		486.8		1,666.7		1,574.2
Income before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	80.6		79.4		227.2		213.7
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Total segment revenues	641.7		566.2		1,893.9		1,787.9
Total segment expenses	561.1		486.8		1,666.7		1,574.2
Washington National [Member]
Revenues:
Health	143.4		141.2		429.0		423.1
Life	3.6		3.9		11.6		11.8
Other	0.8		0.8		2.2		3.0
Net investment income	50.9	[1]	47.3	[1]	151.9	[1]	140.3	[1]
Fee revenue and other income	0.3	[1]	0.4	[1]	0.8	[1]	0.9	[1]
Revenues	199.0		193.6		595.5		579.1
Benefits and expenses:
Insurance policy benefits	111.1		119.0		340.5		349.5
Amortization	11.2		10.8		34.7		35.6
Interest expense on investment borrowings	0.7		0.2		2.2		0.2
Other operating costs and expenses	42.1		42.4		125.6		126.5
Total expenses	165.1		172.4		503.0		511.8
Income before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	33.9		21.2		92.5		67.3
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Total segment revenues	199.0		193.6		595.5		579.1
Total segment expenses	165.1		172.4		503.0		511.8
Colonial Penn [Member]
Revenues:
Health	1.3		1.4		4.0		4.5
Life	53.2		49.4		158.5		147.5
Net investment income	9.9	[1]	10.1	[1]	30.1	[1]	30.9	[1]
Fee revenue and other income	0.2	[1]	0.2	[1]	0.6	[1]	0.6	[1]
Revenues	64.6		61.1		193.2		183.5
Benefits and expenses:
Insurance policy benefits	38.3		36.0		120.0		112.7
Amortization	3.5		3.5		11.1		11.0
Other operating costs and expenses	25.4		22.9		73.9		66.3
Total expenses	67.2		62.4		205.0		190.0
Income before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	(2.6)		(1.3)		(11.8)		(6.5)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Total segment revenues	64.6		61.1		193.2		183.5
Total segment expenses	67.2		62.4		205.0		190.0
Other CNO Business [Member]
Revenues:
Annuities	2.5		3.4		8.3		8.6
Health	6.2		6.9		19.3		21.3
Life	62.9		61.7		196.2		184.9
Other	0.2		0.2		0.6		1.4
Net investment income	86.7	[1]	74.6	[1]	259.2	[1]	256.0	[1]
Revenues	158.5		146.8		483.6		472.2
Benefits and expenses:
Insurance policy benefits	157.1		111.5		401.0		358.2
Amortization	10.5		10.4		25.1		28.4
Interest expense on investment borrowings	5.0		5.3		15.1		15.2
Other operating costs and expenses	39.5		16.8		96.4		55.1
Total expenses	212.1		144.0		537.6		456.9
Income before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	(53.6)		2.8		(54.0)		15.3
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Total segment revenues	158.5		146.8		483.6		472.2
Total segment expenses	212.1		144.0		537.6		456.9
Corporate Operations [Member]
Revenues:
Net investment income	19.4		(6.7)		49.8		10.4
Fee revenue and other income	0.7		0.7		2.0		1.8
Revenues	20.1		(6.0)		51.8		12.2
Benefits and expenses:
Interest expense on investment borrowings	0.1		0.1		0.4		0.1
Interest expense on corporate debt	16.3		18.7		50.4		58.6
Interest expense on borrowings of variable interest entities	5.8		2.4		14.5		8.4
Loss on extinguishment of debt	198.5		1.1		199.2		3.1
Other operating costs and expenses	20.9		19.0		54.5		43.0
Total expenses	241.6		41.3		319.0		113.2
Income before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	(221.5)		(47.3)		(267.2)		(101.0)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]
Total segment revenues	20.1		(6.0)		51.8		12.2
Total segment expenses	$ 241.6		$ 41.3		$ 319.0		$ 113.2

[1] It is not practicable to provide additional components of revenue by product or services.

XML

INCOME TAXES (TABLES)

9 Months Ended

Sep. 30, 2012

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The components of income tax expense were as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Current tax expense	$	2.4		$	2.3		$	9.1		$	7.2
Deferred tax expense (benefit)	11.1			22.9			76.4			68.4
Valuation allowance applicable to current year income	(31.8		)	—			(31.8		)	—
Income tax expense (benefit) calculated based on estimated annual effective tax rate	(18.3		)	25.2			53.7			75.6
Income tax expense (benefit) on discrete items:
Valuation allowance reduction applicable to income in future years	(111.2		)	(143.0		)	(111.2		)	(143.0		)
Deferred tax benefit related to loss on extinguishment of debt and other items	(24.3		)	—			(24.3		)	—
Total income tax benefit	$	(153.8	)	$	(117.8	)	$	(81.8	)	$	(67.4	)

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

A reconciliation of the U.S. statutory corporate tax rate to the estimated annual tax rate, before discrete items, reflected in the consolidated statement of operations is as follows:

	Nine months ended
	September 30,
	2012		2011
U.S. statutory corporate rate	35.0	%	35.0	%
Valuation allowance reduction applicable to current year income	(13.8	)	—
Nondeductible amounts	.5		1.8
State taxes	1.0		1.0
Provision for tax issues, tax credits and other	—		(.8	)
Estimated annual effective tax rate	22.7	%	37.0	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The components of the Company’s income tax assets and liabilities were as follows (dollars in millions):

	September 30, 2012			December 31, 2011
	(Restated)
Deferred tax assets:
Net federal operating loss carryforwards	$	1,366.2		$	1,445.2
Net state operating loss carryforwards	16.3			16.8
Tax credits	37.7			32.6
Capital loss carryforwards	305.4			342.3
Deductible temporary differences:
Insurance liabilities	754.8			744.4
Other	81.7			64.8
Gross deferred tax assets	2,562.1			2,646.1
Deferred tax liabilities:
Investments	(21.9		)	(24.2		)
Present value of future profits and deferred acquisition costs	(333.7		)	(363.7		)
Accumulated other comprehensive income	(688.1		)	(434.8		)
Gross deferred tax liabilities	(1,043.7		)	(822.7		)
Net deferred tax assets before valuation allowance	1,518.4			1,823.4
Valuation allowance	(795.4		)	(938.4		)
Net deferred tax assets	723.0			885.0
Current income taxes accrued	(23.5		)	(19.6		)
Income tax assets, net	$	699.5		$	865.4

Summary of Operating Loss Carryforwards [Table Text Block]

.

As of September 30, 2012, we had $3.9 billion of federal NOLs and $.9 billion of capital loss carryforwards. The following table summarizes the expiration dates of our loss carryforwards assuming the IRS does not ultimately agree with the positions we have taken with respect to the allocation of CODI and the loss on our investment in Senior Health, both as further described below (dollars in millions):

Year of expiration	Net operating loss carryforwards (a)						Capital loss			Total loss
	Life			Non-life			carryforwards			carryforwards
2013	$	—		$	—		$	836.7	(b)	$	836.7
2014	—			—			28.6			28.6
2015	—			—			7.2			7.2
2018	550.9		(a)	—			—			550.9
2021	29.5			—			—			29.5
2022	204.1			—			—			204.1
2023	—		(b)	2,602.8		(a)	—			2,602.8
2024	—			3.2			—			3.2
2025	—			118.8			—			118.8
2027	—			216.8			—			216.8
2028	—			.5			—			.5
2029	—			148.9			—			148.9
2031	—			28.0			—			28.0
Total	$	784.5		$	3,119.0		$	872.5		$	4,776.0

 _________________________

(a) The life/non-life allocation summarized above assumes the IRS does not ultimately agree with the tax position we have taken in our tax returns with respect to the allocation of CODI.  If the IRS ultimately agrees with our tax position, approximately $631 million of the non-life NOLs expiring in 2023 would be characterized as life NOLs expiring in 2018.

(b) The allocation of the capital loss carryforwards summarized above assumes the IRS does not ultimately agree with the tax position we have taken with respect to our investment in Senior Health, which was worthless when it was transferred to the Independent Trust in 2008. If the IRS ultimately agrees with our tax position of classifying this loss as ordinary, capital loss carryforwards expiring in 2013 would decrease and life NOLs expiring in 2023 would increase by $742 million.

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (TABLES)

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments [Table Text Block]

The following notes payable were direct corporate obligations of the Company as of September 30, 2012 and December 31, 2011 (dollars in millions):

	September 30, 2012			December 31, 2011
New Senior Secured Credit Agreement (as defined below)	$	675.0		$	—
7.0% Debentures	93.0			293.0
Previous Senior Secured Credit Agreement (as defined below)	—			255.2
6.375% Senior Secured Notes due October 2020 (the "6.375% Notes")	275.0			—
9.0% Senior Secured Notes due January 2018 (the “9.0% Notes”)	1.2			275.0
Senior Health Note due November 12, 2013 (the “Senior Health Note”)	—			50.0
Unamortized discount on New Senior Secured Credit Agreement	(5.5		)	—
Unamortized discount on 7.0% Debentures	(3.6		)	(12.9		)
Unamortized discount on Previous Senior Secured Credit Agreement	—			(2.4		)
Direct corporate obligations	$	1,035.1		$	857.9

Schedule of Maturities of Long-term Debt [Table Text Block]

cheduled Repayment of our Direct Corporate Obligations

The scheduled repayment of our direct corporate obligations was as follows at September 30, 2012 (dollars in millions):

Year ending September 30,
2013	$	55.4
2014	54.3
2015	79.3
2016	79.3
2017	97.2
Thereafter	678.7
	$	1,044.2

XML

CONSOLIDATED STATEMENT OF CASH FLOWS (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Insurance policy income	$ 1,802.3	$ 1,791.8
Net investment income	1,010.0	1,065.0
Fee revenue and other income	13.6	12.5
Insurance policy benefits	(1,611.5)	(1,555.7)
Interest expense	(84.3)	(70.5)
Deferrable policy acquisition costs	(141.4)	(164.9)
Other operating costs	(558.6)	(513.6)
Taxes	(5.5)	(2.4)
Net cash provided by operating activities	424.6	562.2
Cash flows from investing activities:
Sales of investments	1,852.5	4,390.5
Maturities and redemptions of investments	1,365.4	853.3
Purchases of investments	(3,570.2)	(6,363.8)
Net sales of trading securities	47.2	307.2
Change in cash and cash equivalents held by variable interest entities	26.2	7.1
Other	(24.3)	(23.4)
Net cash used by investing activities	(303.2)	(829.1)
Cash flows from financing activities:
Issuance of notes payable, net	944.5	0
Payments on notes payable	(779.0)	(130.7)
Expenses related to extinguishment of debt	(206.4)	0
Issuance of common stock	2.0	0.6
Payments to repurchase common stock	(99.5)	(55.7)
Common stock dividends paid	(9.4)	0
Amounts received for deposit products	986.0	1,285.8
Withdrawals from deposit products	(1,201.4)	(1,272.0)
Issuance of investment borrowings:
Federal Home Loan Bank	200.0	517.0
Related to variable interest entities	246.7	122.2
Payments on investment borrowings:
Federal Home Loan Bank	(200.0)	(267.0)
Related to variable interest entities and other	(0.8)	(100.4)
Investment borrowings - repurchase agreements, net	(24.8)	57.1
Net cash provided (used) by financing activities	(142.1)	156.9
Net decrease in cash and cash equivalents	(20.7)	(110.0)
Cash and cash equivalents, beginning of period	436.0	571.9
Cash and cash equivalents, end of period	$ 415.3	$ 461.9

XML

INVESTMENT BORROWINGS (TABLES)

9 Months Ended

Sep. 30, 2012

Investment Borrowings [Abstract]

Schedule of Terms of Federal Home Loan Bank Borrowing [Table Text Block]

The following summarizes the terms of the borrowings (dollars in millions):

Amount		Maturity	Interest rate at
borrowed		date	September 30, 2012
$	100.0	November 2013	Variable rate – 0.515%
67.0		February 2014	Fixed rate – 1.830%
50.0		August 2014	Variable rate – 0.565%
100.0		August 2014	Variable rate – 0.476%
50.0		September 2015	Variable rate – 0.747%
150.0		October 2015	Variable rate – 0.571%
146.0		November 2015	Fixed rate – 5.300%
100.0		December 2015	Fixed rate – 4.710%
100.0		June 2016	Variable rate – 0.657%
75.0		June 2016	Variable rate – 0.621%
100.0		October 2016	Variable rate – 0.641%
50.0		November 2016	Variable rate – 0.684%
50.0		November 2016	Variable rate – 0.687%
100.0		June 2017	Variable rate – 0.751%
100.0		July 2017	Fixed rate – 3.900%
50.0		August 2017	Variable rate – 0.635%
75.0		August 2017	Variable rate – 0.577%
100.0		October 2017	Variable rate – 0.885%
37.0		November 2017	Fixed rate – 3.750%
50.0		July 2018	Variable rate – 0.917%
$	1,650.0

XML

INVESTMENTS - SCHEDULE OF OTHER THAN TEMPORARY IMPAIRMENT (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Line Items]
Other-than-temporary impairments included in accumulated other comprehensive income	$ 7.3				$ 7.3
Available-for-sale Securities [Member]
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Roll Forward]
Credit losses on fixed maturity securities, available for sale, beginning of period	(1.7)		(1.6)		(2.0)		(6.1)
Add: credit losses on other-than-temporary impairments not previously recognized	0		0		0		0
Less: credit losses on securities sold	0		0.7		0.3		5.2
Less: credit losses on securities impaired due to intent to sell	0	[1]	0	[1]	0	[1]	0	[1]
Add: credit losses on previously impaired securities	0		0		0		0
Less: increases in cash flows expected on previously impaired securities	0		0		0		0
Credit losses on fixed maturity securities, available for sale, end of period	$ (1.7)		$ (0.9)		$ (1.7)		$ (0.9)

[1] Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.

XML

CHANGES IN COMMON STOCK (DETAILS) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012		Sep. 30, 2011
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount		$ 100.0
Stock Repurchase Program, Increase in Authorized Amount		200.0
Stock Repurchased and Retired During Period, Shares		12,894,178
Stock Repurchased and Retired During Period, Value		99.5		55.7
Common Stock Disclosures [Abstract]
Balance, December 31, 2011		241,304,503
Balance, September 30, 2012	229,506,690	229,506,690
Shares Paid for Tax Withholding for Share Based Compensation		143,000
Stock Repurchase Program, Remaining Repurchase Authorized Amount	130.7	130.7
Common Stock, Dividends, Per Share, Cash Paid	$ 0.02
Dividends, Common Stock		9.4
Stock Options [Member]
Common Stock Disclosures [Abstract]
Shares issued under employee benefit compensation plans		691,950
Restricted Stock [Member]
Common Stock Disclosures [Abstract]
Shares issued under employee benefit compensation plans		404,415	[1]
Common Stock Including Additional Paid in Capital [Member]
Class of Stock [Line Items]
Stock Repurchased and Retired During Period, Value		99.5		55.7
Common Stock Disclosures [Abstract]
Dividends, Common Stock		$ 0

[1] Such amount was reduced by 143 thousand shares which were tendered to the Company for the payment of federal and state taxes owed on the vesting of restricted stock.

XML

CONSOLIDATED BALANCE SHEET (USD $) In Millions, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Investments:
Fixed maturities, available for sale, at fair value (amortized cost: September 30, 2012 - $21,825.7; December 31, 2011 - $21,779.1)	$ 24,742.3	$ 23,516.0
Equity securities at fair value (cost: September 30, 2012 - $174.0; December 31, 2011 - $177.0)	180.0	175.1
Mortgage loans	1,597.2	1,602.8
Policy loans	274.1	279.7
Trading securities	199.4	91.6
Investments held by variable interest entities	829.4	496.3
Other invested assets	265.0	202.8
Total investments	28,087.4	26,364.3
Cash and cash equivalents - unrestricted	415.3	436.0
Cash and cash equivalents held by variable interest entities	48.2	74.4
Accrued investment income	317.8	288.7
Present value of future profits	642.4	697.7
Deferred acquisition costs	623.4	797.1
Reinsurance receivables	2,967.7	3,091.1
Income tax assets, net	699.5	865.4
Assets held in separate accounts	15.7	15.0
Other assets	338.6	292.2
Total assets	34,156.0	32,921.9
Liabilities for insurance products:
Interest-sensitive products	12,930.3	13,165.5
Traditional products	11,004.3	10,482.7
Claims payable and other policyholder funds	977.6	1,034.3
Liabilities related to separate accounts	15.7	15.0
Other liabilities	709.0	556.3
Investment borrowings	1,650.9	1,676.5
Borrowings related to variable interest entities	766.9	519.9
Notes payable - direct corporate obligations	1,035.1	857.9
Total liabilities	29,089.8	28,308.1
Commitments and contingencies
Shareholders' equity:
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: September 30, 2012 – 229,506,690; December 31, 2011 – 241,304,503)	2.3	2.4
Additional paid-in capital	4,251.2	4,361.9
Accumulated other comprehensive income	1,234.4	781.6
Accumulated deficit	(421.7)	(532.1)
Total shareholders' equity	5,066.2	4,613.8
Total liabilities and shareholders' equity	$ 34,156.0	$ 32,921.9

XML

ACCOUNTING FOR DERIVATIVES (DETAILS) (USD $) In Millions, unless otherwise specified	9 Months Ended				9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Equity Swap [Member]	Dec. 31, 2011 Equity Swap [Member]	Sep. 30, 2012 Equity Swap [Member] Investment Income [Member]	Sep. 30, 2011 Equity Swap [Member] Investment Income [Member]	Sep. 30, 2012 Embedded Derivative Financial Instruments [Member]	Dec. 31, 2011 Embedded Derivative Financial Instruments [Member]	Sep. 30, 2012 Embedded Derivative Associated With Modified Coinsurance Agreement [Member]	Dec. 31, 2011 Embedded Derivative Associated With Modified Coinsurance Agreement [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Net					$ 37.5	$ (25.7)
Other Derivatives Not Designated as Hedging Instruments Assets at Fair Value			81.9	37.9
Other Derivatives Not Designated as Hedging Instruments Liabilities at Fair Value							737.9	666.3	6.0	3.5
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	$ 6.7	$ 19.8

XML

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (USD $) In Millions	Total	Common stock and additional paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings (accumulated deficit)
Balance at Dec. 31, 2010	$ 3,811.6	$ 4,426.7	$ 252.7	$ (867.8)
Net income (loss)	271.3	0	0	271.3
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense)	495.0	0	495.0	0
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense)	3.2	0	3.2	0
Cost of shares acquired	(55.7)	(55.7)	0	0
Stock option and restricted stock plans	10.8	10.8	0	0
Balance at Sep. 30, 2011	4,536.2	4,381.8	750.9	(596.5)
Balance at Dec. 31, 2011	4,613.8	4,364.3	781.6	(532.1)
Net income (loss)	119.8	0	0	119.8
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense)	444.9	0	444.9	0
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense)	7.9	0	7.9	0
Extinguishment of beneficial conversion feature related to the repurchase of convertible debentures	(24.0)	(24.0)	0	0
Cost of shares acquired	(99.5)	(99.5)	0	0
Dividends on common stock	(9.4)	0	0	(9.4)
Stock option and restricted stock plans	12.7	12.7	0	0
Balance at Sep. 30, 2012	$ 5,066.2	$ 4,253.5	$ 1,234.4	$ (421.7)

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES - SCHEDULE OF VIEs (DETAILS) (USD $) In Millions, unless otherwise specified	Sep. 30, 2012
Investment Holdings [Line Items]
Total amortized cost	$ 827.7
Total fair value	829.4
Amortized Cost [Member]
Investment Holdings [Line Items]
Due in one year or less	3.0
Due after one year through five years	413.8
Due after five years through ten years	410.9
Total amortized cost	827.7
Estimated Fair Value [Member]
Investment Holdings [Line Items]
Due in one year or less	3.0
Due after one year through five years	413.1
Due after five years through ten years	413.3
Total fair value	$ 829.4

XML

CONSOLIDATED STATEMENT CASH FLOWS (TABLES)

9 Months Ended

Sep. 30, 2012

Supplemental Cash Flow Elements [Abstract]

Reconciliation Of Net Income To Net Cash Provided By Operating Activities [Table Text Block]

The following reconciles net income to net cash provided by operating activities (dollars in millions):

	Nine months ended
	September 30,
	2012			2011
Cash flows from operating activities:
Net income	$	119.8		$	271.3
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization and depreciation	235.2			243.6
Income taxes	(87.3		)	(69.8		)
Insurance liabilities	242.8			244.4
Accrual and amortization of investment income	(123.1		)	62.9
Deferral of policy acquisition costs	(141.4		)	(164.9		)
Net realized investment gains	(63.9		)	(38.6		)
Loss on extinguishment of debt	199.2			3.1
Other	43.3			10.2
Net cash provided by operating activities	$	424.6		$	562.2

Schedule of Other Significant Noncash Transactions [Table Text Block]

Non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions):

	Nine months ended
	September 30,
	2012		2011
Stock option and restricted stock plans	$	10.7	$	10.2

XML

LITIGATION AND OTHER LEGAL PROCEEDINGS

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies Disclosure [Abstract]

LITIGATION AND OTHER LEGAL PROCEEDINGS

LITIGATION AND OTHER LEGAL PROCEEDINGS

Legal Proceedings

The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts.  We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred.  The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict.  In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows.  In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies.  Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.

In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, many of the matters specifically identified below purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company can not reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters.  The Company reviews these matters on an ongoing basis.  When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.

Cost of Insurance Litigation

Valulife/Valuterm Litigation

On March 4, 2008, a complaint was filed in the United States District Court for the Central District of California, Celedonia X. Yue, M. D. on behalf of the class of all others similarly situated, and on behalf of the General Public v. Conseco Life Insurance Company, successor to Philadelphia Life Insurance Company and formerly known as Massachusetts General Life Insurance Company, Cause No. CV08-01506 CAS.  Plaintiff in this putative class action owns a Valulife universal life policy insuring the life of Ruth S. Yue originally issued by Massachusetts General Life Insurance Company in 1995.  Plaintiff is claiming breach of contract on behalf of the proposed national class and seeks injunctive and restitutionary relief pursuant to California Business & Professions Code Section 17200 and declaratory relief.  The putative class consists of all owners of Valulife and Valuterm universal life insurance policies issued by either Massachusetts General or Philadelphia Life and that were later acquired and serviced by Conseco Life.  Plaintiff alleges that members of the class will be damaged by increases in the cost of insurance (a non-guaranteed element ("NGE")) that are set to take place in the twenty first policy year of Valulife and Valuterm policies. No such increases had yet been applied to the subject policies.  During 2010, Conseco Life voluntarily agreed not to implement the cost of insurance rate increase at issue in this litigation and is following a process with respect to any future cost of insurance rate increases as set forth in the regulatory settlement agreement described below under the caption entitled "Regulatory Examinations and Fines". Plaintiff filed a motion for certification of a nationwide class and a California state class.  On December 7, 2009, the court granted that motion. On October 8, 2010, the court dismissed the causes of actions alleged in the California state class.  On January 19, 2011, the court granted the plaintiff's motion for summary judgment as to the declaratory relief claim and on February 2, 2011, the court issued an advisory opinion, in the form of a declaratory judgment, as to what, in its view, Conseco Life could consider in implementing future cost of insurance rate increases related to its Valulife and Valuterm block of policies.  Conseco Life is appealing the court's January 19, 2011 decision and the plaintiff is appealing the court's decision to dismiss the California causes of action.  These appeals are pending. We believe this case is without merit, and intend to defend it vigorously.  

On November 15, 2011, a second complaint was filed by Dr. Yue in the United States District Court for the Central District on California, Celedonia X. Yue, M. D. on behalf of the class of all others similarly situated, and on behalf of the General Public v. Conseco Life Insurance Company, Cause No. CV11-9506 AHM (SHx), involving the same Valulife universal life policy described in the preceding paragraph. Plaintiff, for herself and on behalf of proposed members of a national class and a California class is claiming breach of contract, injunctive and restitutionary relief pursuant to California Business & Professions Code Section 17200, breach of the covenant of good faith and fair dealing, declaratory relief, and temporary, preliminary, and permanent injunctive relief. The putative class consists of all owners and former owners of Valulife and Valuterm universal life insurance policies issued by either Massachusetts General or Philadelphia Life and that were later acquired and serviced by Conseco Life. Plaintiff alleges that members of the classes will be damaged by increases in the cost of insurance (a NGE) that took place on or about November 1, 2011. Plaintiff filed a motion for a preliminary injunction and a motion for certification of a California class. On April 2, 2012, the court granted the plaintiff's motions, which Conseco Life is appealing. Pending the outcome of that appeal, Conseco Life is preliminarily enjoined from imposing the 2011 increase in the cost of insurance on the members of the California class. Plaintiff also filed a motion on March 20, 2012 for certification of a nationwide class. The court has stated that it will not issue a ruling prior to December 17, 2012 on plaintiff's motion for certification of a nationwide class.

Conseco Life has reached a tentative agreement with the plaintiff in the litigation described in the two preceding paragraphs regarding the material economic terms of a settlement, which would upon completion and court approval, resolve those cases as well as the Nicholas litigation described below. The parties are continuing to negotiate additional non-economic settlement terms. The settlement is expected to include a reduction in the cost of insurance increase implemented by Conseco Life in November 2011 and certain policy benefit enhancements. Any final settlement would be subject to a court fairness hearing after notice to the policyholders covered by the settlement, as well as other conditions.

On February 6, 2012, a complaint was filed in the United States District Court for the Northern District of Illinois, Daniel B. Nicholas, on behalf of himself and all others similarly situated v. Conseco Life Insurance Company, Cause No. 12cv845. Plaintiff in this putative class action owns a Valulife universal life policy insuring Plaintiff's life originally issued by Massachusetts General Life Insurance Company (now Conseco Life Insurance Company) in 1991. Plaintiff is claiming breach of contract on behalf of the proposed national class and seeks declaratory, injunctive, and supplemental relief. The putative class consists of all persons who own or have owned one or more universal life policies issued by Conseco Life which provide that the cost of insurance rates will be determined based upon expectations as to future mortality experience and who have experienced an increase in the cost of insurance rates. Plaintiff alleges that members of the class will be damaged by cost of insurance charges that were increased due to general economic downturn, Conseco Life's diminished investment yields, and mounting policy losses. On April 20, 2012, we announced that Conseco Life had reached a tentative settlement in the Nicholas case. On May 17, 2012, the court granted the motion to intervene which had been filed by the Plaintiff in the Yue litigation described above and venue has been transferred to the United States District Court for the Central District of California. The plaintiff in the Nicholas case has filed a motion for preliminary approval of the settlement in the United States District Court for the Central District of California.

In connection with the tentative settlement in the Nicholas litigation, the Company recorded a pre-tax charge of approximately $20 million in its Other CNO Business segment for the quarter ended March 31, 2012. The Company recorded an additional pre-tax charge of $21 million in its Other CNO Business segment for the quarter ended September 30, 2012 relating to the tentative agreement described above in the Yue litigation. The liability the Company has established related to the tentative settlement of these cases includes its best estimates of the costs of implementing the tentative settlement, if finalized and approved by the court. While the Company believes its estimates are adequate to cover these costs, the estimates are subject to significant judgment and it is possible that the estimates will prove insufficient to cover the actual costs.

Lifetrend Litigation

On December 24, 2008, a purported class action was filed in the U.S. District Court for the Northern District of California, Cedric Brady, et. al. individually and on behalf of all other similarly situated v. Conseco, Inc. and Conseco Life Insurance Company Case No. 3:08-cv-05746.  The plaintiffs allege that Conseco Life and Conseco, Inc. committed breach of contract and insurance bad faith and violated various consumer protection statutes in the administration of various interest sensitive whole life products sold primarily under the name “Lifetrend” by requiring the payment of additional cash amounts to maintain the policies in force and by making changes to certain NGEs in their policies.  On April 23, 2009, the plaintiffs filed an amended complaint adding the additional counts of breach of fiduciary duty, fraud, negligent misrepresentation, conversion and declaratory relief.  On May 29, 2009, Conseco, Inc. and Conseco Life filed a motion to dismiss the amended complaint. On July 29, 2009, the court granted in part and denied in part the motion to dismiss.  The court dismissed the allegations that Conseco Life violated various consumer protection statutes, the breach of fiduciary duty count, and dismissed Conseco, Inc. for lack of personal jurisdiction.  

On July 2, 2009, a purported class action was filed in the U.S. District Court for the Middle District of Florida, Bill W. McFarland, and all those similarly situated v. Conseco Life Insurance Company, Case No. 3:09-cv-598-J-32MCR.  The plaintiff alleges that Conseco Life committed breach of contract and has been unjustly enriched in the administration, including changes to certain NGEs, of various interest sensitive whole life products sold primarily under the name “Lifetrend.” The plaintiff seeks declaratory and injunctive relief, compensatory damages, punitive damages and attorney fees.

Conseco Life filed a motion with the Judicial Panel on Multidistrict Litigation (“MDL”), seeking the establishment of an MDL proceeding consolidating the Brady case and the McFarland case into a single action.  On February 3, 2010, the Judicial Panel on MDL ordered these cases be consolidated for pretrial proceedings in the Northern District of California Federal Court. On July 7, 2010, plaintiffs filed an amended motion for class certification of a nationwide class and a California state class.  On October 6, 2010, the court granted the motion for certification of a nationwide class and denied the motion for certification of a California state class.  Conseco Life filed a motion to decertify the nationwide class on July 1, 2011. On December 20, 2011, the court issued an order denying Conseco Life's motion to decertify the class as to current policyholders, but granted the motion to decertify as to former policyholders. On March 5, 2012, the plaintiffs filed a motion for a preliminary injunction requesting that the court enjoin Conseco Life from imposing increased cost of insurance charges until trial with regard to 157 members of the class, and on July 17, 2012, the court granted a preliminary injunction as to 100 members of the class and denied the plaintiff's motion for a preliminary injunction as to the other 57 members. On September 27, 2012, the plaintiffs filed a motion for partial summary judgment on their breach of contract claim. On October 19, 2012, Conseco Life filed a motion to decertify the nationwide class, and on October 30, 2012, Conseco Life filed its motion for summary judgment. Trial in the MDL proceeding has been set for March 25, 2013.  We believe these cases are without merit and intend to defend them vigorously.

On October 25, 2012, a purported nationwide class action was filed in the United States District Court for the Central District of California, William Jeffrey Burnett and Joe H. Camp v. Conseco Life Insurance Company, CNO Financial Group, Inc., CDOC, Inc. and CNO Services, LLC, Case No. EDCV12-01715VAPSPX. The plaintiffs bring this action under Rule 23(B)(3) on behalf of various Lifetrend policyholders who since October 2008 have surrendered their policies or had them lapse. Such policyholders are no longer members of the class covered by the MDL litigation described in the previous paragraph after the court in the MDL litigation granted Conseco Life's motion to decertify as to former policyholders. Additionally, plaintiffs seek certification of a subclass of various Lifetrend policyholders who accepted optional benefits and signed a release pursuant to the regulatory settlement agreement described below under the caption entitled “Regulatory Examinations and Fines.” The plaintiffs allege breach of contract and seek declaratory relief, compensatory damages, attorney fees and costs. We believe this case is without merit and intend to defend it vigorously.

Other Litigation

On December 8, 2008, a purported Florida state class action was filed in the U.S. District Court for the Southern District of Florida, Sydelle Ruderman individually and on behalf of all other similarly situated v. Washington National Insurance Company, Case No. 08-23401-CIV-Cohn/Selzer. The plaintiff alleges that the inflation escalation rider on her policy of long-term care insurance operates to increase the policy's lifetime maximum benefit, and that Washington National Insurance Company breached the contract by stopping her benefits when they reached the lifetime maximum.  The Company takes the position that the inflation escalator only affects the per day maximum benefit.  The Plaintiff filed a motion for class certification, and the motion has been fully briefed by both sides.  The court has not yet ruled on the motion or set it for hearing. Additional parties have asked the court to allow them to intervene in the action, and on January 5, 2010, the court granted the motion to intervene and granted the plaintiff's motion for class certification.  The court certified a (B) (3) Florida state class alleging damages and a (B) (2) Florida state class alleging injunctive relief.  The parties reached a settlement of the (B) (3) class in 2010, which has been implemented. The amount recognized in 2010 related to the settlement in principle was not significant to the Company's consolidated financial condition, cash flows or results of operations. The plaintiff filed a motion for summary judgment as to the (B) (2) class which was granted by the court on September 8, 2010.  The Company has appealed the court's decision and the appeal is pending.  On February 17, 2012, the Eleventh Circuit Court of Appeals referred the case to the Florida Supreme Court, which accepted jurisdiction of the case. We believe this case is without merit, and intend to defend it vigorously.  

On January 26, 2009, a purported class action complaint was filed in the United States District Court for the Northern District of Illinois, Samuel Rowe and Estella Rowe, individually and on behalf of themselves and all others similarly situated v. Bankers Life & Casualty Company and Bankers Life Insurance Company of Illinois, Case No. 09CV491.  The plaintiffs are alleging violation of California Business and Professions Code Sections 17200 et seq. and 17500 et seq., breach of common law fiduciary duty, breach of implied covenant of good faith and fair dealing and violation of California Welfare and Institutions Code Section 15600 on behalf of the proposed national class and seek injunctive relief, compensatory damages, punitive damages and attorney fees.  The plaintiff alleges that the defendants used an improper and misleading sales and marketing approach to seniors that fails to disclose all facts, misuses consumers' confidential financial information, uses misleading sales and marketing materials, promotes deferred annuities that are fundamentally inferior and less valuable than readily available alternative investment products and fails to adequately disclose other principal risks including maturity dates, surrender penalties and other restrictions which limit access to annuity proceeds to a date beyond the applicant's actuarial life expectancy. Plaintiffs have amended their complaint attempting to convert this from a California only class action to a national class action. In addition, the amended complaint adds causes of action under the Racketeer Influenced and Corrupt Organization Act (“RICO”); aiding and abetting breach of fiduciary duty and for unjust enrichment.  On September 13, 2010, the court dismissed the plaintiff's RICO claims.  On October 25, 2010, the plaintiffs filed a second amended complaint re-alleging their RICO claims.  On March 29, 2012, the court denied plaintiff's motion for certification of a nationwide class and denied plaintiff's motion for certification of a California class. The court allowed the plaintiff the opportunity to file a renewed motion for a California class, which the plaintiff did on May 21, 2012. On July 24, 2012, Bankers Life filed a motion for summary judgment. We believe this case is without merit, and intend to defend it vigorously. 

On August 23, 2012, a purported class action was filed in the United States District Court for the District of Massachusetts (Boston), Fay Glick, on behalf of herself and all others similarly situated, v. Bankers Life & Casualty Company, Case No. 1:12-cv-11579. The plaintiff is seeking injunctive and declaratory relief and damages arising from Bankers' alleged systematic business practices of delaying and/or denying the payment of claims for benefits provided for under its healthcare insurance policies and recovery of undisclosed interest that Bankers has charged on any policyholders who paid premiums on a monthly or “modal” basis (as opposed to paying premiums on an annual basis). We believe this case is without merit and intend to defend it vigorously.

Regulatory Examinations and Fines

Insurance companies face significant risks related to regulatory investigations and actions.  Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers.  We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities.  The ultimate outcome of these regulatory actions cannot be predicted with certainty.  In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.

The states of Pennsylvania, Illinois, Texas, Florida and Indiana led a multistate examination of the long-term care claims administration and complaint handling practices of Senior Health and Bankers Life, as well as the sales and marketing practices of Bankers Life.  On May 7, 2008, we announced a settlement among the state insurance regulators and Senior Health and Bankers Life.  This examination covered the years 2005, 2006 and 2007.  More than 40 states are parties to the settlement, which included a Senior Health fine of up to $2.3 million, with up to an additional $10 million payable, on the part of either Senior Health and/or Bankers Life, in the event the process improvements and benchmarks are not met.  The process improvement plan is being monitored by the lead states, and pursuant to the settlement agreement, the lead states are conducting a re-examination of Bankers Life to confirm compliance with the process improvements and benchmarks.

In October 2008, Conseco Life mailed notice to approximately 12,000 holders of its “Lifetrend” life insurance products to inform them of:  (i) changes to certain NGEs of their policies; and (ii) the fact that certain policyholders who were not paying premiums may have failed to receive a notice that their policy was underfunded and that additional premiums were required in order for the policyholders to maintain their guaranteed cash values.  In December 2008, Conseco Life mailed notice to approximately 16,000 holders of its CIUL3+ universal life policies to inform them of an increase in certain NGEs with respect to their policies.  Prior to or around the time that the notices were sent, Conseco Life had informed the insurance regulators in a number of states, including among others Indiana, Iowa and Florida, of these matters and the planned communication with the impacted policyholders.  Several states initiated regulatory actions and inquiries after the notices were sent by Conseco Life, and Conseco Life agreed to take no further actions with respect to those policies during the pendency of a market conduct examination.

After working with various state insurance regulators to review the terms of the Lifetrend and CIUL3+ policies, Conseco Life reached a settlement in principle with the regulators regarding issues involving these policies. During this regulatory review process, Conseco Life had been allowed to move forward with implementing the NGE changes in its CIUL3+ policies while the regulators continued their review.  Conseco Life had also resumed the administration of its Lifetrend policies with administrative changes in place but did not implement the NGE changes pending execution of the final settlement agreement with the regulators.  On June 30, 2010, we announced that Conseco Life had finalized a regulatory settlement agreement that requires the establishment of a $10 million fund for certain owners of its Lifetrend life insurance products and the payment of a $1 million assessment to participating jurisdictions.  Forty-seven jurisdictions, representing almost 98% percent of the Lifetrend policyholders, have signed the settlement agreement.  Conseco Life has notified consumers of the settlement and the increase in their NGEs.  As previously disclosed, we accrued for the financial impact of the settlement in our consolidated financial statements for year-end 2009.

In August 2011, we were notified of an examination to be done on behalf of a number of states for the purpose of determining compliance with unclaimed property laws by the Company and its subsidiaries.  We are continuing to provide information to the examiners in response to their requests. A total of 34 states and the District of Columbia are currently participating in this examination.

On April 5, 2012, we reported that our subsidiaries, Bankers Life and BLC Financial Services, Inc., a broker-dealer licensed in Illinois (“BLCFS”) (collectively “Bankers”), have reached a settlement with the State of Maine Office of Securities and three other state securities regulators regarding allegations that Bankers has acted as a broker-dealer and investment advisor without proper state licensing. Since 2005, Bankers Life and BLCFS had operated under arrangements with unaffiliated broker-dealers (licensed in all states in which Bankers Life operates) under which insurance agents with Bankers Life who became licensed as registered representatives and/or investment advisor representatives of the unaffiliated broker-dealer provided brokerage and investment advisory services to customers under the exclusive control of the unaffiliated broker-dealer. Following this settlement, Bankers Life has continued its arrangement whereby registered representatives of the unaffiliated broker-dealer, who are financial advisors, handle any securities transactions, and BLCFS has been eliminated from its prior role. By putting this legacy issue behind it, Bankers Life believes that this settlement provides additional clarity between the roles of agents and financial advisors and allows the company to continue to focus on providing the products and services its customers need. The consent order issued by Maine in connection with this settlement includes an acknowledgement by the state that the conduct of Bankers Life and BLCFS has resulted in no known direct consumer harm and that licensed agents or representatives of licensed broker-dealers or investment advisors other than Bankers participated in all securities transactions and at locations that were registered with the appropriate securities authorities as broker-dealer locations of broker-dealers other than Bankers. The settlement provides for the payment by Bankers of $9.9 million among the states where these dual agents were located for the period from 2005 - 2011. Bankers also agreed to pay certain costs of the investigation as well as past licensing and registration fees. CNO recorded a pre-tax charge of approximately $10 million in the first quarter of 2012 related to this settlement.

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES (TABLES)

9 Months Ended

Sep. 30, 2012

Investments in Variable Interest Entities [Abstract]

Schedule of Impact On Balance Sheet of Consolidating Variable Interest Entities [Table Text Block]

The following table provides supplemental information about the assets and liabilities of the VIEs which have been consolidated in accordance with authoritative guidance (dollars in millions):

	September 30, 2012
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	829.4	$	—		$	829.4
Notes receivable of VIEs held by insurance subsidiaries	—		(78.5		)	(78.5		)
Cash and cash equivalents held by variable interest entities	48.2		—			48.2
Accrued investment income	3.9		—			3.9
Income tax assets, net	3.2		(2.3		)	.9
Other assets	10.9		—			10.9
Total assets	$	895.6	$	(80.8	)	$	814.8
Liabilities:
Other liabilities	$	52.0	$	(2.3	)	$	49.7
Borrowings related to variable interest entities	766.9		—			766.9
Notes payable of VIEs held by insurance subsidiaries	82.5		(82.5		)	—
Total liabilities	$	901.4	$	(84.8	)	$	816.6

	December 31, 2011
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	496.3	$	—		$	496.3
Notes receivable of VIEs held by insurance subsidiaries	—		(45.3		)	(45.3		)
Cash and cash equivalents held by variable interest entities	74.4		—			74.4
Accrued investment income	1.7		—			1.7
Income tax assets, net	6.8		(1.4		)	5.4
Other assets	7.7		—			7.7
Total assets	$	586.9	$	(46.7	)	$	540.2
Liabilities:
Other liabilities	$	30.3	$	(.1	)	$	30.2
Borrowings related to variable interest entities	519.9		—			519.9
Notes payable of VIEs held by insurance subsidiaries	49.3		(49.3		)	—
Total liabilities	$	599.5	$	(49.4	)	$	550.1

Variable Interest Entities, Fair Value by Contractual Maturity [Table Text Block]

The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at September 30, 2012, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	3.0	$	3.0
Due after one year through five years	413.8		413.1
Due after five years through ten years	410.9		413.3
Total	$	827.7	$	829.4

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES

9 Months Ended

Sep. 30, 2012

Investments in Variable Interest Entities [Abstract]

INVESTMENTS IN VARIABLE INTEREST ENTITIES

INVESTMENTS IN VARIABLE INTEREST ENTITIES

Based on our assessment, we have concluded that we are the primary beneficiary with respect to certain variable interest entities (“VIEs”), which are consolidated in our financial statements.  The following is a description of our significant investments in VIEs:

All of the VIEs are collateralized loan trusts that were established to issue securities and use the proceeds to principally invest in corporate loans and other permitted investments (including a new VIE which was consolidated in the first quarter of 2012).  The assets held by the trusts are legally isolated and not available to the Company.  The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company.  Repayment of the remaining principal balance of the borrowings of the VIEs is based on available cash flows from the assets.  The Company has no further commitments to the VIEs.

Certain of our insurance subsidiaries are noteholders of the VIEs.  Another subsidiary of the Company is the investment manager for the VIEs.  As such, it has the power to direct the most significant activities of the VIEs which materially impacts the economic performance of the VIEs.

The following table provides supplemental information about the assets and liabilities of the VIEs which have been consolidated in accordance with authoritative guidance (dollars in millions):

	September 30, 2012
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	829.4	$	—		$	829.4
Notes receivable of VIEs held by insurance subsidiaries	—		(78.5		)	(78.5		)
Cash and cash equivalents held by variable interest entities	48.2		—			48.2
Accrued investment income	3.9		—			3.9
Income tax assets, net	3.2		(2.3		)	.9
Other assets	10.9		—			10.9
Total assets	$	895.6	$	(80.8	)	$	814.8
Liabilities:
Other liabilities	$	52.0	$	(2.3	)	$	49.7
Borrowings related to variable interest entities	766.9		—			766.9
Notes payable of VIEs held by insurance subsidiaries	82.5		(82.5		)	—
Total liabilities	$	901.4	$	(84.8	)	$	816.6

	December 31, 2011
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	496.3	$	—		$	496.3
Notes receivable of VIEs held by insurance subsidiaries	—		(45.3		)	(45.3		)
Cash and cash equivalents held by variable interest entities	74.4		—			74.4
Accrued investment income	1.7		—			1.7
Income tax assets, net	6.8		(1.4		)	5.4
Other assets	7.7		—			7.7
Total assets	$	586.9	$	(46.7	)	$	540.2
Liabilities:
Other liabilities	$	30.3	$	(.1	)	$	30.2
Borrowings related to variable interest entities	519.9		—			519.9
Notes payable of VIEs held by insurance subsidiaries	49.3		(49.3		)	—
Total liabilities	$	599.5	$	(49.4	)	$	550.1

The investment portfolios held by the VIEs are primarily comprised of corporate fixed maturity securities which are almost entirely rated as below-investment grade securities.  At September 30, 2012, such securities had an amortized cost of $827.7 million; gross unrealized gains of $5.0 million; gross unrealized losses of $3.3 million; and an estimated fair value of $829.4 million.

The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at September 30, 2012, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	3.0	$	3.0
Due after one year through five years	413.8		413.1
Due after five years through ten years	410.9		413.3
Total	$	827.7	$	829.4

During the first nine months of 2012, we recognized net realized investment losses on the VIE investments of $.1 million, which were comprised of $.3 million of net gains from the sales of fixed maturities, and $.4 million of writedowns of investments for other than temporary declines in fair value recognized through net income.  During the first nine months of 2011, we recognized net realized investment losses on the VIE investments of $.2 million, which were comprised of $3.3 million of net gains from the sales of fixed maturities, and $3.5 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

At September 30, 2012, there were no investments held by the VIEs that were in default.

During the first nine months of 2012, $28.0 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $.2 million.

At September 30, 2012, the VIEs held:  (i) investments with a fair value of $228.8 million and gross unrealized losses of $1.7 million that had been in an unrealized loss position for less than twelve months; and (ii) investments with a fair value of $74.7 million and gross unrealized losses of $1.6 million that had been in an unrealized loss position for greater than twelve months.

The investments held by the VIEs are evaluated for other-than-temporary declines in fair value in a manner that is consistent with the Company’s fixed maturities, available for sale.

In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager.  These structured securities include asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, residential mortgage-backed securities and collateralized mortgage obligations.  Our maximum exposure to loss on these securities is limited to our cost basis in the investment.  We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses.

At September 30, 2012, we hold investments in various limited partnerships, in which we are not the primary beneficiary, totaling $28.3 million (classified as other invested assets).  At September 30, 2012, we had unfunded commitments to these partnerships of $20.0 million.  Our maximum exposure to loss on these investments is limited to the amount of our investment.

XML

PARENTHETICAL DATA TO THE CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Comprehensive income (loss), net of tax:
Change in unrealized appreciation (depreciation) of investments, applicable income tax expense	$ 248.9	$ 276.7
Change in noncredit component of impairment losses on fixed maturities, available for sale, applicable income tax expense	$ 4.4	$ 1.8

XML

PARENTHETICAL DATA TO THE CONSOLIDATED BALANCE SHEET (USD $) In Millions, except Share data, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Investments:
Fixed maturities, available for sale, amortized cost	$ 21,825.7	$ 21,779.1
Equity securities cost	$ 174.0	$ 177.0
Shareholders' equity:
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	8,000,000,000	8,000,000,000
Common stock, shares issued	229,506,690	241,304,503
Common stock, shares outstanding	229,506,690	241,304,503

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Abstract]

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

The following notes payable were direct corporate obligations of the Company as of September 30, 2012 and December 31, 2011 (dollars in millions):

	September 30, 2012			December 31, 2011
New Senior Secured Credit Agreement (as defined below)	$	675.0		$	—
7.0% Debentures	93.0			293.0
Previous Senior Secured Credit Agreement (as defined below)	—			255.2
6.375% Senior Secured Notes due October 2020 (the "6.375% Notes")	275.0			—
9.0% Senior Secured Notes due January 2018 (the “9.0% Notes”)	1.2			275.0
Senior Health Note due November 12, 2013 (the “Senior Health Note”)	—			50.0
Unamortized discount on New Senior Secured Credit Agreement	(5.5		)	—
Unamortized discount on 7.0% Debentures	(3.6		)	(12.9		)
Unamortized discount on Previous Senior Secured Credit Agreement	—			(2.4		)
Direct corporate obligations	$	1,035.1		$	857.9

6.375% Notes

On September 28, 2012, we issued $275.0 million in aggregate principal amount of 6.375% Notes pursuant to an Indenture, dated as of September 28, 2012 (the “6.375% Indenture”), among the Company, the subsidiary guarantors party thereto (the “Subsidiary Guarantors”) and Wilmington Trust, National Association, as trustee (the “Trustee") and as collateral agent (the “Collateral Agent”). The net proceeds from the issuance of the 6.375% Notes, together with the net proceeds from the New Senior Secured Credit Agreement (as defined below), were used to repay other outstanding indebtedness, as further described below, and for general corporate purposes.

The 6.375% Notes will mature on October 1, 2020. Interest on the 6.375% Notes accrues at a rate of 6.375% per annum and is payable semiannually in arrears on April 1 and October 1 of each year, commencing on April 1, 2013. The 6.375% Notes and the guarantees thereof (the “Guarantees”) are senior secured obligations of the Company and the Subsidiary Guarantors and rank equally in right of payment with all of the Company's and the Subsidiary Guarantors' existing and future senior obligations, and senior to all of the Company's and the Subsidiary Guarantors' future subordinated indebtedness. The 6.375% Notes are secured by a first-priority lien on substantially all of the assets of the Company and the Subsidiary Guarantors, subject to certain exceptions. The 6.375% Notes and the Guarantees are pari passu with respect to security and in right of payment with all of the Company's and the Subsidiary Guarantors' existing and future secured indebtedness under the New Senior Secured Credit Agreement (as defined below). The 6.375% Notes are structurally subordinated to all of the liabilities and preferred stock of each of the Company's insurance subsidiaries, which are not guarantors of the 6.375% Notes.

The Company may redeem all or part of the 6.375% Notes beginning on October 1, 2015, at the redemption prices set forth in the 6.375% Indenture. The Company may also redeem all or part of the 6.375% Notes at any time and from time to time prior to October 1, 2015, at a price equal to 100% of the aggregate principal amount of the 6.375% Notes to be redeemed, plus a “make-whole” premium and accrued and unpaid interest to, but not including, the redemption date. In addition, prior to October 1, 2015, the Company may redeem up to 35% of the aggregate principal amount of the 6.375% Notes with the net cash proceeds of certain equity offerings at a price equal to 106.375% of the aggregate principal amount of the 6.375% Notes to be redeemed, plus accrued and unpaid interest to, but not including, the redemption date.

Upon the occurrence of a Change of Control (as defined in the 6.375% Indenture), each holder of the 6.375% Notes may require the Company to repurchase all or a portion of the 6.375% Notes in cash at a price equal to 101% of the aggregate principal amount of the 6.375% Notes to be repurchased, plus accrued and unpaid interest, if any, to, but not including, the date of repurchase.

The 6.375% Indenture contains covenants that, among other things, limit (subject to certain exceptions) the Company's ability and the ability of the Company's Restricted Subsidiaries (as defined in the 6.375% Indenture) to:

• incur or guarantee additional indebtedness or issue preferred stock;

• pay dividends or make other distributions to shareholders;

• purchase or redeem capital stock or subordinated indebtedness;

• make investments;

• create liens;

• incur restrictions on the Company's ability and the ability of its Restricted Subsidiaries to pay dividends or make other payments to the Company;

• sell assets, including capital stock of the Company's subsidiaries;

• consolidate or merge with or into other companies or transfer all or substantially all of the Company's assets; and

• engage in transactions with affiliates.

The 6.375% Indenture provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, breach of covenants in the 6.375% Indenture, failure to pay at maturity or acceleration of other indebtedness, a failure to pay certain judgments and certain events of bankruptcy and insolvency. Generally, if an event of default occurs, the Trustee or holders of at least 25% in principal amount of the then outstanding 6.375% Notes may declare the principal of and accrued but unpaid interest, including any additional interest, on all of the 6.375% Notes to be due and payable.

Under the 6.375% Indenture, the Company can make Restricted Payments (as such term is defined in the 6.375% Indenture) up to a calculated limit, provided that the Company's pro forma risk-based capital ratio exceeds 225% after giving effect to the Restricted Payment and certain other conditions are met. Restricted Payments include, among other items, repurchases of common stock and cash dividends on common stock (to the extent such dividends exceed $30 million in the aggregate in any calendar year). The limit of Restricted Payments permitted under the 6.375% Indenture is the sum of (x) 50% of the Company's “Net Excess Cash Flow” (as defined in the 6.375% Indenture) for the period (taken as one accounting period) from July 1, 2012 to the end of the Company's most recently ended fiscal quarter for which financial statements are available at the time of such Restricted Payment, (y) $175.0 million and (z) certain other amounts specified in the 6.375% Indenture. Based on the provisions set forth in the 6.375% Indenture and the Company's Net Excess Cash Flow for the period from July 1, 2012 through September 30, 2012, the Company could have made additional Restricted Payments under this 6.375% Indenture covenant of approximately $244 million as of September 30, 2012. This limitation on Restricted Payments does not apply if the Debt to Total Capitalization Ratio (as defined in the 6.375% Indenture) as of the last day of the Company's most recently ended fiscal quarter for which financial statements are available that immediately precedes the date of any Restricted Payment, calculated immediately after giving effect to such Restricted Payment and any related transactions on a pro forma basis, is equal to or less than 17.5%.

In connection with the issuance of the 6.375% Notes and execution of the 6.375% Indenture, the Company and the Subsidiary Guarantors entered into a security agreement, dated as of September 28, 2012 (the “Security Agreement”), by and among the Company, the Subsidiary Guarantors and the Collateral Agent, pursuant to which the Company and the Subsidiary Guarantors pledged substantially all of their assets to secure their obligations under the 6.375% Notes and the 6.375% Indenture, subject to certain exceptions as set forth in the Security Agreement.

New Senior Secured Credit Agreement

On September 28, 2012, the Company entered into a new senior secured credit agreement, providing for: (i) a $425.0 million six-year term loan facility; (ii) a $250.0 million four-year term loan facility; and (iii) a $50.0 million three-year revolving credit facility, with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the lenders from time to time party thereto (the “New Senior Secured Credit Agreement”). The New Senior Secured Credit Agreement is guaranteed by the Subsidiary Guarantors and secured by a first-priority lien (which ranks pari passu with the liens securing the 6.375% Notes) on substantially all of the Company's and the Subsidiary Guarantors' assets. As of September 30, 2012, the Company had borrowed in full the amounts available under each of the term loan facilities and no amounts have been borrowed under the revolving credit facility. The net proceeds from the New Senior Secured Credit Agreement, together with the net proceeds from the 6.375% Notes, were used to repay other outstanding indebtedness, as further described below, and for general corporate purposes.

The revolving credit facility includes an uncommitted subfacility for swingline loans of up to $5.0 million, and up to $5.0 million of the revolving credit facility is available for the issuance of letters of credit. The six-year term loan facility will amortize in quarterly installments in amounts resulting in an annual amortization of 1% and the four-year term loan facility will amortize in quarterly installments resulting in an annual amortization of 20% during the first and second years and 30% during the third and fourth years. Subject to certain conditions, the Company may incur additional incremental loans under the New Senior Secured Credit Agreement in an amount of up to $250.0 million.

Mandatory prepayments of the New Senior Secured Credit Agreement will be required, subject to certain exceptions, in an amount equal to: (i) 100% of the net cash proceeds from certain asset sales or casualty events; (ii) 100% of the net cash proceeds received by the Company or any of its restricted subsidiaries from certain debt issuances; and (iii) 100% of the amount of certain restricted payments made (including any common stock dividends and share repurchases) as defined in the New Senior Secured Credit Agreement provided that if, as of the end of the fiscal quarter immediately preceding such restricted payment, the debt to total capitalization ratio is: (x) equal to or less than 22.5%, but greater than 17.5%, the prepayment requirement shall be reduced to 33.33%; or (y) equal to or less than 17.5%, the prepayment requirement shall not apply.

Notwithstanding the foregoing, no mandatory prepayments pursuant to item (i) in the preceding paragraph shall be required if: (x) the debt to total capitalization ratio is equal or less than 20% and (y) either (A) the financial strength rating of certain of the Company's insurance subsidiaries is equal or better than A- (stable) from A.M. Best Company ("A.M. Best") or (B) the New Senior Secured Credit Agreement is rated equal or better than BBB- (stable) from S&P and Baa3 (stable) by Moody's Investor Services, Inc. ("Moody's").

The interest rates with respect to loans under: (i) the six-year term loan facility will be, at the Company's option, equal to a eurodollar rate, plus 3.75% per annum, or a base rate, plus 2.75% per annum, subject to a eurodollar rate “floor” of 1.25% and a base rate “floor” of 2.25% (such rate was 5.0 percent at September 30, 2012); (ii) the four-year term loan facility will be, at the Company's option, equal to a eurodollar rate, plus 3.25% per annum, or a base rate, plus 2.25% per annum, subject to a eurodollar rate “floor” of 1.00% and a base rate “floor” of 2.00% (such rate was 4.25 percent at September 30, 2012); and (iii) the revolving credit facility will be, at the Company's option, equal to a eurodollar rate, plus 3.50% per annum, or a base rate, plus 2.50% per annum, in each case, with respect to revolving credit facility borrowings only, subject to certain step-downs based on the debt to total capitalization ratio of the Company.

The New Senior Secured Credit Agreement contains covenants that limit the Company's ability to take certain actions and perform certain activities, including (each subject to exceptions as set forth in the New Senior Secured Credit Agreement):

• limitations on debt (including, without limitation, guarantees and other contingent obligations);

• limitations on issuances of disqualified capital stock;

• limitations on liens and further negative pledges;

• limitations on sales, transfers and other dispositions of assets;

• limitations on transactions with affiliates;

• limitations on changes in the nature of the Company's business;

• limitations on mergers, consolidations and acquisitions;

• limitations on dividends and other distributions, stock repurchases and redemptions and other restricted payments;

• limitations on investments and acquisitions;

• limitations on prepayment of certain debt;

• limitations on modifications or waivers of certain debt documents and charter documents;

• investment portfolio requirements for insurance subsidiaries;

• limitations on restrictions affecting subsidiaries;

• limitations on holding company activities; and

• limitations on changes in accounting policies.

In addition, the New Senior Secured Credit Agreement requires the Company to maintain (each as calculated in accordance with the New Senior Secured Credit Agreement): (i) a debt to total capitalization ratio of not more than 27.5 percent (such ratio was 21.5 percent at September 30, 2012); (ii) an interest coverage ratio of not less than 2.50 to 1.00 for each rolling four quarters (or, if less, the number of full fiscal quarters commencing after the effective date of the New Senior Secured Credit Agreement) (such ratio was not applicable for the period ended September 30, 2012); (iii) an aggregate ratio of total adjusted capital to company action level risk-based capital for the Company's insurance subsidiaries of not less than 250 percent (such ratio was 361 percent at September 30, 2012); and (iv) a combined statutory capital and surplus for the Company's insurance subsidiaries of at least $1,300.0 million (combined statutory capital and surplus at September 30, 2012, was $1,766.8 million).

The New Senior Secured Credit Agreement provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, incorrectness of any representation or warranty in any material respect, breach of covenants in the New Senior Secured Credit Agreement or other loan documents, cross default to certain other indebtedness, certain events of bankruptcy and insolvency, certain ERISA events, a failure to pay certain judgments, certain material regulatory events, the occurrence of a change of control, and the invalidity of any material provision of any loan document or material lien or guarantee granted under the loan documents. If an event of default under the New Senior Secured Credit Agreement occurs and is continuing, the Agent may accelerate the amounts and terminate all commitments outstanding under the New Senior Secured Credit Agreement and may exercise remedies in respect of the collateral.

In connection with the execution of the New Senior Secured Credit Agreement, the Company and the Subsidiary Guarantors entered into a guarantee and security agreement, dated as of September 28, 2012 (the “Guarantee and Security Agreement”), by and among the Company, the Subsidiary Guarantors and the Agent, pursuant to which the Subsidiary Guarantors guaranteed all of the obligations of the Company under the New Senior Secured Credit Agreement and the Company and the Subsidiary Guarantors pledged substantially all of their assets to secure the New Senior Secured Credit Agreement, subject to certain exceptions as set forth in the Guarantee and Security Agreement.

Pari Passu Intercreditor Agreement

In connection with the issuance of the 6.375% Notes and entry into the New Senior Secured Credit Agreement, the Agent and the Collateral Agent, as authorized representative with respect to the 6.375% Notes, entered into a Pari Passu Intercreditor Agreement, dated as of September 28, 2012 (the “Intercreditor Agreement”), which sets forth agreements with respect to the first-priority liens granted by the Company and the Subsidiary Guarantors pursuant to the 6.375% Indenture and the New Senior Secured Credit Agreement.

Under the Intercreditor Agreement, any actions that may be taken with respect to the collateral that secures the 6.375% Notes and the New Senior Secured Credit Agreement, including the ability to cause the commencement of enforcement proceedings against such collateral, to control such proceedings and to approve amendments to releases of such collateral from the lien of, and waive past defaults under, such documents relating to such collateral, will be at the direction of the authorized representative of the lenders under the New Senior Secured Credit Agreement until the earliest of: (i) the Company's obligations under the New Senior Secured Credit Agreement (or refinancings thereof) are discharged; (ii) the earlier of (x) date on which the outstanding principal amount of loans and commitments under the New Senior Secured Credit Agreement is less than $25.0 million and (y) the date on which the outstanding principal amount of another tranche of first-priority indebtedness exceeds the principal amount of loans and commitments under the New Senior Secured Credit Agreement; and (iii) 180 days after the occurrence of both an event of default under the 6.375% Indenture and the authorized representative of the holders of the New Notes making certain representations as described in the Intercreditor Agreement, unless the authorized representative of the lenders under the New Senior Secured Credit Agreement has commenced and is diligently pursuing enforcement action with respect to the collateral or the grantor of the security interest in that collateral (whether the Company or the applicable Subsidiary Guarantor) is then a debtor under or with respect to (or otherwise subject to) any insolvency or liquidation proceeding.

9.0% Notes

On September 28, 2012, the Company completed the cash tender offer for $273.8 million aggregate principal amount of the 9.0% Notes and received consents from such holders to proposed amendments to the indenture governing the 9.0% Notes (the "9.0% Indenture"). In addition, on September 28, 2012 (the “Initial Payment Date”), the Company, the Subsidiary Guarantors and Wilmington Trust, National Association (as successor by merger to Wilmington Trust FSB), as trustee, executed a first supplemental indenture to the 9.0% Indenture (the “Supplemental Indenture”) that eliminates substantially all of the restrictive covenants contained in the 9.0% Indenture and certain events of default and related provisions. The Supplemental Indenture became effective upon execution, and the amendments to the 9.0% Indenture became operative on the Initial Payment Date upon acceptance of and payment for the tendered 9.0% Notes by the Company.

On the Initial Payment Date, the Company paid an aggregate of $326.3 million in order to purchase the 9.0% Notes tendered prior to the Initial Payment Date (representing, in the aggregate, tender offer consideration of approximately $313.1 million, consent payments of approximately $8.2 million and accrued and unpaid interest to, but not including, the Initial Payment Date of approximately $5.0 million).

On September 28, 2012, the Company: (i) issued a notice of redemption to holders of the remaining $1.2 million aggregate principal amount of 9.0% Notes that were not tendered and remained outstanding following the Company's initial acceptance of and payments for the 9.0% Notes tendered in the tender offer prior to the Initial Payment Date; and (ii) deposited with the trustee of the 9.0% Notes sufficient funds to satisfy and discharge the 9.0% Indenture and to fund the make-whole redemption of the remaining outstanding 9.0% Notes and to pay accrued and unpaid interest on the redeemed notes to, but not including, the October 29, 2012 redemption date. Upon the satisfaction and discharge of the 9.0% Indenture, all of the collateral securing the 9.0% Notes was released and any remaining restrictive covenants and certain additional events of default contained in the 9.0% Indenture (as amended by the Supplemental Indenture) ceased to have effect. The remaining $1.2 million of 9.0% Notes were redeemed on October 29, 2012.

7.0% Debentures

In September 2012, the Company entered into a Debenture Repurchase Agreement (the “Debenture Repurchase Agreement”) with Paulson Credit Opportunities Master Ltd. and Paulson Recovery Master Fund Ltd. (collectively, the “Paulson Holders”), funds managed by Paulson & Co. Inc., that held $200.0 million in aggregate principal amount of the Company's 7.0% Debentures. Pursuant to the Debenture Repurchase Agreement, the Company purchased from each of the Paulson Holders the 7.0% Debentures held by such Paulson Holder, for a cash purchase price of $355.1 million that provided for a 2.8% discount to the estimated fair market value of the 7.0% Debentures as defined in the Debenture Repurchase Agreement.

Previous Senior Secured Credit Agreement

In September 2012, the Company used a portion of the net proceeds from its offering of the 6.375% Notes, together with borrowings under the New Senior Secured Credit Agreement to repay the remaining $223.8 million principal amount outstanding under its credit agreement, dated as of December 21, 2010, by and among the Company, Morgan Stanley Senior Funding, Inc., as administrative agent, and the lenders from time to time party thereto (as amended, the "Previous Senior Secured Credit Agreement").

Also, in the first nine months of 2012, as required under the terms of the Previous Senior Secured Credit Agreement, we made mandatory prepayments of $31.4 million due to repurchases of our common stock and payment of a common stock dividend.

Senior Health Note

In March 2012, we paid in full the remaining $50.0 million principal balance on the Senior Health Note, which had been scheduled to mature in November 2013. The repayment in full of the Senior Health Note removed the previous restriction on our ability to pay cash dividends on our common stock.

Loss on Extinguishment of Debt

In the first nine months of 2012, we recognized a loss on extinguishment of debt totaling $199.2 million consisting of:

(i) $136.3 million (all of which was recognized in the third quarter of 2012) due to our repurchase of $200.0 million principal amount of 7.0% Debentures pursuant to the Debenture Repurchase Agreement described above and the write-off of unamortized discount and issuance costs associated with the 7.0% Debentures. Additional paid-in capital was also reduced by $24.0 million to extinguish the beneficial conversion feature associated with a portion of the 7.0% Debentures that were repurchased. As the Code limits the deduction to taxable income for losses on the redemption of convertible debt, a minimal tax benefit was recognized related to the repurchase of the 7.0% Debentures;

(ii) $57.8 million (all of which was recognized in the third quarter of 2012) related to the tender offer and consent solicitation for the 9.0% Notes; the write-off of unamortized issuance costs related to the 9.0% Notes; and other transaction costs; and

(iii) $5.1 million ($4.4 million of which was recognized in the third quarter of 2012) representing the write-off of unamortized discount and issuance costs associated with repayments of our Previous Senior Secured Credit Agreement.

Scheduled Repayment of our Direct Corporate Obligations

The scheduled repayment of our direct corporate obligations was as follows at September 30, 2012 (dollars in millions):

Year ending September 30,
2013	$	55.4
2014	54.3
2015	79.3
2016	79.3
2017	97.2
Thereafter	678.7
	$	1,044.2

XML

DOCUMENT AND ENTITY INFORMATION	9 Months Ended
	Sep. 30, 2012	Oct. 23, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	CNO Financial Group, Inc.
Entity Central Index Key	0001224608
Document Type	10-Q/A
Document Period End Date	Sep. 30, 2012
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Entity Filer Category	Large Accelerated Filer
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Amendment Flag	true
Amendment Description	This Quarterly Report on Form 10-Q/A ("Form 10-Q/A") is being filed as Amendment No. 1 (the "Amendment") to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, which was filed with the Securities and Exchange Commission on November 1, 2012 (the "Original Form 10-Q"). This Form 10-Q/A is being filed to amend the consolidated balance sheet as of September 30, 2012; the consolidated statement of comprehensive income for the three and nine months ended September 30, 2012; the consolidated statement of shareholders' equity for the nine months ended September 30, 2012; and certain disclosures in the notes to the consolidated financial statements. Management and the Audit and Enterprise Risk Committee of CNO Financial Group, Inc. (the "Company") concluded that an inadvertent error involving a component of the calculation of accumulated other comprehensive income existed in the Original Form 10-Q that requires correction. The correction of this error had no impact on net income, earnings per share or cash flows. In addition, the correction had no impact on results, cash flows or capital measures calculated in accordance with statutory accounting principles. Pursuant to generally accepted accounting principles, we are required to adjust certain balance sheet accounts to reflect the impact resulting from assuming that unrealized gains and losses on available for sale securities are realized and the proceeds are invested in securities earning current market yields. Such adjustments are commonly referred to as “shadow adjustments” and may include adjustments to: (i) deferred acquisition costs; (ii) the present value of future profits; (iii) loss recognition reserves; and (iv) income taxes. The net impact of these shadow adjustments is recognized in accumulated other comprehensive income. Amounts related to the shadow adjustments for certain long-term care products previously reported in our Original Form 10-Q have been corrected and are described in the note to the consolidated financial statements entitled "Correction to Previously Issued Financial Statements" contained herein. Shadow adjustments will vary from period to period and are primarily dependent upon the amount of unrealized gains or losses related to available for sale securities and the estimated gross profits of certain lines of business. As a result of the correction, management has also re-assessed the effectiveness of its disclosure controls and procedures and internal control over financial reporting and concluded that they were not effective as of the end of the period covered by this report on Form 10-Q/A because of a material weakness in internal control over financial reporting. Specifically, controls in place to ensure the accurate calculation of shadow adjustments impacting accumulated other comprehensive income did not operate effectively. Therefore, management has subsequently concluded that the Company's disclosure controls and procedures were not effective as of the end of the period covered by this report. As a result of the identification of the error that led to the amendment of our Original Form 10-Q and the related reassessment of disclosure controls and procedures and internal control over financial reporting, we have emphasized the importance of performing and reviewing calculations consistent with the design of our internal control structure in an effort to ensure controls operate effectively. The Company believes this action has remediated the material weakness. The material weakness in internal control over financial reporting is further discussed in Item 4 contained herein. The following sections have been amended from the Original Form 10-Q as a result of the restatement described above: Part I - Item 1. Financial Statements Part I - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Part I - Item 4. Controls and Procedures This Form 10-Q/A also includes as exhibits, certifications from our Chief Executive Officer and Chief Financial Officer dated as of the date of this filing. Except as described above, no other sections have been amended from the Original Form 10-Q. This Form 10-Q/A does not reflect information or events occurring after the November 1, 2012 filing date of the Original Form 10-Q, or modify or update disclosures set forth in the Original Form 10-Q, except to reflect the corrections discussed above.
Entity Common Stock, Shares Outstanding		227,011,634

XML

INVESTMENT BORROWINGS

9 Months Ended

Sep. 30, 2012

Investment Borrowings [Abstract]

INVESTMENT BORROWINGS

INVESTMENT BORROWINGS

Three of the Company’s insurance subsidiaries (Conseco Life Insurance Company (“Conseco Life”), Washington National Insurance Company and Bankers Life and Casualty Company ("Bankers Life")) are members of the Federal Home Loan Bank (“FHLB”).  As members of the FHLB, Conseco Life, Washington National Insurance Company and Bankers Life have the ability to borrow on a collateralized basis from the FHLB.  Conseco Life, Washington National Insurance Company and Bankers Life are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings.  At September 30, 2012, the carrying value of the FHLB common stock was $82.5 million.  As of September 30, 2012, collateralized borrowings from the FHLB totaled $1.7 billion and the proceeds were used to purchase fixed maturity securities.  The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.  The borrowings are collateralized by investments with an estimated fair value of $2.0 billion at September 30, 2012, which are maintained in a custodial account for the benefit of the FHLB.  Such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet.  Interest expense of $21.3 million and $18.9 million in the first nine months of 2012 and 2011, respectively, was recognized related to the borrowings.

The following summarizes the terms of the borrowings (dollars in millions):

Amount		Maturity	Interest rate at
borrowed		date	September 30, 2012
$	100.0	November 2013	Variable rate – 0.515%
67.0		February 2014	Fixed rate – 1.830%
50.0		August 2014	Variable rate – 0.565%
100.0		August 2014	Variable rate – 0.476%
50.0		September 2015	Variable rate – 0.747%
150.0		October 2015	Variable rate – 0.571%
146.0		November 2015	Fixed rate – 5.300%
100.0		December 2015	Fixed rate – 4.710%
100.0		June 2016	Variable rate – 0.657%
75.0		June 2016	Variable rate – 0.621%
100.0		October 2016	Variable rate – 0.641%
50.0		November 2016	Variable rate – 0.684%
50.0		November 2016	Variable rate – 0.687%
100.0		June 2017	Variable rate – 0.751%
100.0		July 2017	Fixed rate – 3.900%
50.0		August 2017	Variable rate – 0.635%
75.0		August 2017	Variable rate – 0.577%
100.0		October 2017	Variable rate – 0.885%
37.0		November 2017	Fixed rate – 3.750%
50.0		July 2018	Variable rate – 0.917%
$	1,650.0

The variable rate borrowings are pre-payable on each interest reset date without penalty.  The fixed rate borrowings are pre-payable subject to payment of a yield maintenance fee based on current market interest rates.  At September 30, 2012, the aggregate fee to prepay all fixed rate borrowings was $51.6 million.

As part of our investment strategy, we may enter into repurchase agreements to increase our investment return. We account for these transactions as collateralized borrowings, where the amount borrowed is equal to the sales price of the underlying securities. Repurchase agreements involve a sale of securities and an agreement to repurchase the same securities at a later date at an agreed-upon price. We had no such borrowings outstanding at September 30, 2012. The primary risks associated with short-term collateralized borrowings are: (i) a substantial decline in the market value of the margined security; and (ii) that a counterparty may be unable to perform under the terms of the contract or be unwilling to extend such financing in future periods especially if the liquidity or value of the margined security has declined. Exposure is limited to any depreciation in value of the related securities.

At September 30, 2012, investment borrowings consisted of:  (i) collateralized borrowings from the FHLB of $1.7 billion; and (ii) other borrowings of $.9 million.

At December 31, 2011, investment borrowings consisted of:  (i) collateralized borrowings from the FHLB of $1.7 billion; (ii) repurchase agreements of $24.8 million; and (iii) other borrowings of $1.7 million.

XML

CONSOLIDATED STATEMENT OF OPERATIONS (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues:
Insurance policy income	$ 690.2	$ 673.5	$ 2,071.3	$ 2,020.3
Net investment income (loss):
General account assets	349.4	338.2	1,045.7	1,016.5
Policyholder and reinsurer accounts and other special- purpose portfolios	39.1	(54.9)	87.4	(14.4)
Realized investment gains (losses):
Net realized investment gains, excluding impairment losses	32.2	33.5	98.4	64.9
Other-than-temporary impairment losses:
Total other-than-temporary impairment losses	(23.1)	(2.9)	(34.5)	(26.3)
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income	0	0	0	0
Net impairment losses recognized	23.1	2.9	34.5	26.3
Total realized gains	9.1	30.6	63.9	38.6
Fee revenue and other income	5.2	4.9	13.6	12.5
Total revenues	1,093.0	992.3	3,281.9	3,073.5
Benefits and expenses:
Insurance policy benefits	745.7	661.0	2,124.4	2,028.6
Interest expense	29.2	27.9	86.7	86.0
Amortization	60.9	58.6	215.8	224.1
Loss on extinguishment of debt	198.5	1.1	199.2	3.1
Other operating costs and expenses	217.5	182.0	617.8	527.8
Total benefits and expenses	1,251.8	930.6	3,243.9	2,869.6
Income (loss) before income taxes	(158.8)	61.7	38.0	203.9
Income tax expense (benefit):
Income tax expense (benefit) on period income	(10.8)	25.2	61.2	75.6
Decrease in valuation allowance for deferred tax assets	(143.0)	(143.0)	(143.0)	(143.0)
Net income (loss)	$ (5.0)	$ 179.5	$ 119.8	$ 271.3
Basic:
Weighted average shares outstanding	231,481,000	246,965,000	236,555,000	249,673,000
Net income (loss)	$ (0.02)	$ 0.73	$ 0.51	$ 1.09
Diluted:
Weighted average shares outstanding	231,481,000	302,708,000	292,983,000	306,085,000
Net income (loss)	$ (0.02)	$ 0.61	$ 0.45	$ 0.92

XML

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHARE

A reconciliation of net income and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands):

	Three months ended					Nine months ended
	September 30,					September 30,
	2012			2011		2012		2011
Net income (loss) for basic earnings per share	$	(5.0	)	$	179.5	$	119.8	$	271.3
Add:  interest expense on 7.0% Convertible Senior Debentures due 2016 (the “7.0% Debentures”), net of income taxes	—			3.7		11.1		11.1
Net income for diluted earnings per share	$	(5.0	)	$	183.2	$	130.9	$	282.4
Shares:
Weighted average shares outstanding for basic earnings per share	231,481			246,965		236,555		249,673
Effect of dilutive securities on weighted average shares:
7% Debentures	—			53,367		53,037		53,367
Stock option and restricted stock plans	—			2,353		2,639		2,712
Warrants	—			23		752		333
Dilutive potential common shares	—			55,743		56,428		56,412
Weighted average shares outstanding for diluted earnings per share	231,481			302,708		292,983		306,085

In the third quarter of 2012, interest expense of $3.7 million (net of income taxes) on the 7% Debentures was not added back to net income; and 56,651,000 equivalent common shares (comprised of 52,366,000 shares related to the 7% Debentures; 2,968,000 shares related to stock option and restricted stock plans; and 1,317,000 shares related to warrants) were not included in the diluted weighted average shares outstanding, because their inclusion would have been antidilutive in such period due to the net loss recognized by the Company.

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding for the period.  Restricted shares (including our performance shares) are not included in basic earnings per share until vested.  Diluted earnings per share reflect the potential dilution that could occur if outstanding stock options and warrants were exercised and restricted stock was vested.  The dilution from options, warrants and restricted shares is calculated using the treasury stock method.  Under this method, we assume the proceeds from the exercise of the options and warrants (or the unrecognized compensation expense with respect to restricted stock) will be used to purchase shares of our common stock at the average market price during the period, reducing the dilutive effect of the exercise of the options and warrants (or the vesting of the restricted stock). The dilution from our 7.0% Debentures is calculated using the "if converted" method. Initially, the 7.0% Debentures will be convertible into 182.1494 shares of our common stock for each $1,000 principal amount of 7.0% Debentures, which is equivalent to an initial conversion price of approximately $5.49 per share. The conversion rate is subject to adjustment following the occurrence of certain events in accordance with the terms of the 7.0% Debentures.

XML

INVESTMENTS

9 Months Ended

Sep. 30, 2012

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS

INVESTMENTS

We classify our fixed maturity securities into one of three categories: (i) “available for sale” (which we carry at estimated fair value with any unrealized gain or loss, net of tax and related adjustments, recorded as a component of shareholders’ equity); (ii) “trading” (which we carry at estimated fair value with changes in such value recognized as net investment income (classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios)); or (iii) “held to maturity” (which we carry at amortized cost).  We had no fixed maturity securities classified as held to maturity during the periods presented in these financial statements.

The trading account includes: (i) investments purchased with the intent of selling in the near term to generate income on price changes; and (ii) investments supporting certain insurance liabilities (including investments backing the market strategies of our multibucket annuity products) and certain reinsurance agreements. The change in fair value of these securities is recognized in income from policyholder and reinsurer accounts and other special-purpose portfolios (a component of net investment income). Investment income from trading securities backing certain insurance liabilities and certain reinsurance agreements is substantially offset by the change in insurance policy benefits related to certain products and agreements.  Prior to June 30, 2011, certain of our trading securities were held to offset the income statement volatility caused by the effect of interest rate fluctuations on the value of embedded derivatives related to our fixed index annuity products.  During the second quarter of 2011, we sold this trading portfolio and invested the proceeds in higher yielding investments which were classified as available for sale. See the note entitled “Accounting for Derivatives” for further discussion regarding these embedded derivatives.  The trading account also includes certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in value of these securities is recognized in realized investment gain (losses). Our trading securities totaled $199.4 million and $91.6 million at September 30, 2012 and December 31, 2011, respectively.

Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments.  These amounts, included in shareholders’ equity as of September 30, 2012 and December 31, 2011, were as follows (dollars in millions):

	September 30, 2012			December 31, 2011
	(Restated)
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	$	9.6		$	(4.4	)
Net unrealized gains on all other investments	2,914.8			1,733.2
Adjustment to present value of future profits (a)	(200.7		)	(214.8		)
Adjustment to deferred acquisition costs	(458.0		)	(289.3		)
Adjustment to insurance liabilities	(334.4		)	—
Unrecognized net loss related to deferred compensation plan	(8.8		)	(8.3		)
Deferred income tax liabilities	(688.1		)	(434.8		)
Accumulated other comprehensive income	$	1,234.4		$	781.6

_________

(a) The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003 (the date our Predecessor emerged from bankruptcy).

At September 30, 2012, adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred income tax assets included $(166.5) million, $(150.8) million, $(334.4) million and $234.6 million, respectively, for premium deficiencies that would exist on certain long-term health products if unrealized gains on the assets backing such products had been realized and the proceeds from our sales of such assets were invested at then current yields.

At September 30, 2012, the amortized cost, gross unrealized gains and losses, estimated fair value, other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than- temporary impairments included in accumulated other comprehensive income
Corporate securities	$	14,586.6	$	2,265.7	$	(28.8	)	$	16,823.5	$	—
United States Treasury securities and obligations of United States government corporations and agencies	164.2		6.9		—			171.1		—
States and political subdivisions	1,785.6		267.9		(5.4		)	2,048.1		—
Debt securities issued by foreign governments	.8		—		—			.8		—
Asset-backed securities	1,391.3		92.0		(6.6		)	1,476.7		—
Collateralized debt obligations	327.6		5.2		(.8		)	332.0		—
Commercial mortgage-backed securities	1,400.7		142.7		(.8		)	1,542.6		—
Mortgage pass-through securities	18.8		1.4		—			20.2		—
Collateralized mortgage obligations	2,150.1		178.1		(.9		)	2,327.3		(7.3		)
Total fixed maturities, available for sale	$	21,825.7	$	2,959.9	$	(43.3	)	$	24,742.3	$	(7.3	)

The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at September 30, 2012, by contractual maturity.  Actual maturities will differ from contractual maturities because certain borrowers may have the right to call or prepay obligations with or without penalties.  In addition, structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as “structured securities”) frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	178.3	$	180.7
Due after one year through five years	1,558.1		1,697.5
Due after five years through ten years	4,491.1		5,038.7
Due after ten years	10,309.7		12,126.6
Subtotal	16,537.2		19,043.5
Structured securities	5,288.5		5,698.8
Total fixed maturities, available for sale	$	21,825.7	$	24,742.3

Net Realized Investment Gains (Losses)

During the first nine months of 2012, we recognized net realized investment gains of $63.9 million, which were comprised of $89.0 million of net gains from the sales of investments (primarily fixed maturities) with proceeds of $1.9 billion, the increase in fair value of certain fixed maturity investments with embedded derivatives of $9.4 million, and $34.5 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

During the first nine months of 2011, we recognized net realized investment gains of $38.6 million, which were comprised of $64.9 million of net gains from the sales of investments (primarily fixed maturities) with proceeds of $4.4 billion and $26.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

At September 30, 2012, fixed maturity securities in default or considered nonperforming had an aggregate amortized cost of $.4 million and a carrying value of $.5 million.

Our fixed maturity investments are generally purchased in the context of a long-term strategy to fund insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities.  In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities.

During the nine months ended September 30, 2012, we sold $393.8 million of fixed maturity investments which resulted in gross investment losses (before income taxes) of $15.3 million.  We sell securities at a loss for a number of reasons including, but not limited to:  (i) changes in the investment environment; (ii) expectation that the market value could deteriorate further; (iii) desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; or (v) changes in expected cash flows.

There were no investments sold at a loss during the first nine months of 2012 that had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis for more than 12 months prior to the sale of the investment.

We regularly evaluate all of our investments with unrealized losses for possible impairment.  Our assessment of whether unrealized losses are “other than temporary” requires significant judgment.  Factors considered include:  (i) the extent to which fair value is less than the cost basis; (ii) the length of time that the fair value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for specific events, developments or circumstances likely to affect the value of the investment; (v) the investment’s rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) whether we intend to sell the investment or it is more likely than not that circumstances will require us to sell the investment before recovery occurs; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values; (ix) projections of, and unfavorable changes in, cash flows on structured securities including mortgage-backed and asset-backed securities; (x) our best estimate of the value of any collateral; and (xi) other objective and subjective factors.

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio.  Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

Impairment losses on equity securities are recognized in net income.  The manner in which impairment losses on fixed maturity securities, available for sale, are recognized in the financial statements is dependent on the facts and circumstances related to the specific security.  If we intend to sell a security or it is more likely than not that we would be required to sell a security before the recovery of its amortized cost, the security is other-than-temporarily impaired and the full amount of the impairment is recognized as a loss through earnings.  If we do not expect to recover the amortized cost basis, we do not plan to sell the security, and if it is not more likely than not that we would be required to sell a security before the recovery of its amortized cost, less any current period credit loss, the recognition of the other-than-temporary impairment is bifurcated.  We recognize the credit loss portion in net income and the noncredit loss portion in accumulated other comprehensive income.

We estimate the amount of the credit loss component of a fixed maturity security impairment as the difference between amortized cost and the present value of the expected cash flows of the security.  The present value is determined using the best estimate of future cash flows discounted at the effective interest rate implicit to the security at the date of purchase or the current yield to accrete an asset-backed or floating rate security.  The methodology and assumptions for establishing the best estimate of future cash flows vary depending on the type of security.

For most structured securities, cash flow estimates are based on bond specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including excess spread, subordination and guarantees.  For corporate bonds, cash flow estimates are derived from scenario-based outcomes of expected corporate restructurings or the disposition of assets using bond specific facts and circumstances. The previous amortized cost basis less the impairment recognized in net income becomes the security’s new cost basis.  We accrete the new cost basis to the estimated future cash flows over the expected remaining life of the security, except when the security is in default or considered nonperforming.

The remaining noncredit impairment, which is recorded in accumulated other comprehensive income, is the difference between the security’s estimated fair value and our best estimate of future cash flows discounted at the effective interest rate prior to impairment.  The remaining noncredit impairment typically represents changes in the market interest rates, current market liquidity and risk premiums.  As of September 30, 2012, other-than-temporary impairments included in accumulated other comprehensive income of $7.3 million (before taxes and related amortization) related to structured securities.

The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the three and nine months ended September 30, 2012 and 2011 (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Credit losses on fixed maturity securities, available for sale, beginning of period	$	(1.7	)	$	(1.6	)	$	(2.0	)	$	(6.1	)
Add:  credit losses on other-than-temporary impairments not previously recognized	—			—			—			—
Less:  credit losses on securities sold	—			.7			.3			5.2
Less:  credit losses on securities impaired due to intent to sell (a)	—			—			—			—
Add:  credit losses on previously impaired securities	—			—			—			—
Less:  increases in cash flows expected on previously impaired securities	—			—			—			—
Credit losses on fixed maturity securities, available for sale, end of period	$	(1.7	)	$	(.9	)	$	(1.7	)	$	(.9	)

__________

(a) Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.

Gross Unrealized Investment Losses

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active investment management. Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities.

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at September 30, 2012 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
States and political subdivisions	$	40.2	$	(2.0	)	$	68.7	$	(3.4	)	$	108.9	$	(5.4	)
Corporate securities	300.5		(9.2		)	278.1		(19.6		)	578.6		(28.8		)
Asset-backed securities	42.1		(.3		)	137.8		(6.3		)	179.9		(6.6		)
Collateralized debt obligations	12.7		(.1		)	47.2		(.7		)	59.9		(.8		)
Commercial mortgage-backed securities	16.0		(.1		)	14.3		(.7		)	30.3		(.8		)
Mortgage pass-through securities	—		—			2.0		—			2.0		—
Collateralized mortgage obligations	58.5		(.5		)	36.0		(.4		)	94.5		(.9		)
Total fixed maturities, available for sale	$	470.0	$	(12.2	)	$	584.1	$	(31.1	)	$	1,054.1	$	(43.3	)
Equity securities	$	2.1	$	(.1	)	$	—	$	—		$	2.1	$	(.1	)

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2011 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	9.1	$	—		$	.2	$	—		$	9.3	$	—
States and political subdivisions	6.9		(.2		)	155.4		(13.4		)	162.3		(13.6		)
Debt securities issued by foreign governments	.5		—			—		—			.5		—
Corporate securities	1,394.7		(57.0		)	466.2		(79.9		)	1,860.9		(136.9		)
Asset-backed securities	437.6		(14.5		)	147.5		(22.2		)	585.1		(36.7		)
Collateralized debt obligations	268.8		(6.3		)	1.7		—			270.5		(6.3		)
Commercial mortgage-backed securities	168.8		(5.2		)	33.0		(2.7		)	201.8		(7.9		)
Mortgage pass-through securities	1.2		—			2.2		(.1		)	3.4		(.1		)
Collateralized mortgage obligations	645.0		(20.8		)	29.7		(.6		)	674.7		(21.4		)
Total fixed maturities, available for sale	$	2,932.6	$	(104.0	)	$	835.9	$	(118.9	)	$	3,768.5	$	(222.9	)
Equity securities	$	41.6	$	(3.0	)	$	.4	$	—		$	42.0	$	(3.0	)

Based on management’s current assessment of investments with unrealized losses at September 30, 2012, the Company believes the issuers of the securities will continue to meet their obligations (or with respect to equity-type securities, the investment value will recover to its cost basis).  While we do not have the intent to sell securities with unrealized losses and it is not more likely than not that we will be required to sell securities with unrealized losses prior to their anticipated recovery, our intent on an individual security may change, based upon market or other unforeseen developments.  In such instances, if a loss is recognized from a sale subsequent to a balance sheet date due to these unexpected developments, the loss is recognized in the period in which we had the intent to sell the security before its anticipated recovery.

XML

CONSOLIDATED STATEMENT CASH FLOWS

9 Months Ended

Sep. 30, 2012

Supplemental Cash Flow Elements [Abstract]

CONSOLIDATED STATEMENT OF CASH FLOWS

CONSOLIDATED STATEMENT OF CASH FLOWS

The following disclosures supplement our consolidated statement of cash flows.

The following reconciles net income to net cash provided by operating activities (dollars in millions):

	Nine months ended
	September 30,
	2012			2011
Cash flows from operating activities:
Net income	$	119.8		$	271.3
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization and depreciation	235.2			243.6
Income taxes	(87.3		)	(69.8		)
Insurance liabilities	242.8			244.4
Accrual and amortization of investment income	(123.1		)	62.9
Deferral of policy acquisition costs	(141.4		)	(164.9		)
Net realized investment gains	(63.9		)	(38.6		)
Loss on extinguishment of debt	199.2			3.1
Other	43.3			10.2
Net cash provided by operating activities	$	424.6		$	562.2

Non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions):

	Nine months ended
	September 30,
	2012		2011
Stock option and restricted stock plans	$	10.7	$	10.2

XML

CHANGES IN COMMON STOCK

9 Months Ended

Sep. 30, 2012

Equity [Abstract]

CHANGES IN COMMON STOCK

CHANGES IN COMMON STOCK

Changes in the number of shares of common stock outstanding were as follows (shares in thousands):

Balance, December 31, 2011	241,305
Treasury stock purchased and retired	(12,894	)
Stock options exercised	692
Restricted stock vested	404		(a)
Balance, September 30, 2012	229,507

________

(a) Such amount was reduced by 143 thousand shares which were tendered to the Company for the payment of federal and state taxes owed on the vesting of restricted stock.

In May 2011, the Company announced a common share repurchase program of up to $100.0 million of the Company's outstanding common stock. In February 2012 and June 2012, the Company's board of directors approved, in aggregate, an additional $200.0 million to repurchase the Company's outstanding common stock. In the first nine months of 2012, we repurchased 12.9 million shares of common stock for $99.5 million pursuant to the program. The Company had remaining repurchase authority of $130.7 million as of September 30, 2012.

In May 2012, we initiated a common stock dividend program. In both the second and third quarters of 2012, dividends declared and paid on common stock were $0.02 per common share totaling $9.4 million.

XML

REINSURANCE

9 Months Ended

Sep. 30, 2012

Reinsurance Disclosures [Abstract]

REINSURANCE

REINSURANCE

The cost of reinsurance ceded totaled $48.0 million and $58.3 million in the third quarters of 2012 and 2011, respectively, and $164.5 million and $176.3 million in the first nine months of 2012 and 2011, respectively. We deduct this cost from insurance policy income.  Reinsurance recoveries netted against insurance policy benefits totaled $56.4 million and $45.4 million in the third quarters of 2012 and 2011, respectively, and $172.2 million and $160.2 million in the first nine months of 2012 and 2011, respectively.

From time-to-time, we assume insurance from other companies.  Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs.  Reinsurance premiums assumed totaled $15.9 million and $18.1 million in the third quarters of 2012 and 2011, respectively, and $54.7 million and $64.6 million in the first nine months of 2012 and 2011, respectively.  Reinsurance premiums included amounts assumed pursuant to marketing and quota-share agreements with Coventry Health Care (“Coventry”) of $11.4 million and $12.8 million in the third quarters of 2012 and 2011, respectively, and $39.9 million and $47.6 million in the first nine months of 2012 and 2011, respectively.

See the note entitled “Accounting for Derivatives” for a discussion of the derivative embedded in the payable related to certain modified coinsurance agreements.

XML

FAIR VALUE MEASUREMENTS - NARRATIVE (DETAILS)	9 Months Ended
	Sep. 30, 2012
Fair Value Disclosures [Abstract]
Fair value of level 3 fixed maturity securities valued using broker quotes, percentage	22.00%
Available for sale fixed maturities classified as level 3, investment grade, percent	89.00%
Available for Sale Maturities with Significant Unobservable Inputs, Collateralized Debt Obligations, Percent	45.00%
Available for sale fixed maturities classified as level 3, corporate securities, percent	43.00%

XML

BUSINESS SEGMENTS

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

BUSINESS SEGMENTS

BUSINESS SEGMENTS

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; Other CNO Business, comprised primarily of products we no longer sell actively; and corporate operations, comprised of holding company activities and certain noninsurance company businesses.  

We measure segment performance by excluding realized investment gains (losses) and fair value changes in embedded derivative liabilities because we believe that this performance measure is a better indicator of the ongoing business and trends in our business.  Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business.

Realized investment gains (losses) and fair value changes in embedded derivative liabilities depend on market conditions and do not necessarily relate to the underlying business of our segments.  Realized investment gains (losses) and fair value changes in embedded derivative liabilities may affect future earnings levels since our underlying business is long-term in nature and changes in our investment portfolio may impact our ability to earn the assumed interest rates needed to maintain the profitability of our business.

Operating information by segment was as follows (dollars in millions):

	Three months ended					Nine months ended
	September 30,					September 30,
	2012		2011			2012		2011
Revenues:
Bankers Life:
Insurance policy income:
Annuities	$	6.8	$	9.6		$	21.9	$	26.7
Health	335.1		334.0			1,010.6		1,017.1
Life	74.2		61.0			209.1		170.4
Net investment income (a)	221.6		158.0			642.1		564.5
Fee revenue and other income (a)	4.0		3.6			10.2		9.2
Total Bankers Life revenues	641.7		566.2			1,893.9		1,787.9
Washington National:
Insurance policy income:
Health	143.4		141.2			429.0		423.1
Life	3.6		3.9			11.6		11.8
Other	.8		.8			2.2		3.0
Net investment income (a)	50.9		47.3			151.9		140.3
Fee revenue and other income (a)	.3		.4			.8		.9
Total Washington National revenues	199.0		193.6			595.5		579.1
Colonial Penn:
Insurance policy income:
Health	1.3		1.4			4.0		4.5
Life	53.2		49.4			158.5		147.5
Net investment income (a)	9.9		10.1			30.1		30.9
Fee revenue and other income (a)	.2		.2			.6		.6
Total Colonial Penn revenues	64.6		61.1			193.2		183.5
Other CNO Business:
Insurance policy income:
Annuities	2.5		3.4			8.3		8.6
Health	6.2		6.9			19.3		21.3
Life	62.9		61.7			196.2		184.9
Other	.2		.2			.6		1.4
Net investment income (a)	86.7		74.6			259.2		256.0
Total Other CNO Business revenues	158.5		146.8			483.6		472.2
Corporate operations:
Net investment income	19.4		(6.7		)	49.8		10.4
Fee and other income	.7		.7			2.0		1.8
Total corporate revenues	20.1		(6.0		)	51.8		12.2
Total revenues	1,083.9		961.7			3,218.0		3,034.9

(continued on next page)

(continued from previous page)

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Expenses:
Bankers Life:
Insurance policy benefits	$	434.6		$	360.6		$	1,252.2		$	1,174.3
Amortization	35.6			44.1			143.0			159.5
Interest expense on investment borrowings	1.3			1.2			4.1			3.5
Other operating costs and expenses	89.6			80.9			267.4			236.9
Total Bankers Life expenses	561.1			486.8			1,666.7			1,574.2
Washington National:
Insurance policy benefits	111.1			119.0			340.5			349.5
Amortization	11.2			10.8			34.7			35.6
Interest expense on investment borrowings	.7			.2			2.2			.2
Other operating costs and expenses	42.1			42.4			125.6			126.5
Total Washington National expenses	165.1			172.4			503.0			511.8
Colonial Penn:
Insurance policy benefits	38.3			36.0			120.0			112.7
Amortization	3.5			3.5			11.1			11.0
Other operating costs and expenses	25.4			22.9			73.9			66.3
Total Colonial Penn expenses	67.2			62.4			205.0			190.0
Other CNO Business:
Insurance policy benefits	157.1			111.5			401.0			358.2
Amortization	10.5			10.4			25.1			28.4
Interest expense on investment borrowings	5.0			5.3			15.1			15.2
Other operating costs and expenses	39.5			16.8			96.4			55.1
Total Other CNO Business expenses	212.1			144.0			537.6			456.9
Corporate operations:
Interest expense on corporate debt	16.3			18.7			50.4			58.6
Interest expense on borrowings of variable interest entities	5.8			2.4			14.5			8.4
Interest expense on investment borrowings	.1			.1			.4			.1
Loss on extinguishment of debt	198.5			1.1			199.2			3.1
Other operating costs and expenses	20.9			19.0			54.5			43.0
Total corporate expenses	241.6			41.3			319.0			113.2
Total expenses	1,247.1			906.9			3,231.3			2,846.1
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes:
Bankers Life	80.6			79.4			227.2			213.7
Washington National	33.9			21.2			92.5			67.3
Colonial Penn	(2.6		)	(1.3		)	(11.8		)	(6.5		)
Other CNO Business	(53.6		)	2.8			(54.0		)	15.3
Corporate operations	(221.5		)	(47.3		)	(267.2		)	(101.0		)
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes	$	(163.2	)	$	54.8		$	(13.3	)	$	188.8

___________________

(a) It is not practicable to provide additional components of revenue by product or services.

A reconciliation of segment revenues and expenses to consolidated revenues and expenses is as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Total segment revenues	$	1,083.9		$	961.7		$	3,218.0		$	3,034.9
Net realized investment gains	9.1			30.6			63.9			38.6
Consolidated revenues	$	1,093.0		$	992.3		$	3,281.9		$	3,073.5
Total segment expenses	$	1,247.1		$	906.9		$	3,231.3		$	2,846.1
Insurance policy benefits - fair value changes in embedded derivative liabilities	4.6			33.9			10.7			33.9
Amortization related to fair value changes in embedded derivative liabilities	(1.6		)	(14.1		)	(4.0		)	(14.1		)
Amortization related to net realized investment gains	1.7			3.9			5.9			3.7
Consolidated expenses	$	1,251.8		$	930.6		$	3,243.9		$	2,869.6

XML

ACCOUNTING FOR DERIVATIVES

9 Months Ended

Sep. 30, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

ACCOUNTING FOR DERIVATIVES

ACCOUNTING FOR DERIVATIVES

Our fixed index annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the “participation rate”) of the amount of increase in the value of a particular index, such as the Standard & Poor’s 500 Index, over a specified period.  Typically, on each policy anniversary date, a new index period begins.  We are generally able to change the participation rate at the beginning of each index period during a policy year, subject to contractual minimums.  We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy’s return is linked.  We reflect changes in the estimated fair value of these options in net investment income (classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios).  Net investment gains (losses) related to fixed index products were $37.5 million and $(25.7) million in the nine months ended September 30, 2012 and 2011, respectively. These amounts were substantially offset by a corresponding change to insurance policy benefits.  The estimated fair value of these options was $81.9 million and $37.9 million at September 30, 2012 and December 31, 2011, respectively.  We classify these instruments as other invested assets.

The Company accounts for the options attributed to the policyholder for the estimated life of the annuity contract as embedded derivatives.  The expected future cost of options on fixed index annuity products is used to determine the value of embedded derivatives.  The Company purchases options to hedge liabilities for the next policy year on each policy anniversary date and must estimate the fair value of the forward embedded options related to the policies.  These accounting requirements often create volatility in the earnings from these products.  We record the changes in the fair values of the embedded derivatives in current earnings as a component of insurance policy benefits.  The fair value of these derivatives, which are classified as “liabilities for interest-sensitive products”, was $737.9 million at September 30, 2012 and $666.3 million at December 31, 2011. Prior to June 30, 2011, we maintained a specific block of investments in our trading securities account (which we carried at estimated fair value with changes in such value recognized as investment income from policyholder and reinsurer accounts and other special-purpose portfolios) to offset the income statement volatility caused by the effect of interest rate fluctuations on the value of embedded derivatives related to our fixed index annuity products.  During the second quarter of 2011, we sold this trading portfolio, which resulted in $6.7 million and $19.8 million of decreased earnings in the first nine months of 2012 and 2011, respectively, since the volatility caused by the accounting requirements to record embedded options at fair value were no longer being offset.

If the counterparties for the call options we hold fail to meet their obligations, we may have to recognize a loss.  We limit our exposure to such a loss by diversifying among several counterparties believed to be strong and creditworthy.  At September 30, 2012, substantially all of our counterparties were rated “BBB+” or higher by Standard & Poor’s Corporation (“S&P”).

Certain of our reinsurance payable balances contain embedded derivatives.  Such derivatives had an estimated fair value of $6.0 million and $3.5 million at September 30, 2012 and December 31, 2011, respectively.  We record the change in the fair value of these derivatives as a component of investment income (classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios).  We maintain the investments related to these agreements in our trading securities account, which we carry at estimated fair value with changes in such value recognized as investment income (also classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios).  The change in value of these trading securities offsets the change in value of the embedded derivatives.

We purchase certain fixed maturity securities that contain embedded derivatives that are required to be bifurcated from the instrument and held at fair value on the consolidated balance sheet. For certain of these securities, we have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income for operational ease.

XML

INCOME TAXES

9 Months Ended

Sep. 30, 2012

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

The Company's interim tax expense is based upon the estimated annual effective tax rate for the respective period. Under authoritative guidance, certain items are required to be excluded from the estimated annual effective tax rate calculation. Such items include changes in judgment about the realizability of deferred tax assets resulting from changes in projections of income expected to be available in future years, and items deemed to be unusual, infrequent, or that can not be reliably estimated. In these cases, the actual tax expense or benefit applicable to that item is treated discretely and is reported in the same period as the related item. The reductions to the valuation allowance applicable to future years income were treated as discrete items in the three month periods ended September 30, 2012 and 2011. In addition, the loss on extinguishment of debt of $198.5 million was treated as a discrete item in the three month period ended September 30, 2012. The components of income tax expense were as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Current tax expense	$	2.4		$	2.3		$	9.1		$	7.2
Deferred tax expense (benefit)	11.1			22.9			76.4			68.4
Valuation allowance applicable to current year income	(31.8		)	—			(31.8		)	—
Income tax expense (benefit) calculated based on estimated annual effective tax rate	(18.3		)	25.2			53.7			75.6
Income tax expense (benefit) on discrete items:
Valuation allowance reduction applicable to income in future years	(111.2		)	(143.0		)	(111.2		)	(143.0		)
Deferred tax benefit related to loss on extinguishment of debt and other items	(24.3		)	—			(24.3		)	—
Total income tax benefit	$	(153.8	)	$	(117.8	)	$	(81.8	)	$	(67.4	)

A reconciliation of the U.S. statutory corporate tax rate to the estimated annual tax rate, before discrete items, reflected in the consolidated statement of operations is as follows:

	Nine months ended
	September 30,
	2012		2011
U.S. statutory corporate rate	35.0	%	35.0	%
Valuation allowance reduction applicable to current year income	(13.8	)	—
Nondeductible amounts	.5		1.8
State taxes	1.0		1.0
Provision for tax issues, tax credits and other	—		(.8	)
Estimated annual effective tax rate	22.7	%	37.0	%

The components of the Company’s income tax assets and liabilities were as follows (dollars in millions):

	September 30, 2012			December 31, 2011
	(Restated)
Deferred tax assets:
Net federal operating loss carryforwards	$	1,366.2		$	1,445.2
Net state operating loss carryforwards	16.3			16.8
Tax credits	37.7			32.6
Capital loss carryforwards	305.4			342.3
Deductible temporary differences:
Insurance liabilities	754.8			744.4
Other	81.7			64.8
Gross deferred tax assets	2,562.1			2,646.1
Deferred tax liabilities:
Investments	(21.9		)	(24.2		)
Present value of future profits and deferred acquisition costs	(333.7		)	(363.7		)
Accumulated other comprehensive income	(688.1		)	(434.8		)
Gross deferred tax liabilities	(1,043.7		)	(822.7		)
Net deferred tax assets before valuation allowance	1,518.4			1,823.4
Valuation allowance	(795.4		)	(938.4		)
Net deferred tax assets	723.0			885.0
Current income taxes accrued	(23.5		)	(19.6		)
Income tax assets, net	$	699.5		$	865.4

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and net operating loss carryforwards (“NOLs”). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred income tax assets depends upon generating sufficient future taxable income during the periods in which our temporary differences become deductible and before our capital loss carryforwards and NOLs expire.

Based on our assessment, it appears more likely than not that $893 million of our NOLs and capital loss carryforwards will be realized through future taxable earnings. Accordingly, we have identified reductions to our deferred tax valuation allowance of $155.0 million, of which $143.0 million was recognized in the three months ended September 30, 2012 and $12.0 million will be recognized in the three months ended December 31, 2012, as we reflect the impact of a lower estimated annual effective tax rate on estimated income for the entire year. We will continue to assess the need for a valuation allowance in the future. If future results are less than projected, a valuation allowance may be required to reduce the deferred tax asset, which could have a material impact on our results of operations in the period in which it is recorded.

There are two principal components of the reduction to our valuation allowance for deferred tax assets in 2012. First, our 2012 taxable income (including taxable investment gains), is expected to exceed the amount previously reflected in our deferred tax valuation model, resulting in a reduction to the valuation allowance of $43.8 million. This reduction is reflected in the estimate of our annual effective tax rate and, therefore, will be recognized as follows: $31.8 million in the three months ended September 30, 2012 and $12.0 million in the three months ended December 31, 2012. In addition, our recent higher levels of operating income resulted in the projection of higher levels of future years taxable income based on evidence we consider to be objective and verifiable. This change is further described in the following paragraph and resulted in a reduction to the valuation allowance for deferred tax assets of $111.2 million, all of which was recognized in the three months ended September 30, 2012.

Our analysis at September 30, 2012, is consistent with the deferred tax valuation model used in the prior year. Our deferred tax valuation model reflects projections of future taxable income based on a normalized average annual taxable income for the last three years, plus 5 percent growth for the next five years and no growth thereafter. In our new projections, our three year average increased to $293 million, compared to $260 million in our prior projection. The projections used to support the recovery of our NOLs do not anticipate the use of tax planning strategies that we could consider in the future to avoid a tax benefit from expiring. We have evaluated each component of the deferred tax asset and assessed the effect of limitations and/or interpretations on the value of each component to be fully recognized in the future.

Recovery of our deferred tax assets is dependent on achieving the future taxable income used in our deferred tax valuation model and failure to do so would result in an increase in the valuation allowance in a future period.  Any future increase in the valuation allowance may result in additional income tax expense and reduce shareholders’ equity, and such an increase could have a significant impact upon our earnings in the future.  In addition, the use of the Company’s NOLs is dependent, in part, on whether the Internal Revenue Service (the “IRS”) ultimately agrees with the tax positions we have taken in our tax returns with respect to the allocation of cancellation of indebtedness income ("CODI") resulting from the bankruptcy of our Predecessor and the classification of the loss we recognized as a result of the transfer of the stock of Senior Health Insurance Company of Pennsylvania (“Senior Health”) to Senior Health Care Oversight Trust, an independent trust (the “Independent Trust”).

The Internal Revenue Code (the “Code”) limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of:  (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities).  There is no similar limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities).

Section 382 of the Code imposes limitations on a corporation’s ability to use its NOLs when the company undergoes an ownership change.  Future transactions and the timing of such transactions could cause an ownership change for Section 382 income tax purposes.  Such transactions may include, but are not limited to, additional repurchases under our share repurchase program, issuances of common stock (including upon conversion of our outstanding 7.0% Debentures), and acquisitions or sales of shares of CNO stock by certain holders of our shares, including persons who have held, currently hold or may accumulate in the future five percent or more of our outstanding common stock for their own account.  Many of these transactions are beyond our control.  If an additional ownership change were to occur for purposes of Section 382, we would be required to calculate an annual restriction on the use of our NOLs to offset future taxable income.  The annual restriction would be calculated based upon the value of CNO’s equity at the time of such ownership change, multiplied by a federal long-term tax exempt rate (3.02 percent at September 30, 2012), and the annual restriction could effectively eliminate our ability to use a substantial portion of our NOLs to offset future taxable income.  We regularly monitor ownership change (as calculated for purposes of Section 382) and, as of September 30, 2012, we were below the 50 percent ownership change level that would trigger further impairment of our ability to utilize our NOLs.

As of September 30, 2012, we had $3.9 billion of federal NOLs and $.9 billion of capital loss carryforwards. The following table summarizes the expiration dates of our loss carryforwards assuming the IRS does not ultimately agree with the positions we have taken with respect to the allocation of CODI and the loss on our investment in Senior Health, both as further described below (dollars in millions):

Year of expiration	Net operating loss carryforwards (a)						Capital loss			Total loss
	Life			Non-life			carryforwards			carryforwards
2013	$	—		$	—		$	836.7	(b)	$	836.7
2014	—			—			28.6			28.6
2015	—			—			7.2			7.2
2018	550.9		(a)	—			—			550.9
2021	29.5			—			—			29.5
2022	204.1			—			—			204.1
2023	—		(b)	2,602.8		(a)	—			2,602.8
2024	—			3.2			—			3.2
2025	—			118.8			—			118.8
2027	—			216.8			—			216.8
2028	—			.5			—			.5
2029	—			148.9			—			148.9
2031	—			28.0			—			28.0
Total	$	784.5		$	3,119.0		$	872.5		$	4,776.0

 _________________________

(a) The life/non-life allocation summarized above assumes the IRS does not ultimately agree with the tax position we have taken in our tax returns with respect to the allocation of CODI.  If the IRS ultimately agrees with our tax position, approximately $631 million of the non-life NOLs expiring in 2023 would be characterized as life NOLs expiring in 2018.

(b) The allocation of the capital loss carryforwards summarized above assumes the IRS does not ultimately agree with the tax position we have taken with respect to our investment in Senior Health, which was worthless when it was transferred to the Independent Trust in 2008. If the IRS ultimately agrees with our tax position of classifying this loss as ordinary, capital loss carryforwards expiring in 2013 would decrease and life NOLs expiring in 2023 would increase by $742 million.

We had deferred tax assets related to NOLs for state income taxes of $16.3 million and $16.8 million at September 30, 2012 and December 31, 2011, respectively.  The related state NOLs are available to offset future state taxable income in certain states through 2019.

In July 2006, the Joint Committee of Taxation accepted the audit and the settlement which characterized $2.1 billion of the tax losses on our Predecessor's investment in Conseco Finance Corp. as life company losses and the remaining $3.8 billion as non-life losses prior to the application of the CODI attribute reductions described below.

The Code provides that any income realized as a result of the CODI in bankruptcy must reduce NOLs. We realized $2.5 billion of CODI when we emerged from bankruptcy. Pursuant to the Company's interpretation of the tax law, the CODI reductions were all used to reduce non-life NOLs and this position has been taken in our tax returns. However, the IRS has issued a proposed adjustment which is not in agreement with our position. We have requested an appeal of the IRS proposed adjustment through their early appeals process. Due to uncertainties with respect to the position the IRS may take and limitations on our ability to utilize NOLs based on projected life and non-life income, we have consistently considered the $631 million of CODI to be a reduction to life NOLs when determining our valuation allowance, pending resolution. If the IRS ultimately agrees with our position that the $631 million of CODI is a reduction to non-life NOLs, our valuation allowance would be reduced by approximately $140 million based on the income projections used in determining our valuation allowance. The outcome of this uncertainty cannot be predicted.

We recognized a $742 million loss on our investment in Senior Health which was worthless when it was transferred to the Independent Trust in 2008. We have treated the loss as a capital loss when determining the deferred tax benefit we may receive. We also established a full valuation allowance as we believe we will not generate capital gains to utilize the benefit. However, due to uncertainties in the Code, we have reflected this loss as an ordinary loss in our tax return, contrary to certain IRS rulings. If classifying this loss as ordinary is ultimately determined to be correct, our valuation allowance would be reduced by approximately $140 million based on the income projections used in determining our valuation allowance.

Tax years 2008 through 2010 are under examination by the IRS. This examination is expected to accelerate the resolution of the uncertainty related to the loss on our investment in Senior Health.  The Company’s various state income tax returns are generally open for tax years 2009 through 2011 based on the individual state statutes of limitation. Generally, for tax years which generate NOLs, capital losses or tax credit carryforwards, the statute of limitations does not close until the expiration of the statute of limitations for the tax year in which such carryforwards are utilized.

XML

FAIR VALUE MEASUREMENTS - ADDITIONAL INFORMATION (DETAILS) (USD $) In Millions, unless otherwise specified			9 Months Ended			9 Months Ended			9 Months Ended			9 Months Ended			9 Months Ended			9 Months Ended			9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012 Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Fair Value, Inputs, Level 3 [Member] Estimate of Fair Value, Fair Value Disclosure [Member]		Sep. 30, 2012 Corporate securities [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Corporate securities [Member] Fair Value, Inputs, Level 3 [Member] Estimate of Fair Value, Fair Value Disclosure [Member]		Sep. 30, 2012 Asset-backed securities [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Asset-backed securities [Member] Fair Value, Inputs, Level 3 [Member] Estimate of Fair Value, Fair Value Disclosure [Member]		Sep. 30, 2012 Collateralized debt obligations [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Collateralized debt obligations [Member] Fair Value, Inputs, Level 3 [Member] Estimate of Fair Value, Fair Value Disclosure [Member]		Sep. 30, 2012 Equity Securities [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Equity Securities [Member] Fair Value, Inputs, Level 3 [Member] Estimate of Fair Value, Fair Value Disclosure [Member]		Sep. 30, 2012 Venture capital investments [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Venture capital investments [Member] Fair Value, Inputs, Level 3 [Member] Estimate of Fair Value, Fair Value Disclosure [Member]		Sep. 30, 2012 Minimum [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Minimum [Member] Corporate securities [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Minimum [Member] Asset-backed securities [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Minimum [Member] Collateralized debt obligations [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Minimum [Member] Venture capital investments [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Maximum [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Maximum [Member] Corporate securities [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Maximum [Member] Asset-backed securities [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Maximum [Member] Collateralized debt obligations [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Maximum [Member] Venture capital investments [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Interest Sensitive Products [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Interest Sensitive Products [Member] Minimum [Member] Fair Value, Inputs, Level 3 [Member]	Sep. 30, 2012 Interest Sensitive Products [Member] Maximum [Member] Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments	$ 28,087.4	$ 26,364.3		$ 787.4			$ 212.4	[1]		$ 33.0	[2]		$ 339.0	[3]		$ 2.2	[4]		$ 38.1	[5]
Other Investments	265.0	202.8		162.7	[6]
Liabilities For Interest Sensitive Products	$ 12,930.3	$ 13,165.5		$ 743.9	[7]
Investments, Fair Value Disclosure, Significant Assumptions, Discount Rate																						1.95%	2.96%	1.30%			3.27%	3.28%	10.00%
Investments, Fair Value Disclosure, Significant Assumptions, Weighted Average Discount Rate						2.78%			3.15%			2.39%
Investments, Fair Value Disclosure, Significant Assumptions, Recoveries															21.00%									61.00%					66.00%
Investments, Fair Value Disclosure, Significant Assumptions, Weighted Average Constant Prepayment Rate												20.00%
Investments, Fair Value Disclosure, Significant Assumptions, Annual Default Rate																								1.32%					5.81%
Investments, Fair Value Disclosure, Significant Assumptions, Weighted Average Annual Default Rate												3.27%
Investments, Fair Value Disclosure, Significant Assumptions, Portfolio CCC Percent																								1.90%					22.17%
Investments, Fair Value Disclosure, Significant Assumptions, Weighted Average Portfolio CCC Percent												12.78%
Investments, Fair Value Disclosure, Significant Assumptions, EBITDA Multiple																									4.8					29.0
Investments, Fair Value Disclosure, Significant Assumptions, Weighted Average EBITDA Multiple																		11.46
Investments, Fair Value Disclosure, Significant Assumptions, Revenue Multiple																									0.9					7.0
Investments, Fair Value Disclosure, Significant Assumptions, Weighted Average Revenue Multiple																		4.2
Investments, Fair Value Disclosure, Significant Assumptions, Book Equity Multiple																									0.8					3.8
Investments, Fair Value Disclosure, Significant Assumptions, Weighted Average Book Equity Multiple																		2.3
Liabilities, Fair Value Disclosure, Significant Assumptions, Projected Portfolio Yields																																5.35%	5.61%
Liabilities, Fair Value Disclosure, Significant Assumptions, Weighted Average Projected Portfolio Yields																															5.55%
Liabilities, Fair Value Disclosure, Significant Assumptions, Discount Rates																					0.00%					3.50%
Liabilities, Fair Value Disclosure, Significant Assumptions, Weighted Average Discount Rates			1.30%
Liabilities, Fair Value Disclosure, Significant Assumptions, Surrender Rates																					4.00%					43.00%
Liabilities, Fair Value Disclosure, Significant Assumptions, Weighted Average Surrender Rates			19.00%

[1] Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

[2] Asset-backed securities - The significant unobservable input used in the fair value measurement of our asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

[3] Collateralized debt obligations - The significant unobservable inputs used in the fair value measurement of our collateralized debt obligations relate to collateral performance, including default rate, recoveries and constant prepayment rate, as well as discount margins of the underlying collateral. Significant increases (decreases) in default rate in isolation would result in a significantly lower (higher) fair value measurement. Generally, a significant increase (decrease) in the constant prepayment rate and recoveries in isolation would result in a significantly higher (lower) fair value measurement. Generally a significant increase (decrease) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the annual default rate is accompanied by a directionally similar change in the assumption used for discount margins and portfolio CCC % and a directionally opposite change in the assumption used for constant prepayment rate and recoveries. A tranche's payment priority and investment cost basis could alter generalized fair value outcomes.

[4] Equity securities - The significant unobservable input used in the fair value measurement of our equity securities is the anticipated cash recovery. Significant increases (decreases) in the anticipated recovery would result in a significantly higher (lower) fair value measurement.

[5] Venture capital investments - The significant unobservable inputs used in the fair value measurement of our venture capital investments are the EBITDA multiple and revenue multiple. Generally, a significant increase (decrease) in the EBITDA or revenue multiples in isolation would result in a significantly higher (lower) fair value measurement.

[6] Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

[7] Interest sensitive products - The significant unobservable inputs used in the fair value measurement of our interest sensitive products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

XML

FAIR VALUE MEASUREMENTS - UNOBSERVABLE INPUT ACTIVITY (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011
Available-for-sale Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	$ 53.0		$ 110.7		$ 160.7		$ 207.0
Sales	(34.7)		(144.6)		(77.8)		(447.9)
Issuances	0		0		0		0
Settlements	0		0		0		0
Purchases, sales, issuances and settlements, net	18.3	[1]	(33.9)	[2]	82.9	[3]	(240.9)	[4]
Available-for-sale Securities [Member] | Corporate Debt Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	27.0		1.8		70.3		1.8
Sales	(13.0)		(113.0)		(15.4)		(290.8)
Issuances	0		0		0		0
Settlements	0		0		0		0
Purchases, sales, issuances and settlements, net	14.0	[1]	(111.2)	[2]	54.9	[3]	(289.0)	[4]
Available-for-sale Securities [Member] | US Treasury and Government [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	0				0
Sales	(1.5)				(1.6)
Issuances	0				0
Settlements	0				0
Purchases, sales, issuances and settlements, net	(1.5)	[1]	0	[2]	(1.6)	[3]	0	[4]
Available-for-sale Securities [Member] | US States and Political Subdivisions Debt Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases							0
Sales							(2.8)
Issuances							0
Settlements							0
Purchases, sales, issuances and settlements, net	0	[1]	0	[2]	0	[3]	(2.8)	[4]
Available-for-sale Securities [Member] | Asset-backed Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	15.0		4.2		15.0		4.1
Sales	0		(3.0)		(3.6)		(4.7)
Issuances	0		0		0		0
Settlements	0		0		0		0
Purchases, sales, issuances and settlements, net	15.0	[1]	1.2	[2]	11.4	[3]	(0.6)	[4]
Available-for-sale Securities [Member] | Collateralized Debt Obligations [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	0		84.2		30.1		106.6
Sales	(6.3)		(11.5)		(41.7)		(103.1)
Issuances	0		0		0		0
Settlements	0		0		0		0
Purchases, sales, issuances and settlements, net	(6.3)	[1]	72.7	[2]	(11.6)	[3]	3.5	[4]
Available-for-sale Securities [Member] | Mortgage Pass Through Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	0		0		0		0
Sales	(0.1)		(0.2)		(0.2)		(0.5)
Issuances	0		0		0		0
Settlements	0		0		0		0
Purchases, sales, issuances and settlements, net	(0.1)	[1]	(0.2)	[2]	(0.2)	[3]	(0.5)	[4]
Available-for-sale Securities [Member] | Collateralized Mortgage Obligations [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	11.0		20.5		45.3		94.5
Sales	(13.8)		(16.9)		(15.3)		(46.0)
Issuances	0		0		0		0
Settlements	0		0		0		0
Purchases, sales, issuances and settlements, net	(2.8)	[1]	3.6	[2]	30.0	[3]	48.5	[4]
Equity Securities Classification [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Sales	(1.0)
Issuances	0
Settlements	0
Purchases, sales, issuances and settlements, net	(1.0)
Equity Securities Classification [Member] | Equity Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases			27.3				64.0
Sales			0				0
Issuances			0				0
Settlements			0				0
Purchases, sales, issuances and settlements, net	(1.0)	[1]	27.3	[2]	(1.0)	[3]	64.0	[4]
Equity Securities Classification [Member] | Corporate Debt Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	0
Purchases, sales, issuances and settlements, net	(1.0)	[1]			(1.0)	[3]
Trading Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases, sales, issuances and settlements, net	2.8	[1]	0	[2]	7.0	[3]	(0.4)	[4]
Collateralized Mortgage Obligations [Member] | Trading Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases							0
Sales							(0.4)
Issuances							0
Settlements							0
Purchases, sales, issuances and settlements, net			0	[2]	0	[3]	(0.4)	[4]
Collateralized Debt Obligations [Member] | Trading Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	2.8				7.0
Sales	0				0
Issuances	0				0
Settlements	0				0
Purchases, sales, issuances and settlements, net	2.8	[1]			7.0	[3]
Corporate Debt Securities [Member] | Equity Securities Classification [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases					0
Sales					(1.0)
Issuances					0
Settlements					0
Purchases, sales, issuances and settlements, net					(1.0)
Corporate Debt Securities [Member] | Trading Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases, sales, issuances and settlements, net	0	[3]			0
Interest Sensitive Products [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues, Settlements [Abstract]
Purchases	(23.5)		(33.1)		(75.3)		(85.5)
Sales	0.2		41.7		41.9		51.8
Issuances	(10.2)		(2.6)		(50.6)		(28.4)
Settlements	10.8		10.3		31.9		27.1
Purchases, sales, issuances and settlements, net	(22.7)	[1]	16.3	[2]	(52.1)	[3]	(35.0)	[4]
Corporate Securities [Member] | Investments Held By Variable Interest Entities [Member] | Corporate Securities Held By Variable Interest Entities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, Sales, Issues, Settlements [Abstract]
Purchases, sales, issuances and settlements, net			0	[2]			(7.9)	[4]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues, Settlements [Abstract]
Purchases							0
Sales							(7.9)
Issuances							0
Settlements							0
Purchases, sales, issuances and settlements, net							$ (7.9)

[1] Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the three months ended September 30, 2012 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, netAssets: Fixed maturities, available for sale: Corporate securities$27.0 $(13.0) $— $— $14.0United States Treasury securities and obligations of United States government corporations and agencies— (1.5) — — (1.5)Asset-backed securities15.0 — — — 15.0Collateralized debt obligations— (6.3) — — (6.3)Mortgage pass-through securities— (.1) — — (.1)Collateralized mortgage obligations11.0 (13.8) — — (2.8)Total fixed maturities, available for sale53.0 (34.7) — — 18.3Equity securities - corporate securities— (1.0) — — (1.0)Trading securities - collateralized debt obligations2.8 — — — 2.8Liabilities: Liabilities for insurance products: Interest-sensitive products(23.5) .2 (10.2) 10.8 (22.7)

[2] Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the three months ended September 30, 2011 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, netAssets: Fixed maturities, available for sale: Corporate securities$1.8 $(113.0) $— $— $(111.2)Asset-backed securities4.2 (3.0) — — 1.2Collateralized debt obligations84.2 (11.5) — — 72.7Mortgage pass-through securities— (.2) — — (.2)Collateralized mortgage obligations20.5 (16.9) — — 3.6Total fixed maturities, available for sale110.7 (144.6) — — (33.9)Equity securities27.3 — — — 27.3Liabilities: Liabilities for insurance products: Interest-sensitive products(33.1) 41.7 (2.6) 10.3 16.3

[3] For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.

[4] Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the nine months ended September 30, 2011 (dollars in millions): Purchases Sales Issuances Settlements Purchases, sales, issuances and settlements, netAssets: Fixed maturities, available for sale: Corporate securities$1.8 $(290.8) $— $— $(289.0)States and political subdivisions— (2.8) — — (2.8)Asset-backed securities4.1 (4.7) — — (.6)Collateralized debt obligations106.6 (103.1) — — 3.5Mortgage pass-through securities— (.5) — — (.5)Collateralized mortgage obligations94.5 (46.0) — — 48.5Total fixed maturities, available for sale207.0 (447.9) — — (240.9)Equity securities64.0 — — — 64.0Trading securities: Collateralized mortgage obligations— (.4) — — (.4)Investments held by variable interest entities: Corporate securities— (7.9) — — (7.9)Liabilities: Liabilities for insurance products: Interest-sensitive products(85.5) 51.8 (28.4) 27.1 (35.0)

XML

RECENTLY ISSUED ACCOUNTING STANDARDS (Tables)

9 Months Ended

Sep. 30, 2012

Accounting Changes and Error Corrections [Abstract]

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

The adoption of ASU 2010-26 affected prior period information as follows (dollars in millions, except per share amounts):

	Three months ended							Nine months ended
	September 30, 2011							September 30, 2011
	As originally reported		Effect of adoption of ASU 2010-26			As adjusted		As originally reported		Effect of adoption of ASU 2010-26			As adjusted
Amortization	$	87.2	$	(28.6	)	$	58.6	$	325.4	$	(101.3	)	$	224.1
Other operating costs and expenses	127.6		54.4			182.0		367.1		160.7			527.8
Total benefits and expenses	904.8		25.8			930.6		2,810.2		59.4			2,869.6
Income before income taxes	87.5		(25.8		)	61.7		263.3		(59.4		)	203.9
Tax expense on period income	34.5		(9.3		)	25.2		96.9		(21.3		)	75.6
Net income	196.0		(16.5		)	179.5		309.4		(38.1		)	271.3
Earnings per common share:
Basic:
Net income	$	.79	$	(.06	)	$	.73	$	1.24	$	(.15	)	$	1.09
Diluted:
Net income	.66		(.05		)	.61		1.05		(.13		)	.92

	Nine months ended
	September 30, 2011
	As originally reported			Effect of adoption of ASU 2010-26			As adjusted
Cash flows from operating activities:
Deferrable policy acquisition costs	$	(328.6	)	$	163.7		$	(164.9	)
Other operating costs	(349.9		)	(163.7		)	(513.6		)
Net cash used by operating activities	562.2			—			562.2

Schedule of Changes in Deferred Acquisition Costs [Table Text Block]

Changes in deferred acquisition costs were as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Restated)						(Restated)
Balance, beginning of period	$	653.5		$	975.5		$	797.1		$	999.6
Additions	46.7			58.3			141.4			164.9
Amortization	(44.5		)	(35.5		)	(146.4		)	(134.7		)
Amounts related to fair value adjustment of fixed maturities, available for sale	(32.3		)	(163.8		)	(168.7		)	(195.3		)
Balance, end of period	$	623.4		$	834.5		$	623.4		$	834.5

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (SCHEDULE OF FUTURE REPAYMENTS) (DETAILS) (USD $) In Millions, unless otherwise specified	Sep. 30, 2012
Year ending September 30,
2013	$ 55.4
2014	54.3
2015	79.3
2016	79.3
2017	97.2
Thereafter	678.7
Long-term Debt	$ 1,044.2

XML

RECENTLY ISSUED ACCOUNTING STANDARDS

9 Months Ended

Sep. 30, 2012

Accounting Changes and Error Corrections [Abstract]

RECENTLY ISSUED ACCOUNTING STANDARDS

RECENTLY ISSUED ACCOUNTING STANDARDS

Accounting Standard Adopted on a Retrospective Basis

In October 2010, the Financial Accounting Standards Board ("FASB") issued authoritative guidance that modified the definition of the types of costs incurred by insurance entities that could be capitalized in the acquisition of new and renewal contracts.  The guidance impacts the timing of GAAP reported financial results, but has no impact on cash flows, statutory financial results or the ultimate profitability of the business.

The guidance specifies that an insurance entity shall only capitalize incremental direct costs related to the successful acquisition of new or renewal insurance contracts.  The guidance also states that advertising costs should be included in deferred acquisition costs only if the capitalization criteria in the direct-response advertising guidance is met.  The guidance was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2011. As permitted by the guidance, we elected to apply the provisions on a retrospective basis. The guidance reduced the balance of deferred acquisition costs, its amortization and the amount of costs capitalized. We are able to defer most commission payments, plus other costs directly related to the production of new business. The change did not impact the balance of the present value of future profits. Therefore, in contrast to the reduction in amortization of deferred acquisition costs, there was no change in the amortization of the present value of future profits.

The adoption of ASU 2010-26 affected prior period information as follows (dollars in millions, except per share amounts):

	Three months ended							Nine months ended
	September 30, 2011							September 30, 2011
	As originally reported		Effect of adoption of ASU 2010-26			As adjusted		As originally reported		Effect of adoption of ASU 2010-26			As adjusted
Amortization	$	87.2	$	(28.6	)	$	58.6	$	325.4	$	(101.3	)	$	224.1
Other operating costs and expenses	127.6		54.4			182.0		367.1		160.7			527.8
Total benefits and expenses	904.8		25.8			930.6		2,810.2		59.4			2,869.6
Income before income taxes	87.5		(25.8		)	61.7		263.3		(59.4		)	203.9
Tax expense on period income	34.5		(9.3		)	25.2		96.9		(21.3		)	75.6
Net income	196.0		(16.5		)	179.5		309.4		(38.1		)	271.3
Earnings per common share:
Basic:
Net income	$	.79	$	(.06	)	$	.73	$	1.24	$	(.15	)	$	1.09
Diluted:
Net income	.66		(.05		)	.61		1.05		(.13		)	.92

	Nine months ended
	September 30, 2011
	As originally reported			Effect of adoption of ASU 2010-26			As adjusted
Cash flows from operating activities:
Deferrable policy acquisition costs	$	(328.6	)	$	163.7		$	(164.9	)
Other operating costs	(349.9		)	(163.7		)	(513.6		)
Net cash used by operating activities	562.2			—			562.2

Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For universal life or investment products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate.

When we realize a gain or loss on investments backing our universal life or investment-type products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust deferred acquisition costs for the change in amortization that would have been recorded if our fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We limit the total adjustment related to the impact of unrealized losses to the total of costs capitalized plus interest related to insurance policies issued in a particular year. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity.

We regularly evaluate the recoverability of the unamortized balance of the deferred acquisition costs. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the deferred acquisition costs may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the deferred acquisition costs over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years.

Changes in deferred acquisition costs were as follows (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
	(Restated)						(Restated)
Balance, beginning of period	$	653.5		$	975.5		$	797.1		$	999.6
Additions	46.7			58.3			141.4			164.9
Amortization	(44.5		)	(35.5		)	(146.4		)	(134.7		)
Amounts related to fair value adjustment of fixed maturities, available for sale	(32.3		)	(163.8		)	(168.7		)	(195.3		)
Balance, end of period	$	623.4		$	834.5		$	623.4		$	834.5

Adopted Accounting Standards

In June 2011, the FASB issued authoritative guidance to increase the prominence of items reported in other comprehensive income by eliminating the option to present components of other comprehensive income as part of the statement of changes in shareholders' equity. Such guidance requires that all non-owner changes in shareholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement approach, the first statement should present total net income and its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income and the total of comprehensive income. The guidance was applied retrospectively and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of this guidance resulted in a change in the presentation of our financial statements but did not have any impact on our financial condition, operating results or cash flows. In December 2011, the FASB issued authoritative guidance to defer the requirement to present reclassification adjustments out of accumulated other comprehensive income to net income on the face of the financial statements. All other aspects of the original guidance are still effective.

In May 2011, the FASB issued authoritative guidance which clarifies or updates requirements for measuring fair value and for disclosing information about fair value measurements. The guidance clarifies: (i) the application of the highest and best use and valuation premise concepts; (ii) measuring the fair value of an instrument classified in a reporting entity's shareholders' equity; and (iii) disclosure of quantitative information about the unobservable inputs used in a fair value measurement that is categorized within Level 3 of the fair value hierarchy. The guidance changes certain requirements for measuring fair value or disclosing information about fair value measurements including: (i) measuring the fair value of financial instruments that are managed within a portfolio; (ii) application of premiums and discounts in a fair value measurement; and (iii) additional disclosures about fair value measurements. Such additional disclosures include a description of the valuation process used for measuring Level 3 instruments and the sensitivity of the Level 3 fair value measurement to changes in unobservable inputs and the interrelationships between those unobservable inputs, if any. The guidance was effective prospectively for interim and annual periods beginning after December 15, 2011. Refer to the note to our consolidated financial statements entitled "Fair Value Measurements" for additional disclosures required by this guidance. The adoption of this guidance expanded our disclosures, but did not have a material impact on our financial condition, operating results or cash flows.

XML

CORRECTION TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS (TABLES)

9 Months Ended

Sep. 30, 2012

Accounting Changes and Error Corrections [Abstract]

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

The following summarizes the increase (decrease) to the principal items impacted by the corrections (dollars in millions):

	As reported in Form 10-Q		Corrections to shadow adjustments			As reported in Form 10-Q/A
Deferred acquisition costs	$	580.7	$	42.7		$	623.4
Income tax assets	594.5		105.0			699.5
Change in total assets			$	147.7
Liabilities for insurance products	$	24,593.5	$	334.4		$	24,927.9
Accumulated other comprehensive income	1,421.1		(186.7		)	1,234.4
Change to total liabilities and shareholders' equity			$	147.7
Comprehensive income:
For the three months ended September 30, 2012	$	425.3	$	(186.7	)	$	238.6
For the nine months ended September 30, 2012	$	759.3	$	(186.7	)	$	572.6

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (SCHEDULE OF DIRECT CORPORATE OBLIGATIONS) (DETAILS) (USD $) In Millions, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Debt Instrument [Line Items]
Debenture interest rate	7.00%
Debt Instruments [Abstract]
Direct corporate obligations	$ 1,035.1	$ 857.9
New Senior Secured Credit Agreement [Member]
Debt Instruments [Abstract]
Direct corporate obligations	675.0	0
Unamortized Discount	(5.5)	0
Convertible Subordinated Debt [Member]
Debt Instrument [Line Items]
Debenture interest rate	7.00%
Debt Instruments [Abstract]
Direct corporate obligations	93.0	293.0
Unamortized Discount	(3.6)	(12.9)
Previous Senior Secured Credit Agreement [Member]
Debt Instruments [Abstract]
Direct corporate obligations	0	255.2
Unamortized Discount	0	(2.4)
Senior Secured Note 6.375% [Member]
Debt Instrument [Line Items]
Debenture interest rate	6.375%
Debt Instruments [Abstract]
Direct corporate obligations		0
Senior Secured Notes 9 Percent [Member]
Debt Instrument [Line Items]
Debenture interest rate	9.00%
Debt Instruments [Abstract]
Direct corporate obligations	1.2	275.0
Other Notes Payable [Member]
Debt Instruments [Abstract]
Direct corporate obligations	$ 0	$ 50.0

XML

INVESTMENTS - REALIZED GAINS (LOSSES) (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 security	Sep. 30, 2011
Gain (Loss) on Investments [Abstract]
Net realized investment gains (losses)	$ 9.1	$ 30.6	$ 63.9	$ 38.6
Gain (Loss) on Investments, Excluding Other-than-temporary Impairments and Changes in Fair Value of Fixed Maturity Investments with Embedded Derivatives			89.0
Net realized investment gains, excluding impairment losses	32.2	33.5	98.4	64.9
Sales of investments			1,852.5	4,390.5
Gain on embedded derivative related to change in fair value of certain fixed maturity investments			9.4
Total other-than-temporary impairment losses	(23.1)	(2.9)	(34.5)	(26.3)
Aggregate amortized cost of fixed maturity securities in default or considered nonperforming	0.4		0.4
Carrying value of nonperforming fixed maturity securities	0.5		0.5
Value of sold fixed maturity investments			393.8
Gross investment losses from sale of fixed maturity investments, before tax			$ 15.3
Investments sold at a loss			0
Continuous unrealized loss position exceeding amortized cost, percent			20.00%

XML

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Statement of Other Comprehensive Income [Abstract]
Net income (loss)	$ (5.0)	$ 179.5	$ 119.8	$ 271.3
Other comprehensive income, before tax:
Unrealized gains for the period	689.4	973.6	1,252.8	1,248.1
Amortization of present value of future profits and deferred acquisition costs	(38.0)	(125.9)	(114.2)	(163.0)
Amount related to premium deficiencies assuming the net unrealized gains had been realized	(267.6)	(241.0)	(380.7)	(241.0)
Reclassification adjustments:
For net realized investment gains included in net income	(4.6)	(55.1)	(57.2)	(69.1)
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains included in net income	1.7	3.9	5.9	3.7
Unrealized gains on investments	380.9	555.5	706.6	778.7
Change related to deferred compensation plan	(2.1)	(2.4)	(0.5)	(2.0)
Other comprehensive income before tax	378.8	553.1	706.1	776.7
Income tax expense related to items of accumulated other comprehensive income	(135.2)	(197.7)	(253.3)	(278.5)
Other comprehensive income, net of tax	243.6	355.4	452.8	498.2
Comprehensive income	$ 238.6	$ 534.9	$ 572.6	$ 769.5

XML

CORRECTION TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS

9 Months Ended

Sep. 30, 2012

Accounting Changes and Error Corrections [Abstract]

CORRECTION TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS

CORRECTION TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS

As further described below, the consolidated balance sheet as of September 30, 2012; the consolidated statement of comprehensive income for the three and nine months ended September 30, 2012; the consolidated statement of shareholders' equity for the nine months ended September 30, 2012; and certain disclosures in the notes to the consolidated financial statements have been amended to correct an inadvertent error related to a component of accumulated other comprehensive income. The correction of this error had no impact on net income, earnings per share or cash flows. In addition, the correction had no impact on results, cash flows or capital measures calculated in accordance with statutory accounting principles.

Pursuant to GAAP, we are required to adjust certain balance sheet accounts to reflect the impact resulting from assuming that unrealized gains and losses on available for sale securities are realized and the proceeds are invested in securities earning current market yields. Such adjustments are commonly referred to as “shadow adjustments” and may include adjustments to: (i) deferred acquisition costs; (ii) the present value of future profits; (iii) loss recognition reserves; and (iv) income taxes. The net impact of these shadow adjustments is recognized in accumulated other comprehensive income. Amounts related to the shadow adjustments for certain long-term care products previously reported in our Form 10-Q for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on November 1, 2012, have been corrected. Shadow adjustments will vary from period to period and are primarily dependent upon the amount of unrealized gains or losses related to available for sale securities and the estimated gross profits of certain lines of business. The following summarizes the increase (decrease) to the principal items impacted by the corrections (dollars in millions):

	As reported in Form 10-Q		Corrections to shadow adjustments			As reported in Form 10-Q/A
Deferred acquisition costs	$	580.7	$	42.7		$	623.4
Income tax assets	594.5		105.0			699.5
Change in total assets			$	147.7
Liabilities for insurance products	$	24,593.5	$	334.4		$	24,927.9
Accumulated other comprehensive income	1,421.1		(186.7		)	1,234.4
Change to total liabilities and shareholders' equity			$	147.7
Comprehensive income:
For the three months ended September 30, 2012	$	425.3	$	(186.7	)	$	238.6
For the nine months ended September 30, 2012	$	759.3	$	(186.7	)	$	572.6

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES (DETAILS) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Variable Interest Entity [Line Items]
Investments held by variable interest entities	$ 829.4		$ 496.3
Cash and cash equivalents held by variable interest entities	48.2		74.4
Borrowings related to variable interest entities	766.9		519.9
Variable interest entity amortized cost securities held	827.7
Variable interest entity, gross unrealized gains fixed maturity securities	5.0
Variable interest entity gross unrealized losses fixed maturity securities	3.3
Variable interest entities net realized gain (loss) on investments	(0.1)	(0.2)
Variable interest entities net gains from sale of fixed maturity investments	0.3	3.3
Total other-than-temporary impairment losses on investments held by variable interest entities	0.4	3.5
Variable Interest Entities, Investments Sold	28.0
Variable Interest Entity, Available For Sale Securities, Gross Investment Losses From Sale, Before Tax	(0.2)
Investments held in limited partnerships	28.3
Unfunded committments to limited partnerships	20.0
VIEs [Member]
Variable Interest Entity [Line Items]
Investments held by variable interest entities	829.4		496.3
Notes receivable of VIEs held by insurance subsidiaries	0		0
Cash and cash equivalents held by variable interest entities	48.2		74.4
Accrued investment income	3.9		1.7
Income tax assets, net	3.2		6.8
Other assets	10.9		7.7
Total assets	895.6		586.9
Other liabilities	52.0		30.3
Borrowings related to variable interest entities	766.9		519.9
Notes payable of VIEs held by insurance subsidiaries	82.5		49.3
Total liabilities	901.4		599.5
Eliminations [Member]
Variable Interest Entity [Line Items]
Investments held by variable interest entities	0		0
Notes receivable of VIEs held by insurance subsidiaries	(78.5)		(45.3)
Cash and cash equivalents held by variable interest entities	0		0
Accrued investment income	0		0
Income tax assets, net	(2.3)		(1.4)
Other assets	0		0
Total assets	(80.8)		(46.7)
Other liabilities	(2.3)		(0.1)
Borrowings related to variable interest entities	0		0
Notes payable of VIEs held by insurance subsidiaries	(82.5)		(49.3)
Total liabilities	(84.8)		(49.4)
Net Effect On Consolidated Balance Sheet [Member]
Variable Interest Entity [Line Items]
Investments held by variable interest entities	829.4		496.3
Notes receivable of VIEs held by insurance subsidiaries	(78.5)		(45.3)
Cash and cash equivalents held by variable interest entities	48.2		74.4
Accrued investment income	3.9		1.7
Income tax assets, net	0.9		5.4
Other assets	10.9		7.7
Total assets	814.8		540.2
Other liabilities	49.7		30.2
Borrowings related to variable interest entities	766.9		519.9
Notes payable of VIEs held by insurance subsidiaries	0		0
Total liabilities	816.6		550.1
Less Than Twelve Months [Member]
Variable Interest Entity [Line Items]
Fair value investments held by variable interest entity that had been in an unrealized loss position	228.8
Gross unrealized losses on investments held by variable interest entity	1.7
Greater Than Twelve Months [Member]
Variable Interest Entity [Line Items]
Fair value investments held by variable interest entity that had been in an unrealized loss position	74.7
Gross unrealized losses on investments held by variable interest entity	$ 1.6

XML

INVESTMENTS (TABLES)

9 Months Ended

Sep. 30, 2012

Investments, Debt and Equity Securities [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments.  These amounts, included in shareholders’ equity as of September 30, 2012 and December 31, 2011, were as follows (dollars in millions):

	September 30, 2012			December 31, 2011
	(Restated)
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	$	9.6		$	(4.4	)
Net unrealized gains on all other investments	2,914.8			1,733.2
Adjustment to present value of future profits (a)	(200.7		)	(214.8		)
Adjustment to deferred acquisition costs	(458.0		)	(289.3		)
Adjustment to insurance liabilities	(334.4		)	—
Unrecognized net loss related to deferred compensation plan	(8.8		)	(8.3		)
Deferred income tax liabilities	(688.1		)	(434.8		)
Accumulated other comprehensive income	$	1,234.4		$	781.6

_________

(a) The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003 (the date our Predecessor emerged from bankruptcy).

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

At September 30, 2012, the amortized cost, gross unrealized gains and losses, estimated fair value, other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than- temporary impairments included in accumulated other comprehensive income
Corporate securities	$	14,586.6	$	2,265.7	$	(28.8	)	$	16,823.5	$	—
United States Treasury securities and obligations of United States government corporations and agencies	164.2		6.9		—			171.1		—
States and political subdivisions	1,785.6		267.9		(5.4		)	2,048.1		—
Debt securities issued by foreign governments	.8		—		—			.8		—
Asset-backed securities	1,391.3		92.0		(6.6		)	1,476.7		—
Collateralized debt obligations	327.6		5.2		(.8		)	332.0		—
Commercial mortgage-backed securities	1,400.7		142.7		(.8		)	1,542.6		—
Mortgage pass-through securities	18.8		1.4		—			20.2		—
Collateralized mortgage obligations	2,150.1		178.1		(.9		)	2,327.3		(7.3		)
Total fixed maturities, available for sale	$	21,825.7	$	2,959.9	$	(43.3	)	$	24,742.3	$	(7.3	)

Investments Classified by Contractual Maturity Date [Table Text Block]

The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at September 30, 2012, by contractual maturity.  Actual maturities will differ from contractual maturities because certain borrowers may have the right to call or prepay obligations with or without penalties.  In addition, structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as “structured securities”) frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	178.3	$	180.7
Due after one year through five years	1,558.1		1,697.5
Due after five years through ten years	4,491.1		5,038.7
Due after ten years	10,309.7		12,126.6
Subtotal	16,537.2		19,043.5
Structured securities	5,288.5		5,698.8
Total fixed maturities, available for sale	$	21,825.7	$	24,742.3

Other than Temporary Impairment, Credit Losses Recognized in Earnings [Table Text Block]

The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the three and nine months ended September 30, 2012 and 2011 (dollars in millions):

	Three months ended						Nine months ended
	September 30,						September 30,
	2012			2011			2012			2011
Credit losses on fixed maturity securities, available for sale, beginning of period	$	(1.7	)	$	(1.6	)	$	(2.0	)	$	(6.1	)
Add:  credit losses on other-than-temporary impairments not previously recognized	—			—			—			—
Less:  credit losses on securities sold	—			.7			.3			5.2
Less:  credit losses on securities impaired due to intent to sell (a)	—			—			—			—
Add:  credit losses on previously impaired securities	—			—			—			—
Less:  increases in cash flows expected on previously impaired securities	—			—			—			—
Credit losses on fixed maturity securities, available for sale, end of period	$	(1.7	)	$	(.9	)	$	(1.7	)	$	(.9	)

__________

(a) Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.

Schedule of Unrealized Loss on Investments [Table Text Block]

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at September 30, 2012 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
States and political subdivisions	$	40.2	$	(2.0	)	$	68.7	$	(3.4	)	$	108.9	$	(5.4	)
Corporate securities	300.5		(9.2		)	278.1		(19.6		)	578.6		(28.8		)
Asset-backed securities	42.1		(.3		)	137.8		(6.3		)	179.9		(6.6		)
Collateralized debt obligations	12.7		(.1		)	47.2		(.7		)	59.9		(.8		)
Commercial mortgage-backed securities	16.0		(.1		)	14.3		(.7		)	30.3		(.8		)
Mortgage pass-through securities	—		—			2.0		—			2.0		—
Collateralized mortgage obligations	58.5		(.5		)	36.0		(.4		)	94.5		(.9		)
Total fixed maturities, available for sale	$	470.0	$	(12.2	)	$	584.1	$	(31.1	)	$	1,054.1	$	(43.3	)
Equity securities	$	2.1	$	(.1	)	$	—	$	—		$	2.1	$	(.1	)

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2011 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	9.1	$	—		$	.2	$	—		$	9.3	$	—
States and political subdivisions	6.9		(.2		)	155.4		(13.4		)	162.3		(13.6		)
Debt securities issued by foreign governments	.5		—			—		—			.5		—
Corporate securities	1,394.7		(57.0		)	466.2		(79.9		)	1,860.9		(136.9		)
Asset-backed securities	437.6		(14.5		)	147.5		(22.2		)	585.1		(36.7		)
Collateralized debt obligations	268.8		(6.3		)	1.7		—			270.5		(6.3		)
Commercial mortgage-backed securities	168.8		(5.2		)	33.0		(2.7		)	201.8		(7.9		)
Mortgage pass-through securities	1.2		—			2.2		(.1		)	3.4		(.1		)
Collateralized mortgage obligations	645.0		(20.8		)	29.7		(.6		)	674.7		(21.4		)
Total fixed maturities, available for sale	$	2,932.6	$	(104.0	)	$	835.9	$	(118.9	)	$	3,768.5	$	(222.9	)
Equity securities	$	41.6	$	(3.0	)	$	.4	$	—		$	42.0	$	(3.0	)

XML

CORRECTION TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS (DETAILS) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Jun. 30, 2012	Dec. 31, 2011	Jun. 30, 2011	Dec. 31, 2010
Deferred acquisition costs	$ 623.4	$ 834.5	$ 623.4	$ 834.5	$ 653.5	$ 797.1	$ 975.5	$ 999.6
Income tax assets, net	699.5		699.5			865.4
Total assets	34,156.0		34,156.0			32,921.9
Liabilities for insurance products	24,927.9		24,927.9
Accumulated other comprehensive income	1,234.4		1,234.4			781.6
Total liabilities and shareholders' equity	34,156.0		34,156.0			32,921.9
Comprehensive income	238.6	534.9	572.6	769.5
Correction of Component of Accumulated Other Comprehensive Income [Member] | Scenario, Previously Reported [Member]
Deferred acquisition costs	580.7		580.7
Income tax assets, net	594.5		594.5
Liabilities for insurance products	24,593.5		24,593.5
Accumulated other comprehensive income	1,421.1		1,421.1
Comprehensive income	425.3		759.3
Correction of Component of Accumulated Other Comprehensive Income [Member] | Restatement Adjustment [Member]
Deferred acquisition costs	42.7		42.7
Income tax assets, net	105.0		105.0
Total assets	147.7		147.7
Liabilities for insurance products	334.4		334.4
Accumulated other comprehensive income	(186.7)		(186.7)
Total liabilities and shareholders' equity	147.7		147.7
Comprehensive income	$ (186.7)		$ (186.7)

XML

SALES INDUCEMENTS

9 Months Ended

Sep. 30, 2012

Deferred Sales Inducements [Abstract]

SALES INDUCEMENTS

SALES INDUCEMENTS

Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract.  Certain of our life insurance products offer persistency bonuses credited to the contract holders balance after the policy has been outstanding for a specified period of time.  These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP.  Such amounts are deferred and amortized in the same manner as deferred acquisition costs.  Sales inducements deferred totaled $3.1 million and $9.7 million during the nine months ended September 30, 2012 and 2011, respectively.  Amounts amortized totaled $20.5 million and $21.2 million during the nine months ended September 30, 2012 and 2011, respectively.  The unamortized balance of deferred sales inducements at September 30, 2012 and December 31, 2011 was $131.8 million and $149.2 million, respectively.  The balance of insurance liabilities for persistency bonus benefits was $36.6 million and $50.0 million at September 30, 2012 and December 31, 2011, respectively.